Molecules for disease detection and treatment

ABSTRACT

The invention provides human molecules for disease detection and treatment (MDDT) and polynucleotides which identify and encode MDDT. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of MDDT.

TECHNICAL FIELD

[0001] This invention relates to nucleic acid and amino acid sequences of molecules for disease detection and treatment and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, autoimmunelinflammatory, developmental, and neurological disorders, and infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of molecules for disease detection and treatment.

BACKGROUND OF THE INVENTION

[0002] It is estimated that only 2% of mammalian DNA encodes proteins, and only a small fraction of the genes that encode proteins are actually expressed in a particular cell at any time. The various types of cells in a multicellular organism differ dramatically both in structure and function, and the identity of a particular cell is conferred by its unique pattern of gene expression. In addition, different cell types express overlapping but distinctive sets of genes throughout development. Cell growth and proliferation, cell differentiation, the immune response, apoptosis, and other processes that contribute to organismal development and survival are governed by regulation of gene expression. Appropriate gene regulation also ensures that cells function efficienfly by expressing only those genes whose functions are required at a given time. Factors that influence gene expression include extracellular signals that mediate cell-cell communication and coordinate the activities of different cell types. Gene expression is regulated at the level of DNA and RNA transcription, and at the level of mRNA translation.

[0003] Aberrant expression or mutations in genes and their products may cause, or increase susceptibility to, a variety of human diseases such as cancer and other cell proliferative disorders. The identification of these genes and their products is the basis of an ever-expanding effort to find markers for early detection of diseases and targets for their prevention and treatment. For example, cancer represents a type of cell proliferative disorder that affects nearly every tissue in the body. The development of cancer, or oncogenesis, is often correlated with the conversion of a normal gene into a cancer-causing gene, or oncogene, through abnormal expression or mutation. Oncoproteins, the products of oncogenes, include a variety of molecules that influence cell proliferation, such as growth factors, growth factor receptors, intracellular signal transducers, nuclear transcription factors, and cell-cycle control proteins. In contrast, tumor-suppressor genes are involved in inhibiting cell proliferation. Mutations which reduce or abrogate the function of tumor-suppressor genes result in aberrant cell proliferation and cancer. Thus a wide variety of genes and their products have been found that are associated with cell proliferative disorders such as cancer, but many more may exist that are yet to be discovered.

[0004] DNA-based arrays can provide an efficient, high-throughput method to examine gene expression and genetic variability. For example, SNPs, or single nucleotide polymorphisms, are the most common type of human genetic variation. DNA-based arrays can dramatically accelerate the discovery of SNPs in hundreds and even thousands of genes. Likewise, such arrays can be used for SNP genotyping in which DNA samples from individuals or populations are assayed for the presence of selected SNPs. These approaches will ultimately lead to the systematic identification of all genetic variations in the human genome and the correlation of certain genetic variations with disease susceptibility, responsiveness to drug treatments, and other medically relevant information. (See, for example, Wang, D. G. et al. (1998) Science 280:1077-1082.)

[0005] DNA-based array technology is especially important for the rapid analysis of global gene expression patterns. For example, genetic predisposition, disease, or therapeutic treatment may directly or indirectly affect the expression of a large number of genes in a given tissue. In this case, it is useful to develop a profile, or transcript image, of all the genes that are expressed and the levels at which they are expressed in that particular tissue. A profile generated from an individual or population affected with a certain disease or undergoing a particular therapy may be compared with a profile generated from a control individual or population. Such analysis does not require knowledge of gene function, as the expression profiles can be subjected to mathematical analyses which simply treat each gene as a marker. Furthermore, gene expression profiles may help dissect biological pathways by identifying all the genes expressed, for example, at a certain developmental stage, in a particular tissue, or in response to disease or treatment. (See, for example, Lander, E. S. et al. (1996) Science 274:536-539.)

[0006] Certain genes are known to be associated with diseases because of their chromosomal location, such as the genes in the myotonic dystrophy (DM) regions of mouse and human. The mutation underlying DM has been localized to a gene encoding the DM-kinase protein, but another active gene, DMR-N9, is in close proximity to the DM-kinase gene (Jansen, G. et al. (1992) Nat. Genet. 1:261-266). DMR-N9 encodes a 650 amino acid protein that contains WD repeats, motifs found in cell signaling proteins. DMR-N9 is expressed in all neural tissues and in the testis, suggesting a role for DMR-N9 in the manifestation of mental and testicular symptoms in severe cases of DM (Jansen, G. et al. (1995) Hum. Mol. Genet. 4:843-852).

[0007] Other genes are identified based upon their expression patterns or association with disease syndromes. For example, autoantibodies to subcellular organelles are found in patients with systemic rheumatic diseases. A recently identified protein, golgin-67, belongs to a family of Golgi autoantigens having alphα-helical coiled-coil domains (Bystathioy, T. et al. (2000) J. Autoimmun. 14:179-187). The Stac gene was identified as a brain specific, developmentally regulated gene. The Stac protein contains an SH3 domain, and is thought to be involved in neuron-specific signal transduction (Suzuki, H. et al. (1996) Biochem. Biophys. Res. Commun. 229:902-909).

[0008] Structural and Cytoskeleton-Associated Proteins

[0009] The cytoskeleton is a cytoplasmic network of protein fibers that mediate cell shape, structure, and movement. The cytoskeleton supports the cell membrane and forms tracks along which organelles and other elements move in the cytosol. The cytoskeleton is a dynamic structure that allows cells to adopt various shapes and to carry out directed movements. Major cytoskeletal fibers include the microtibules, the microfilaments, and the intermediate filaments. Motor proteins, including myosin, dynein, and kinesin, drive movement of or along the fibers. The motor protein dynamin drives the formation of membrane vesicles. Accessory or associated proteins modify the structure or activity of the fibers while cytoskeletal membrane anchors connect the fibers to the cell membrane.

[0010] Microtubules and Associated Proteins

[0011] Tubulins

[0012] Microtubules, cytoskeletal fibers with a diameter of about 24 nm, have multiple roles in the cell. Bundles of microtubules form cilia and flagella, which are whip-like extensions of the cell membrane that are necessary for sweeping materials across an epithelium and for swimming of sperm, respectively. Marginal bands of microtubules in red blood cells and platelets are important for these cells' pliability. Organelles, membrane vesicles, and proteins are transported in the cell along tracks of microtubules. For example, microtubules run through nerve cell axons, allowing bidirectional transport of materials and membrane vesicles between the cell body and the nerve terminal. Failure to supply the nerve terminal with these vesicles blocks the transmission of neural signals. Microtubules are also critical to chromosomal movement during cell division. Both stable and short-lived populations of microtubules exist in the cell.

[0013] Microtubules are polymers of GTP-binding tubulin protein subunits. Each subunit is a heterodimer of α- and β-tubulin, multiple isoforms of which exist The hydrolysis of GTP is linked to the addition of tubulin subunits at the end of a microtubule. The subunits interact head to tail to form protofilaments; the protofilaments interact side to side to form a microtubule. A microtubule is polarized, one end ringed with α-tubulin and the other with β-tubulin, and the two ends differ in their rates of assembly. Generally, each microtubule is composed of 13 protofilaments although 11 or 15 protofilament-microtubules are sometimes found. Cilia and flagella contain doublet microtubules. Microtubules grow from specialized structures known as centrosomes or microtubule-organizing centers (QIOCs). MTOCs may contain one or two centrioles, which are pinwheel arrays of triplet microtubules. The basal body, the organizing center located at the base of a cilium or flagellum, contains one centriole. Gamma tubulin present in the KMC is important for nucleating the polymerization of α- and β-tubulin heterodimers but does not polymerize into microtubules.

[0014] Microtubule-Associated Proteins

[0015] Microtubule-associated proteins (MAPs) have roles in the assembly and stabillzation of microtubules. One major family of MAPs, assembly MAPs, can be identified in neurons as well as non-neuronal cells. Assembly MAPs are responsible for cross-linking microtubules in the cytosol. These MAPs are organized into two domains: a basic microtubule-binding domain and an acidic projection domain. The projection domain is the binding site for membranes, intermediate filaments, or other microtubules. Based on sequence analysis, assembly MAPs can be further grouped into two types: Type I and Type II. Type I MAPs, which include MAP1A and MAPLB, are large, filamentous molecules that co-purify with microtubules and are abundantly expressed in brain and testes. Type I MAPs contain several repeats of a positively-charged amino acid sequence motif that binds and neutralizes negatively charged tubulin, leading to stabilization of microtubules. MAPLA and MAPIB are each derived from a single precursor polypeptide that is subsequently proteolytically processed to generate one heavy chain and one light chain.

[0016] Another light chain, LC3, is a 16.4 kDa molecule that binds MAP1A, MAP1B, and microtubules. It is suggested that LC3 is synthesized from a source other than the MAPLA or MAP1b transcripts, and that the expression of LC3 may be important in regulating the microtubule binding activity of MAP1A and MAP1B during cell proliferation (Mann, S. S. et al. (1994) J. Biol. Chem. 269:11492-11497).

[0017] Type II MAPs, which include MAP2a, MAP2b, MAP2c, MAP4, and Tau, are characterized by three to four copies of an 18-residue sequence in the microtubule-binding domain. MAP2a, MAP2b, and MAP2c are found only in dendrites, MAP4 is found in non-neuronal cells, and Tau is found in axons and dendrites of nerve cells. Alternative splicing of the Tau mRNA leads to the existence of multiple forms of Tau protein. Tau phosphorylation is altered in neurodegenerative disorders such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia and Parkinsonism linked to chromosome 17. The altered Tau phosphorylation leads to a collapse of the microtubule network and the formation of intraneuronal Tau aggregates (Spillantni, M. G. and M. Goedert (1998) Trends Neurosci. 21:428-433).

[0018] Another microtubule associated protein, STOP (stable tubule only polypeptide), is a calmodulin-regulated protein that regulates stability (Denarier, E. et al. (1998) Biochem. Biophys. Res. Commun. 24:791-796). In order for neurons to maintain conductive connections over great distances, they rely upon axodendritic extensions, which in turn are supported by miicrotubules. STOP proteins function to stabilize the microtubular network. STOP proteins are associated with axonal microtubules, and are also abundant in neurons (Guillaud, L. et al. (1998) J. Cell Biol. 142:167-179). STOP proteins are necessary for nornal neurite formation, and have been observed to stabilize microtubules, in vitro, against cold-, calcium-, or drug-induced dissassembly (Margolis, R. L. et al. (1990) EMBO 9:4095-502).

[0019] Microfilaments and Associated Proteins

[0020] Actins

[0021] Microfilaments, cytoskeletal filaments with a diameter of about 7-9 nm, are vital to cell locomotion, cell shape, cell adhesion, cell division, and muscle contraction. Assembly and disassembly of the microfilaments allow cells to change their morphology. Microfilaments are the polymerized form of actin, the most abundant intracellular protein in the eukaryotic cell. Human cells contain six isoforms of actin. The three α-actins are found in different kinds of muscle, nonmuscle β-actin and nonmuscle mγ-actin are found in nonmuscle cells, and another γ-actin is found in intestinal smooth muscle cells. G-actin, the monomeric form of actin, polymerizes into polarized, helical F-actin filaments, accompanied by the hydrolysis of ATP to ADP. Actin filaments associate to form bundles and networks, providing a framework to support the plasma membrane and determine cell shape. These bundles and networks are connected to the cell membrane. In muscle cells, thin filaments containing actin slide past thick filaments containing the motor protein myosin during contraction. A family of actin-related proteins exist that are not part of the actin cytoskeleton, but rather associate with microtubules and dynein.

[0022] Actin-Associated Proteins

[0023] Actin-associated proteins have roles in cross-iniking, severing, and stabilization of actin filaments and in sequestering actin monomers. Several of the actin-associated proteins have multiple functions. Bundles and networks of actin filaments are held together by actin cross-hinking proteins. These proteins have two actin-binding sites, one for each filament. Short cross-linking proteins promote bundle formation while longer, more flexible cross-linking proteins promote network formation. Actin-interacting proteins (AIPs) participate in the regulation of actin filament organization. Other actin-associated proteins such as TARA, a novel F-actin binding protein, function in a similar capacity by regulating actin cytoskeletal organization. Calmodulin-like calcium-binding domains in actin cross-linking proteins allow calcium regulation of cross-linking. Group I cross-linking proteins have unique actin-binding domains and include the 30 kD protein, EF-1a, fascin, and scruin. Group II cross-linking proteins have a 7,000-MW actin-binding domain and include villin and dematin. Group m cross-linking proteins have pairs of a 26,000-MW actin-binding domain and include fimbrin, spectrn, dystrophin, ABP 120, and filamin.

[0024] Severing proteins regulate the length of actin filaments by breaking them into short pieces or by blocking their ends. Severing proteins include gCAP39, severin (fragmin), gelsolin, and villin. Capping proteins can cap the ends of actin filaments, but cannot break filaments. Capping proteins include CapZ and tropomodulin. The proteins thymosin and profilin sequester actin monomers in the cytosol, allowing a pool of unpolymerized actin to exist. The actin-associated proteins tropomyosin, troponin, and caldesmon regulate muscle contraction in response to calcium.

[0025] Microtubule and actin filament networks cooperate in processes such as vesicle and organelle transport, cleavage furrow placement, directed cell migration, spindle rotation, and nuclear migration. Microtubules and actin may coordinate to transport vesicles, organelles, and cell fate determinants, or transport may involve targeting and capture of microtubule ends at cortical actin sites. These cytoskeletal systems may be bridged by myosin-kinesin complexes, myosin-CLIP170 complexes, formin-homology (PH) proteins, dynein, the dynactin complex, Kar9p, coronin, ERM proteins, and kelch repeat-containing proteins (for a review, see Goode, B. L. et al. (2000) Curr. Opin. Cell Biol. 12:63-71). The kelch repeat is a motif originally observed in the kelch protein, which is involved in formation of cytoplasmic bridges called ring canals. A variety of mammalian and other kelch family proteins have been identified. The kelch repeat domain is believed to mediate interaction with actin (Robinson, D. N. and L. Cooley (1997) J. Cell Biol. 138:799-810).

[0026] ADF/cofilins are a family of conserved 15-18 kDa actin-binding proteins that play a role in cytokinesis, endocytosis, and in development of embryonic tissues, as well as in tissue regeneration and in pathologies such as ischemia, oxidative or osmotic stress. LM kinase 1 downregulates ADF (Carlier, M. F. et al. (1999) J. Biol. Chem. 274:33827-33830).

[0027] LIM is an acronym of three transcription factors, Lin-ll, lsl-1, and Mec-3, in which the motif was first identified. The LIM domain is a double zinc-finger motif that mediates the protein-protein interactions of tanscription factors, signaling, and cytoskeleton-associated proteins (Roof, D. J. et al. (1997) J. Cell Biol. 138:575-588). These proteins are distributed in the nucleus, cytoplasm, or both (B3 rown, S. et al. (1999) J. Biol. Chem. 274:27083-27091). Recently, ALP (actinin-associated LIM protein) has been shown to bind alphα-actinin-2 (Bouju, S. et al. (1999) Neuromuscul. Disord. 9:3-10).

[0028] The Frabin protein is another example of an actin-filament binding protein (Obaishi, H. et al. (1998) J. Biol. Chem. 273:18697-18700). Frabin (EGD1-related F-actin-hinding protein) possesses one actin-filament binding (FAB) domain, one Dbl homology (H) domain, two pleckstrin homology (PH) domains, and a single cysteine-rich FYVE (Fablp, XOTB, Yaclp, and BEA1 (early endosomal antigen 1)) domain. Frabin has shown GDP/GTP exchange activity for Cdc42 small G protein (Cdc42), and indirectly induces activation of Rac small G protein (Rac) in intact cells. Through the activation of Cdc42 and Rac, Frabin is able to induce formation of both filopodia- and lamellipodia-like processes (Ono, Y. et al. (2000) Oncogene 19:3050-3058). The Rho family small GTP-binding proteins are important regulators of actin-dependent cell functions including cell shape change, adhesion, and motility. The Rho family consists of three major subfamilies: Cdc42, Rac, and Rho. Rho family members cycle between GDP-bound inactive and GTP-bound active forms by means of a GDP/GTP exchange factor (GFF) (Umikawa, M. et al. (1999) J. Biol. Chem. 274:25197-25200). The Rho GEF family is crucial for microfilament organization.

[0029] Intermediate Filaments and Associated Proteins

[0030] Intermediate filaments (IFs) are cytoskeletal fibers with a diameter of about 10 nm, intermediate between that of microfilaments and microtubules. IFs serve structural roles in the cell, reinforcing cells and organizing cells into tissues. IFs are particularly abundant in epidermal cells and in neurons. IFs are extremely stable, and, in contrast to microfilaments and microtubules, do not function in cell motility.

[0031] Five types of IF proteins are known in mammals. Type I and Type II proteins are the acidic and basic keratins, respectively. Heterodimers of the acidic and basic keratins are the building blocks of keratin IFs. Keratins are abundant in soft epithelia such as skin and cornea, hard epithelia such as nails and hair, and in epithelia that line internal body cavities. Mutations in keratin genes lead to epithelial diseases including epidermolysis bullosa simplex, bullous congenital ichthyosiform erythroderma (epidermolytic hyperkeratosis), non-epidermolytic and epidermolytic palmoplantar keratoderma, ichthyosis bullosa of Siemens, pachyonychia congenita, and white sponge nevus. Some of these diseases result in severe slin blistering. (See, e.g., Wawersik, M. et al. (1997) J. Biol. Chem. 272:32557-32565; and Corden L. D. and W. H. McLean (1996) Exp. Dermatol. 5:297-307.)

[0032] Type III IF proteins include desmin, glial fibrillary acidic protein, vimentin, and peripherin. Desmin filaments in muscle cells link myofibrils into bundles and stabilize sarcomeres in contracting muscle. Glial fibrillary acidic protein filaments are found in the glial cells that surround neurons and astrocytes. Vimentin filaments are found in blood vessel endothelial cells, some epithelial cells, and mesenchymal cells such as fibroblasts, and are commonly associated with microtubules. Vimentin filaments may have roles in keeping the nucleus and other organelles in place in the cell. Type IV IFs include the neurofilaments and nestin. Neurofilaments, composed of three polypeptides NF-L, NF-M, and NF—H, are frequently associated with microtubules in axons. Neurofilaments are responsible for the radial growth and diameter of an axon, and ultimately for the speed of nerve impulse transmission. Changes in phosphorylation and metabolism of neurofilaments are observed in neurodegenerative diseases including amyotrophic lateral sclerosis, Parkinson's disease, and Alzheimer's disease (Julien, J. P. and W. E. Mushynski (1998) Prog. Nucleic Acid Res. Mol. Biol. 61:1-23). Type V IFs, the lamins, are found in the nucleus where they support the nuclear membrane.

[0033] IFs have a central α-helical rod region interrupted by short nonhelical linker segments. The rod region is bracketed, in most cases, by non-helical head and tail domains. The rod regions of intermediate filament proteins associate to form a coiled-coil dimer. A highly ordered assembly process leads from the dimers to the IFs. Neither ATP nor GTP is needed for IF assembly, unlike that of microfilaments and microtubules.

[0034] IF-associated proteins (IFAPs) mediate the interactions of IFs with one another and with other cell structures. IFAPs cross-link IFs into a bundle, into a network, or to the plasma membrane, and may cross-link IFs to the microffiament and microtubule cytoskeleton. Microtubules and IFs are particularly closely associated. IFAPs include BPAG1, plakoglobin, desmoplakin I, desmoplakin II, plectin, ankyrin, filaggrin, and lamin B receptor.

[0035] Cytoskeletal-Membrane Anchors

[0036] Cytoskeletal fibers are attached to the plasma membrane by specific proteins. These attachments are important for maintaining cell shape and for muscle contraction. In erythrocytes, the spectrin-actin cytoskeleton is attached to the cell membrane by three proteins, band 4.1, ankyrin, and adducin. Defects in this attachment result in abnormally shaped cells which are more rapidly degraded by the spleen, leading to anemia. In platelets, the spectrin-actin cytoskeleton is also linked to the membrane by ankyrin; a second actin network is anchored to the membrane by filamin. In muscle cells the protein dystrophin links actin filaments to the plasma membrane; mutations in the dystrophin gene lead to Duchenne muscular dystrophy.

[0037] Focal Adhesions

[0038] Focal adhesions are specialized structures in the plasma membrane involved in the adhesion of a cell to a substrate, such as the extracellular matrix. Focal adhesions form the connection between an extracellular substrate and the cytoskeleton, and affect such functions as cell shape, cell motility and cell proliferation. Transmembrane integrin molecules form the basis of focal adhesions. Upon ligand binding, integrins cluster in the plane of the plasma membrane. Cytoskeletal linker proteins such as the actin binding proteins α-actinin, talin, tensin, vinculin, paxillin, and filamin are recruited to the clustering site. Key regulatory proteins, such as Rho and Ras family proteins, focal adhesion kinase, and Src family members are also recruited. These events lead to the reorganization of actin filaments and the formation of stress fibers. These intracellular rearrangements promote furter integrin-ECM interactions and integdin clustering. Thus, integrins mediate aggregation of protein complexes on both the cytosolic and extracellular faces of the plasma membrane, leading to the assembly of the focal adhesion. Many signal transduction responses are mediated via various adhesion complex proteins, including Src, FAK, paxillin, and tensin. (For a review, see Yamada, KM. and B. Geiger, (1997) Curr. Opin. Cell Biol. 9:76-85.)

[0039] IFs are also attached to membranes by cytoskeletal-membrane anchors. The nuclear lamina is attached to the inner surface of the nuclear membrane by the lamin B receptor. Vimentin IFs are attached to the plasma membrane by ankyrin and plectin. Desmosome and hemidesmosome membrane junctions hold together epithelial cells of organs and skin. These membrane junctions allow shear forces to be distributed across the entire epithelial cell layer, thus providing strength and rigidity to the epithelium. IFs in epithelial cells are attached to the desmosome by plakoglobin and desmoplakins. The proteins that link IFs to hemidesmosomes are not known. Desmin IFs surround the sarcomere in muscle and are linked to the plasma membrane by paranemin, synemin, and ankyrin.

[0040] The protein components of tight junctions include ZO-1 and ZO-2 (zona occludens), cytoplasmic proteins associated with the plasma membrane at tight junctions. ZO-1 is a PDZ domain-containing protein which associates with spectrin and thus may link tight junctions to the actin cytoskeleton. Other cytoplasmic components of tight junctions include cingulin, 7H6 antigen, symplekin, and small rab family GTPases. The first identified component of the tight junction strands, which form the actual junction between cells, was the integral membrane protein occludin, a 65 kD protein with four transmembrane domains. ZO-1 binds to the carboxy-terminal region of occludin and may localize occludin to the tight junction. A recently identified family of proteins, the claudins, are also components of tight junction strands.

[0041] Motor Proteins

[0042] Myosin-Related Motor Proteins

[0043] Myosins are actin-activated ATPases, found in eukaryotic cells, that couple hydrolysis of ATP with motion. Myosin provides the motor function for muscle contraction and intracellular movements such as phagocytosis and rearrangement of cell contents during mitotic cell division (cytokinesis). The contractile unit of skeletal muscle, termed the sarcomere, consists of highly ordered arrays of thin actin-containing filaments and thick myosin-containing filaments. Crossbridges form between the thick and thin filaments, and the ATP-dependent movement of myosin heads within the thick filaments pulls the thin filaments, shortening the sarcomere and thus the muscle fiber.

[0044] Myosins are composed of one or two heavy chains and associated light chains. Myosin heavy chains contain an amino-terminal motor or head domain, a neck that is the site of light-chain binding, and a carboxy-terminal tail domain. The tail domains may associate to form an c-helical coiled coil. Conventional myosins, such as those found in muscle tissue, are composed of two myosin heavy-chain subunits, each associated with two light-chain subunits that bind at the neck region and play a regulatory role. Unconventional myosins, believed to function in intracellular motion, may contain either one or two heavy chains and associated light chains. There is evidence for about 25 myosin heavy chain genes in vertebrates, more than half of them unconventional.

[0045] Dynein-Related Motor Proteins

[0046] Dyneins are (−) end-directed motor proteins which act on microtubules. Two classes of dyneins, cytosolic and axonemal, have been identified. Cytosolic dyneins are responsible for translocation of materials along cytoplasmic microtubules, for example, transport from the nerve terminal to the cell body and trnsport of endocytic vesicles to lysosomes. As well, viruses often take advantage of cytoplasmic dyneins to be transported to the nucleus and establish a successful infection (Sodeik, B. et al. (1997) J. Cell Biol. 136:1007-1021). Virion proteins of herpes simplex virus 1, for example, interact with the cytoplasmic dynein intermediate chain (Ye, G. J. et al. (2000) J. Virol. 74:1355-1363). Cytoplasmic dyneins are also reported to play a role in mitosis. Axonemal dyneins are responsible for the beating of flagella and cilia. Dynein on one microtubule doublet walks along the adjacent microtubule doublet. This sliding force produces bending that causes the flagellum or cilium to beat. Dyneins have a native mass between 1000 and 2000 kDa and contain either two or three force-producing heads driven by the hydrolysis of ATP. The heads are linked via stalks to a basal domain which is composed of a highly variable number of accessory intermediate and light chains. Cytoplasmic dynein is the largest and most complex of the motor proteins.

[0047] Kinesin-Related Motor Proteins

[0048] Kinesins are (+) enddirected motor proteins which act on microtubules. The prototypical kinesin molecule is involved in the transport of membrane-bound vesicles and organelles. This function is particularly important for axonal transport in neurons. Kinesin is also important in all cell types for the transport of vesicles from the Golgi complex to the endoplasmic reticulum. This role is critical for maintaining the identity and functionality of these secretory organelles.

[0049] Kinesins define a ubiquitous, conserved family of over 50 proteins that can be classified into at least 8 subfamilies based on primary amino acid sequence, domain structure, velocity of movement, and cellular function. (Reviewed in Moore, J. D. and S. A. Endow (1996) Bioessays 18:207-219; and Hoyt, A. M. (1994) Curr. Opin. Cell Biol. 6:63-68.) The prototypical linesin molecule is a heterotetramer comprised of two heavy polypeptide chains (KHCs) and two light polypeptide chains (KLCs). The KHC subunits are typically referred to as “kinesin.” KHC is about 1000 amino acids in length, and KLC is about 550 amino acids in length. Two KHCs dimerize to form a rod-shaped molecule with three distinct regions of secondary structure. At one end of the molecule is a globular motor domain that functions in ATP hydrolysis and microtubule binding. Kinesin motor domains are highly conserved and share over 70% identity. Beyond the motor domain is an α-helical coiled-coil region which mediates dimerization. At the other end of the molecule is a fan-shaped tail that associates with molecular cargo. The tail is formed by the interaction of the KRC C-termini with the two KLCs.

[0050] Members of the more divergent subfamilies of kinesins are called kinesin-related proteins (KRPs), many of which function during mitosis in eukaryotes (Hoyt, supra. Some KRPs are required for assembly of the mitotic spindle. In vivo and in vitro analyses suggest that these KRPs exert force on microtubules that comprise the mitotic spindle, resulting in the separation of spindle poles. Phosphorylation of KRP is required for this activity. Failure to assemble the mitotic spindle results in abortive mitosis and chromosomal aneuploidy, the latter condition being characteristic of cancer cells. In addition, a unique KRP, centromere protein E, localizes to the Iinetochore of human mitotic chromosomes and may play a role in their segregation to opposite spindle poles.

[0051] Dynamin-Related Motor Proteins

[0052] Dynamin is a large GTPase motor protein that functions as a “molecular pinchase,” generating a mechanochemical force used to sever membranes. This activity is important in forming clathiincoated vesicles from coated pits in endocytosis and in the biogenesis of synaptic vesicles in neurons. Binding of dynamin to a membrane leads to dynamin's self-assembly into spirals that may act to constrict a flat membrane surface into a tubule. GTP hydrolysis induces a change in conformation of the dynamin polymer that pinches the membrane tubule, leading to severing of the membrane tubule and formation of a membrane vesicle. Release of GDP and inorganic phosphate leads to dynamin disassembly. Following disassembly the dynamin may either dissociate from the membrane or remain associated to the vesicle and be transported to another region of the cell. Three homologous dynamin genes have been discovered, in addition to several dynamin-related proteins. Conserved dynamin regions are the N-terminal GTP-binding domain, a central pleckstrin homology domain that binds membranes, a central coiled-coil region that may activate dynamin's GTPase activity, and a C-terminal proline-rich domain that contains several motifs that bind SH3 domains on other proteins. Some dynamin-related proteins do not contain the pleckstrin homology domain or the proline-rich domain. (See McNiven, M. A. (1998) Cell 94:151-154; Scaife, R. M. and R. L. Margolis (1997) Cell. Signal. 9:395-401.)

[0053] The cytoskeleton is reviewed in Lodish, H. et al. (1995) Molecular Cell Biology, Scientific American Books, New York N.Y.

[0054] Nucleic Acid-Associated Proteins

[0055] Multicellular organisms are comprised of diverse cell types that differ dramatically both in structure and function. The identity of a cell is determined by its characteristic pattern of gene expression, and different cell types express overlapping but distinctive sets of genes throughout development. Spatial and temporal regulation of gene expression is critical for the control of cell proliferation, cell differentiation, apoptosis, and other processes that contribute to organismal development. Furthermore, gene expression is regulated in response to extracellular signals that mediate cell-cell communication and coordinate the activities of different cell types. Appropriate gene regulation also ensures that cels function efficiently by expressing only those genes whose functions are required at a given time.

[0056] Transcription Factors

[0057] Transcriptional regulatory proteins are essential for the control of gene expression. Some of these proteins function as transcription factors that initiate, activate, repress, or terminate gene transcription. Transcription factors generally bind to the promoter, enhancer, and upstream regulatory regions of a gene in a sequence-specific manner, although some factors bind regulatory elements within or downstream of a gene coding region. Transcription factors may bind to a specific region of DNA singly or as a complex with other accessory factors. (Reviewed in Lewin, B. (1990) Genes IV, Oxford University Press, New York, N.Y., and Cell Press, Cambridge, Mass., pp. 554-570.)

[0058] The double helix structure and repeated sequences of DNA create topological and chemical features which can be recognized by transcription factors. These features are hydrogen bond donor and acceptor groups, hydrophobic patches, major and minor grooves, and regular, repeated stretches of sequence which induce distinct bends in the helix. Typically, transcription factors recognize specific DNA sequence motifs of about 20 nucleotides in length. Multiple, adjacent transcription factor-binding motifs may be required for gene regulation.

[0059] Many transcription factors incorporate DNA-binding structural motifs which comprise either a helices or B sheets that bind to the major groove of DNA. Four well-characterized struct motifs are helix-turn-helix, zinc finger, leucine zipper, and helix-loop-helix. Proteins containing these motifs may act alone as monomers, or they may form homo- or heterodimers that interact with DNA.

[0060] The helix-turn-helix motif consists of two a helices connected at a fixed angle by a short chain of amino acids. One of the helices binds to the major groove. Helix-turn-helix motifs are exemplified by the homeobox motif which is present in homeodomain proteins. These proteins are critical for specifying the anterior-posterior body axis during development and are conserved throughout the animal kingdom. The Antennapedia and Ultrabithorax proteins of Drosophila melanogaster are prototypical homeodomain proteins. (Pabo, C. O. and R. T. Sauer (1992) Ann. Rev. Biochem. 61:1053-1095.)

[0061] The zinc finger motif, which binds zinc ions, generally contains tandem repeats of about 30 amino acids consisting of periodically spaced cysteine and histidine residues. Examples of this sequence pattern, designated C₂H₂ and C3HC4 (“RING” finger), have been described. (Lewin, supra.) Zinc finger proteins each contain an a helix and an antiparallel B sheet whose proximity and conformation are maintained by the zinc ion. Contact with DNA is made by the arginine preceding the a helix and by the second, third, and sixth residues of the a helix. Variants of the zinc finger motif include poorly defined cysteine-rich motifs which bind zinc or other metal ions. These motifs may not contain histidine residues and are generally nonrepetitive. The zinc finger motif may be repeated in a tandem array within a protein, such that the a helix of each zinc finger in the protein makes contact with the major groove of the DNA double helix. This repeated contact between the protein and the DNA produces a strong and specific DNA-protein interaction. The strength and specificity of the interaction can be regulated by the number of zinc finger motifs within the protein. Though originally identified in DNA-binding proteins as regions that interact directly with DNA, zinc fingers occur in a variety of proteins that do not bind DNA (Lodish, H. et al. (1995) Molecular Cell Biology, Scientific American Books, New York, N.Y., pp. 447451). For example, Galcheva-Gargova, Z. et al. (1996) Science 272:1797-1802) have identified zinc finger proteins that interact with various cytoline receptors.

[0062] The C2H2-type zinc finger signature motif contains a 28 amino acid sequence, including 2 conserved Cys and 2 conserved His residues in a C-2-C-12-H-3-H type motif. The motif generally occurs in multiple tandem repeats. A cysteine-rich domain including the motif Asp-His-His-Cys (DHHC—CRD) has been identified as a distinct subgroup of zinc finger proteins. The DHHC—CRD region has been implicated in growth and development. One DHHC—CRD mutant shows defective function of Ras, a small membrane-associated GTP-binding protein that regulates cell growth and differentiation, while other DHHCCRD proteins probably function in pathways not involving Ras (Bartels, D. J. et al. (1999) Mol. Cell Biol. 19:6775-6787).

[0063] Zinc-finger transcription factors are often accompanied by modular sequence motifs such as the Kruppel-associated box (KRAB) and the SCAN domain. For example, the hypoalphalipoproteinemia susceptibility gene ZNF202 encodes a SCAN box and a KRAB domain followed by eight C₂H₂ zinc-finger motifs (Honer, C. et al. (2001) Biochim. Biophys. Acta 1517:441-448). The SCAN domain is a highly conserved, leucine-rich motif of approximately 60 amino acids found at the amino-terminal end of zinc finger transcription factors. SCAN domains are most often linked to C₂H₂ zinc finger motifs through their carboxyl-terminal end. Biochemical binding studies have established the SCAN domain as a selective hetero- and homotypic oligomerization domain. SCAN domain-mediated protein complexes may function to modulate the biological function of transcription factors (Schumacher, C. et al., (2000) J. Biol. Chem. 275:17173-17179).

[0064] The KRAB (Kruppel-associated box) domain is a conserved amino acid sequence spanning approximately 75 amino acids and is found in almost one-third of the 300 to 700 genes encoding C₂H₂ zinc fingers. The KRAB domain is found N-terminally with respect to the finger repeats. The KRAB domain is generally encoded by two exons; the KRAB-A region or box is encoded by one exon and the KRAB-B region or box is encoded by a second exon. The function of the KRAB domain is the repression of transcription. Transcription repression is accomplished by recruitment of either the KRAB-associated protein-i, a transcriptional corepressor, or the KRAB-A interacting protein. Proteins containing the KRAB domain are likely to play a regulatory role during development (Williams, A. J. et al., (1999) Mol. Cell Biol. 19:8526-8535). A subgroup of highly related human KRAB zinc finger proteins detectable in all human tissues is highly expressed in human T lymphoid cells (Bellefroid, E. J. et al. (1993) EMBO J. 12:1363-1374). The ZNF85 KRAB zinc finger gene, a member of the human ZNF91 family, is highly expressed in normal adult testis, in seminomas, and in the NT2/D1 teratocarcinoma cell line (Poncelet, D. A. et al. (1998) DNA Cell Biol. 17:931-943).

[0065] The C4 motif is found in hormone-regulated proteins. The C4 motif generally includes only 2 repeats. A number of eukaryotic and viral proteins contain a conserved cysteine-rich domain of 40 to 60 residues (called C3HC4 zinc-finger or RING finger) that binds two atoms of zinc, and is probably involved in mediating protein-protein interactions. The 3D “cross-brace” structure of the zinc ligation system is unique to the RING domain. The spacing of the cysteines in such a domain is C-x(2)-C-x(9 to 39)—C-x(1 to 3)—H-x(2 to 3)—C-x(2)—C-x(4 to 48)—C-x(2)-C. T C4HC3 zinc-finger-like motif found in nuclear proteins thought to be involved in chromatin-mediated transcriptional regulation.

[0066] GATA-type transcription factors contain one or two zinc finger domains which bind specifically to a region of DNA that contains the consecutive nucleotide sequence GATA. NMR studies indicate that the zinc finger comprises two irregular anti-parallel b sheets and an a helix, followed by a long loop to the C-terminal end of the finger (Ominchinski, J. G. (1993) Science 261:438446). The helix and the loop connecting the two b-sheets contact the major groove of the DNA, while the C-terminal part, which determines the specificity of binding, wraps around into the minor groove.

[0067] The LIM motif consists of about 60 amino acid residues and contains seven conserved cysteine residues and a histidine within a consensus sequence (Schmeichel, K. L. and Beckerle, M. C. (1994) Cell 79:211-219). The LIM family includes transcription factors and cytoskeletal proteins which may be involved in development, differentiation, and cell growth. One example is actin-binding LIM protein, which may play roles in regulation of the cytoskeleton and cellular morphogenesis (Roof, D. J. et al. (1997) J. Cell Biol. 138:575-588). The N-terminal domain of actin-binding LIM protein has four double zinc finger motifs with the LIM consensus sequence. The C-terminal domain of actin-binding LIM protein shows sequence similarity to known actin-binding proteins such as dematin and vilin. Actin-binding LIM protein binds to F-actin through its dematin-like C-terminal domain. The LIM domain may mediate protein-protein interactions with other LIM-binding proteins.

[0068] Myeloid cell development is controlled by tissue-specific transcription factors. Myeloid zinc finger proteins (MZF) include MZF-1 and MZF-2. MZF-1 functions in regulation of the development of neutrophilic granulocytes. A murine homolog MZF-2 is expressed in myeloid cells, particularly in the cells committed to the neutrophilic lineage. MZF-2 is down-regulated by G-CSF and appears to have a unique function in neutrophil development (Murai, L et al. (1997) Genes Cells 2:581-591).

[0069] The leucine zipper motif comprises a stretch of amino acids rich in leucine which can form an amphipathic a helix. This structure provides the basis for dimerization of two leucine zipper proteins. The region adjacent to the leucine zipper is usually basic, and upon protein dimerization, is optimally positioned for binding to the major groove. Proteins containing such motifs are generally referred to as bZP transcription factors. The leucine zipper motif is found in the proto-oncogenes Fos and Jun, which comprise the heterodimeric transcription factor AP1 involved in cell growth and the determination of cell lineage (Papavassiliou, A. G. (1995) N. Engl. J. Med. 332:45-47).

[0070] The helix-loop-helix motif ( ) consists of a short a helix connected by a loop to a longer a helix. The loop is flexible and allows the two helices to fold back against each other and to bind to DNA. The transcription factor Myc contains a prototypical HLH motif.

[0071] The NF-kappa-B/Rel signature defines a family of eukaryotic transcription factors involved in oncogenesis, embryonic development, differentiation and immune response. Most transcription factors containing the Rel homology domain (RHD) bind as dimers to a consensus DNA sequence motif termed kappa-B. Members of the Rel family share a highly conserved 300 amino acid domain termed the Rel homology domain. The characteristic Rel C-terminal domain is involved in gene activation and cytoplasmic anchoring functions. Proteins known to contain the RHI) domain include vertebrate nuclear factor NF-kappa-B, which is a heterodimer of a DNA-binding subunit and the transcription factor p65, mammalian transcription factor RelB, and vertebrate proto-oncogene c-rel, a protein associated with differentiation and Iymphopoiesis (Kabrun, N., and Enrietto, P. J. (1994) Semin. Cancer Biol. 5:103-112).

[0072] A DNA binding motif termed ARID (AT-rich interactive domain) distinguishes an evolutionarily conserved family of proteins. The approximately 100-residue ARID sequence is present in a series of proteins strongly implicated in the regulation of cell growth, development, and tissue-specific gene expression. ARID proteins include Bright (a regulator of B-cell-specific gene expression), dead ringer (involved in development), and MRF-2 (which represses expression from the cytomegalovirus enhancer) (Dallas, P. B. et al. (2000) Mol. Cell Biol. 20:3137-3146).

[0073] The ELM2 (Egl-27 and MTA1 homology 2) domain is found in metastasis-associated protein MTA1 and protein ER1. The Caenorhabditis elegans gene egl-27 is required for embryonic patterning MTA1, a human gene with elevated expression in metastatic carcinomas, is a component of a protein complex with histone deacetylase and nucleosome remodelling activities (Solari, F. et al. (1999) Development 126:2483-2494). The ELM2 domain is usually found to the N terminus of a myb-like DNA binding domain. ELM2 is also found associated with an ARID DNA.

[0074] Most transcription factors contain characteristic DNA binding motifs, and variations on the above motifs and new motifs have been and are currently being characterized. (Faisst, S. and S. Meyer (1992) Nucl. Acids Res. 20:3-26.)

[0075] Chromatin Associated Proteins

[0076] In the nucleus, DNA is packaged into chromatin, the compact organization of which limits the accessibility of DNA to transcription factors and plays a key role in gene regulation. (Lewin, supra, pp. 409-410.) The compact structure of chromatin is determined and influenced by chromatinassociated proteins such as the histones, the high mobility group UHMG) proteins, and the chromodomain proteins. There are five classes of histones, H1, H2A, H2B, H3, and H4, all of which are highly basic, low molecular weight proteins. The fundamental unit of chromatin, the nucleosome, consists of 200 base pairs of DNA associated with two copies each of H2A, H2B, H3, and H4. H1 links adjacent nucleosomes. HMG proteins are low molecular weight, non-histone proteins that may play a role in unwinding DNA and stabilizing single-stranded DNA. Chromodomain proteins play a key role in the formation of highly compacted heterochromatin, which is transcriptionally silent

[0077] Diseases and Disorders Related to Gene Regulation

[0078] Many neoplastic disorders in humans can be attributed to inappropriate gene expression. Malignant cell growth may result from either excessive expression of tumor promoting genes or insufficient expression of tumor suppressor genes. (Cleary, M. L. (1992) Cancer Surv. 15:89-104.) The zinc finger-type transcriptional regulator WT1 is a tumor-suppressor protein that is inactivated in children with Wilm's tumor. The oncogene bcl-6, which plays an important role in large-cell lymphoma, is also a zinc-finger protein (Papavassiliou, A. G. (1995) N. Engl. J. Med. 332:45-47). Chromosomal translocations may also produce chimeric loci that fuse the coding sequence of one gene with the regulatory regions of a second unrelated gene. Such an arrangement likely results in inappropriate gene transcription, potentially contributing to malignancy. In Burkitt's lymphoma, for example, the transcription factor Myc is translocated to the immunoglobulin heavy chain locus, greatly enhancing Myc expression and resulting in rapid cell growth leading to leukemia (Latchman, D. S. (1996) N. Engl. J. Med. 334:28-33).

[0079] In addition, the immune system responds to infection or trauma by activating a cascade of events that coordinate the progressive selection, amplification, and mobilization of cellular defense mechanisms. A complex and balanced program of gene activation and repression is involved in this process. However, hyperactivity of the immune system as a result of improper or insufficient regulation of gene expression may result in considerable tissue or organ damage. This damage is welldocumented in immunological responses associated with arthritis, allergens, heart attack, stroke, and infections. (Isselbacher et al. Harrison's Principles of Internal Medicine 13/e, McGraw Hill, Inc. and Teton Data Systems Software, 1996.) The causative gene for autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) was recently isolated and found to encode a protein with two PHD-type zinc finger motifs (Bjorses, P. et al. (1998) Hum. Mol. Genet. 7:1547-1553).

[0080] Furthermore, the generation of multicellular organisms is based upon the induction and coordination of cell differentiation at the appropriate stages of development. Central to this process is differential gene expression, which confers the distinct identities of cells and tissues throughout the body. Failure to regulate gene expression during development could result in developmental disorders. Human developmental disorders caused by mutations in zinc finger-type transcriptional regulators include: urogenital developmental abnormalities associated with WT1; Greig cephalopolysyndactyly, Pallister-Hall syndrome, and postaxial polydactyly type A (GLI3), and Townes-Brocks syndrome, characterized by anal, renal, limb, and ear abnormalities (SALL1) (Engelkamp, D. and V. van Heyningen (1996) Curr. Opin. Genet. Dev. 6:334-342; Kohlhase, J. et al. (1999) Am. J. Hum. Genet. 64:435-445).

[0081] Synthesis of Nucleic Acids

[0082] Polymerases

[0083] DNA and RNA replication are critical processes for cell replication and function. DNA and RNA replication are mediated by the enzymes DNA and RNA polymerase, respectively, by a “templating” process in which the nucleotide sequence of a DNA or RNA strand is copied by complementary base-pairing into a complementary nucleic acid sequence of either DNA or RNA. However, there are fundamental differences between the two processes.

[0084] DNA polymerase catalyzes the stepwise addition of a deoxyribonucleotide to the 3′-OH end of a polynucleotide strand (the primer strand) that is paired to a second (template) strand. The new DNA strand therefore grows in the 5′ to 3′ direction (Alberts, B. et al. (1994) The Molecular Biology of the Cell, Garland Publishing Inc., New York, N.Y., pp 251-254). The substrates for the polymerization reaction are the corresponding deoxynucleotide triphosphates which must base-pair with the correct nucleotide on the template strand in order to be recognized by the polymerase. Because DNA exists as a double-stranded helix, each of the two strands may serve as a template for the formation of a new complementary strand. Each of the two daughter cells of a dividing cell therefore inherits a new DNA double helix containing one old and one new strand. Thus, DNA is said to be replicated “semiconservatively” by DNA polymerase. In addition to the synthesis of new DNA, DNA polymerase is also involved in the repair of damaged DNA as discussed below under “Ligases.”

[0085] In contrast to DNA polymerase, RNA polymerase uses a DNA template strand to “transcribe” DNA into RNA using ribonucleotide triphosphates as substrates. Like DNA polymerization, RNA polymerization proceeds in a 5′ to 3′ direction by addition of a ribonucleoside monophosphate to the 3′-OH end of a growing RNA chain. DNA transcription generates messenger RNAs (mRNA) that carry information for protein synthesis, as well as the transfer, ribosomal, and other RNAs that have structural or catalytic functions. In eukaryotes, three discrete RNA polymerases synthesize the three different types of RNA (Alberts et al., supra pp. 367-368). RNA polymerase I makes the large ribosomal RNAs, RNA polymerase II makes the mRNAs that will be translated into proteins, and RNA polymerase m makes a variety of small, stable RNAs, including 5S ribosomal RNA and the transfer RNAs (tRNA). In all cases, RNA synthesis is initiated by binding of the RNA polymerase to a promoter region on the DNA and synthesis begins at a start site within the promoter. Synthesis is completed at a stop (termination) signal in the DNA whereupon both the polymerase and the completed RNA chain are released.

[0086] Ligases

[0087] DNA repair is the process by which accidental base changes, such as those produced by oxidative damage, hydrolytic attack, or uncontrolled methylation of DNA, are corrected before replication or transcription of the DNA can occur. Because of the efficiency of the DNA repair process, fewer than one in a thousand accidental base changes causes a mutation (Alberts et al., supra pp. 245-249). The three steps common to most types of DNA repair are (1) excision of the damaged or altered base or nucleotide by DNA nucleases, (2) insertion of the correct nucleotide in the gap left by the excised nucleotide by DNA polymerase using the complementary strand as the template and, (3) sealing the break left between the inserted nucleotide(s) and the existing DNA strand by DNA ligase. En the last reaction, DNA ligase uses the energy from ATP hydrolysis to activate the 5′ end of the broken phosphodiester bond before forming the new bond with the 3′-OH of the DNA strand. In Bloom's syndrome, an inherited human disease, individuals are partially deficient in DNA ligation and consequently have an increased incidence of cancer (Alberts et al., supra p. 247).

[0088] Nucleases

[0089] Nucleases comprise enzymes that hydrolyze both DNA (DNase) and RNA (Rnase). They serve different purposes in nucleic acid metabolism. Nucleases hydrolyze the phosphodiester bonds between adjacent nucleotides either at internal positions (endonucleases) or at the terminal 3′ or 5′ nucleotide positions (exonucleases). A DNA exonuclease activity in DNA polymerase, for example, serves to remove improperly paired nucleotides attached to the 3′-OH end of the growing DNA strand by the polymerase and thereby serves a “proofreading” function. As mentioned above, DNA endonuclease activity is involved in the excision step of the DNA repair process.

[0090] RNases also serve a variety of functions. For example, RNase P is a ribonucleoprotein enzyme which cleaves the 5′ end of pre-tRNAs as part of their maturation process. RNase H digests the RNA strand of an RNA/DNA hybrid. Such hybrids occur in cells invaded by retroviruses, and RNase H is an important enzyme in the retroviral replication cycle. Pancreatic RNase secreted by the pancreas into the intestine hydrolyzes RNA present in ingested foods. RNase activity in serum and cell extracts is elevated in a variety of cancers and infectious diseases (Schein, C. H. (1997) Nat. Biotechnol. 15:529-536). Regulation of RNase activity is being investigated as a means to control tumor angiogenesis, allergic reactions, viral infection and replication, and fungal infections.

[0091] Modification of Nucleic Acids

[0092] Methylases

[0093] Methylation of specific nucleotides occurs in both DNA and RNA, and serves different functions in the two macromolecules. Methylation of cytosine residues to form 5-methyl cytosine in DNA occurs specifically in CG sequences which are base-paired with one another in the DNA double-helix. The pattern of methylation is passed from generation to generation during DNA replication by an enzyme called “maintenance methylase” that acts preferentially on those CG sequences that are base-paired with a CG sequence that is already methylated. Such methylation appears to distinguish active from inactive genes by preventing the binding of regulatory proteins that “turn on” the gene, but permiting the binding of proteins that inactivate the gene (Alberts et al. supra pp. 448451). In RNA metabolism, “TRNA methylase” produces one of several nucleotide modifications in tRNA that affect the conformation and base-pairing of the molecule and facilitate the recognition of the appropriate mRNA codons by specific tRNAs. The primary methylation pattern is the dimethylation of guanine residues to form N,N-dimethyl guanine.

[0094] Helicases and Single-Stranded Binding Proteins

[0095] Helicases are enzymes that destabilize and unwind double helix structures in both DNA and RNA. Since DNA replication occurs more or less simultaneously on both strands, the two strands must first separate to generate a replication “fork” for DNA polymerase to act on. Two types of replication proteins contribute to this process, DNA helicases and single-stranded binding proteins. DNA helicases hydrolyze ATP and use the energy of hydrolysis to separate the DNA strands. Single-stranded binding proteins (SSBs) then bind to the exposed DNA strands, without covering the bases, thereby temporarily stabilizing them for templating by the DNA polymerase (Alberts et al. supra pp. 255-256).

[0096] RNA helicases also alter and regulate RNA conformation and secondary structure. Like the DNA helicases, RNA helicases utilize energy derived from ATP hydrolysis to destabilize and unwind RNA duplexes. The most well-characterized and ubiquitous family of RNA helicases is the DEAD-box family, so named for the conserved B-type ATP-binding motif which is diagnostic of proteins in this family. Over 40 DEAD-box helicases have been identified in organisms as diverse as bacteria, insects, yeast, amphibians, mammals, and plants. DEAD-box helicases function in diverse processes such as translation initiation, splicing, ribosome assembly, and RNA editing, transport, and stability. Examples of these RNA helicases include yeast Drsl protein, which is involved in ribosomal RNA processing; yeast TIF1 and TIF2 and mammalian eIF4A, which are essential to the initiation of RNA translation; and human p68 antigen, which regulates cell growth and division (Ripmaster, T. L. et al. (1992) Proc. Natl. Acad. Sci. USA 89:11131-11135; Chang, T.-H. et al. (1990) Proc. Nail. Acad. Sci. USA 87:1571-1575). These RNA helicases demonstrate strong sequence homology over a stretch of some 420 amino acids. Included among these conserved sequences are the consensus sequence for the A motif of an ATP binding protein; the “EAD box” sequence, associated with ATPase activity; the sequence SAT, associated with the actual helicase unwinding region; and an octapeptide consensus sequence, required for RNA binding and ATP hydrolysis (Pause, A. et al. (1993) Mol. Cell Biol. 13:67896798). Differences outside of these conserved regions are believed to reflect differences in the functional roles of individual proteins (Chang, T. H. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1571-1575).

[0097] Some DEAD-box helicases play tissue- and stage-specific roles in spermatogenesis and embryogenesis. Overexpression of the DEAD-box 1 protein (DDX1) may play a role in the progression of neuroblastoma (Nb) and retinoblastoma (Rb) tumors (Godbout, R. et al. (1998) J. Biol. Chem. 273:21161-21168). These observations suggest that DDXL may promote or enhance tumor progression by altering the normal secondary structure and expression levels of RNA in cancer cells. Other DEAD-box helicases have been implicated either directly or indirectly in tumorigenesis. (Discussed in Godbout, supra.) For example, murine p68 is mutated in ultraviolet light-induced tumors, and human DDX6 is located at a chromosomal breakpoint associated with B-cell lymphoma. Similarly, a chimeric protein comprised of DDX10 and NUP98, a nucleoporin protein, may be involved in the pathogenesis of certain myeloid malignancies.

[0098] Topoisomerases

[0099] Besides the need to separate DNA strands prior to replication, the two strands must be “unwound” from one another prior to their separation by DNAhelicases. This function is performed by proteins known as DNA topoisomerases. DNA topoisomerase effectively acts as a reversible nuclease that hydrolyzes a phosphodiesterase bond in a DNA strand, permits the two strands to rotate freely about one another to remove the strain of the helix, and then rejoins the original phosphodiester bond between the two strands. Topoisomerases are essential enzymes responsible for the topological rearrangement of DNA brought about by transcription, replication, chromatin formation, recombination, and chromosome segregation. Superhelical coils are introduced into DNA by the passage of processive enzymes such as RNA polymerase, or by the separation of DNA strands by a helicase prior to replication. Knotting and concatenation can occur in the process of DNA synthesis, storage, and repair. All topoisomerases work by breaking a phosphodiester bond in the ribosephosphate backbone of DNA. A catalytic tyrosine residue on the enzyme makes a nucleophilic attack on the scissile phosphodiester bond, resulting in a reaction intermediate in which a covalent bond is formed between the enzyme and one end of the broken strand. A tyrosine-DNA phosphodiesterase functions in DNA repair by hydrolyzing this bond in occasional dead-end topoisomerase I-DNA intermediates (Pouliot, J. J. et al. (1999) Science 286:552-555).

[0100] Two types of DNA topoisomerase exist, types I and II. Type I topoisomerases work as monomers, making a break in a single strand of DNA while type II topoisomerases, working as homodimers, cleave both strands. DNA Topoisomerase I causes a single-strand break in a DNA helix to allow the rotation of the two strands of the helix about the remaining phosphodiester bond in the opposite strand. DNA topoisomerase II causes a transient break in both strands of a DNA helix where two double helices cross over one another. This type of topoisomerase can efficiently separate two interlocked DNA circles (Alberts et al. supra pp.260-262). Type II topoisomerases are largely confined to proliferating cells in eukaryotes, such as cancer cells. For this reason they are targets for anticancer drugs. Topoisomerase II has been implicated in multi-drug resistance (MDR) as it appears to aid in the repair of DNA damage inflicted by DNA binding agents such as doxorubicin and vincristine.

[0101] The topoisomerase I family includes topoisomerases I and m (topo I and topo E). The crystal structure of human topoisomerase I suggests that rotation about the intact DNA strand is partially controlled by the enzyme. In this “controlled rotation” model, protein-DNA interactions limit the rotation, which is driven by torsional strain in the DNA (Stewart, L. et al. (1998) Science 379:1534-1541). Structurally, topo I can be recognized by its catalytic tyrosine residue and a number of other conserved residues in the active site region. Topo I is thought to function during transcription. Two topo Ells are known in humans, and they are homologous to prokaryotic topoisomerase I, with a conserved tyrosine and active site signature specific to this family. Topo m has been suggested to play a role in meiotic recombination. A mouse topo ImI is highly expressed in testis tissue and its expression increases with the increase in the number of cells in pachytene (Seki, T. et al. (1998) J. Biol. Chem. 273:28553-28556).

[0102] The topoisomerase II family includes two isozymes (IIa and IIb) encoded by different genes. Topo II cleaves double stranded DNA in a reproducible, nonrandom fashion, preferentially in an AT rich region, but the basis of cleavage site selectivity is not known. Structurally, topo II is made up of four domains, the first two of which are structurally similar and probably distantly homologous to similar domains in eukaryotic topo I. The second domain bears the catalytic tyrosine, as well as a highly conserved pentapeptide. The Ila isoform appears to be responsible for unlinking DNA during chromosome segregation. Cell lines expressing IIa but not IIb suggest that IIb is dispensable in cellular processes; however, IIb knockout mice died perinatally due to a failure in neural development. That the major abnormalities occurred in predominantly late developmental events (neurogenesis) suggests that IIb is needed not at mitosis, but rather during DNA repair (Yang, X. et al. (2000) Science 287:131-134).

[0103] Topoisomerases have been implicated in a number of disease states, and topoisomerase poisons have proven to be effective anti-tumor drugs for some human malignancies. Topo I is mislocalized in Fanconi's anemia, and may be involved in the chromosomal breakage seen in this disorder (Wunder, E. (1984) Hum. Genet. 68:276-281). Overexpression of a truncated topo m in ataxia-telangiectasia (A-T) cells partially suppresses the A-T phenotype, probably through a dominant negative mechanism. This suggests that topo III is deregulated in A-T (Fritz, E. et al. (1997) Proc. Nad. Acad. Sci. USA 94:45384542). Topo III also interacts with the Bloom's Syndrome gene product, and has been suggested to have a role as a tumor suppressor (Wu, L. et al. (2000) J. Biol. Chem. 275:9636-9644). Aberrant topo II activity is often associated with cancer or increased cancer risk. Greatly lowered topo II activity has been found in some, but not all A-T cell lines (Mohamed, R. et al. (1987) Biochem. Biophys. Res. Commun. 149:233-238). On the other hand, topo II can break DNA in the region of the A-T gene (ATM), which controls all DNA damage-responsive cell cycle checkpoints (Kaufmann, W. K (1998) Proc. Soc. Exp. Biol. Med. 217:327-334). The ability of topoisomerases to break DNA has been used as the basis of antitumor drugs. Topoisomerase poisons act by increasing the number of dead-end covalent DNA-enzyme complexes in the cell, ultimately triggering cell death pathways (Fortune, J. M. and N. Osheroff (2000) Prog. Nucleic Acid Res. Mol. Biol. 64:221-253; Guichard, S. M. and M. K. Danks (1999) Curr. Opin. Oncol. 11:482489). Antibodies against topo I are found in the serum of systemic sclerosis patients, and the levels of the antibody may be used as a marker of pulmonary involvement in the disease (Diot, E. et al. (1999) Chest 116:715-720). Finally, the DNA binding region of human topo I has been used as a DNA delivery vehicle for gene therapy (Chen, T. Y. et al. (2000) Appl. Microbiol. Biotechnol. 53:558-567).

[0104] Recombinases

[0105] Genetic recombination is the process of rearranging DNA sequences within an organism's genome to provide genetic variation for the organism in response to changes in the environment. DNA recombination allows variation in the particular combination of genes present in an individual's genome, as well as the timing and level of expression of these genes. (See Alberts et al. supra pp. 263-273.) Two broad classes of genetic recombination are commonly recognized, general recombination and site-specific recombination. General recombination involves genetic exchange between any homologous pair of DNA sequences usually located on two copies of the same chromosome. The process is aided by enzymes, recombinases, that “nick” one strand of a DNA duplex more or less randomly and permit exchange with a complementary strand on another duplex. The process does not normally change the arrangement of genes in a chromosome. In site-specific recombination, the recombinase recognizes specific nucleotide sequences present in one or both of the recombining molecules. Base-pairing is not involved in this form of recombination and therefore it does not require DNA homology between the recombining molecules. Unlike general recombination, this form of recombination can alter the relative positions of nucleotide sequences in chromosomes.

[0106] RNA Metabolism

[0107] Ribonucleic acid (RNA) is a linear single-stranded polymer of four nucleotides, ATP, CTP, UTP, and GTP. In most organisms, RNA is transcribed as a copy of deoxyribonucleic acid (DNA), the genetic material of the organism. In retroviruses RNA rather than DNA serves as the genetic material. RNA copies of the genetic material encode proteins or serve various structural, catalytic, or regulatory roles in organisms. RNA is classified according to its cellular localization and function. Messenger RNAs (mRNAs) encode polypeptides. Ribosomal RNAs (rRNAs) are assembled, along with ribosomal proteins, into ribosomes, which are cytoplasmic particles that translate mRNA into polypeptides. Transfer RNAs (tRNAs) are cytosolic adaptor molecules that function in mRNA translation by recognizing both an mRNA codon and the amino acid that matches that codon. Heterogeneous nuclear RNAs (hnRNAs) include mRNA precursors and other nuclear RNAs of various sizes. Small nuclear RNAs (snRNAs) are a part of the nuclear spliceosome complex that removes intervening, non-coding sequences (introns) and rejoins exons in pre-mRNAs.

[0108] Proteins are associated with RNA during its transcription from DNA, RNA processing, and translation of mRNA into protein. Proteins are also associated with RNA as it is used for structural, catalytic, and regulatory purposes.

[0109] RNA Processing

[0110] Ribosomal RNAs (rRNAs) are assembled, along with ribosomal proteins, into ribosomes, which are cytoplasmic particles that translate messenger RNA (mRNA) into polypeptides. The eukaryotic ribosome is composed of a 60S (large) subunit and a 40S (small) subunit, which together form the 80S ribosome. In addition to the 18S, 28S, 5S, and 5.8S rRNAs, ribosomes contain from 50 to over 80 different ribosomal proteins, depending on the organism. Ribosomal proteins are classified according to which subunit they belong (i.e., L, if associated with the large 60S large subunit or S if associated with the small 40S subunit). E. coli ribosomes have been the most thoroughly studied and contain 50 proteins, many of which are conserved in all life forms. The structures of nine ribosomal proteins have been solved to less than 3.0D resolution (i.e., S5, S6, S17, L1, L6, L9, L12, L14, revealing common motifs, such as b-a-b protein folds in addition to acidic and basic RNA-binding motifs positioned between b-strands. Most ribosomal proteins are believed to contact rRNA directly (reviewed in Liljas, A. and Garber, M. (1995) Curr. Opin. StrucL Biol. 5:721-727; see also Woodson, S. A. and Leontis, N. B. (1998) Curr. Opin. Struct. Biol. 8:294300; Ramakrishnan, V. and White, S. W. (1998) Trends Biochem. Sci. 23:208-212).

[0111] Ribosomal proteins may undergo post-translational modifications or interact with other ribosome-associated proteins to regulate translation. For example, the highly homologous 40S ribosomal protein S6 kinases (S6K1 and S6)₂) play a key role in the regulation of cell growth by controlling the biosynthesis of translational components which make up the protein synthetic apparatus (including the ribosomal proteins). In the case of S6K1, at least eight phosphorylation sites are believed to mediate kinase activation in a hierarchical fashion (Dufner and Thomas. (1999) Exp. Cell. Res. 253:100-109). Some of the ribosomal proteins, including L1, also function as translational repressors by binding to polycistronic mRNAs encoding ribosomal proteins (reviewed in Liljas, A. supra and Garber, M. supra).

[0112] Recent evidence suggests that a number of ribosomal proteins have secondary functions independent of their involvement in protein biosynthesis. These proteins function as regulators of cell proliferation and, in some instances, as inducers of cell death. For example, the expression of human ribosomal protein L13a has been shown to induce apoptosis by arresting cell growth in the G2/M phase of the cell cycle. Inhibition of expression of L13a induces apoptosis in target cells, which suggests that this protein is necessary, in the appropriate amount, for cell survival. Similar results have been obtained in yeast where inactivation of yeast homologues of L13a, rp22 and rp23, results in severe growth retardation and death. A closely related ribosomal protein, L7, arrests cells in G1 and also induces apoptosis. Thus, it appears that a subset of ribosomal proteins may function as cell cycle checkpoints and compose a new family of cell proliferation regulators.

[0113] Mapping of individual ribosomal proteins on the surface of intact ribosomes is accomplished using 3D immunocryoelectronmicroscopy, whereby antibodies raised against specific ribosomal proteins are visualized. Progress has been made toward the mapping of L1, L7, and L12 while the structure of the intact ribosome has been solved to only 20-25D resolution and inconsistencies exist among different crude structures (Frank, J. (1997) Curr. Opin. Struct. Biol. 7:266-272).

[0114] Three distinct sites have been identified on the ribosome. The aminoacyl-tRNA acceptor site (A site) receives charged tRNAs (with the exception of the initiator-tRNA). The peptidyl-tRNA site (P site) binds the nascent polypeptide as the amino acid from the A site is added to the elongating chain. Deacylated tRNAs bind in the exit site (B site) prior to their release from the ribosome. The structure of the ribosome is reviewed in Stryer, L. (1995) Biochemistry W. H. Freeman and Company, New York N.Y. pp. 888-9081; Lodish, H. et al. (1995) Molecular Cell Biology Scientific American Books, New York N.Y. pp. 119-138; and Lewin, B (1997) Genes VI Oxford University Press, Inc. New York, N.Y.).

[0115] Various proteins are necessary for processing of transcribed RNAs in the nucleus. Pre-mRNA processing steps include capping at the 5′ end with methylguanosine, polyadenylating the 3′ end, and splicing to remove introns. The primary RNA transript from DNA is a faithful copy of the gene containing both exon and intron sequences, and the latter sequences must be cut out of the RNA transcript to produce a mRNA that codes for a protein. This “splicing” of the mRNA sequence takes place in the nucleus with the aid of a large, multicomponent ribonucleoprotein complex known as a spliceosome. The spliceosomal complex is comprised of five small nuclear ribonucleoprotein particles (snRNPs) designated U1, U2, U4, U5, and U6. Each snRNP contains a single species of snRNA and about ten proteins. The RNA components of some snRNPs recognize and base-pair with intron consensus sequences. The protein components mediate spliceosome assembly and the splicing reaction. Autoantibodies to snRNP proteins are found in the blood of patients with systemic lupus erytematosus (Stryer, L. (1995) Biochemistry WH. Freeman and Company, New York N.Y., p. 863).

[0116] Several splicing regulatory proteins have been identified in Drosophila. Human (HsSWAP) and mouse (MmSWAP) homologs of the suppressor-of-white-apricot (su(wa)) gene have been cloned and characterized. HSSWAP and MmSWAP both have five highly homologous regions to su(wa), including an arginine/serine-rich domain and two repeated modules that are homologous to regions in the constitutive splicing factor, SPP91/PRP21. Mammalian SWAP mRNAs are alternatively spliced at the same splice sites as in Drosophila. The splice junctions of the Drosophila and mammalian regulated introns are conserved. Thus, research suggests that the mammalian SWAP gene functions as a vertebrate alternative splicing regulator (Denhez, F. and Lafyatis, R. (1994) Biol. Chem. 269:16170-16179).

[0117] Serine- and arginine-rich pre-mRNA splicing factors (SR proteins) are phosphorylated before they regulate splicing events. SRrp86 (SR-related protein of 86 kDa) is a novel SR protein containing a single amino-terminal RNA recognition motif and two carboxy-terminal domains rich in serine-arginine (SR) dipeptides. SRrp86 activates splicing in the presence of SRp20. However, it inhibits the in vitro and in vivo activation of specific splice sites by SR proteins, including ASF/SF2, SC35, and SRp55. Research suggests that pairwise combination of SRrp86 with specific SR proteins leads to altered splicing efficiency and differential splice site selection (Banard, D. C. and Patton, J. G. (2000) Mol. Cell. Biol. 20:3049-3057).

[0118] Heterogeneous nuclear ribonucleoproteins (hnRNPs) have been identified that have roles in splicing, exporting of the mature RNAs to the cytoplasm, and mRNA translation (Biamonti, G. et al. (1998) Clin. Exp. Rheumatol. 16:317-326). Some examples of hnRNPs include the yeast proteins Hrplp, involved in cleavage and polyadenylation at the 3′ end of the RNA; Cbp80p, involved in capping the 5′ end of the RNA; and Npl3p, a homolog of mammalian hnRNP A1, involved in export of mRNA from the nucleus (Shen, E. C. et al. (1998) Genes Dev. 12:679-691). HnRNPs have been shown to be

[0119] important targets of the autoirmmune response in rheumatic diseases (Biamonti, supra.

[0120] Many snRNP and hnRNP proteins are characterized by an RNA recognition motif (RRM). (Reviewed in Bimey, E. et al. (1993) Nucleic Acids Res. 21:5803-5816.) The RRM is about 80 amino acids in length and forms four b-strands and two a-helices arranged in an a/b sandwich. The RRM contains a core RNP-1 octapeptide motif along with surrounding conserved sequences. In addition to snRNP proteins, examples of RNA-binding proteins which contain the above motifs include heteronuclear ribonucleoproteins which stabilize nascent RNA and factors which regulate alternative splicing. Alternative splicing factors include developmentally regulated proteins, specific examples of which have been identified in lower eukaryotes such as Drosophila melanogaster and Caenorhabditis elegans. These proteins play key roles in developmental processes such as pattern formation and sex determination, respectively. (See, for example, Hodgkin, J. et al. (1994) Development 120:3681-3689.)

[0121] The 3′ ends of most eukaryote mRNAs are also posuranscriptionally modified by polyadenylation. Polyadenylation proceeds through two enzymatically distinct steps: (i) the endonucleolytic cleavage of nascent mRNAs at cis-acting polyadenylation signals in the 3′-untranslated (non-coding) region and (ii) the addition of a poly(A) tract to the 5′ mRNA fragment. The presence of cis-acting RNA sequences is necessary for both steps. These sequences include 5′-AAUAAA-3′ located 10-30 nucleotides upstream of the cleavage site and a less well-conserved GU- or U-rich sequence element located 10-30 nucleotides downstream of the cleavage site. Cleavage stimulation factor (CstF), cleavage factor I (CF I), and cleavage factor II (CF II) are involved in the cleavage reaction while cleavage and polyadenylation specificity factor (CPSF) and poly(A) polymerase (PAP) are necessary for both cleavage and polyadenylation. An additional enzyme, poly(A)-binding protein II (PAB II), promotes poly(A) tract elongation (Ruegsegger, U. et al. (1996) J. Biol. Chem. 271:6107-6113; and references within).

[0122] Translation

[0123] Correct translation of the genetic code depends upon each amino acid forming a linkage with the appropriate transfer RNA (tRNA). The aminoacyl-tRNA synthetases (aaRSs) are essential proteins found in all living organisms. The aaRSs are responsible for the activation and correct attachment of an amino acid with its cognate tRNA, as the first step in protein biosynthesis. Prokaryotic organisms have at least twenty different types of aaRSs, one for each different amino acid, while eukaryotes usually have two aaRSs, a cytosolic form and a mitochondrial form, for each different amino acid. The 20 aaRS enzymes can be divided into two structural classes. Class I enzymes add amino acids to the 2′ hydroxyl at the 3′ end of tRNAs while Class II enzymes add amino acids to the 3′ hydroxyl at the 3′ end of tRNAs. Each class is characterized by a distinctive topology of the catalytic domain. Class I enzymes contain a catalytic domain based on the nucleotide-binding Rossman ‘fold’. In particular, a consensus tetrapeptide motif is highly conserved (Prosite Document PDOC00161, Aminoacyl-transfer RNA synthetases class-I signature). Class I enzymes are specific for arginine, cysteine, glutamic acid, glutamine, isoleucine, leucine, methionine, tyrosine, tryptophan, and valine. Class II enzymes contain a central catalytic domain, which consists of a seven-stranded antiparallel B-sheet domain, as well as N- and C-terminal regulatory domains. Class II enzymes are separated into two groups based on the heterodimeric or homodimeric structure of the enzyme; the latter group is further subdivided by the structure of the N- and C-terminal regulatory domains (Hartlein, M. and Cusack, S. (1995) J. Mol. Evol. 40:519-530). Class II enzymes are specific for alanine, asparagine, aspartic acid, glycine, histidine, lysine, phenylalanine, proline, serine, and threonine.

[0124] Certain aaRSs also have editing functions. IleRS, for example, can misactivate valine to form Val-tRNA^(Ile), but this product is cleared by a hydrolytic activity that destroys the mischarged product. This editing activity is located within a second catalytic site found in the connective polypeptide 1 region (CP1), a long insertion sequence within the Rossman fold domain of Class I enzymes (Schimmel, P. et al. (1998) FASEB J. 12:1599-1609). AaRSs also play a role in tRNA processing. It has been shown that mature tRNAs are charged with their respective amino acids in the nucleus before export to the cytoplasm, and charging may serve as a quality control mechanism to insure the tRNAs are functional (Martinis, S. A. et al. (1999) EMBO J. 18:4591-4596).

[0125] Under optimal conditions, polypeptide synthesis proceeds at a rate of approximately 40 amino acid residues per second. The rate of misincorporation during translation in on the order of 101 and is primarily the result of aminoacyl-t-RNAs being charged with the incorrect amino acid. Incorrectly charged tRNA are toxic to cells as they result in the incorporation of incorrect amino acid residues into an elongating polypeptide. The rate of translation is presumed to be a compromise between the optimal rate of elongation and the need for translational fidelity. Mathematical calculations predict that 10⁻⁴ is indeed the maximum acceptable error rate for protein synthesis in a biological system (reviewed in Stryer, L. supra and Watson, J. et al. (1987) The Benjamin/Cummings Publishing Co., Inc. Menlo Park, Calif.). A particularly error prone aminoacyl-tRNA charging event is the charging of tRNA^(Gln) with Gln. A mechanism exits for the correction of this mischarging event which likely has its origins in evolution. Gln was among the last of the 20 naturally occurring amino acids used in polypeptide synthesis to appear in nature. Gram positive eubacteria, cyanobacteria, Archeae, and eukaryotic organelles possess a noncanonical pathway for the synthesis of Gln-tRNA^(Gln) based on the transformation of Glu-tRNA^(Gln) (synthesized by Glu-tRNA synthetase, GluRS) using the enzyme GluRNAG amidotransferase (Glu-AdT). The reactions involved in the transamidation pathway are as follows (Curnow, A. W. et al. (1997) Nucleic Acids Symposium 36:24):

[0126] GluRS

tRNA^(Gln)+Glu+ATP→Glu-tRNA^(Gln)+AMP+PP_(i)

[0127] Glu-AdT

Glu-tRNA^(Gln)+Gln+ATP→Gln-tRNA^(Gln)+Glu+ADP+P

[0128] A similar enzyme, Asp-tRNA^(Asn) amidotransferase, exists in Archaea, which transforms Asp-tRNA^(Asn) to Asn-tRNA^(Asn). Formylase, the enzyme that transforms Met-tRNA^(fMet) to fMet-tRNA_(fMet) in eubacteria, is likely to be a related enzyme. A hydrolytic activity has also been identified that destroys mischarged Val-tRNA^(Ile) (Schimmel, P. et al. (1998) FASEB J. 12:1599-1609). One likely scenario for the evolution of Glu-AdT in primitive life forms is the absence of a specific glutaminyl-tRNA synthetase (GlnRS), requiring an alternative pathway for the synthesis of Gln-tRNA^(Gln). In fact, deletion of the Glu-AdT operon in Gram positive bacteria is lethal (Curnow, A. W. et al. (1997) Proc. Natl. Acad. Sci. U.S.A. 94:11819-11826). The existence of GluRS activity in other organisms has been inferred by the high degree of conservation in translation machinery in nature; however, GluRS has not been identified in all organisms, including Homo sapiens. Such an enzyme would be responsible for ensuring translational fidelity and reducing the synthesis of defective polypeptides,

[0129] In addition to their function in protein synthesis, specific aminoacyl tRNA synthetases also play roles in cellular fidelity, RNA splicing, RNA trafficling, apoptosis, and transcriptional and translational regulation. For example, human tyrosyl-tRNA synthetase can be proteolytically cleaved into two fragments with distinct cytokine activities. The carboxy-teiminal domain exhibits monocyte and leukocyte chemotaxis activity as well as stimulating production of myeloperoxidase, tumor necrosis factor-a, and tissue factor. The N-terminal domain binds to the interleukin-8 type A receptor and functions as an interleukin-8-like cytokine. Human tyrosyl-tRNA synthetase is secreted from apoptotic tumor cells and may accelerate apoptosis (Wakasugi, K., and Schimmel, P. (1999) Science 284:147-151). Mitochondrial Neurospora crassa TyrRS and S. cerevisiae LeuRS are essential factors for certain group I intron splicing activities, and human mitochondrial LeuRS can substitute for the yeast LeuRS in a yeast null strain. Certain bacterial aaRSs are involved in regulating their own transcription or translation (Martini, supra). Several aaRSs are able to synthesize diadenosine oligophosphates, a class of signalling molecules with roles in cell proliferation, differentiation, and apoptosis (Kisselev, L. L et al. (1998) FEBS Lezt 427:157-163; Vartanian, A. et al. (1999) FEBS Lett. 456:175-180).

[0130] Autoantibodies against aminoacyl-tRNAs are generated by patients with autoimmune diseases such as rheumatic arthritis, dernatomyositis and polymyositis, and correlate strongly with complicating interstitial lung disease (ILD) (Preist, W. et al. (1999) Biol. Chem. 380:623-646; Freist, W. et al. (1996) Biol. Chem. Hoppe Seyler 377:343-356). These antibodies appear to be generated in response to viral infection, and coxsackie virus has been used to induce experimental viral myositis in animals.

[0131] Comparison of aaRS structures between humans and pathogens has been useful in the design of novel antibiotics (Schimmel, supra). Genetically engineered aaRSs have been utilized to allow site-specific incorporation of unnatural amino acids into proteins in vivo (Liu, D. R. et al. (1997) Proc. Natl. Acad. Sci. USA 94:10092-10097).

[0132] tRNA Modifications

[0133] The modified ribonucleoside, pseudouridine (y), is present ubiquitously in the anticodon regions of transfer RNAs (tRNAs), large and small ribosomal RNAs (rRNAs), and small nuclear RNAs (snRNAs). y is the most common of the modified nucleosides (i.e., other than G, A, U, and C) present in tRNAs. Only a few yeast tRNAs that are not involved in protein synthesis do not contain y (Cortese, R. et al. (1974) J. Biol. Chem. 249:1103-1108). The enzyme responsible for the conversion of uridine to y, pseudouridine synthase (pseudouridylate synthase), was first isolated from Salmonella typhimurium (Arena, F. et al. (1978) Nuc. Acids Res. 5:45234536). The enzyme has since been isolated from a number of mammals, including steer and mice (Green, C. J. et al. (1982) J. Biol. Chem. 257:3045-52 and Chen, J. and Patton, J. R. (1999) RNA 5:409-419). tRNA pseudouridine synthases have been the most extensively studied members of the family. They require a thiol donor (e.g., cysteine) and a monovalent cation (e.g., ammonia or potassium) for optimal activity. Additional cofactors or high energy molecules (e.g., ATP or GTP) are not required (Green, supra). Other eukaryotic pseudouridine synthases have been identified that appear to be specific for rRNA (revieved in Smith, C. M. and Steitz, J. A. (1997) Cell 89:669-672) and a dual-specificity enzyme has been identified that uses both tRNA and rRNA substrates (Wrzesinski, J. et al. (1995) RNA 1: 437-448). The absence of y in the anticodon loop of tRNAs results in reduced growth in both bacteria (Singer, C. E. et al. (1972) Nature New Biol. 238:72-74) and yeast (Lecointe, F. (1998) 273:1316-1323), although the genetic defect is not lethal.

[0134] Another ribonucleoside modification that occurs primarily in eukaryotic cells is the conversion of guanosine to N²,N²-dimethylguanosine (m² ₂G) at position 26 or 10 at the base of the D-stem of cytosolic and mitochondrial tRNAs. This posttranscriptional modification is believed to stabilize tRNA structure by preventing the formation of alternative tRNA secondary and tertiary structures. Yeast tRNA^(Asp) is unusual in that it does not contain this modification. The modification does not occur in eubacteria, presurnably because the structure of tRNAs in these cells and organelles is sequence constrained and does not require posttranscriptional modification to prevent the formation of alternative structures (Steinberg, S. and Cedergren, R. (1995) RNA 1:886-891, and references within). The enzyme responsible for the conversion of guanosine to m² ₂G is a 63 kDa S-adenosylmethionine (SAM)-dependent tRNA N²,N²-dimethyl-guanosine methyltransferase (also referred to as the TRM1 gene product and herein referred to as TRM) 3dqvist, J. (1995) Biochimie 77:54-61). The enzyme localizes to both the nucleus and the mitochondria (Li, J-M. et al. (1989) J. Cell Biol. 109:1411-1419). Based on studies with TRM from Xenopus laevis, there appears to be a requirement for base pairing at positions C11-G24 and G10-C25 immediately preceding the G26 to be modified, with other structural features of the tRNA also being required for the proper presentation of the G26 substrate (Edqvist. J. et al. (1992) Nuc. Acids Res. 20:6575-81). Studies in yeast suggest that cells carrying a weak ochre tRNA suppressor (sup3-i) are unable to suppress translation termination in the absence of TRM activity, suggesting a role for TRM in modifying the frequency of suppression in eukaryotic cells (Niederberger, C. et al. (1999) FEBS Leet 464:67-70), in addition to the more general function of ensuring the proper three-dimensional structures for tRNA.

[0135] Translation Initiation

[0136] Initiation of translation can be divided into three stages. The first stage brings an initiator transfer RNA (Met-tRNA_(f)) together with the 40S ribosomal subunit to form the 43S preinitiation complex. The second stage binds the 43S preinitiation complex to the mRNA, followed by migration of the complex to the correct AUG initiation codon. The third stage brings the 60S ribosomal subunit to the 40S subunit to generate an 80S ribosome at the inititation codon. Regulation of translation primarily involves the first and second stage in the initiation process (V. M. Pain (1996) Eur. J. Biochem. 236:747-771).

[0137] Several initiation factors, many of which contain multiple subunits, are involved in bringing an initiator tRNA and the 40S ribosomal subunit together. eIF2, a guanine nucleotide binding protein, recruits the initiator tRNA to the 40S ribosomal subunit. Only when eIF2 is bound to GTP does it associate with the initiator tRNA. eIF2B, a guanine nucleotide exchange protein, is responsible for converting eIF2 from the GDP-bound inactive form to the GTP-bound active form. Two other factors, eIF1A and eIF3 bind and stabilize the 40S subunit by interacting with the 18S ribosomal RNA and specific ribosomal structural proteins. eIF3 is also involved in association of the 40S ribosomal subunit with mRNA. The Met-tRNAf, eIF1A, eIF3, and 40S ribosomal subunit together make up the 43S preinitiation complex (Pain, supra).

[0138] Additional factors are required for binding of the 43S preinitiation complex to an mRNA molecule, and the process is regulated at several levels. eIF4F is a complex consisting of three proteins: eIF4E, eIF4A, and eIF4G. eIF4E recognizes and binds to the mRNA 5′-terminal m⁷GTP cap, eIF4A is a bidirectional RNA-dependent helicase, and eEF4G is a scaffolding polypeptide. eIF4G has three binding domains. The N-terminal third of eIF4G interacts with eIF4E, the central third interacts with eIF4A, and the C-terminal third interacts with eIF3 bound to the 43S preinitiation complex. Thus, eEF4G acts as a bridge between the 40S ribosomal subunit and the mRNA (M. W. Hentze (1997) Science 275:50SO₅₀₁).

[0139] The ability of eIF4F to initiate binding of the 43S preinitiation complex is regulated by structural features of the mRNA. The mRNA molecule has an untranslated region (UTR) between the 5′ cap and the AUG start codon. In some mRNAs this region forms secondary structures that impede binding of the 43S preinitiation complex. The helicase activity of eIF4A is thought to function in removing this secondary structure to facilitate binding of the 43S preinitiation complex (Pain, supra).

[0140] Translation Elongation

[0141] Elongation is the process whereby additional amino acids are joined to the initiator methionine to form the complete polypeptide chain. The elongation factors EF1 a, EF1 b g, and EF2 are involved in elongating the polypeptide chain following initiation. EF1 a is a GTP-binding protein. In EF1 a's GTP-bound form, it brings an aminoacyl-tRNA to the ribosome's A site. The amino acid attached to the newly arrived aminoacyl-tRNA forms a peptide bond with the initiatior methionine. The GTP on EF1 a is hydrolyzed to GDP, and EF1 a-GDP dissociates from the ribosome. EF1 b g binds EF1 a GDP and induces the dissociation of GDP from EF1 a, allowing EF1 a to bind GTP and a new cycle to begin.

[0142] As subsequent aminoacyl-tRNAs are brought to the ribosome, EF-G, another GTP-binding protein, catalyzes the translocation of tRNAs from the A site to the P site and finally to the E site of the ribosome. This allows the ribosome and the mRNA to remain attached during translation.

[0143] Translation Termination

[0144] The release factor eRF carries out termination of translation. eRF recognizes stop codons in the mRNA, leading to the release of the polypeptide chain from the ribosome.

[0145] Expression Profiling

[0146] Array technology can provide a simple way to explore the expression of a single polymorphic gene or the expression profile of a large number of related or unrelated genes. When the expression of a single gene is examined, arrays are employed to detect the expression of a specific gene or its variants. When an expression profile is examined, arrays provide a platform for identifying genes that are tissue specific, are affected by a substance being tested in a toxicology assay, are part of a signaling cascade, carry out housekeeping functions, or are specifically related to a particular genetic predisposition, condition, disease, or disorder.

[0147] Expression

[0148] Tumor necrosis factor α is a pleiotropic cytokine that mediates immune regulation and inflammatory responses. TNF-α-related cytokines generate partially overlapping cellular responses, including differentiation, proliferation, nuclear factor-κb (NF-κB) activation, and cell death, by triggering the aggregation of receptor monomers (Smith, C. A. et al. (1994) Cell 76:959-962). The cellular responses triggered by TNF-α are initiated through its interaction with distinct cell surface receptors (TNFRs). NF-κB is a transcription factor with a pivotal role in inducing genes involved in physiological processes as well as in the response to injury and infection. Activation of NF-κB involves the phosphorylation and subsequent degradation of an inhibitory protein, IKB, and many of the proximal kinases and adaptor molecules involved in this process have been elucidated. Additionally, the NF-κB activation pathway from cell membrane to nucleus for IL-1 and TNF-α is now understood (Bowie, A. and L. A. O'Neill (2000) Biochem. Pharmacol. 59:13-23).

[0149] Treatment of confluent cultures of vascular smooth muscle cells (SMCs) with TNF-α suppresses the incorporation of efflproline into both collagenase-digestible proteins (CDP) and noncollagenous proteins (NCP). Such suppression by TNF-α is not observed in confluent bovine aortic endothelial cells and human fibroblastic DMR-90 cells. TNF-α decreases the relative proportion of collagen types IV and V suggesting that TNF-α modulates collagen synthesis by SMCs depending on their cell density and therefore may modify formation of atherosclerotic lesions (Hiraga, S. et al. (2000) Life Sci. 66:235-244).

[0150] Human aortic endothelial cells (HAECs) are primary cells derived from the endothelium of a human aorta. Human iliac artery endothelial cells (Cs) are primary cells derived from the endothelium of an iliac artery. Human umbilical vein endothelial cells (HUVECs) are primary cells derived from the endothelium of an umbilical vein. Primary human endothelial cell lines have been used as an experimental model for investigating in vitro the role of the endothelium in human vascular biology. Activation of the vascular endothelium is considered to be a central event in a wide range of both physiological and pathophysiological processes, such as vascular tone regulation, coagulation and thrombosis, atherosclerosis, and inflammation.

[0151] Thus, vascular tissue genes differentially expressed during treatment of HALC, HIAEC, and HUVEC cell cultures with TNFU may reasonably be expected to be markers of the atherosclerotic process.

[0152] The discovery of new molecules for disease detection and treatment, and the polynucleotides encoding them, satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, autoimmune/inflammatory, developmental, and neurological disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of molecules for disease detection and treatment.

SUMMARY OF THE INVENTION

[0153] The invention features purified polypeptides, molecules for disease detection and treatment, referred to collectively as “MDDT” and individually as “% MDDT-1,” “MDDT-2,” “MDDT-3,” “MDDT-4,” “DDT-5,” “MDDT-6,” “DDT-7,” “MDDT-8,” “MDDT-9,” “MDDT-10,” “MDDT-11,” “MDDT-12,” “MDDT-13,” “MDDT-14,” “MDDT-15,” “MDDT-16,” “MDDT-17,” “MDDT18,” “MDDT-19,” “MDDT-20,” “MDDT-21,” “MDDT-22,” and “MDDT-23.” In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-23.

[0154] The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-23. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:24-46.

[0155] Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, b) a polypeptide comprising a natally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a tralsgenic organism comprising the recombinant polynucleotide.

[0156] The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

[0157] Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23.

[0158] The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

[0159] Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

[0160] The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

[0161] The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-23. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional MDDT, comprising administering to a patient in need of such treatment the composition.

[0162] The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional MDDT, comprising administering to a patient in need of such treatment the composition.

[0163] Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional MDDT, comprising administering to a patient in need of such treatment the composition.

[0164] The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

[0165] The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

[0166] The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

[0167] The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

[0168] Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

[0169] Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog, and the PROTEOME database identification numbers and annotations of PROTEOME database homologs, for polypeptides of the invention. The probability scores for the matches between each polypeptide and its homolog(s) are also shown.

[0170] Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

[0171] Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

[0172] Table 5 shows the representative cDNA library for polynucleotides of the invention.

[0173] Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

[0174] Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

[0175] Table 8 shows single nucleotide polymorphisms found in polynucleotide sequences of the invention, along with allele frequencies in different human populations.

DESCRIPTION OF TEIE INVENTION

[0176] Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

[0177] It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a host cell” includes a plurality of such host cells, and a reference to “an antibody” is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

[0178] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0179] Definitions

[0180] “MDDT” refers to the amino acid sequences of substantially purified MDDT obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

[0181] The term “agonist” refers to a molecule which intensifies or mimics the biological activity of MDDT. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of MDDT either by directly interacting with MDDT or by acting on components of the biological pathway in which MDDT participates.

[0182] An “allelic variant” is an alternative form of the gene encoding MDDT. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

[0183] “Altered” nucleic acid sequences encoding MDDT include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as MDDT or a polypeptide with at least one functional characteristic of MDDT. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding MDDT, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding MDDT. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent MDDT. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of MDDT is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

[0184] The terms “amino acid” and “amino acid sequence” refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where “amino acid sequence” is recited to refer to a sequence of a naturally occurring protein molecule, “amino acid sequence” and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

[0185] “Amplification” relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

[0186] The term “antagonist” refers to a molecule which inhibits or attenuates the biological activity of MDDT. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of MDDT either by directly interacting with MDDT or by acting on components of the biological pathway in which MDDT participates.

[0187] The term “antibody” refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab′)₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind MDDT polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLi). The coupled peptide is then used to immunize the animal.

[0188] The term “antigenic determinant” refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

[0189] The term “aptamer” refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target. Aptamers are derived from an in vitro evolutionary process (e.g., SELIEX (Systematic Evolution of Ligands by EXponential Enrichment), described in U.S. Pat. No. 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries. Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2′-OH group of a ribonucleotide may be replaced by 2′-F or 2′-NH), which may improve a desired property, e.g., resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules, e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system. Aptamers may be specificaly cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker. (See, e.g., Brody, E. N. and L. Gold (2000) J. Biotechnol. 74:5-13.) The term “intramer” refers to an aptamer which is expressed in vivo. For example, a vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Nad Acad. Sci. USA 96:3606-3610).

[0190] The term “spiegelmer” refers to an aptamer which includes L-DNA, L-RNA, or other left-handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.

[0191] The term “antisense” refers to any composition capable of base-pairing with the “sense” (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2′-methoxyethyl sugars or 2′-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2′-deoxyuracil, or 7-deaza-2′-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation “negative” or “minus” can refer to the antisense strand, and the designation “positive” or “plus” can refer to the sense strand of a reference DNA molecule.

[0192] The term “biologically active” refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, “inunologically active” or “immunogenic” refers to the capability of the natural, recombinant, or synthetic MDDT, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

[0193] “Complementary” describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5′-AGT-3′ pairs with its complement, 3′-TCA-5′.

[0194] A “composition comprising a given polynucleotide sequence” and a “composition comprising a given amino acid sequence” refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding MDDT or fragments of MDDT may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

[0195] “Consensus sequence” refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City Calif.) in the 5′ and/or the 3′ direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison Wis.) or Phrap (University of Washington, Seattle Wash.). Some sequences have been both extended and assembled to produce the consensus sequence.

[0196] “Conservative amino acid substitutions” are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions. Original Residue Conservative Substitution Ala Gly, Ser Arg His, Lys Asn Asp, Gln, His Asp Asn, Glu Cys Ala, Ser Gln Asn, Glu, His Glu Asp, Gln, His Gly Ala His Asn, Arg, Gln, Glu Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe His, Met, Leu, Trp, Tyr Ser Cys, Thr Thr Ser, Val Trp Phe, Tyr Tyr His, Phe, Trp Val Ile, Leu, Thr

[0197] Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

[0198] A “deletion” refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

[0199] The term “derivative” refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

[0200] A “detectable label” refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

[0201] “Differential expression” refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

[0202] “Exon shuffling” refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.

[0203] A “fragment” is a unique portion of MDDT or the polynucleotide encoding MDDT which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

[0204] A fragment of SEQ ID NO:24-46 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:24-46, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:24-46 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:24-46 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:24-46 and the region of SEQ ID NO:24-46 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

[0205] A fragment of SEQ ID NO:1-23 is encoded by a fragment of SEQ ID NO:24-46. A fragment of SEQ ID NO: 1-23 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-23. For example, a fragment of SEQ ID NO:1-23 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-23. The precise length of a fragment of SEQ ID NO:1-23 and the region of SEQ ID NO:1-23 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

[0206] A “full length” polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A “full length” polynucleotide sequence encodes a “full length” polypeptide sequence.

[0207] “Homology” refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

[0208] The terms “percent identity” and “% identity,” as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optinize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

[0209] Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison Wis. CLUSTAL V is described in Higgins, D. G. and P. M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D. G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and “diagonals saved”=4. The “weighted” residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polynucleotide sequences.

[0210] Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S. F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, Md., and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including “blastn,” that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called “BLAST 2 Sequences” that is used for direct pairwise comparison of two nucleotide sequences. “BLAST 2 Sequences” can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/b12.html. The “BLAST 2 Sequences” tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the “BLAST 2 Sequences” tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

[0211] Matrix: BLOSUM62

[0212] Rewardfor match: 1

[0213] Penalty for mzsmatch: −2

[0214] Open Gap: S and Extension Gap: 2 penalties

[0215] Gap×drop-off. 50

[0216] Expect: 10

[0217] Word Size: 11

[0218] Filter: on

[0219] Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

[0220] Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

[0221] The phrases “percent identity” and “% identity,” as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

[0222] Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MRGALUGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and “diagonals saved”=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polypeptide sequence pairs.

[0223] Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the “BLAST 2 Sequences” tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

[0224] Matrix: BLOSUM62

[0225] Open Gap: 11 and Extension Gap: 1 penalties

[0226] Gap×drop-off. 50

[0227] Expect: 10

[0228] Word Size: 3

[0229] Filter: on

[0230] Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

[0231] “Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

[0232] The term “humanized antibody” refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

[0233] “Hybridization” refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68° C. in the presence of about 6×SSC, about 1% (w/v) SDS, and about 100 μg/ml sheared, denatured salmon sperm DNA.

[0234] Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5° C. to 20° C. lower than the thermal melting point (T_(m)) for the specific sequence at a defined ionic strength and pH. The T_(m) is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_(m) and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2^(nd) ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; specifically see volume 2, chapter 9.

[0235] High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68° C. in the presence of about 0.2×SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65C, 60C, 55° C., or 42° C. may be used. SSC concentration may be varied from about 0.1 to 2×SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 μgml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

[0236] The term “hybridization complex” refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C₀t or R₀t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

[0237] The words “insertion” and “addition” refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

[0238] “Immune response” can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

[0239] An “immunogenic fragment” is a polypeptide or oligopeptide fragment of MDDT which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term “immunogenic fragment” also includes any polypeptide or oligopeptide fragment of MDDT which is useful in any of the antibody production methods disclosed herein or known in the art.

[0240] The term “microarray” refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

[0241] The terms “element” and “array element” refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

[0242] The term “modulate” refers to a change in the activity of MDDT. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of MDDT.

[0243] The phrases “nucleic acid” and “nucleic acid sequence” refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

[0244] “Operably linked” refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

[0245] “Peptide nucleic acid” (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

[0246] “Post-translational modification” of an MDDT may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of MDDT.

[0247] “Probe” refers to nucleic acid sequences encoding MDDT, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. “Primers” are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

[0248] Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

[0249] Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2^(nd) ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; Ausubel, F. M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York N.Y.; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego Calif. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge Mass.).

[0250] Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas Tex.) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge Mass.) allows the user to input a “mispriming library,” in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (M11e source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

[0251] A “recombinant nucleic acid” is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

[0252] Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

[0253] A “regulatory element” refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5′ and 3′ untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

[0254] “Reporter molecules” are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

[0255] An “RNA equivalent,” in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

[0256] The term “sample” is used in its broadest sense. A sample suspected of containing MDDT, nucleic acids encoding MDDT, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

[0257] The terms “specific binding” and “specifically binding” refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope “A,” the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody wifi reduce the amount of labeled A that binds to the antibody.

[0258] The term “substantially purified” refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

[0259] A “substitution” refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

[0260] “Substrate” refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

[0261] A “transcript image” or “expression profile” refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

[0262] “Transformation” describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term “transformed cells” includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

[0263] A “transgenic organism,” as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. In one alternative, the nucleic acid can be introduced by infection with a recombinant viral vector, such as a lentiviral vector (Lois, C. et al. (2002) Science 295:868-872). The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

[0264] A “variant” of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the “BLAST 2 Sequences” tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an “allelic” (as defined above), “splice,” “species,” or “polymorphic” variant A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass “single nucleotide polymorphisms” (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

[0265] A “variant” of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the “BLAST 2 Sequences” tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

[0266] The Invention

[0267] The invention is based on the discovery of new human molecules for disease detection and treatment (MDDT), the polynucleotides encoding MDDT, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, autoimmune/inflammatory, developmental, and neurological disorders, and infections.

[0268] Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (kncyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (lncyte Polynucleotide ID) as shown. Column 6 shows the Incyte ID numbers of physical, full length clones corresponding to the polypeptide and polynucleotide sequences of the invention. The full length clones encode polypeptides which have at least 95% sequence identity to the polypeptide sequences shown in column 3.

[0269] Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database and the PROTEOME database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding bicyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (GenBank ID NO:) of the nearest GenBank homolog and the PROTEOME database identification numbers (PROTEOME ID NO:) of the nearest PROTEOME database homologs. Column 4 shows the probability scores for the matches between each polypeptide and its homolog(s). Column 5 shows the annotation of the GenBank and PROTBOME database homolog(s) along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

[0270] Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison Wis.). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

[0271] Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are molecules for disease detection and treatment. For example, SEQ ID NO:1 is 42% identical, from residue M1 to residue D482, to hulnan R052 gene product (GenBank ID g747927) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 9.8e-97, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:1 also contains a SPRY domain, a B-box zinc finger domain, and a RING finger C3HC4 type zinc finger domain, as determined by searching for statistically significant matches in the hidden Markov model (NM) based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:1 is a transcription factor. In another example, SEQ ID NO:9 is 86% identical, from residue M1 to residue R722, to mouse DNA binding protein DESRT (GenBank ID g9622226) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:9 also contains an ARID DNA binding domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. Data from further BLAST analyses provide ftnther corroborative evidence that SEQ ID NO:9 is a DNA-binding protein. In a further example, SEQ ID NO:11 is 81% identical, from residue R8 to residue S86, to human HERV-E integrase (GenBank ID g2587026) as determined by the Basic Local Alignment Search Tool (BLAST). The BLAST probability score is 2.7e-32, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. Data from BLAST analyses provide further corroborative evidence that SEQ ID NO:11 is an integrase protease. In yet a further example, SEQ ID NO:16 is 98% identical, from residue M1 to residue A928, to human prostate antigen PARIS-1 (GenBank ID g12963885) as determined by the Basic Local Alignment Search Tool (BLAST). The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:16 also contains a PH domain and a TBC domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. Data from BUMPS and BLAST analyses provide further corroborative evidence that SEQ ID NO:16 is a full-length human protein for disease detection and treatment. SEQ ID NO:2-8, SEQ ID NO:10, SEQ ID NO:12-15, and SEQ ID NO:17-23 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-23 are described in Table 7.

[0272] As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Column 1 lists the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:), the corresponding Incyte polynucleotide consensus sequence number (Incyte ID) for each polynucleotide of the invention, and the length of each polynucleotide sequence in basepairs. Column 2 shows the nucleotide start (5′) and stop (3′) positions of the cDNA and/or genormic sequences used to assemble the full length polynucleotide sequences of the invention, and of fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:24-46 or that distinguish between SEQ ID NO:24-46 and related polynucleotide sequences.

[0273] The polynucleotide fragments described in Column 2 of Table 4 may refer specifically, for example, to Incyte cDNAs derived from tissue-specific cDNA libraries or from pooled cDNA libraries. Alternatively, the polynucleotide fragments described in column 2 may refer to GenBank cDNAs or ESTs which contributed to the assembly of the full length polynucleotide sequences. In addition, the polynucleotide fragments described in column 2 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, UK) database (ie., those sequences including the designation “ENST”). Alternatively, the polynucleotide fragments described in column 2 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (i.e., those sequences including the designation ‘N’ or ‘VT’) or the NCBI RefSeq Protein Sequence Records (i.e., those sequences including the designation “NP”). Alternatively, the polynucleotide fragments described in column 2 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an “exon stitching” algorithm. For example, a polynucleotide sequence identified as FLXXXXXX_N_(1—)N_(2—)YYYYY_N_(—3)N₄represents a “stitched” sequence in which XXXXXX is the identification number of the cluster of sequences to which the algorithm was applied, and YYYYY is the number of the prediction generated by the algorithm, and Nlz3, if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the polynucleotide fragments in column 2 may refer to assemblages of exons brought together by an “exon-stretching” algorithm. For example, a polynucleotide sequence identified as FL_XXXXXX_gAAAAA_gBBBBB_(—)1_N is a “stretched” sequence, with XXV=being the Incyte project identification number, gAAAAA being the GenBank identification number of the human genomic sequence to which the “exon-stretching” algorithm was applied, GBBBBB being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and Nreferring to specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the “exon-stretching” algorithm, a RefSeq identifier (denoted by “NM,” “NP,” or “NT”) may be used in place of the GenBank identifier (i.e., GBBBB).

[0274] Alternatively, a prefix identifies component sequences that were hand-edited, predicted from genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V). Prefix Type of analysis and/or examples of programs GNN, GFG, Exon prediction from genomic sequences using, ENST for example, GENSCAN (Stanford University, CA, USA) or FGENES (Computer Genomics Group, The Sanger Centre, Cambridge, UK). GBI Hand-edited analysis of genomic sequences. FL Stitched or stretched genomic sequences (see Example V). INCY Full length transcript and exon prediction from mapping of EST sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript.

[0275] In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in Table 4 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

[0276] Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

[0277] Table 8 shows single nucdeotide polymorphisms (SNPs) found in polynucleotide sequences of the invention, along with allele frequencies in different human populations. Columns 1 and 2 show the polynucleotide sequence identification number (SEQ ID NO:) and the corresponding Incyte project identification number (PID) for polynucleotides of the invention. Column 3 shows the Incyte identification number for the EST in which the SNP was detected (EST ID), and column 4 shows the identification number for the SNP(SNP ID). Column 5 shows the position within the EST sequence at which the SNP is located (EST SNP), and column 6 shows the position of the SNP within the full-length polynucleotide sequence (CB1 SNP). Column 7 shows the allele found in the EST sequence. Columns 8 and 9 show the two alleles found at the SNP site. Column 10 shows the amino acid encoded by the codon including the SNP site, based upon the allele found in the EST. Columns 11-14 show the frequency of allele 1 in four different human populations. An entry of n/d (not detected) indicates that the frequency of allele 1 in the population was too low to be detected, while n/a (not available) indicates that the allele frequency was not determined for the population.

[0278] The invention also encompasses MDDT variants. A preferred MDDT variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the MDDT amino acid sequence, and which contains at least one functional or structural characteristic of MDDT.

[0279] The invention also encompasses polynucleotides which encode MDDT. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:24-46, which encodes MDDT. The polynucleotide sequences of SEQ ID NO:24-46, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

[0280] The invention also encompasses a variant of a polynucleotide sequence encoding MDDT. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding MDDT. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:24-46 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:24-46. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of MDDT.

[0281] In addition, or in the alternative, a polynucleotide variant of the invention is a splice variant of a polynucleotide sequence encoding MDDT. A splice variant may have portions which have significant sequence identity to the polynucleotide sequence encoding MDDT, but will generally have a greater or lesser number of polynucleotides due to additions or deletions of blocks of sequence arising from alternate splicing of exons during mRNA processing. A splice variant may have less than about 70%, or alternatively less than about 60%, or alternatively less than about 50% polynucleotide sequence identity to the polynucleotide sequence encoding MDDT over its entire length; however, portions of the splice variant will have at least about 70%, or alternatively at least about 85%, or alternatively at least about 95%, or alternatively 100% polynucleotide sequence identity to portions of the polynucleotide sequence encoding MDDT. For example, a polynucleotide comprising a sequence of SEQ ID NO:25 is a splice variant of a polynucleotide comprising a sequence of SEQ ID NO:45, and a polynucleotide comprising a sequence of SEQ ID NO:36 is a splice variant of a polynucleotide comprising a sequence of SEQ ID NO:46. Any one of the splice variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of MDDT.

[0282] It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding MDDT, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring MDDT, and all such variations are to be considered as being specifically disclosed.

[0283] Although nucleotide sequences which encode MDDT and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring MDDT under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding MDDT or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding MDDT and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

[0284] The invention also encompasses production of DNA sequences which encode MDDT and MDDT derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding MDDT or any fragment thereof.

[0285] Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:24-46 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A. R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in “Definitions.”

[0286] Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland Ohio), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway N.J.), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg Md.). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno Nev.), PTC200 thermal cycler (MJ Research, Watertown Mass.) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale Calif.), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F. M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York N.Y., unit 7.7; Meyers, R. A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York N.Y., pp. 856-853.)

[0287] The nucleic acid sequences encoding MDDT may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:81-86.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the arL (See, e.g., Parker, J. D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMO IER R libraries (Clontech, Palo Alto Calif.) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intronlexon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth Minn.) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68° C. to 72° C.

[0288] When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5′ regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5′ non-transcribed regulatory regions.

[0289] Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotidespecific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

[0290] In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode MDDT may be cloned in recombinant DNA molecules that direct expression of MDDT, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express MDDT.

[0291] The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter MDDT-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated sitedirected mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

[0292] The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara Calif.; described in U.S. Pat. No. 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F. C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of MDDT, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through “artificial” breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

[0293] In another embodiment, sequences encoding MDDT may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M. H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, MDDT itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York N.Y., pp. 5560; and Roberge, J. Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of MDDT, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

[0294] The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R. M. and F. Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

[0295] In order to express a biologically active MDDT, the nucleotide sequences encoding MDDT or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5′ and 3′ untranslated regions in the vector and in polynucleotide sequences encoding MDDT. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding MDDT. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding MDDT and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

[0296] Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding MDDT and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y., ch. 4, 8, and 16-17; Ausubel, F. M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York N.Y., ch. 9, 13, and 16.)

[0297] A variety of expression vector/host systems may be utilizd to contain and express sequences encoding MDDT. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York N.Y., pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Nail. Acad. Sci. USA 81:3655-3659; and Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R. M. et al. (1985) Nature 317(6040):813-815; McGregor, D. P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I. M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

[0298] In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding MDDT. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding MDDT can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla Calif.) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding MDDT into the vector's multiple cloning site disrupts the lacZ gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of MDDT are needed, e.g. for the production of antibodies, vectors which direct high level expression of MDDT may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

[0299] Yeast expression systems may be used for production of MDDT. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G. A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C. A. et al. (1994) Bio/Technology 12:181-184.)

[0300] Plant systems may also be used for expression of MDDT. Transcription of sequences encoding MDDT may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York N.Y., pp. 191-196.)

[0301] In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding MDDT may be ligated into an adenovirus transcription/trnnslation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses MDDT in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

[0302] Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355.)

[0303] For long term production of recombinant proteins in mammalian systems, stable expression of MDDT in cell lines is preferred. For example, sequences encoding MDDT can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

[0304] Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in tk and apr cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dhfr confers resistance to methotrexate; neo confers resistance to the aminoglycosides neomycin and G418; and als and pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, P. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., trpB and hisD, which alter cellular requirements for metabolites. (See, e.g., Hartman, S. C. and R. C. Mulligan (1988) Proc. Nad. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), B glucuronidase and its substrate B-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C. A. (1995) Methods Mol. Biol. 55:121-131.)

[0305] Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding MDDT is inserted within a marker gene sequence, transformed cells containing sequences encoding MDDT can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding MDDT under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

[0306] In general, host cells that contain the nucleic acid sequence encoding MDDT and that express MDDT may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

[0307] Imnunological methods for detecting and measuring the expression of MDDT using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on MDDT is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul Minn., Sect IV; Coligan, Jo. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York N.Y.; and Pound, J. D. (1998) Immunochemical Protocols, Humana Press, Totowa N.J.)

[0308] A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding MDDT include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding MDDT, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison Wis.), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

[0309] Host cells transformed with nucleotide sequences encoding MDDT may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a trrnsformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode MDDT may be designed to contain signal sequences which direct secretion of MDDT through a prokaryotic or eukaryotic cell membrane.

[0310] In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a “prepro” or “pro” form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and W138) are available from the American Type Culture Collection (ATCC, Manassas Va.) and may be chosen to ensure the correct modification and processing of the foreign protein.

[0311] In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding MDDT may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric MDDT protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of MDDT activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6His, FLAG, c-myc, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, c-myc, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the MDDT encoding sequence and the heterologous protein sequence, so that MDDT may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

[0312] In a further embodiment of the invention, synthesis of radiolabeled MDDT may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

[0313] MDDT of the present invention or fragments thereof may be used to screen for compounds that specifically bind to MDDT. At least one and up to a plurality of test compounds may be screened for specific binding to MDDT. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

[0314] In one embodiment, the compound thus identified is closely related to the natural ligand of MDDT, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J. E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which MDDT binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express MDDT, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing MDDT or cell membrane fractions which contain MDDT are then contacted with a test compound and binding, stimulation, or inhibition of activity of either MDDT or the compound is analyzed.

[0315] An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with MDDT, either in solution or affixed to a solid support, and detecting the binding of MDDT to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cel-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

[0316] MDDT of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of MDDT. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for MDDT activity, wherein MDDT is combined with at least one test compound, and the activity of MDDT in the presence of a test compound is compared with the activity of MDDT in the absence of the test compound. A change in the activity of MDDT in the presence of the test compound is indicative of a compound that modulates the activity of MDDT. Alternatively, a test compound is combined with an in vitro or cell-free system comprising MDDT under conditions suitable for MDDT activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of MDDT may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

[0317] In another embodiment, polynucleotides encoding MDDT or their mammalian homologs may be “knocked out” in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Pat. No. 5,175,383 and U.S. Pat. No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M. R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J. D. (1996) Clin. Invest. 97:1999-2002; Wagner, K. U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

[0318] Polynucleotides encoding MDDT may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes Clhomson, I. A. et al. (1998) Science 282:1145-1147).

[0319] Polynucleotides encoding MDDT can also be used to create “knockin” humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding MDDT is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress MDDT, e.g., by secreting MDDT in its mkk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

[0320] Therapeutics

[0321] Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of MDDT and molecules for disease detection and treatment. In addition, examples of tissues and cell lines expressing MDDT are vascular smooth muscle cells, human aortic endothelial cells, human iliac artery endothelial cells, and human umbilical vein endothelial cells, and also can be found in Table 6. Therefore, MDDT appears to play a role in cell proliferative, autoimmune/infaatory, developmental, and neurological disorders, and infections. In the treatment of disorders associated with increased MDDT expression or activity, it is desirable to decrease the expression or activity of MDDT. In the treatment of disorders associated with decreased MDDT expression or activity, it is desirable to increase the expression or activity of MDDT.

[0322] Therefore, in one embodiment, MDDT or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MDDT. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCID), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as inflammation, actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetiflis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), episodic lymphopenia with lymphocytotoxins, complications of cancer, hemodialysis, and extracorporeal circulation, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma; a developmental disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seiuure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorder of the central nervous system, cerebral palsy, a neuroskeletal disorder, an autonomic nervous system disorder, a cranial nerve disorder, a spinal cord disease, muscular dystrophy and other neuromuscular disorder, a peripheral nervous system disorder, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathy, myasthenia gravis, periodic paralysis, a mental disorder including mood, anxiety, and schizophrenic disorder, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; and an infection, such as those caused by a viral agent classified as adenovirus (acute respiratory disease, pneumonia), arenavirus (lymphocytic choriomeningitis), bunyavirus (Hantavirus), calicivirus, coronavirus (pneumonia, chronic bronchitis), filovirus, hepadnavirus (hepatitis), herpesvirus (herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus), flavivirus (yellow fever), orthomyxovirus (influenza), parvovirus, papovavirus or papillomaviruse (cancer), paramyxovirus (measles, mumps), picornavirus (rhinovirus, poliovirus, coxsackie-virus), polyomnaviruse (BK virus, JC virus), poxviruse (smallpox), reoviru (Colorado tick fever), retroviruse (human immunodeficiency virus, human T lymphotropic virus), rhabdoviruse (rabies), rotaviruse (gastroenteritis), and togaviruse (encephalitis, rubella); an infection caused by a bacterial agent classified as pneumococcus, staphylococcus, streptococcus, bacillus, corynebacterium, clostridium, meningococcus, gonococcus, listeria, moraxella, Iingella, haemophilus, legionelia, bordetella, gram-negative enterobacterium including shigella, salmonella, or campylobacter, pseudomonas, vibrio, brucella, francisella, yersinia, bartonella, norcardium, actinomyces, mycobacterium, spirochaetale, rickettsia, chlamydia, or mycoplasma; an infection caused by a fungal agent classified as aspergillus, blastomyces, dermatophytes, cryptococcus, coccidioides, malasezzia, histoplasma, or other mycosis-causing fungal agent; and an infection caused by a parasite classified as plasmodium or mralaa-causing, parasitic entamoeba, leishmania, trypanosoma, toxoplasma, pneumocystis carinii, intestinal protozoa such as giardia, trichomonas, tissue nematode such as trichinella, intestinal nematode such as ascaris, lymphatic filarial nematode, trematode such as schistosoma, and cestode such as tapeworm.

[0323] In another embodiment, a vector capable of expressing MDDT or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MDDT including, but not limited to, those described above.

[0324] In a further embodiment, a composition comprising a substantially purified MDDT in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MDDT including, but not limited to, those provided above.

[0325] In still another embodiment, an agonist which modulates the activity of MDDT may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MDDT including, but not limited to, those listed above.

[0326] In a further embodiment, an antagonist of MDDT may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of MDDT. Examples of such disorders include, but are not limited to, those cell proliferative, autoimmune/inflammatory, developmental, and neurological disorders, and infections described above. In one aspect, an antibody which specifically binds MDDT may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express MDDT.

[0327] In an additional embodiment, a vector expressing the complement of the polynucleotide encoding MDDT may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of MDDT including, but not limited to, those described above.

[0328] In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

[0329] An antagonist of MDDT may be produced using methods which are generally known in the art. In particular, purified MDDT may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind MDDT. Antibodies to MDDT may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use. Single chain antibodies (e.g., from camels or llamas) may be potent enzyme inhibitors and may have advantages in the design of peptide mimetics, and in the development of immuno-adsorbents and biosensors (Muyldermans, S. (2001) J. Biotechnol. 74:277-302).

[0330] For the production of antibodies, various hosts including goats, rabbits, rats, mice, camels, dromedaries, llamas, humans, and others may be immunized by injection with MDDT or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Preund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

[0331] It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to MDDT have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of MDDT amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

[0332] Monoclonal antibodies to MDDT may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:3142; Cote, R. J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S. P. et al. (1984) Mol. Cell Biol. 62:109-120.)

[0333] In addition, techniques developed for the production of “chimeric antibodies,” such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S. L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M. S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce MDDT-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D. R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

[0334] Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

[0335] Antibody fragments which contain specific binding sites for MDDT may also be generated. For example, such fragments include, but are not limited to, F(ab′)₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab′)₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W. D. et al. (1989) Science 246:1275-1281.)

[0336] Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between MDDT and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering MDDT epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

[0337] Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for MDDT. Affinity is expressed as an association constant, K_(a), which is defined as the molar concentration of MDDT-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_(a) determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple MDDT epitopes, represents the average affinity, or avidity, of the antibodies for MDDT. The K_(a) determined for a preparation of monoclonal antibodies, which are monospecific for a particular MDDT epitope, represents a true measure of affinity. High-affinity antibody preparations with K_(a) ranging from about 10⁹ to 10¹² L/mole are preferred for use in immunoassays in which the MDDT-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_(a) ranging from about 10⁶ to 10⁷ L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of MDDT, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington D.C.; Liddell, J. E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York N.Y.).

[0338] The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of MDDT-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, suWra, and Coligan et al. supra.)

[0339] In another embodiment of the invention, the polynucleotides encoding MDDT, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding MDDT. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding MDDT. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa N.J.)

[0340] In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J. E. et al. (1998) J. Allergy Clin. Immunol. 102(3):469475; and Scanlon, KJ. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A. D. (1990) Blood 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J. J. (1995) Br. Med. Bull. 51(1):217-225; Boado, R. J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morris, M. C. et al. (1997) Nucleic Acids Res. 25(14):2730-2736.)

[0341] In another embodiment of the invention, polynucleotides encoding MDDT may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R. M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIR or Factor IX deficiencies (Crystal, R. G. (1995) Science 270:404410; Verma, I. M. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA 93:11395-11399), hepatitis B or C virus (IBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in MDDT expression or regulation causes disease, the expression of MDDT from an appropriate population of trsduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

[0342] In a further embodiment of the invention, diseases or disorders caused by deficiencies in MDDT are treated by constructing mammalian expression vectors encoding MDDT and introducing these vectors by mechanical means into MDDT-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R. A. and W. F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H. Recipon (1998) Curr. Opin. Biotechnol. 9:445-450).

[0343] Expression vectors that play be effective for the expression of MDDT include, but are not limited to, the PCDNA 3.1, EPr1AG, PRCCMV2, PREP, PVAX, PCR2-TOPOTA vectors (Invitrogen, Carlsbad Calif.), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla Calif.), and PThT-OFF, PET-ON, PTRE2, PTME2-LUC, PTK-HYG (Clontech, Palo Alto Calif.). MDDT may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (1S), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F. M. V. and H. M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (nvitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F. M. V. and H. M. Blau, supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding MDDT from a normal individual.

[0344] Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F. L. and A. J. Eb (1973) Virology 52:456467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

[0345] In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to MDDT expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding MDDT under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M. A. et al. (1987) J. Virol. 61:1639-1646; Adam, M. A. and A. D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Pat. No. 5,910,434 to Rigg (“Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviual supernatant”) discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M. L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Nad. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

[0346] In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding MDDT to cells which have one or more genetic abnormalities with respect to the expression of MDDT. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas' (Csete, M. E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Pat. No. 5,707,618 to Armentano (“Adenovirus vectors for gene therapy”), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P. A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I. M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

[0347] In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding MDDT to target cells which have one or more genetic abnormalities with respect to the expression of MDDT. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing MDDT to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Pat. No. 5,804,413 to DeLuca (“Herpes simplex virus strains for gene transfer”), which is hereby incorporated by reference. U.S. Pat. No. 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W. F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

[0348] In another alternative, an alphaviris (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding MDDT to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Cuir. Opin. Biotechnol. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for MDDT into the alphavirus genome in place of the capsid-coding region results in the production of a large number of MDDT-coding RNAs and the synthesis of high levels of MDDT in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S. A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of MDDT into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

[0349] Oligonucleotides derived from the transcription initiation site, e.g., between about positions −10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J. E. et al. (1994) in Huber, B. E. and B. I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco N.Y., pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

[0350] Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding MDDT.

[0351] Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene contaiining the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

[0352] Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding MDDT. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as 17 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

[0353] RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5′ and/or 3′ ends of the molecule, or the use of phosphorothioate or 2′ O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

[0354] An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding MDDT. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased MDDT expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding MDDT may be therapeutically useful, and in the treatment of disorders associated with decreased MDDT expression or activity, a compound which specifically promotes expression of the polynucleotide encoding MDDT may be therapeutically useful.

[0355] At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding MDDT is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding MDDT are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding MDDT. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Pat. No. 5,932,435; Arndt, G. M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M. L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T. W. et al. (1997) U.S. Pat. No. 5,686,242; Bruice, T. W. et al. (2000) U.S. Pat. No. 6,022,691).

[0356] Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C. K et al. (1997) NaL Biotechnol. 15:462-466.)

[0357] Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

[0358] An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton Pa.). Such compositions may consist of MDDT, antibodies to MDDT, and mimetics, agonists, antagonists, or inhibitors of MDDT.

[0359] The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

[0360] Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fastacting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J. S. et al., U.S. Pat. No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

[0361] Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

[0362] Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising MDDT or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, MDDT or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S. R. et al. (1999) Science 285:1569-1572).

[0363] For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

[0364] A therapeutically effective dose refers to that amount of active ingredient, for example MDDT or fragments thereof, antibodies of MDDT, and agonists, antagonists or inhibitors of MDDT, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED₅₀ (the dose therapeutically effective in 50% of the population) or LD, (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD₅₀/ED₅₀ ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

[0365] The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

[0366] Normal dosage amounts may vary from about 0.1 μg to 100,000 μg, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

[0367] Diagnostics

[0368] In another embodiment, antibodies which specifically bind MDDT may be used for the diagnosis of disorders characterized by expression of MDDT, or in assays to monitor patients being treated with MDDT or agonists, antagonists, or inhibitors of MDDT. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for MDDT include methods which utilize the antibody and a label to detect MDDT in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

[0369] A variety of protocols for measuring MDDT, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of MDDT expression. Normal or standard values for MDDT expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to MDDT under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of MDDT expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

[0370] In another embodiment of the invention, the polynucleotides encoding MDDT may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAS. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of MDDT may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of MDDT, and to monitor regulation of MDDT levels during therapeutic intervention.

[0371] In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding MDDT or closely related molecules may be used to identify nucleic acid sequences which encode MDDT. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5′ regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding MDDT, allelic variants, or related sequences.

[0372] Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the MDDT encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:24-46 or from genomic sequences including promoters, enhancers, and introns of the MDDT gene.

[0373] Means for producing specific hybridization probes for DNAs encoding MDDT include the cloning of polynucleotide sequences encoding MDDT or MDDT derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ³²P or ³⁵S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

[0374] Polynucleotide sequences encoding MDDT may be used for the diagnosis of disorders associated with expression of MDDT. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as inflammation, actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal noctumal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Wemer syndrome, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), episodic lymphopenia with lymphocytotoxins, complications of cancer, hemodialysis, and extracorporeal circulation, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma; a developmental disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuni, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorder of the central nervous system, cerebral palsy, a neuroskeletal disorder, an autonomic nervous system disorder, a cranial nerve disorder, a spinal cord disease, muscular dystrophy and other neuromuscular disorder, a peripheral nervous system disorder, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathy, myasthenia gravis, periodic paralysis, a mental disorder including mood, anxiety, and schizophrenic disorder, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; and an infection, such as those caused by a viral agent classified as adenovirus (acute respiratory disease, pneumonia), arenavirus (lymphocytic choriomeningitis), bunyavirus (Hantavirus), calicivirus, coronavirus (pneumonia, chronic bronchitis), filovirus, hepadnavirus (hepatitis), herpesvirus (herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus), flavivirus (yellow fever), orthomyxovirus (influenza), parvovirus, papovavirus or papillomaviruse (cancer), paramyxovirus (measles, mumps), picornavirus (rhinovirus, poliovirus, coxsackie-virus), polyomaviruse (BK virus, JC virus), poxviruse (smallpox), reoviru (Colorado tick fever), retroviruse (human immunodeficiency virus, human T lymphotropic virus), rhabdoviruse (rabies), rotaviruse (gastroenteritis), and togaviruse (encephalitis, rubella); an infection caused by a bacterial agent classified as pneumococcus, staphylococcus, streptococcus, bacillus, corynebacterium, clostridium, meningococcus, gonococcus, listeria, moraxella, kingella, haemophilus, legionella, bordetella, gram-negative enterobacterium including shigella, salmonella, or campylobacter, pseudomonas, vibrio, brucella, francisefla, yersinia, bartonella, norcardium, actinomyces, mycobacterium, spirochaetale, rickettsia, chlamydia, or mycoplasma; an infection caused by a fungal agent classified as aspergillus, blastomyces, dermatophytes, cryptococcus, coccidioides, malasezzia, histoplasma, or other mycosis-causing fungal agent-, and an infection caused by a parasite classified as plasmodium or malariacausing, parasitic entamoeba, leishmania, trypanosoma, toxoplasma, pneumocystis carinii, intestinal protozoa such as giardia, trichomonas, tissue nematode such as trichinella, intestinal nematode such as ascaris, lymphatic filarial nematode, trematode such as schistosoma, and cestode such as tapeworm. The polynucleotide sequences encoding MDDT may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISAlike assays; and in microarrays utilizing fluids or tissues from patients to detect altered MDDT expression. Such qualitative or quantitative methods are well known in the art.

[0375] In a particular aspect, the nucleotide sequences encoding MDDT may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding MDDT may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding MDDT in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

[0376] In order to provide a basis for the diagnosis of a disorder associated with expression of MDDT, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding MDDT, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

[0377] Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

[0378] With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

[0379] Additional diagnostic uses for oligonucleotides designed from the sequences encoding MDDT may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding MDDT, or a fragment of a polynucleotide complementary to the polynucleotide encoding MDDT, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

[0380] In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding MDDT may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding MDDT are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (is SNP), are capable of identifyg polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computerbased methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego Calif.).

[0381] SNPs may be used to study the genetic basis of human disease. For example, at least 16 common SNPs have been associated with non-insulin-dependent diabetes merlitus. SNPs are also useful for examining differences in disease outcomes in monogenic disorders, such as cystic fibrosis, sickle cell anemia, or chronic granulomatous disease. For example, variants in the mannose-binding lectin, MBL2, have been shown to be correlated with deleterious pulnonary outcomes in cystic fibrosis. SNPs also have utility in pharmacogenomics, the identification of genetic variants that influence a patient's response to a drug, such as life-threatening toxicity. For example, a variation in N-acetyl trausferase is associated with a high incidence of peripheral neuropathy in response to the anti-tuberculosis drug isoniazid, while a variation in the core promoter of the ALOX5 gene results in diminished clinical response to treatment with an anti-asthma drug that targets the 5-lipoxygenase pathway. Analysis of the distribution of SNPs in different populations is useful for investigating genetic drift, mutation, recombination, and selection, as well as for tracing the origins of populations and their migrations. (Taylor, J. G. et al. (2001) Trends Mol. Med. 7:507-512; Kwok, P.-Y. and Z. Gu (1999) Mol. Med. Today 5:538-543; Nowotny, P. et al. (2001) Curr. Opin. Neurobiol. 11:637-641.) Methods which may also be used to quantify the expression of MDDT include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P. C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

[0382] In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

[0383] In another embodiment, MDDT, fragments of MDDT, or antibodies specific for MDDT may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

[0384] A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifyg the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., “Comparative Gene Transcript Analysis,” U.S. Pat. No. 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

[0385] Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

[0386] Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E. F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N. L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released Feb. 29, 2000, available at http://www.niehs.nih.gov/oc/news/toxchip.htm.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

[0387] In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

[0388] Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra. The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

[0389] A proteomic profile may also be generated using antibodies specific for MDDT to quantify the levels of MDDT expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-111; Mendoze, L. G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiolor amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

[0390] Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, NL. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

[0391] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

[0392] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

[0393] Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:1061410619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCi application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

[0394] In another embodiment of the invention, nucleic acid sequences encoding MDDT may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355; Price, C. M. (1993) Blood Rev. 7:127-134; and Trask, B. J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E. S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

[0395] Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Uhrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding MDDT on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

[0396] In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R. A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

[0397] In another embodiment of the invention, MDDT, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between MDDT and the agent being tested may be measured.

[0398] Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with MDDT, or fragments thereof, and washed. Bound MDDT is then detected by methods well known in the art. Purified MDDT can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

[0399] In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding MDDT specifically compete with a test compound for binding MDDT. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with MDDT.

[0400] In additional embodiments, the nucleotide sequences which encode MDDT may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

[0401] Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

[0402] The disclosures of all patents, applications and publications, mentioned above and below, including U.S. Ser. No. 60/280,387, U.S. Ser. No. 60/282,335, U.S. Ser. No. 60/283,663, U.S. Ser. No. 60/285,484, U.S. Ser. No. 60/350,702, and U.S. Ser. No. 60/351,749, are expressly incorporated by reference herein.

EXAMPLES

[0403] I. Construction of cDNA Libraries

[0404] Incyte cDNAs were derived from cDNA libraries described in the UFESEQ GOLD database (Incyte Genomics, Palo Alto Calif.). Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

[0405] Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth Calif.), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin Tex.).

[0406] In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, suora, units 5.1-6.6.) Reverse transcription was initiated using oligo dM or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CLAB column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad Calif.), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto Calif.), pRARE (hncyte Genomics), or pINCY (Incyte Genomics), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DHSa, DH10B, or ElectroMAX DH10B from Life Technologies.

[0407] H. Isolation of cDNA Clones

[0408] Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg Md.); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWEIL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP. 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4° C.

[0409] Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V. B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene Oreg.) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

[0410] III. Sequencing and Analysis

[0411] Incyte cDNA recovered in plasmids as described in Example H were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Termrinator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

[0412] The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM; PROTEOME databases with sequences from Homo sapiens, Rattus norvegicus, Mus musculus, Caenorhabditis elegans, Saccharomvces cerevisiae, Schizosaccharomvces pombe, and Candida albicans (Incyte Genomics, Palo Alto Calif.); hidden Markov model (HM-based protein family databases such as PFAM, INCY, and TIGRFAM (Haft, D. H. et al. (2001) Nucleic Acids Res. 29:4143); and HMM-based protein domain databases such as SMART (Schultz et al. (1998) Proc. Natl. Acad. Sci. USA 95:5857-5864; Letunic, I. et al. (2002) Nucleic Acids Res. 30:242-244). (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S. R. (1996) Curr. Opin. Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLMPS, and HMR. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using progams based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, the PROTEOME databases, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, hidden Markov model (HMM)-based protein family databases such as PFAM, INCY, and TIGRFAM; and HMM-based protein domain databases such as SMART. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco Calif.) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

[0413] Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

[0414] The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:24-46. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 2.

[0415] IV. Identification and Editing of Coding Sequences from Genomic DNA

[0416] Putative molecules for disease detection and treatment were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode molecules for disease detection and treatment, the encoded polypeptides were analyzed by querying against PFAM models for molecules for disease detection and treatment. Potential molecules for disease detection and treatment were also identified by homology to Incyte cDNA sequences that had been annotated as molecules for disease detection and treatment. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

[0417] V. Assembly of Genomic Sequence Data with cDNA Sequence Data

[0418] “Stitched” Sequences

[0419] Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example m were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then “stitched” together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

[0420] “Stretched” Sequences

[0421] Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example m were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore “stretched” or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

[0422] VI. Chromosomal Mapping of MDDT Encoding Polynucleotides

[0423] The sequences which were used to assemble SEQ ID NO:24-46 were compared with sequences from the Incyte LIESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:24-46 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

[0424] Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI “GeneMap'99” World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap/), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

[0425] VII. Analysis of Polynucleotide Expression

[0426] Northern analysis is a laboratory technique used to detect the presence of a trauscript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.)

[0427] Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or UFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as: $\frac{{BLAST}\quad {Score} \times {Percent}\quad {Identity}}{5 \times {minimum}\quad \left\{ {{{length}\left( {{Seq}.\quad 1} \right)},{{length}\left( {{Seq}.\quad 2} \right)}} \right\}}$

[0428] The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and 4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

[0429] Alternatively, polynucleotide sequences encoding MDDT are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example E). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding MDDT. cDNA sequences and cDNA library/tissue information are found in the LESEQ. GOLD database (Incyte Genomics, Palo Alto Calif.).

[0430] VIII. Extension of MDDT Encoding Polynucleotides

[0431] Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5′ extension of the known fragment, and the other primer was synthesized to initiate 3′ extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68° C. to about 72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

[0432] Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

[0433] High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 mmol of each primer, reaction buffer containing Mg²⁺, (NH₄)₂SO₄, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 at 4° C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 940C, 3 min; Step 2: 94° C., 15 sec; Step 3: 57° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2,3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C.

[0434] The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene Oreg.) dissolved in 1×TE and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton Mass.), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a 1% agarose gel to determine which reactions were successful in extending the sequence.

[0435] The extended nucleotides were desalted and concentrated, transferred to 384well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison Wis.), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly Mass.) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37° C. in 384-well plates in LB/2× carb liquid media.

[0436] The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 72° C., 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72° C., 5 min; Step 7: storage at 4° C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIREC kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

[0437] In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5′ regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

[0438] IX. Identification of Single Nucleotide Polymorphisms in MDDT Encoding Polynucleotides

[0439] Common DNA sequence variants known as single nucleotide polymorphisms (SNPs) were identified in SEQ ID NO:24-46 using the UFESEQ database (Incyte Genomics). Sequences from the same gene were clustered together and assembled as described in Example m, allowing the identification of all sequence variants in the gene. An algorithm consisting of a series of filters was used to distinguish SNPs from other sequence variants. Preliminary filters removed the majority of basecall errors by requiring a minimum Phred quality score of 15, and removed sequence alignment errors and errors resulting from improper trimming of vector sequences, chimeras, and splice variants. An automated procedure of advanced chromosome analysis analysed the original chromatogram files in the vicinity of the putative SNP. Clone error filters used statistically generated algorithms to identify errors introduced during laboratory processing, such as those caused by reverse transcriptase, polymerase, or somatic mutation. Clustering error filters used statistically generated algorithms to identify errors resulting from clustering of close homologs or pseudogenes, or due to contamination by non-human sequences. A final set of filters removed duplicates and SNPs found in immunoglobulins or T-cell receptors.

[0440] Certain SNPs were selected for further characterization by mass spectrometry using the high throughput MASSARRAY system (Sequenom, Inc.) to analyze allele frequencies at the SNP sites in four different human populations. The Caucasian population comprised 92 individuals (46 male, 46 female), including 83 from Utah, four French, three Venezualan, and two Amish individuals. The African population comprised 194 individuals (97 male, 97 female), all African Americans. The Hispanic population comprised 324 individuals (162 male, 162 female), all Mexican Hispanic. The Asian population comprised 126 individuals (64 male, 62 female) with a reported parental breakdown of 43% Chinese, 31% Japanese, 13% Korean, 5% Vietnamese, and 8% other Asian. Allele frequencies were first analyzed in the Caucasian population; in some cases those SNPs which showed no allelic variance in this population were not further tested in the other three populations.

[0441] X. Labeling and Use of Individual Hybridization Probes

[0442] Hybridization probes derived from SEQ ID NO:24-46 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μCi of [γ-³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston Mass.). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

[0443] The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham N.H.). Hybridization is carried out for 16 hours at 40° C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1× saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

[0444] XI. Microarrays

[0445] The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra.), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

[0446] Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorbtion and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

[0447] Tissue or Cell Sample Preparation

[0448] Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 μg/μl oligo-(dT) primer (21 mer), 1×first strand buffer, 0.03 units/μL RNase inhibitor, 500 μM dATP, 500 μM dGfP, 500 μM dTTP, 40 μM dCTP, 40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37° C. for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85° C. to the stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto Calif.) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook N.Y.) and resuspended in 14 μl 5×SSC/0.2% SDS.

[0449] Microarray Preparation

[0450] Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

[0451] Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester Pa.), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110° C. oven.

[0452] Array elements are applied to the coated glass substrate using a procedure described in U.S. Pat. No. 5,807,522, incorporated herein by reference. 1 μL of the array element DNA, at an average concentration of 100 ng/μl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

[0453] Microarrays are UV-crosslinked using a STRATALJNER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford Mass.) for 30 minutes at 60° C. followed by washes in 0.2% SDS and distilled water as before.

[0454] Hybridization

[0455] Hybridization reactions contain 9 μl of sample mixture consisting of 0.2 μg each of Cy3 and Cy5 labeled cDNA synthesis products in SX SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65° C. for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μl of 5×SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 600C. The arrays are washed for 10 min at 45° C. in a first wash buffer (1×SSC, 0.1% SDS), three times for 10 minutes each at 45° C. in a second wash buffer (0.1×SSC), and dried.

[0456] Detection

[0457] Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara Calif.) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20× microscope objective (Nikon, Inc., Melville N.Y.). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and rasterscanned past the objective. The 1.8 cm×1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

[0458] In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater N.J.) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

[0459] The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

[0460] The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood Mass.) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

[0461] A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

[0462] Expression

[0463] TNF-α Treatment of HAEC Cultures

[0464] HAECs were maintained in EGM-2 medium (Clonetics, San Diego Calif.) containing 2% FBS, recombinant HEGF (0.5 ng.ml⁻¹), Gentamicin (50 μg.ml⁻¹), and Amphotericin-B (50 ng.ml⁻¹) (as supplied by Clonetics), at 37° C. in a 5% CO₂ atmosphere. In addition, hydrocortisone, VEGF, R3-IGF-1, ascorbic acid, hFGF-B, and heparin were included in the medium according to manufacturer's instruction (Clonetics). The cells were grown to 85% confluency and then treated with TNF-α (10 ng.ml⁻¹) for 1, 2, 4, 6, 8, 10, 24, and 48 hours. These TNF-α treated cells were compared to untreated HAECs collected at 85% confluency (t=0 hour).

[0465] For SEQ ID NO:38, the expression of a component of this polynucleotide sequence, having Incyte clone ID 2662817, is downregulated by at least two-fold when treated with TNF-α in three primary endothelial cell lines, HAEC, HIAEC, and HUVEC. Incyte clone ID 2662817 spans nucleotides 474 through 1176 of Incyte polynucleotide 2457335CB1 (SEQ ID NO:38).

[0466] XII. Complementary Polynucleotides

[0467] Sequences complementary to the MDDT-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring MDDT. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of MDDT. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5′ sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the MDDT-encoding transcript.

[0468] XIII. Expression of MDDT

[0469] Expression and purification of MDDT is achieved using bacterial or virus-based expression systems. For expression of MDDT in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the typ-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express MDDT upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of MDDT in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding MDDT by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:32243227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

[0470] In most expression systems, MDDT is synthesized as a fusion protein with, e.g., glutathione S-transferase (GSI) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-lilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from MDDT at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, Ira, ch. 10 and 16). Purified MDDT obtained by these methods can be used directly in the assays shown in Examples XVI, XVI, and XIX, where applicable.

[0471] XIV. Functional Assays

[0472] MDDT function is assessed by expressing the sequences encoding MDDT at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad Calif.), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cvtometrv, Oxford, New York N.Y.

[0473] The influence of MDDT on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding MDDT and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success N.Y.). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding MDDT and other genes of interest can be analyzed by northern analysis or microarray techniques.

[0474] XV. Production of MDDT Specific Antibodies

[0475] MDDT substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M. G. (1990) Methods Enzymol. 182:488495), or other purification techniques, is used to immunize animals (e.g., rabbits, mice, etc.) and to produce antibodies using standard protocols.

[0476] Alternatively, the MDDT amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the arL Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

[0477] Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using FMOC chemistry and coupled to KUH (SigmaAldrich, St. Louis Mo.) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, suora.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvanl Resulting antisera are tested for antipeptide and anti-MDDT activity by, for example, binding the peptide or MDDT to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

[0478] XVI. Purification of Naturally Occurring MDDT Using Specific Antibodies

[0479] Naturally occurring or recombinant MDDT is substantially purified by immunoaffinity chromatography using antibodies specific for MDDT. An irnnunoaffinity column is constructed by covalently coupling anti-MDDT antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

[0480] Media containing MDDT are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of MDDT (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/MDDT binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and MDDT is collected.

[0481] XVII. Identification of Molecules Which Interact with MDDT

[0482] MDDT, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton, A. E. and W. M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled MDDT, washed, and any wells with labeled MDDT complex are assayed. Data obtained using different concentrations of MDDT are used to calculate values for the number, affinity, and association of MDDT with the candidate molecules.

[0483] Alternatively, molecules interacting with MDDT are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MA MAKER system (Clontech).

[0484] MDDT may also be used in the PATHCALLING process (CuraGen Corp., New Haven CI) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Pat. No. 6,057,101).

[0485] XVIII. Demonstration of MDDT Activity

[0486] A microtubule motility assay for MDDT measures motor protein activity. In this assay, recombinant MDDT is immobilized onto a glass slide or similar substrate. Taxol-stabilized bovine brain microtubules (commercially available) in a solution containing ATP and cytosolic extract are perfused onto the slide. Movement of microtubules as driven by MDDT motor activity can be visualized and quantified using video-enhanced light microscopy and image analysis techniques. MDDT activity is directly proportional to the frequency and velocity of microtubule movement.

[0487] Alternatively, an assay for MDDT activity measures the formation of protein filaments in vitro. A solution of MDDT at a concentration greater than the “critical concentration” for polymer assembly is applied to carbon-coated grids. Appropriate nucleation sites may be supplied in the solution. The grids are negatively stained with 0.7% (w/v) aqueous uranyl acetate and examined by electron microscopy. The appearance of filaments of approximately 25 nm (microtubules), 8 nm (actin), or 10 nm (intermediate filaments) is a demonstration of MDDT activity.

[0488] In another alternative, MDDT activity is measured by the binding of MDDT to protein filaments. ³⁵S-Met labeled MDDT sample is incubated with the appropriate filament protein (actin, tubulin, or intermediate filament protein) and complexed protein is collected by immunoprecipitation using an antibody against the filament protein. The immunoprecipitate is then run out on SDS-PAGE and the amount of MDDT bound is measured by autoradiography.

[0489] MDDT activity is measured by its ability to stimulate transcription of a reporter gene (Liu, H. Y. et al. (1997) EMBO J. 16:5289-5298). The assay entails the use of a well characterized reporter gene construct, LexA_(op)-LacZ, that consists of LexA DNA transcriptional control elements (LexA_(op)) fused to sequences encoding the E. coli LacZ enzyme. The methods for constructing and expressing fusion genes, introducing them into cells, and measuring LacZ enzyme activity, are well known to those skilled in the art. Sequences encoding MDDT are cloned into a plasmid that directs the synthesis of a fusion protein, LexA-MDDT, consisting of MDDT and a DNA binding domain derived from the LexA transcription factor. The resulting plasmid, encoding a LexA-MDDT fusion protein, is introduced into yeast cells along with a plasmid containing the LexA.p-LacZ reporter gene. The amount of LacZ enzyme activity associated with LexA-MDDT transfected cells, relative to control cells, is proportional to the amount of transcription stimulated by the MDDT.

[0490] Alternatively, MDDT activity is measured by its ability to bind zinc. A 5-10 mM sample solution in 2.5 mM ammonium acetate solution at pH 7.4 is combined with 0.05 M zinc sulfate solution (Aldrich, Milwaukee Wis.) in the presence of 100 mM dithiothreitol with 10% methanol added. The sample and zinc sulfate solutions are allowed to incubate for 20 minutes. The reaction solution is passed through a VYDAC column (Grace Vydac, Hesperia, Calif.) with approximately 300 Angstrom bore size and 5 mM particle size to isolate zinc-sample complex from the solution, and into a mass spectrometer (PE Sciex, Ontario, Canada). Zinc bound to sample is quantified using the functional atomic mass of 63.5 Da observed by Whittal, R. M. et al. ((2000) Biochemistry. 39:8406-8417).

[0491] In the alternative, a method to determine nucleic acid binding activity of MDDT involves a polyacrylamide gel mobility-shift assay. In preparation for this assay, MDDT is expressed by transforming a mammalian cell line such as COS7, HeLa or CHO with a eukaryotic expression vector containing MDDT cDNA. The cells are incubated for 48-72 hours after transformation under conditions appropriate for the cell line to allow expression and accumulation of MDDT. Extracts containing solubilized proteins can be prepared from cells expressing MDDT by methods well known in the art. Portions of the extract containing MDDT are added to [³²P]-labeled RNA or DNA. Radioactive nucleic acid can be synthesized in vitro by techniques well known in the art. The mixtures are incubated at 25° C. in the presence of RNase- and DNase-inhibitors under buffered conditions for 5-10 minutes. After incubation, the samples are analyzed by polyacrylamide gel electrophoresis followed by autoradiography. The presence of a band on the autoradiogram indicates the formation of a complex between MDDT and the radioactive transcript. A band of simnilar mobility will not be present in samples prepared using control extracts prepared from untransformed cells.

[0492] In the alternative, a method to determine methylase activity of MDDT measures transfer of radiolabeled methyl groups between a donor substrate and an acceptor substrate. Reaction mixtures (50 μl final volume) contain 15 mM HEPES, pH 7.9, 1.5 mM MgCl₂, 10 mM dithiothreitol, 3% polyvinylalcohol, 1.5 μCi [methyl-³H]AdoMet (0.375 μM AdoMet) (DuPont-NEN), 0.6 μg MDDT, and acceptor substrate (e.g., 0.4 μg [³S]RNA, or 6-mercaptopurine (6-MP) to 1 mM final concentration). Reaction mixtures are incubated at 30° C. for 30 minutes, then 65° C. for 5 minutes.

[0493] Analysis of [methyl-³H]RNA is as follows: (1) 50 μl of 2× loading buffer (20 mM Tris-HCl, pH 7.6, 1 M LiCl, 1 mM EDTA, 1% sodium dodecyl sulphate (SDS)) and 50 μl oligo d(T)-cellulose (10 mg/ml in 1× loading buffer) are added to the reaction mixture, and incubated at ambient temperature with shaking for 30 minutes. (2) Reaction mixtures are transferred to a 96-well filtration plate attached to a vacuum apparatus. (3) Each sample is washed sequentially with three 2.4 ml aliquots of 1×oligo d(I) loading buffer containing 0.5% SDS, 0.1% SDS, or no SDS. (4) RNA is eluted with 300 μl of water into a 96-well collection plate, transferred to scintillation vials containing liquid scintillant, and radioactivity determined.

[0494] Analysis of [methyl-³H]6-MP is as follows: (1) 500 μl 0.5 M borate buffer, pH 10.0, and then 2.5 ml of 20% (v/v) isoamyl alcohol in toluene are added to the reaction mixtures. (2) The samples are mixed by vigorous vortexing for ten seconds. (3) After centrifugation at 700 g for 10 minutes, 1.5 ml of the organic phase is transferred to scintillation vials containing 0.5 ml absolute ethanol and liquid scintillant, and radioactivity determined. (4) Results are corrected for the extraction of 6-MP into the organic phase (approximately 41%).

[0495] In the alternative, type I topoisomerase activity of MDDT can be assayed based on the relaxation of a supercoiled DNA substrate. MDDT is incubated with its substrate in a buffer lacking Me²⁺ and ATP, the reaction is terminated, and the products are loaded on an agarose gel. Altered topoisomers can be distinguished from supercoiled substrate electrophoretically. This assay is specific for type I topoisomerase activity because Mg²⁺ and ATP are necessary cofactors for type II topoisomerases.

[0496] Type II topoisomerase activity of MDDT can be assayed based on the decatenation of a kinetoplast DNA (KDNA) substrate. MDDT is incubated with KDNA, the reaction is terminated, and the products are loaded on an agarose gel. Monomeric circular KDNA can be distinguished from catenated KDNA electrophoretically. Kits for measuring type I and type II topoisomerase activities are available commercially from Topogen (Columbus Ohio).

[0497] ATP-dependent RNA helicase unwinding activity of MDDT can be measured by the method described by Zhang and Grosse (1994; Biochemistry 33:3906-3912). The substrate for RNA unwinding consists of ³²P-labeled RNA composed of two RNA strands of 194 and 130 nucleotides in length containing a duplex region of 17 base-pairs. The RNA substrate is incubated together with ATP, Mg²⁺, and varying amounts of MDDT in a Tris-HCl buffer, pH 7.5, at 37° C. for 30 minutes. The single-stranded RNA product is then separated from the double-stranded RNA substrate by electrophoresis through a 10% SDS-polyacrylamide gel, and quantitated by autoradiography. The amount of single-stranded RNA recovered is proportional to the amount of MDDT in the preparation.

[0498] In the alternative, MDDT function is assessed by expressing the sequences encoding MDDT at physiologically elevated levels in manmalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen Corporation, Carlsbad Calif.), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected.

[0499] Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; CLONTECH), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties.

[0500] FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York N.Y.

[0501] The influence of MDDT on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding MDDT and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Inc., Lake Success N.Y.). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding MDDT and other genes of interest can be analyzed by northern analysis or microarray techniques.

[0502] Pseudouridine synthase activity of MDDT is assayed using a tritium (CH) release assay modified from Nurse et al. ((1995) RNA 1:102-112), which measures the release of ³H from the C₅ position of the pyrimidine component of uridylate (U) when 3H-radiolabeled U in RNA is isomerized to pseudouridine (y). A typical 500 μl assay mixture contains 50 mM HEPES buffer (pH 7.5), 100 mM ammonium acetate, 5 mM dithiothreitol, 1 mM EDTA, 30 units RNase inhibitor, and 0.1-4.2 μM [5-³H]tRNA (approximately 1 μCi/mnol tRNA). The reaction is initiated by the addition of <5 μl of a concentrated solution of MDDT (or sample containing MDDT) and incubated for 5 min at 37° C. Portions of the reaction mixture are removed at various times (up to 30 min) following the addition of MDDT and quenched by dilution into 1 ml 0.1 M HCl containing Norit-SA3 (12% w/v). The quenched reaction mixtures are centrifuged for 5 min at maximum speed in a ricrocentrifuge, and the supernatants are filtered through a plug of glass wool. The pellet is washed twice by resuspension in 1 ml 0.1 M HCl, followed by centrifugation. The supernatants from the washes are separately passed through the glass wool plug and combined with the original filtrate. A portion of the combined filtrate is mixed with scintillation fluid (up to 10 ml) and counted using a scintillation counter. The amount of ³H released from the RNA and present in the soluble filtrate is proportional to the amount of peudouridine synthase activity in the sample (Ramamurthy, V. (1999) J. Biol. Chem. 274:22225-22230).

[0503] In the alternative, pseudouridine synthase activity of MDDT is assayed at 300C to 370C in a mixture containing 100 mM Tris-HCl (pH 8.0), 100 mM ammonium acetate, 5 mM MgC2, 2 mM dithiothreitol, 0.1 mM EDTA, and 1-2 fnol of [³²P]-radiolabeled runoff transcripts (generated in vitro by an appropriate RNA polymerase, i.e., T7 or SP6) as substrates. MDDT is added to initiate the reaction or omitted from the reaction in control samples. Following incubation, the RNA is extracted with phenol-chloroform, precipitated in ethanol, and hydrolyzed completely to 3-nucleotide monophosphates using RNase T₂. The hydrolysates are analyzed by two-dimensional thin layer chromatography, and the amount of ³²P radiolabel present in the yMP and UMP spots are evaluated after exposing the thin layer chromatography plates to film or a Phosphorlmager screen. Taling into account the relative number of uridylate residues in the substrate RNA, the relative amount yMP and UMP are determined and used to calculate the relative amount of y per tRNA molecule (expressed in mol y/mol of tRNA or mol y/mol of tRNA/minute), which corresponds to the amount of pseudouridine synthase activity in the MDDT sample (Lecointe, F. et al. (1998) J. Biol. Chem. 273:1316-1323).

[0504] N²,N²-diethylguanosine transferase ((m² ₂G)methyltrnnsferase) activity of MDDT is measured in a 160 μl reaction mixture containing 100 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 10 mM MgCl₂, 20 rM NH4Cl, 1 mM dithiothreitol, 6.2 μM S-adenosyl-L[methyl-3H]methionine (30-70 Ci/mM), 8 Ag m² ₂G-deficient tRNA or wild type tRNA from yeast, and approximately 100 μg of purified MDDT or a sample comprising MDDT. The reactions are incubated at 30° C. for 90 min and chilled on ice. A portion of each reaction is diluted to 1 ml in water containing 100 μg BSA. 1 ml of 2 M HCl is added to each sample and the acid insoluble products are allowed to precipitate on ice for 20 min before being collected by filtration through glass fiber filters. The collected material is washed several times with HCl and quantitated using a liquid scintillation counter. The amount of ³H incorporated into the m² ₂G-deficient, acid-insoluble tRNAs is proportional to the amount of N²,N²-diethylguanosine transferase activity in the MDDT sample. Reactions comprising no substrate tRNAs, or wild-type tRNAs that have already been modified, serve as control reactions which should not yield acid-insoluble ³H-labeled products.

[0505] Polyadenylation activity of MDDT is measured using an in vitro polyadenylation reaction. The reaction mixture is assembled on ice and comprises 10 μl of 5 mM dithiothreitol, 0.025% (v/v) NONIDET P40, 50 mM creatine phosphate, 6.5% (w/v) polyvinyl alcohol, 0.5 unit/μl RNAGUARD (Pharmacia), 0.025 μg/μl creatine linase, 1.25 mM cordycepin 5′-triphosphate, and 3.75 mM MgCl₂, in a total volume of 25 μl. 60 fmol of CstF, 50 fmol of CPSF, 240 finol of PAP, 4 μl of crude or partially purified CF II and various amounts of amounts CF I are then added to the reaction mix. The volume is adjusted to 23.5 μl with a buffer containing 50 mM Tris HCl, pH 7.9, 10% (v/v) glycerol, and 0.1 mM Na-EDTA. The final ammonium sulfate concentration should be below 20 mM. The reaction is initiated (on ice) by the addition of 15 finol of ³²P-labeled pre-mRNA template, along with 2.5 μg of unlabeled tRNA, in 1.5 μl of water. Reactions are then incubated at 30° C. for 75-90 min and stopped by the addition of 75 μl (approximately two-volumes) of proteinase K mix (0.2 M Tris-HCl, pH 7.9, 300 mM NaCl, 25 mM Na-EDTA, 2% (w/v) SDS), 1 μl of 10 mg/ml proteinase K, 0.25 μl of 20 mg/ml glycogen, and 23.75 μl of water). Following incubation, the RNA is precipitated with ethanol andanalyzed on a 6% (w/v) polyacrylamide, 8.3 M urea sequencing gel. The dried gel is developed by autoradiography or using a phosphoimager. Cleavage activity is determined by comparing the amount of cleavage product to the amount of pre-mRNA template. The omission of any of the polypeptide components of the reaction and substitution of MDDT is useful for identifying the specific biological function of MDDT in pre-mRNA polyadenylation (Ruegsegger, U. et al. (1996) J. Biol. Chem. 271:6107-6113; and references within). tRNA synthetase activity is measured as the aminoacylation of a substrate tRNA in the presence of [¹⁴C]-labeled amino acid. MDDT is incubated with [¹⁴C]-labeled amino acid and the appropriate cognate tRNA (for example, [¹⁴C]alanine and tRNA^(ala)) in a buffered solution. ¹4C-labeled product is separated from free [¹⁴C]amino acid by chromatography, and the incorporated ¹⁴C is quantified by scintillation counter. The amount of ¹⁴C-labeled product detected is proportional to the activity of MDDT in this assay.

[0506] In the alternative, MDDT activity is measured by incubating a sample containing MDDT in a solution containing 1 mM ATP, 5 mM Hepes-KOH (pH 7.0), 2.5 mM KCl, 1.5 mM magnesium chloride, and 0.5 mM DTT along with misacylated [¹⁴C]-Glu-tRNAGln (e.g., 1 μM) and a similar concentration of unlabeled Lglutamine. Following the quenching of the reaction with 3 M sodium acetate (pH 5.0), the mixture is extracted with an equal volume of water-saturated phenol, and the aqueous and organic phases are separated by centrifugation at 15,000×g at room temperature for 1 min. The aqueous phase is removed and precipitated with 3 volumes of ethanol at −70° C. for 15 nmin. The precipitated aminoacyl-tRNAs are recovered by centrifugation at 15,000×g at 4° C. for 15 min. The pellet is resuspended in of 25 mM KOH, deacylated at 65° C. for 10 min., neutralized with 0.1 M HCl (to final pH 6-7), and dried under vacuum. The dried pellet is resuspended in water and spotted onto a cellulose TLC plate. The plate is developed in either isopropanol/formic acid/water or ammonia/water/chloroform/methanol. The image is subjected to densitometric analysis and the relative amounts of Glu and Gln are calculated based on the Rf values and relative intensities of the spots. MDDT activity is calculated based on the amount of Gln resulting from the transformation of Glu while acylated as Glu-tRNAGIn (adapted from Curnow, A. W. et al. (1997) Proc. Natl. Acad. Sci. 94:11819-26).

[0507] XIX. Identification of MDDT Agonists and Antagonists

[0508] Agonists or antagonists of MDDT activation or inhibition may be tested using the assays described in section XVII. Agonists cause an increase in MDDT activity and antagonists cause a decrease in MDDT activity.

[0509] Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims. TABLE 1 Incyte Polypeptide Incyte Polynucleotide Polynucleotide Incyte Project ID SEQ ID NO: Polypeptide ID SEQ ID NO: ID CA2 Reagents 71230017 1 71230017CD1 24 71230017CB1 3125036 2 3125036CD1 25 3125036CB1 1758089 3 1758089CD1 26 1758089CB1 3533891 4 3533891CD1 27 3533891CB1 1510943 5 1510943CD1 28 1510943CB1 2119377 6 2119377CD1 29 2119377CB1 2119377CA2 3176058 7 3176058CD1 30 3176058CB1 2299818 8 2299818CD1 31 2299818CB1 90135665CA2 2729451 9 2729451CD1 32 2729451CB1 878534 10 878534CD1 33 878534CB1 2806157 11 2806157CD1 34 2806157CB1 2806157CA2, 7976113CA2 5883626 12 5883626CD1 35 5883626CB1 2201431CA2, 2957907CA2, 5890236CA2, 5891113CA2, 5891191CA2 2674016 13 2674016CD1 36 2674016CB1 5994159 14 5994159CD1 37 5994159CB1 3564793CA2 2457335 15 2457335CD1 38 2457335CB1 2267802 16 2267802CD1 39 2267802CB1 3212060 17 3212060CD1 40 3212060CB1 3591224CA2 3121069 18 3121069CD1 41 3121069CB1 3142557CA2 3280626 19 3280626CD1 42 3280626CB1 484404 20 484404CD1 43 484404CB1 2830063 21 2830063CD1 44 2830063CB1 7506096 22 7506096CD1 45 7506096CB1 7505914 23 7505914CD1 46 7505914CB1

[0510] TABLE 2 GenBank Polypeptide ID NO: or SEQ Incyte PROTEOME ID Probability ID NO: Polypeptide ID NO: Score Annotation 1 71230017CD1 g15982946 0.0 SSA protein SS-56 [Homo sapiens] Billaut-Mulot, O. et al. (2001) SS-56, a novel cellular target of autoantibody responses in Sjogren syndrome and systemic lupus erythematosus. J. Clin. Invest. 108: 861-869 2 3125036CD1 g5690435 4.0E−116 [Xenopus laevis] nuclear protein Sojo g10432382 1.7E−234 [Homo sapiens] dJ717I23.1 (novel protein similar to Xenopus laevis Sojo protein) 3 1758089CD1 g10567164 0.0 [Homo sapiens] gene amplified in squamous cell carcinoma-1 Yang, Z. Q. et al. (2000) Cancer Res. 60: 4735-4739 4 3533891CD1 g5823146 2.9E−74 [Rattus norvegicus] testis specific protein 5 1510943CD1 g13604149 0.0 tangerin C′ [Mus musculus] 6 2119377CD1 g18034072 1.0E−122 SPRY domain-containing SOCS box protein SSB-1 [Homo sapiens] 9 2729451CD1 g12856615 1.0E−144 DNA BINDING PROTEIN DESRT˜data source: SPTR, source key: Q9JIX4, evidence: ISS˜putative [Mus musculus] Carninci, P. and Hayashizaki, Y. (1999) High-efficiency full-length cDNA cloning. Meth. Enzymol. 303: 19-44 Carninci, P. et al. (2000) Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes. Genome Res. 10: 1617-1630 11 2806157CD1 g2587026 2.7E−32 [Homo sapiens] HERV-E integrase Lindeskog, M. et al. (1998) Virology 244: 219-229 14 5994159CD1 g7768636 3.5E−31 [Xenopus laevis] Kielin Matsui, M. et al. (2000) Proc. Natl. Acad. Sci. USA. 97: 5291-5296 g6979313 2.0E−16 cysteine-rich repeat-containing protein CRIM1 [Mus musculus] 15 2457335CD1 g12584947 8.3E−134 [Homo sapiens] ovary-specific acidic protein 16 2267802CD1 g12963885 0.0 [Homo sapiens] (AY026527) prostate antigen PARIS-1 21 2830063CD1 g13539684 0.0 zinc finger protein 291 [Homo sapiens] 22 7506096CD1 g2773363 1.4E−49 [Drosophila melanogaster] microtubule binding protein D-CLIP-190 Lantz, V. A. and Miller, K. G. (1998) A class VI unconventional myosin is associated with a homologue of a microtubule-binding protein, cytoplasmic linker protein-170, in neurons and at the posterior pole of Drosophila embryos. J. Cell Biol. 140: 897-910 339768|CENPE 1.4E−49 [Homo sapiens][Motor protein; Hydrolase; ATPase][Nuclear] Centromere protein E, a kinesin-like minus-end directed motor protein, associated with kinetochores, required for chromosome alignment during metaphase and metaphase to anaphase transition, may have a role in rheumatoid arthritis and systematic sclerosis. Kullmann, F. et al. (1999) Arthritis Res. 1: 71-80 568434|GOLGA4 1.7E−48 [Homo sapiens]Golgi; Cytoplasmic; Plasma membrane] Golgi autoantigen golgin subfamily a 4 (golgin-245), contains a novel Golgi-targeting GRIP domain, may function in vesicular transport from the trans-Golgi, vesicle biogenesis, or Golgi structural organization; autoantigen in Sjogren's syndrome patients. 335126|EEA1 4.4E−45 [Homo sapiens][Small molecule-binding protein][Endosonie/Endosomal vesicles; Nuclear; Cytoplasmic; Plasma membrane] Early endosome antigen 1, effector of endosomal small GTPase RAB5, required for endosome fusion, may specify transport directionality from the plasma membrane to early endosomes; autoantigen associated with subacute cutaneous systemic lupus erythematosus. Mu, F. T. et al. (1995) J. Biol. Chem. 270: 13503-13511. 23 7505914CD1 g18642530 0.0 SR rich protein [Homo sapiens] 610045|Srrp86 3.2E−27 [Rattus norvegicus][Spliceosomal subunit; RNA-binding protein] [Nuclear] Serine arginine-rich splicing regulatory protein 86, contains an RNA recognition motif and serine-arginine-rich domains, interacts with other serine-arginine-rich splicing factors, involved in splicing regulation and differential splice site selection Barnard, D. C., and Patton, J. G. (2000) Identification and characterization of a novel serine-arginine-rich splicing regulatory protein. Mol. Cell. Biol. 20: 3049-3057

[0511] TABLE 3 Amino SEQ Incyte Acid Potential Potential ID Polypeptide Resi- Phosphorylation Glycosylation Analytical Methods NO: ID dues Sites Sites Signature Sequences, Domains and Motifs and Databases 1 71230017CD1 485 S183 S252 S355 N230 N268 N438 Signal peptide: M1-S50 SPScan T170 T172 T179 N471 Y313 SPRY domain: S355-D482 HMMER-PFAM B-box zinc finger.: L93-M134 HMMER-PFAM Zinc finger, C3HC4 type (RING finger): C16-C60 HMMER-PFAM Zinc finger, C3HC4 type (RING finger), signature: ProfileScan I10-R67 Zinc finger, C3HC4 type: C31-C39 BLIMPS-BLOCKS Domain in SP1a: PF00622A: K110-S123 PF00622B: BLIMPS-PFAM E339-W360 PF00622C: V423-F436 Midline zinc finger, RING, stonus toxin, putative BLAST-PRODOM transcription factor PD002421: L298-F462 Butyrophilin, zinc finger, DNA-binding PD002445: BLAST-PRODOM L260-Q351 Receptor, ryanodine, transmembrane, calcium BLAST-PRODOM channel, butyrophilin PD001178: S355-F449 RFP transforming protein DM02346: P19474|59-337: BLAST-DOMO R67-Q351 A57041|64-348: Q65-G356 P14373|61- 366: R67-C352 RFP transforming protein DM01944: P19474|339-465: BLAST-DOMO S355-D482 Zinc finger, C3HC4 type (RING finger), signature: MOTIFS C31-L40 Leucine zipper pattern: L227-L248 MOTIFS 2 3125036CD1 1404 S4 S24 S38 S47 N134 N296 N481 Coiled coil protein; myosin repeat, heavy, ATP- BLAST-PRODOM S59 S61 S79 S90 N495 N586 N725 binding, filament, heptad PD000002: L878-L1127 S115 S156 S183 N1344 S199 S209 S213 S316 S365 S407 S408 S444 S500 S504 S521 S587 S588 S599 S680 S711 S727 S771 S783 S831 S852 S927 S1005 S1018 S1096 S1119 S1164 S1169 S1180 S1194 S1256 S1273 S1305 S1336 S1341 S1352 S1391 T139 T283 T298 Tropomyosin repeat, coiled coil PD000023: N870- BLAST-PRODOM T493 T543 T595 S1096 T645 T753 T764 T815 T861 T863 T882 T910 T934 T978 T983 T1310 T1337 T1348 Y243 Y715 Coiled coil, heptad repeat, ATP-binding PD075049: BLAST-PRODOM L865-D1123 Dynein chain, motor, microtubules, ATP-binding, BLAST-PRODOM heptad repeat PD003395: H568-D1263 Trichohyalin DM03839|P37709|632-1103: Q739- BLAST-DOMO D1193 Heptad repeat pattern: DM05319|P30427|568-1938: BLAST-DOMO K532-L1345 Leucine zipper pattern: L116-L137, L900-L921, MOTIFS L907-L928 3 1758089CD1 1096 S12 S104 S140 N125 PHD-finger: G750-H791, K851-Y897 HMMER-PFAM S153 S364 S373 S378 S407 S452 S458 S483 S566 S610 S632 S633 S641 S647 S707 S735 S863 S956 S978 S1051 S1072 T17 T21 T59 T94 jmjC domain: Y176-F292 HMMER-PFAM T109 T156 T167 T294 T308 T340 T351 T560 T571 T699 T811 T946 T967 T1017 T1025 Y993 jmjN domain: K14-D61 HMMER-PFAM PHD-finger: Y871-A885 BLIMPS-PFAM XE169, nuclear, zinc finger, DNA-binding PROTEIN BLAST-PRODOM INTERGENIC REGION XE169 PD005470: E97- R329 zinc finger, nuclear, DNA-binding, ALL1, BLAST-PRODOM translocation, protooncogene PD006688: E796-H906 Finger, SMCX, SMCY, YDR096W, DM01930: BLAST-DOMO P39956|83-380: L118-M318 P29375|346-638: W149- C307 S44139|245-535: W149-C307 P41229|377-669: W149-C307 Cell attachment sequence RGD: R1020-D1022 MOTIFS 4 3533891CD1 167 S64 S70 S89 S122 N42 Signal peptide: M38-A91 SPScan S163 T8 T101 5 1510943CD1 1523 S141 S176 S191 N104 N967 Calponin homology (CH) domain: V1037-T1142 HMMER-PFAM S239 S264 S290 N1061 N1292 S310 S337 S361 S390 S533 S714 S852 S993 S998 S1016 S1042 T32 S1065 S1123 T45 S1168 S1257 S1288 S1297 S1338 S1346 S1390 S1511 S1515 T164 T219 T258 Transmembrane domain: E755-G771 N-terminus is TMAP T284 T405 T470 non-cytosolic T521 T572 T646 T653 T669 T704 T730 T866 T971 T1142 T1159 T1326 Y1086 Y1362 Alpha-actinin actin-binding domain DM00325: BLAST-DOMO P18091|28-252: V1037-F1140 Q08043|39-263: S1038-F1140 A44159|48-277: S1038-L1134 P35609|32-256: S1038-F1140 Leucine zipper pattern: L1404-L1425 MOTIFS Binding-protein-dependent transport systems inner MOTIFS membrane comp. signal: V1207-P1235 6 2119377CD1 273 S8 S135 S244 S265 Signal peptide: M1-A55 SPScan T119 T223 Mouse BAC library, BAC284H12 12P13 PD039422: BLAST-PRODOM P34-Q273 Trp-Asp (WD) repeats signature: T130-L144 MOTIFS 7 3176058CD1 341 S10 S80 S136 S191 N75 N153 C11D2.4 protein PD137800: M1-R337 BLAST-PRODOM S204 S218 S269 T155 T196 8 2299818CD1 341 S45 S78 S91 Y97 N7 N31 N201 Signal peptide: M1-D37 SPScan S169 S203 S328 N263 N331 N336 T33 T192 T281 Protein HES1SEC63 B0024.11 409AA PD005058: BLAST-PRODOM K4-L186, R130-I258 9 2729451CD1 1185 S37 S72 S99 S239 N237 N273 N427 ARID DNA binding domain: E315-E426 HMMER-PFAM S264 S304 S428 N434 N518 N606 S451 S469 S480 N622 N864 S483 S504 S510 N1105 S524 S526 S573 S715 S754 S776 S869 S972 S999 S1012 S1029 S1038 S1044 S1150 S1182 T47 T65 T233 Transmembrane domain: I201-V216 N-terminus is TMAP T337 T369 T394 non-cytosolic T441 T608 T624 T642 T765 T850 T915 Y344 Nuclear DNA-binding protein, transcription, DRIL1, BLAST-PRODOM retinoblastoma, trans-acting factor PD004601: F324- P416 10 878534CD1 1042 S95 S168 S245 N47 N142 N172 Signal peptide: M1-A34 SPScan S276 S337 S375 N207 N225 N226 S407 S411 S434 N230 N620 S457 S535 S565 S582 S598 S614 S659 S704 S714 S718 S795 S826 S834 S838 S882 S884 S916 S925 S958 S1005 T49 T68 T162 T166 T347 T362 T419 T508 T622 T765 T811 T812 T946 T1001 T1009 T1040 11 2806157CD1 86 T72 T77 T83 Similar to HERV H protease and HERV E integrase BLAST-PRODOM protease PD064787: P53-S86 12 5883626CD1 138 S24 S68 Signal peptide: M4-D71 SPScan Transmembrane domain: C53-C69 N-terminus is non- TMAP cytosolic 13 2674016CD1 805 S30 S52 S68 S204 N487 N648 DNA-binding protein PD001830: K581-K799, K553- BLAST-PRODOM S264 S286 S290 S783, R594-S804 S305 S321 S396 S401 S408 S467 S491 S542 S546 S551 S559 S577 S584 S597 S619 S653 S705 S706 S717 S728 S736 S740 S748 S752 S757 S760 S767 S787 S790 S795 T231 Topoisomerase I, DNA isomerase, DNA-binding, BLAST-PRODOM T271 T326 T350 intermediate filament heptad PD000422: E603-R796, T366 T410 T448 R640-K797 T485 T565 T628 T744 Type B repeat DM05511: S26650|1-1203: E462- BLAST-DOMO T745, K500-R803, R472-S760 P18583|113-1296: E462-T745, G506-R803, D402-K675 Caldesmon: DM06224|P12957|1-755: S405-S779, BLAST-DOMO A193-K750 Tumor recognition, prolyl: DM08077|P30414|230- BLAST-DOMO 1403: E481-S804, E603-S802, E244-E324 14 5994159CD1 426 S72 S115 S133 N110 N250 Signal peptide: M22-S72 SPScan S212 S218 S312 S373 S419 T103 T172 T396 von Willebrand factor type C domain: C158-C213, HMMER-PFAM C100-C155 von Willebrand factor type C repeat BLAST-DOMO DM00551|A38963|649-756: R59-C155 C-type lectin domain: C120-C141 MOTIFS von Willebrand factor C domain signature: C120- MOTIFS C155, C178-C213 15 2457335CD1 267 S29 S34 S35 S213 N199 Signal peptide: M1-A58 SPScan S220 T85 T102 T156 T175 T196 T197 T201 Transmembrane domain: N36-Y64 TMAP 16 2267802CD1 928 S21 S207 S253 N205 N288 N301 PH domain: K46-W142 HMMER-PFAM S267 S324 S346 N675 S391 S422 S558 S690 S756 S768 S859 S909 S920 T83 T121 T231 T303 T567 Y815 TBC domain: L622-L839 HMMER-PFAM Transmembrane domain: V783-L806 N-terminus is TMAP cytosolic Probable rabGAP domain PF00566: I670-P679, BLIMPS-PFAM Y711-N716 Transmembrane protein, cell division, oncogene BLAST-PRODOM PD001799: D693-L843 Membrane protein DM01737 S62481|395-698: E617- BLAST-DOMO R823 Q09830|395-698: E617-R823 P53258|152-437: L612-R823 P48566|107-461: R533-H782, L785-R823 17 3212060CD1 684 S116 S121 S194 N273 N351 DnaB-like helicase PF00772: L390-Y428, T439- BLIMPS-PFAM S232 S254 S369 Y471, I510-M521, T56-K91 S382 S419 S493 S576 S653 S654 S680 T44 T56 T189 T263 T496 T529 T679 Y233 Y484 Similarity to ATP/GTP-binding site motif A BLAST-PRODOM PD145092: E153-A460, W474-S629 Cell attachment sequence: R132-D134 MOTIFS ATP/GTP-binding site motif A (P-loop): G415-T422 MOTIFS 18 3121069CD1 267 S36 S98 T27 T86 N45 N54 N82 Transmembrane domains: T4-T27, T181-I207 N- TMAP S183 S219 S232 N114 N128 N135 terminus is cytosolic S234 T137 T141 N154 N179 T156 T203 T249 19 3280626CD1 537 S37 S123 S137 N312 N318 S267 S274 S308 S314 S438 S456 T157 T171 T320 T477 Y190 Y246 Y483 20 484404CD1 312 S55 S85 S95 S117 N219 S123 S142 S159 S198 S304 T32 T145 T170 T233 Y250 21 2830063CD1 1400 S37 S52 S126 S177 N192 N468 N506 Transmembrane domains: N1040-R1068, I1103- TMAP S221 S254 S294 N823 N995 L1120, A1133-V1153, S1159-D1179, H1185-K1205, S298 S349 S359 N1000 N1004 Q1214-S1236 N-terminus is non-cytosolic S417 S502 S508 N1033 N1087 S535 S543 S753 N1207 S773 S832 S840 S888 S895 S930 S1011 S1090 S1159 S1203 S1219 S1290 T24 T59 T62 T67 Coiled coil, myosin repeat, ATP-binding, heptad BLAST-PRODOM T77 T188 T350 PD000002: M527-K767, E529-K749, Q570-E770 T466 T539 T566 T786 T935 T961 T1041 T1077 T1154 T1195 Y118 Y1105 Coiled coil, tropomyosin repeat PD000023: K568- BLAST-PRODOM E770, R536-Q763 Trichohyalin DM03839: P37709|632-1103: A400- BLAST-DOMO K767, E542-N894, R536-D920 Q07283|91-443: BLAST-DOMO E501-L771, V493-K767 P22793|921-1475: R538- BLAST-DOMO K767, E529-N947 Tropomyosin DM00077|P37709|1104-1277: K545- BLAST-DOMO R727, K545-Q705, E596-K767 Zinc finger, C2H2 type, domain: C794-H816 MOTIFS 22 7506096CD1 1384 S4 S24 S38 S47 N134 N276 N461 PROTEIN COILED COIL CHAIN MYOSIN BLAST_PRODOM S59 S61 S79 S90 N475 N566 N705 REPEAT HEAVY ATP-BINDING FILAMENT S115 S156 S183 N1324 HEPTAD PD000002: L858-L1107, K569-K815, S199 S209 S213 Q133-K357 S296 S345 S387 S388 S424 S480 S484 S501 S567 S568 S579 S660 S691 S707 S751 S763 S811 S832 S907 S985 S998 S1076 S1099 S1144 S1149 S1160 S1174 S1236 S1253 S1285 S1316 S1321 S1332 S1371 T139 T278 T473 MYOSIN MYOSIN 3 ISOFORM HEAVY CHAIN BLAST_PRODOM T523 T575 T625 TYPE II COILED COIL ATP-BINDING PD031043: T733 T744 T795 L242-E1212 T841 T843 T862 T890 T914 T958 T963 T1290 T1317 T1328 Y243 Y695 PROTEIN REPEAT TROPOMYOSIN COILED BLAST_PRODOM COIL ALTERNATIVE SPLICING SIGNAL PRECURSOR CHAIN PD000023: N850-S1076 SCABROUS PROTEIN PRECURSOR BLAST_PRODOM DEVELOPMENTAL NEUROGENESIS SIGNAL PD144674: V182-K629 MYOSIN-LIKE PROTEIN MLP1 BLAST_DOMO DM07884|Q02455|35-1728: M1-L1325 TRICHOHYALIN BLAST_DOMO DM03839|P37709|632-1103: Q719-D1173, Q185- L658 HEPTAD REPEAT PATTERN REPEAT BLAST_DOMO DM05319|P30427|568-1938: L210-I1235 Leucine zipper pattern: L116-L137, L880-L901, MOTIFS L887-L908 23 7505914CD1 787 S30 S52 S68 S204 N469 N630 signal_cleavage: M1-A47 SPSCAN S264 S286 S290 S305 S321 S378 S383 S390 S449 S473 S524 S528 S533 S541 S559 S566 S579 S601 S635 S687 S688 S699 S710 S718 S722 S730 S734 S739 S742 S749 S769 S772 S777 T231 T271 Protamine P1 proteins BL00048: R596-R622 BLIMPS_BLOCKS T326 T350 T366 T392 T430 T467 T547 T610 T726 PROTEIN DNA BINDING CODED FOR BY C BLAST_PRODOM ELEGANS cDNA CHROMOSOME HOMOLOG PD001830: K563-K781, K535-S765, R576-S784, E485-G735, D459-D683 PROTEIN TOPOISOMERASE I DNA ISOMERASE BLAST_PRODOM REPEAT DNA BINDING INTERMEDIATE FILAMENT HEPTAD PD000422: E585-R778, R622- R785 TYPE B REPEAT REPEAT DM05511 BLAST_DOMO |S26650|1-1203: E444-T727, K482-R785, R539- R787 |P18583|113-1296: E444-T727, G488-R785, D384-K657, R539-R787

[0512] TABLE 4 Polynucleotide SEQ ID NO:/ Incyte ID/Sequence Length Sequence Fragments 24/71230017CB1/ 1-236, 1-266, 16-634, 230-686, 243-825, 259-932, 487-759, 513-969, 677-939, 677-1275, 677-1294, 847-1117, 908- 3332 1017, 938-1287, 974-1510, 1018-1071, 1018-1255, 1028-1572, 1031-1265, 1040-1677, 1052-1672, 1168-1716, 1218- 1836, 1286-1803, 1312-1757, 1354-1734, 1354-1954, 1491-2101, 1494-1950, 1496-2141, 1514-1754, 1514-2053, 1533-1733, 1533-1817, 1555-1848, 1591-1876, 1651-2255, 1651-2296, 1673-2296, 1736-2279, 1741-1962, 1746- 2323, 1756-2247, 1757-2361, 1768-2383, 1783-1980, 1796-2429, 1816-2020, 1843-2163, 1845-2482, 1850-2515, 1916-2500, 1923-2581, 1963-2252, 1971-2616, 1978-2161, 1995~2516, 2009-2648, 2013-2679, 2020-2185, 2023- 2430, 2034-2672, 2069-2453, 2072-2229, 2079-2341, 2079~2586, 2084-2610, 2092-2367, 2092-2379, 2100-2680, 2106-2556, 2111-2712, 2122-2672, 2147-2769, 2163-2808, 2167-2731, 2187-2737, 2193-2438, 2199-2410, 2199- 2414, 2229-2756, 2253-2864, 2271-2564, 2286-2850, 2286-2861, 2391-2951, 2438-3228, 2439-3228, 2495-3228, 2497-3249, 2620-3012, 2624-3193, 2627-2873, 2628-2931, 2629-3244, 2632-2895, 2650-2896, 2651-2928, 2651-3143, 2652-3130, 2675-3267, 2677-3256, 2682-3231, 2683-3256, 2689-3266, 2692-3237, 2708- 3080, 2734-2977, 2734-3067, 2744-3013, 2747-3 193, 2776-3085, 2793-3090, 2803-3002, 2804-3063, 2817-3273, 2818-3085, 2837-3139, 2850-3276, 2851-3273, 2854-3065, 2854-3273, 2861-3101, 2871-3280, 2874-3101, 2876- 3167, 2878-3276, 2880-3108, 2908-3284, 2919-3270, 2935-3277, 2958-3276, 2960-3275, 2995-3248, 3031-3332, 3036-3273, 3039-3276, 3047-3273, 3097-3322 25/3125036CB1/ 1-134, 1-3732, 285-772, 285-774, 285-779, 288-583, 302-578, 425-797, 525-797, 706-857, 852-901, 854-1003, 1395- 4410 3393, 1487-2022, 2023-2309, 2023-3501, 2029-2146, 2138-2386, 21382628, 2184-2445, 2185-2735, 2185-2767, 2449-2614, 2469-2688, 2469-2941, 2614-2730, 2651-3318, 2674-3318, 26953001, 2695-3096, 2695-3151, 2726- 3214, 2737-3341, 2740-3328, 2794-3333, 2799-3341, 2826-293 1, 2868-3418, 2899-3408, 2927-3188, 2927-3362, 2927-3364, 2927-3404, 2927-3423, 2986-3141, 2986-3558, 2988-3512, 3006-3226, 3006-3499, 3020-3695, 3043- 3250, 3063-3334, 3075-3612, 3100-3457, 3127-3377, 3127-3379, 3127-3393, 3151-3413, 3179-3732, 3181-3705, 3190-3368, 3195-3492, 3216-3404, 3236-3733, 3240-3526, 3242-3922, 3247-3732, 3254-3724, 3339-3732, 3341- 3928, 3362-3732, 3436-3732, 3447-3539, 3449-4037, 3530-3603, 3530-3604, 3530-3605, 3530-3710, 3530-3732, 3530-3733, 3531-3603, 3565-3732, 3733-4201, 3802-4376, 3879-4410, 3884-4410, 3924-4084, 3939-4404, 3946- 4410, 3991-4409, 3991-4410, 4043-4409, 4169-4344, 4189-4410, 4241-4344 26/1758089CB1/ 1-625, 13-519, 19-673, 45-539, 45-540, 117-434, 157-760, 157-882, 161-383, 176-896, 227-839, 316-931, 401- 5032 1057, 401-1061, 401-1065, 401-1098, 430-467, 539-718, 555-1108, 603-1147, 611-1311, 717-1311, 797-1214, 921- 1535, 929-1558, 961-1114, 1028-5022, 1049-1311, 1207-1861, 1312-1360, 1312-1490, 1312-1861, 1334-2183, 1351- 1996, 1391-1623, 1459-1966, 1537-2141, 1546-1805, 1673-2193, 1726-2275, 1745-2183, 1799-2499, 1857-2370, 1910-2509, 1916-2509, 2011-2254, 2024-2568, 2097-2748, 2112-2632, 2398-2746, 2399-3091, 2421-3010, 2746- 2934, 2798-2934, 2839-3320, 2911-3163, 2923-3023, 2933-3097, 2983-3236, 3001-3634, 3102-3574, 3102-3642, 3120-3489, 3123-3715, 3227-3487, 3297-3871, 3395-3690, 3403-3659, 3403-3857, 3432-3857, 3461-3855, 3466- 3859, 3475-3857, 3502-3861, 3533-3763-3533-3857, 3557-3857, 3596-4142, 3616-4212, 3621-3863, 3648-3895, 3666-4096, 3666-4302, 3668-4015, 3668-4121, 3668-4136, 3673-3826, 3708-3857, 3709-4121, 3732-4060, 3739- 4089, 3739-4294, 3744-3967, 3751-4035, 3763-4069, 3764-4061, 3784-3915, 3811-4202, 38314068, 3851-4361, 3853-4054, 3853-4116, 3853-4179, 3860-4117, 3870-4149, 3872-4155, 3881-4141, 3881-4457, 3888-4491, 3922-4218, 3932-4226, 3950-4131, 3950-4229, 3969-4146, 3971-4264, 3989-4257, 3989-4506, 3992-4259, 3993- 4262, 3994-4249, 3999-4209, 4002-4239, 4015-4235, 4015-4565, 4016-4276, 4026-4338, 4028-4251, 4035-4245, 4035-4610, 4049-4241, 4052-4326, 4053-4547, 4066-4756, 4104-4191, 4105-4372, 4145-4343, 4184-4426, 4187- 4820, 4211-4832, 4224-4496, 4234-4476, 4240-4536, 4246-4523, 4270-4526, 4270-4774, 4273-4610, 4284-5021, 4292-4560, 4304-4774, 43244530, 4324-5022, 4357-4618, 4384-4701, 4389-4653, 4393-4907, 4405-4962, 4419- 5032, 4424-5032, 4425-4680, 4426-4687, 4462-5014, 4462-5032, 4469-4732, 4514-4810, 4526-5032, 4535-5032, 4562-4780, 4562-4807, 4563-4794, 4571-5032, 4574-4807, 4594-5032, 4608-4807, 4617-4808, 4662-4929, 4665- 4938, 4665-5032, 4666-5032, 4678-4807, 4703-5032, 4708-4807, 4730-4805 27/3533891CB1/ 1-660, 3-529, 3-591, 21-664, 51-302, 51-516, 51-621, 382-696, 499-624, 499-1008, 664-934, 705-912, 722-1300, 1355 723-1038, 812-1355 28/1510943CB1/ 1-550, 129-711, 153-792, 165-845, 180-845, 205-718, 233-944, 272-689, 300-936, 3 15-989, 389-828, 407-845, 416- 4912 1050, 455-654, 494-4912, 497-1030, 498-988, 646-779, 683-1065, 755-1322, 782-1028, 784-1401, 826-990, 871- 1038, 890-1038, 899-1409, 914-990, 980-1038, 989-1229, 1012-1668, 1035-1118, 1035-1140, 1035-1143, 1035- 1149, 1055-1140, 1066-1140, 1069-1243, 1073-1711, 1117-1140, 1166-1709, 1213-1660, 1249-1931, 1292-1714, 1295-1922, 1312-1896, 1333-1781, 1337-1834, 1374-1779, 1413-1672, 1452-2172, 1489-1945, 1503-1954, 1521- 1943, 1535-1571, 1535-1589, 1535-1593, 1535-1625, 1535-1680, 1535-1683, 1535-1762, 1535-1846, 1535-1935, 1535-1956, 1535-1976, 1535-1996, 1535-2015, 1539-2086, 1543-2043, 1550-2217, 1559-1948, 1563-2186, 1605- 1716, 1618-1915, 1618-2011, 1652-2186, 1685-2186, 1687-2186, 1691-1903, 1691-2186, 1697-2186, 1704-2186, 1714-2186, 1732-2034, 1742-2008, 1747-2305, 1750-2186, 1762-2186, 1772-2297, 1776-2186, 1780-2326, 1796- 2186, 1802-2368, 1805-2290, 1805-2325, 1808-1842, 1817-2270, 1827-2186, 1848-2325, 1849-1897, 1875-2380, 1902-2326, 1941-2521, 2005-2328, 2024-2271, 2055-2574, 2090-2832, 2093-2769, 2099-2338, 2106-2132, 2107- 2132, 2107-2352, 2137-2158, 2179-2805, 2182-2476, 2190-2376, 2219-2786, 2225-2509, 2240-2725, 2256-2287, 2268-2637, 2272-2378, 2313-2870, 2326-2401, 2337-2378, 2337-2392, 2345-2375, 2371-2791, 2456-3016, 2456- 3033, 2460-2502, 2460-2545, 2460-2582, 2460-2583, 2465-2545, 2465-2583, 2468-2560, 2476-2542, 2486-2583, 2487-2526, 2487-2528, 2487-2534, 2487-2542, 2492-2583, 2495-3160, 2519-2583, 2532-2591, 2551-2850, 2595- 2644, 2595-2669, 2595-2680, 2595-2718, 2598-2757, 2598-3270, 2603-2675, 2611-2669, 2611-2686, 2613-3222, 2627-2879, 2627-2884, 2627-3159, 2630-2718, 2653-2925, 2653-3186, 2668-3144, 2671-2876, 2671-2881, 2671- 2885, 2671-2889, 2787-3007, 2810-3146, 2831-3501, 2836-3444, 2857-3456, 2867-3384, 3004-3244, 3006-3427, 3010-3264, 3012-3281, 3033-3227, 3033-3365, 3051-3336, 3053-3738, 3057-3333, 3062-3121, 3062-3264, 3088- 3590, 3099-3701, 3127-3363, 3130-3668, 3138-3752, 3147-3264, 3259-3296, 3261-3779, 3282-3874, 3409-3955, 3409-3995, 28 3409-3997, 3409-4020, 3591-3666, 3640-4104, 3641-3806, 3693-4116, 3766-4041, 39214168, 3921-4303, 3970- 4453, 39834282, 3984-4096, 39844302, 3985-4453, 3994-4264, 39954176, 4003-4273, 4003-4304, 4005-4453, 4020-4253, 4020-4273, 40364249, 4036-4279, 4037-4272, 40374509, 40724317, 40814645, 4089-4309, 4098- 4453, 4106-4430, 4112-4306, 4112-4320, 41124323, 4116-4310, 4135-4425, 4140-4411, 4150-4370, 4154-4762, 4166-4430, 4187-4444, 4189-4912, 4214-4912, 4244-4420, 4244-4527, 42514912, 4254-4453, 4254-4912, 4268- 4527, 4271-4453, 4284-4908, 4305-4824, 4309-4453, 43194902, 4328-4453, 4347-4912, 4361-4466, 4363-4661, 4367-4522, 4374-4912, 4377-4657, 4420-4912, 4426-4912, 4427-4912, 4429-4912, 4430-4887, 4430-4895, 4433- 4912, 4434-4902, 4437-4896, 4437-4902, 4454-4572, 44544587, 4454-4600, 4454-4661, 4454-4695, 4454-4796, 4454-4835, 4454-4853, 4454-4859, 4454-4872, 4454-4873, 4454-4877, 4454-4882, 44544883, 4454-4887, 4454- 4897, 4454-4901, 4454-4902, 4454-4912, 4455-4885, 4461-4912, 4464-4897, 4466-4702, 4467-4871, 4471-4577, 4471-4902, 4471-4912, 4473-4912, 4474-4912, 44754912, 4476-4912, 4477-4770, 4482-4912, 4483-4912, 4486-4912, 4491-4912, 4493-4912, 4499- 4902, 4692-4731, 4788-4912, 4865-4890 29/2119377CB1/ 1-269, 1-461, 1-508, 1-515, 1-554, 1-584, 1-655, 1-707, 1-708, 1-711, 1-716, 2461, 4-577, 43-663, 69-715, 275-832, 2241 275-913, 312-1048, 331-952, 342-865, 342-915, 343-980, 364-916, 413-947, 423-935, 427-874, 450-1053, 482- 1144, 501-962, 501-1210, 552-1193, 552-1360, 560-1218, 562-1218, 567-1218, 567-1264, 591-1210, 592-1245, 593- 1221, 594-1332, 604-1249, 613-1116, 638-1317, 639-1246, 639-1254, 648-1308, 670-1034, 680-1374, 701-1375, 704-1496, 711-1431, 717-1393, 744-1603, 853-1383, 901-1444, 921-1256, 924-1435, 975-1557, 1115-1388, 1115- 1620, 1141-1754, 1370-1799, 1399-1680, 1440-2027, 1516-1990, 1560-2198, 1603-2202, 1672-2241, 1698-2218, 1699-1973, 1733-2226, 1744-2226, 1745-2226, 1748-2222, 1748-2226, 1761-2218, 1764-2215, 1780-2215, 1784- 2218, 1814-2218, 1827-2241, 1833-2226, 1853-2092, 1853-2174, 1853-2215, 1868-2241, 1897-2223, 2005-2215, 2007-2215, 2009-2215, 2138-2214 30/3176058CB1/ 1-595, 4-520, 35463, 37-181, 38-243, 41-325, 41-613, 41-727, 45-577, 75-509, 79-509, 148-863, 172-408, 173-417, 1853 173-706, 210-649, 263-875, 319-857, 320-509, 408-761, 434-1081, 506-1109, 563-826, 597-783, 597-873, 597-878, 749-1161, 843-1089, 843-1305, 843-1359, 843-1621, 875-1223, 882-1400-934-1390, 992-1244, 1071-1588, 1138- 1687, 1175-1675, 1253-1838, 1263-1459, 1271-1400, 1273-1853, 1306-1448, 1307-1750, 1445-1478, 1448-1481, 1578-1610, 1578-1611, 1756-1801 31/2299818CB1/ 1-271, 104-185, 139-393, 203-774, 292-905, 304-438, 343-438, 406-438, 409-649, 473-760, 473-788, 499-661, 503- 2541 661, 521-2541, 532-588, 551-588, 653-875, 653-890, 662-788, 662-1187, 667-890, 670-788, 891-1015, 891-1167, 903-1457, 919-1205, 924-1379, 963-1384, 970-1384, 973-1377, 986-1236, 986-1501, 1007-1526, 1021-1376, 1034- 1255, 1034-1344, 1034-1479, 1039-1301, 1059-1659, 1078-1356, 1080-1347, 1131-1671, 1174-1434, 1203-1374, 1203-1437, 1270-2061, 1290-1516, 1307-1551, 1351-1633, 1351-1635, 1351-2046, 1406-1989, 1444-1862, 1501- 2124, 1533-2109, 1533-2126, 1622-2170, 1631-1865, 1631-2092, 1637-2162, 1652-2200, 1683-1947, 1714-2293, 1718-2234, 1723-2172, 1736-2030, 1738-2320, 1750-1979, 1752-2445, 1767-2178, 1782-2001, 1823-2410, 1830- 2471, 1832-2471, 1872-2413, 1872-2426, 1893-2382, 1893-25 11, 1897-2309, 1906-2385, 1957-2485, 1975-2275, 1976-2478, 1979-2478, 1997-2238, 2048-2485, 2066-2288, 2080-2347, 2081-2524, 2093-2485, 2111-2470, 2111- 2485, 2114-2522, 2115-2361, 2132-2485, 2154-2485, 2166-2409, 2180-2528, 2182-2485, 2275-2484, 2297-2528, 2336-2481 2336-2486, 2410-2457 32/2729451CB1/ 1-495, 1-578, 1-597, 1-623, 1-696, 2-419, 2-453, 2-606, 2-640, 10-471, 12-7 14, 23-408, 72-412, 124-398, 178-712, 4144 188-473, 198-714, 254-958, 323-906, 357-862, 403-896, 47 1-697, 47 1-982, 655-1224, 739-853, 770-1030, 805- 1349, 860-1089, 860-1331, 866-1451, 903-1483, 919-1150, 925-1487, 936-1213, 946-1424, 973-1751, 980-1495, 995-1729, 997-1519, 997-1635, 1030-1738, 1090-1728, 1095-1376, 1108-1205, 1143-1595, 1173-1855, 1204-3186, 1248-1870, 1328-1493, 1337-1906, 1343-1488, 1349-1976, 1349-1978, 1349-2056, 1351-1825, 1366-1943, 1374- 2032, 1448-1753, 1460-1996, 1478-1935, 1486-2226, 1490-1721, 1508-1787, 1530-2325, 1593-2325, 1674-2325, 1698-1845, 1712-1914, 1729-2325, 1787-2325, 1810-2252, 1824-2325, 1846-2505, 1851-2517, 1863-2325, 1872- 2325, 1885-2517, 1910-2325, 1991-2126, 2005-2573, 2005-2617, 2005-2629, 2073-2517, 2100-2264, 2100-2363, 2395-3004, 2434-3004, 2528-2753, 2528-3068, 2625-2835, 2800-3351, 2800-3462, 2876-3159, 3064-3534, 3149- 3627, 3233-3505, 3235-3564, 3296-3551, 3296-3862, 3341-3802, 3431-4066, 3589-3851, 3872-4144 33/878534CB1/ 1-566, 323-571, 323-720, 323-1039, 380-1054, 393-1007, 458-1059, 460-1155, 482-922, 485-1076, 520-766, 554- 5218 1041, 559-977, 641-1205, 850-1118, 853-1386, 108 1-1354, 1135-15 11, 1295-1900, 1401-1661, 1443-1935, 1488- 1979, 1625-1818, 1634-2112, 1730-2393, 1814-2204, 1893-2503, 1929-2458, 1929-2543, 1991-2344, 1999-2693, 2050-2506, 2171-2516, 2230-2692, 2254-2565, 2255-2676, 2282-2726, 2355-2647, 2394-2567, 2401-2764, 2545- 2831, 2658-2938, 2658-3193, 2784-2980, 2827-3414, 2899-3135, 2899-3184, 2958-3212, 3018-3823, 3070-3355, 3097-3364, 3192-3523, 3204-3448, 3273-3535, 3294-3543, 3319-3576, 3319-3817, 3333-3736, 3377-3668, 3391- 3965, 3404-3736, 3517-3793, 3549-3814, 3604-3869, 3622-3861, 3637-3905, 3637-4172, 3638-4195, 3648-4025, 3648-4199, 3662-4200, 3694-3905, 3712-3933, 3713-3981, 3727-3919, 3729-3972, 3729-4246, 3827-4212, 3830- 4102, 3875-4171, 3878-4123, 3883-4107, 3885-4171, 3902-4183, 3916-4186, 3968-4530, 3990-4264, 3995-4569, 4005-4285, 4051-4186, 4068-4363, 4069-4348, 4073-4351, 4075-4239, 4117-4368, 4144-4530, 4149-4425, 4187- 4775, 4203-4364, 4203-4767, 4229-4758, 4231-4481, 4241-4391, 4254-4528, 4256-4723, 4271-4524, 4271-4534, 4298-4560, 4301-4801, 4302-4785, 4331-4590, 4331-4824, 4374- 4665, 4379-4982, 4465-4683, 4465-4996, 4495-4764, 4567-4707, 4595-4771, 4658-5218, 4690-4862, 4724-4958, 4724-5197, 4724-5214, 4725-5217, 4728-5027, 4772-5183, 4794-5217, 4798-5029, 4862-5093, 4913-5097 34/2806157CB1/ 1-602, 4-277, 16-613, 32-212, 32-486, 33-291, 34-3 10, 34-322, 34-330, 58-355, 58-649, 96-328, 100-346, 110-365, 763 473-763, 495-763 35/5883626CB1/ 1-150, 1-234, 1-250, 1-263, 1-272, 1-276, 1-278, 1-287, 8-202, 9-264, 15-590, 16-148, 17-320, 23-280, 23-594, 28- 869 525, 34-288, 34-308, 63-325, 75-561, 128-721, 139-844, 182-439, 201-448, 203-662, 235-847, 279-326, 292-601, 292-744, 350-772, 411-855, 433-856, 460-856, 522-856, 526-852, 544-856, 551-856, 586-633, 590-633, 629-671, 629-677, 768-855, 768-869, 769-866 36/2674016CB1/ 1-702, 9-245, 9-272, 9-525, 9-526, 9-547, 9-554, 9-626, 9-646, 11-459, 13-502, 13-597, 19-299, 19-393, 19-490, 23- 2875 102, 24-102, 24-219, 24-272, 24-273, 24-326, 25-102, 25-255, 25-270, 25-272, 25-273, 25-289, 25-292, 25-297, 25- 305, 25-472, 25-480, 26-269, 26-292, 27-307, 29-321, 30-320, 31-102, 31-285, 3 1-448, 33-334, 34-102, 34-261, 34- 308, 34-317, 34-381, 34-498, 34-538, 34-567, 36-282, 36-329, 36-338, 38-102, 39-3 19, 39-491, 41-248, 41-359, 45- 322, 48-335, 48-354, 50-243, 50-529, 52-301, 52-336, 55-376, 57-276, 59-285, 59-307, 63-366, 64-337, 64-407, 73- 102, 74-337, 90-375, 140-414, 144-720, 153-761, 182-345, 182-351, 182-353, 182-357, 182-370, 182-380, 182-733 182-847, 182-857, 185-787, 186-389, 200-738, 214-879, 226-952, 236-661, 251-824, 254-783, 289-955, 290-817, 294-720, 309-935, 323-963, 339-1190, 347-932, 362-877, 387-663, 388-980, 402-935, 445-720, 455-890, 458-1044, 474-773, 476-963, 477-934, 493-1132, 494-1022, 496-763, 503-789, 504-959, 5 12-738, 5 16-764, 521-826, 526-550, 531-1048, 536-1011, 538-739, 538-1037, 539-845, 542-821, 542-993, 542-1005, 546-1153, 547-993, 550-1005, 557- 1005, 564-1005, 575-993, 577-1211, 601-808, 612-821, 632-767, 650-947, 650-1091, 654-939, 668-898, 67 1-933, 808-1061, 810-1202, 897-1132, 901-1142, 1012- 1214, 1012-1232, 1012-1520, 1026-1215, 1026-1281, 1028-1702, 1099-1681, 1104-1696, 1148-1403, 1239-1710, 1246-1488, 1297-1509, 1299-1540, 1382-2042, 1384-1998, 1410-1702, 1410-1725, 1428-1981, 1455-2060, 1467- 2043, 1476-1932, 1494-1989, 1499-1766, 1499-1767, 1499-1900, 1504-1969, 1542-2186, 1570-2214, 1611-2158, 1614-2208, 1632-2167, 1641-2085, 1653-1934, 1654-2224, 1661-1932, 1672-1960, 1673-1926, 1677-1697, 1689- 2023, 1699-1959, 1705-2093, 1705-2147, 1711-1978, 1712-1992, 1713-2299, 1714-1978, 1714-1994, 1714-2010, 1714-2015, 1720-1960, 1722-1961, 1727-2050, 1735-2073, 1738-2016, 1738-2260, 1743-2000, 1743-2015, 1744- 1990, 1745-2036, 1747-2254, 1748-1917, 1748-2253, 1749-2070, 1765-2024, 1772-1998, 1779-2105, 1799-1971, 1823-2095, 1828-2094, 1829-1919, 1831-2104, 1846-2118, 1846-2421, 1867-2112, 1881-2253, 1881-2290, 1884- 2148, 1885-2150, 1889-2155, 1889-2201, 1893-2150, 1893-2159, 1893-2190, 1911-2165, 1915-2194, 1917-2302, 1918-2202, 1929-2296, 1931-2285, 1949-2242, 1973-2256, 1975-2283, 2028-2296, 2029-2300, 2032-2277, 2045-2334, 2052-2289, 2069-2276, 2082-2233, 2086-2335, 2090-2673, 2110-2302, 2149-2220, 2163-2433, 2171- 2434, 2171-2471, 2186-2875, 2207-2288, 2207-2417, 2214-2428, 2215-2442, 2216-2681, 2235-2553, 2242-2511, 2242-2710 37/5994159CB1/ 1-291, 1-354, 1-449, 1-502, 67-485, 120-365, 189-725, 215-525, 215-570, 274-528, 331-915, 359-642, 376-914, 417- 1839 899, 526-1031, 539-699, 573-629, 605-1020, 628-782, 690-950, 692-1140, 727-1222, 731-1045, 778-1373, 791- 1105, 820-1057, 829-1105, 841-1373, 856-1130, 856-1144, 856-1148, 919-1490, 933-1490, 934-1241, 1001-1315, 1012-1231, 1021-1490, 1021-1523, 1069-1587, 1140-1457, 1152-1573, 1172-1589, 1211-1816, 1235-1643, 1266- 1769, 1269-1813, 1294-1709, 1336-1839, 1387-1592, 1391-1839, 1413-1839, 1538-1839, 1706-1826, 1707-1826 38/2457335CB1/ 1-229, 1-271, 3-220, 3-224, 3-227, 3-240, 3-267, 22-278, 22-358, 25-260, 26-237, 26-259, 26-282, 26-387, 26-395, 1232 26-489, 26-558, 26-576, 32-263, 32-289, 45-644, 47-292, 84-329, 116-374, 140-554, 350-616, 578-1167, 590-1014, 600-1151, 642-1232 39/2267802CB1/ 1-479, 26-502, 34-539, 55-512, 58-496, 71-666, 79-842, 91-860, 116-705, 116-758, 116-760, 116-768, 116-775, 116- 3250 776, 116-779, 120-779, 123-779, 132-779, 142-779, 154-779, 159-779, 171-779, 212-779, 236-779, 265-779, 283- 962, 300-537, 300-620, 300-779, 352-1000, 395-779, 404-779, 632-843, 632-1078, 644-1421, 651-1152, 921-1352, 939-1243, 976-1487, 1045-1238, 1048-1352, 1090-1305, 1262-1873, 1308-1796, 1371-2096, 1380-1890, 1465- 1948, 1482-2113, 1483-2044, 1566-2019, 1628-2200, 1632-2175, 1771-2055, 1789-2352, 1799-2024, 1799-2101, 1799-2186, 1802-2040, 1867-2130, 1921-2123, 2083-2319, 2084-2369, 2084-2584, 2089-2326, 2156-2467, 2164- 2565, 2168-2755, 2175-2455, 2175-2612, 2260-2497, 2260-2758, 2299-2583, 2301-2564, 2303-2485, 2443-2719, 2501-3153, 2508-2758, 2508-2998, 2510-2754, 2510-2778, 2538-2845, 2541-2706, 2550-3239, 2558-3207, 2611- 2915, 2611-3206, 2611-3210, 2617-2892, 2630-3235, 2647-2948, 2666-2915, 2666-3234, 2670-3222, 2673-3234, 2690-3219, 2697-3231, 2730-2968, 2741-3194, 2745-3219, 2749-3016, 2754-3020, 2766-3236, 2796-3250, 2826- 3052, 2836-3113, 2863-3162, 2864-3229, 2882-3227, 2883-3241, 2885-3157, 2918-3213, 2918-3222, 2918-3250, 2935-3179, 2958-3237, 3046-3250, 3053- 3241, 3064-3250, 3075-3238 40/3212060CB1/ 1-317, 1-543, 1-591, 1-3602, 3-60, 14-296, 15-60, 17-60, 18-60, 18-662, 25-60, 28-60, 29-564, 238-995, 265-696, 3621 310-602, 330-1001, 344-883, 382-822, 420-1260, 456-912, 458-1172, 461-888, 520-1093, 540-1151, 612-1287, 616- 1100, 662-1158, 666-1390, 686-1373, 732-1433, 787-1380, 811-1400, 823-1447, 856-1430, 860-1386, 895-1223, 918-1287, 933-1409, 944-1408, 961-1576, 977-1636, 1015-1524, 1048-1602, 1052-1623, 1068-1614, 1098-1395, 1100-1758, 1159-3621, 1207-1813, 1215-1499, 1222-1517, 1243-1815, 1259-1664, 1316-1937, 1325-1852, 1331- 1835, 1352-1967, 1356-2038, 1370-1784, 1407-1590, 1411-1984, 1436-1900, 1467-1725, 1493-2057, 1510-1978, 1588-2290, 1624-2161, 1645-2097, 1645-2268, 1648-1813, 1785-2391, 1811-2373, 1821-2311, 1834-2131, 1834- 2143, 1843-2124, 1894-2346, 1897-2107, 1899-2159, 1899-2187, 1899-2288, 1899-2360, 1917-2468, 1934-2671, 1936-2276, 1961-2227, 1961-2391, 1996-2461, 2007-2315, 2026-2216, 2040-2691, 2046-2520, 2065-2391, 2098- 2391, 2105-2375, 2114-2302, 2129-2623, 2129-2669, 2130-2449, 2153-2354, 2171-2391, 2211-2391, 2218-2391, 2235-2391, 2247-2893, 2256-2805, 2274-2523, 2276-2391, 2300-2548, 2306-2646, 2306-2845, 2307-2748, 2313-2548, 2315-2391, 2348-2391, 2355-2391, 2359-2590, 2360-2826, 2391-2454, 2391-2521, 2391- 2541, 2391-2590, 2391-2600, 2391-2656, 2391-2659, 2391-2760, 2391-2850, 2391-2885, 2391-2910, 2391-2932, 2391-2949, 2391-2960, 2391-2983, 2394-2970, 2395-3038, 2397-2600, 2411-2872, 2419-2952, 2420-3009, 2442- 3034, 2449-3143, 2452-3021, 2458-2714, 2462-2639, 2503-3162, 25 16-3054, 2526-2997, 2528-2978, 2531-2868, 2545-3054, 2550-2843, 2555-2865, 2674-2868, 2679-2971, 2684-3134, 2714-2977, 2732-2931, 2732-3288, 2741- 3007, 2741-3152, 2805-3054, 2939-3137, 2945-3586, 2956-3544, 3011-3592, 3023-3295, 3025-3594, 3040-3485, 3089-3341, 3089-3580, 3089-3601, 3091-3361, 3127-3595, 3130-3602, 3136-3582, 3141-3601, 3151-3607, 3154- 3414, 3155-3573, 3155-3608, 3158-3606, 3166-3609, 3167-3481, 3167-3503, 3167-3516, 3169-3600, 3170-3270, 3181-3604, 3185-3407, 3189-3608, 3207-3611, 3233-3621, 3249-3602, 3265-3601, 3292-3573, 3376-3602, 3399- 3595, 3399-3621, 3401-3599, 3447-3601, 3490-3565, 3490-3621, 3513-3616 41/3121069CB1/ 1-270, 1-475, 1-481, 1-507, 1-514, 3-475, 134-207, 134-319, 242-319, 385-994, 515-1030, 559-920, 690-1369, 711- 1693 1161, 792-1040, 792-1460, 794-1038, 860-1119, 894-1180, 1006-1693, 1115-1407 42/3280626CB1/ 1-388, 2-120, 121 -433, 286-507, 313-720, 434-1070, 596-881, 737-1363, 738-988, 738-1159, 738-1298, 741-1425, 2289 773-1283, 802-975, 873-1558, 950-1700, 957-1485, 988-1293, 1046-1329, 1050-1384, 1096-1729, 1105-1767, 1135- 1400, 1150-1958, 1168-1784, 1208-1668, 1219-1897, 1230-1823, 1295-1965, 1342-2065, 1368-2031, 1369-1741, 1387-1787, 1443-1670, 1501-1629, 1538-2146, 1567-2289 43/484404CB1/ 1-641, 267-483, 269-311, 269-393, 269-400, 269-402, 269-455, 269-465, 269-486, 269-491, 269-500, 269-503, 269- 1304 509, 269-512, 269-519, 269-520, 269-523, 269-528, 269-531, 269-534, 269-537, 269-552, 269-555, 269-560, 269- 561, 269-562, 269-568, 269-574, 269-585, 269-600, 269-613, 269-678, 269-688, 269-713, 269-746, 269-764, 269- 769, 269-795, 269-810, 269-1287, 270-402, 270-478, 270-521, 270-534, 271-402, 271-746, 274-300, 275-516, 276- 524, 276-525, 279-591, 287-522, 287-529, 287-550, 287-580, 287-603, 292-529, 294-402, 294-540, 296-678, 297- 489, 311-494, 312-402, 312-496, 312-498, 312-505, 312-553, 312-575, 312-585, 312-677, 312-678, 312-795, 316- 835, 328-603, 386-589, 404-465, 404-501, 404-607, 404-632, 404-639, 404-646, 404-960, 404-986, 448-939, 460- 731, 466-717, 472-773, 489-678, 490-736, 492-727, 494-925, 508-780, 532-1122, 567-678, 57 1-678, 580-817, 583- 916, 584-917, 585-857, 601-678, 608-1191, 640-862, 663-1216, 664-941, 674-946, 678-1087, 689-945, 700-1287, 716-1272, 716-1304, 717-941, 719-1002, 726-980, 729-940, 731-809, 731-812, 731-875, 731-884, 731-892, 731- 907, 731-1203, 731-1276, 733-1260, 733-1285, 736-790, 738-997, 739-987, 744-939, 744-984, 744-1030, 745-1004, 745-1014, 754-946, 754-964, 771-947, 771- 1039, 783-1038, 783-1066, 783-1087, 791-1082, 791-1213, 797-1302, 800-1094, 807-1287, 810-1289, 814-980, 824- 1082, 824-1083, 831-1280, 831-1287, 836-1137, 839-1287, 839-1294, 840-1002, 847-1301, 848-1286, 850-1038, 850-1105, 851-1190, 855-1205, 856-1109, 860-1287, 879-1151, 897-919, 917-1165, 920-1188, 924-1225, 935-1037, 935-1292, 973-1291, 1035-1304, 1036-1236, 1036-1275, 1049-1302, 1071-1287, 1113-1287, 1165-1287, 1171-1287 44/2830063CB1/ 1-584, 92-315, 95-350, 95-473, 95-475, 101-742, 104-332, 106-590, 108-475, 130-487, 158-338, 234-501, 234-502, 4850 248-468, 312-473, 312-492, 312-711, 312-802, 351-803, 386-407, 444-1145, 462-1105, 624-910, 712-1029, 789- 1066, 789-1387, 873-1153, 913-1142, 963-1174, 1019-1696, 1069-1712, 1074-1508, 1103-1500, 1178-1393, 1178- 1714, 1178-1808, 1200-2046, 1225-1296, 1225-1318, 1225-1436, 1225-1439, 1225-1600, 1277-1592, 1379-1598, 1440-1504, 1440-1610, 1533-1792, 1533-2010, 1574-2151, 1581-1836, 1581-2009, 160Q-1854, 1600-1891, 1632- 1909, 1687-2117, 1695-2170, 1696-1938, 1761-2351, 1817-2345, 1817-2363, 1818-2344, 1865-2459, 1905-2446, 1914-2588, 1918-2038, 1972-2282, 2017-2637, 2021-2468, 2066-2271, 2100-2478, 2137-2536, 2153-2493, 2205- 2802, 2217-2613, 2237-2478, 2237-2494, 2237-2514, 2238-2605, 2247-2759, 2276-2635, 2280-2592, 2293-2427, 2306-2534, 2318-2893, 2327-2843, 2329-2581, 2329-2624, 2329-2648, 2338-2776, 2370-3043, 2482-2787, 2536- 2800, 2567-2808, 2617-3235, 44 2617-3405, 2627-2845, 2627-2898, 2627-2959, 2627-3078, 2627-3283, 2627-3306, 2627-3310, 2627-3315, 2627- 3339, 2627-3348, 2627-3369, 2627-3372, 2627-3405, 2629-3374, 2630-3009, 2632-2769, 2773-3593, 2803-3450, 2809-2978, 2809-3341, 2811-3305, 2830-3688, 2834-3271, 2837-3678, 2847-3607, 2903-3067, 2903-3305, 2909- 3212, 2909-3503, 2910-3626, 2917-3545, 2924-3727, 2930-3271, 2958-3543, 2971-3582, 2971-3588, 2987-3740, 2987-3756, 2993-3767, 2996-3271, 3018-3674, 3023-3861, 3024-3723, 3031-3873, 3041-327 1, 3047-3759, 3048- 3319, 3053-3390, 3064-3695, 3066-3332, 3067-3855, 3067-3908, 3078-3477, 3082-3789, 3084-3683, 3095-3919, 3114-3741, 3139-3838, 3147-3881, 3152-3713, 3156-3684, 3163-3688, 3170-3750, 3183-3776, 3190-3666, 3191- 3792, 3195-3666, 3195-3769, 3207-3827, 3210-3864, 3211-4068, 3212-3545, 3227-3778, 3237-3469, 3241-3833, 3244-3984, 3248-3991, 3259-3674, 3265-3875, 3268-4010, 3278-4120, 3282-3914, 3296-4016, 3296-4122, 3298- 4164, 3300-4135, 3301-3849, 3315-3582, 3315-3606, 3318-3991, 3319-4158, 3320-3982, 3326-3982, 3336-3911, 3337-3953, 3343-3585, 3345-3958, 3347-3818, 3350-3944, 3352-4282, 33754014, 3375-4046, 3380-4174, 3401-4034, 3401-4039, 3435-4106, 3435-4149, 3439-4134, 3454-3984, 3465-4166, 3474-4062, 3476-4238, 3481- 4096, 3481-4169, 3482-4062, 3482-4320, 3495-4191, 3531-4155, 3531-4197, 3531-4251, 3531-4269, 3531-4307, 3531-4319, 3531-4382, 3532-4312, 3536-4277, 3563-4200, 3566-4190, 35664204, 3569-3841, 3573-3613, 3590- 4295, 3592-3926, 3593-4098, 3606-4429, 3643-4447, 3656-4422, 3663-4346, 3668-4372, 3678-4318, 3688-4376, 3694-4470, 3713-4510, 3722-4377, 3729-4587, 3730-4569, 3739-4370, 3740-4329, 37464379, 3752-4355, 3759- 4435, 3762-4595, 3762-4602, 3773-4518, 3787-4427, 3787-4479, 3796-3857, 3797-4652, 3805-457 1, 3821-4651, 3831-4503, 3833-4690, 3841-4376, 3845-4678, 3854-4489, 3856-4414, 3856-4729, 38584585, 3865-4327, 3865- 4329, 3865-4426, 3865-4433, 3865-4471, 3865-4524, 38654531, 3865-4538, 3865-4578, 3865-4582, 3865-4652, 3865-4674, 3865-4680, 3865-4688, 3868-4548, 3868-4550, 3868-4758, 3872-4459, 3876-4496, 3877-4578, 3886- 4424, 3889-4738, 3891-4456, 3891-4628, 38934306, 39124777, 3926-4448, 3926-4713, 3926-4834, 3929-4834, 3933-4448, 3938-4678, 3949-4547, 3958-4834, 3960-4448, 3962-4452, 3982-4414, 3989-4834, 4000-4622, 4012-4414, 4013-4521, 4018-4834, 4024-4471, 4032-4834, 4035-4834, 4037-4834, 4044-4693, 4044-4843, 4048- 4310, 4048-4414, 4099-4827, 4144-4846, 4146-4850, 4167-4845, 4178-4657, 4187-4464, 4187-4673, 4201-4820, 4246-4813, 4252-4549, 4273-4537, 4284-4733 45/7506096CB1/ 1-4346, 1-4350, 425-841, 502-943, 503-937, 525-841, 530-943, 539-943, 650-943, 666-923, 1580-1905, 2124-2385, 4350 2125-2674, 2125-2707, 2409-2628, 2409-2881, 2409-3115, 2614-3257, 2635-2941, 2635-3036, 2635-3091, 2667- 3154, 2677-3281, 2681-3262, 2734-3273, 2739-3281, 2926-3081, 3015-3552, 3041-3396, 3742-4316, 3819-4350, 3824-4350, 3886-4350, 3931-4348, 3931-4350, 3932-4349, 3932-4350, 3983-4345, 4109-4284, 4131-4350, 4181- 4284 46/7505914CB1/ 1-702, 2-2822, 9-245, 9-272, 9-526, 9-547, 11-459, 13-597, 16-832, 19-299, 24-219, 24-271, 24-272, 24-273, 24- 2959 326, 24-619, 25-199, 25-204, 25-222, 25-270, 25-272, 25-273, 25-292, 25-305, 25-317, 25-431, 25434, 25-647, 25- 735, 25-787, 26-220, 26-255, 26-269, 26-289, 26-292, 26-297, 27-304, 27-307, 29-321, 30-298, 30-320, 30-693, 31- 285, 31-448, 33-334, 34-255, 34-261, 34-288, 34-291, 34-308, 34-317, 34-349, 34-492, 34-505, 34-538, 34-567, 34- 575, 34-635, 34-677, 34-911, 35-206, 35-272, 35-364, 36-282, 36-329, 36-338, 36-622, 36-658, 37-295, 37-301, 37- 322, 37-343, 39-276, 39-296, 39-319, 39-491, 39-600, 39-656, 39-659, 39-701, 40-296, 41-169, 41-248, 41-274, 41- 300, 41-359, 41-531, 41-557, 41-559, 41-813, 43-537, 46-295, 46-308, 47-322, 48-354, 49-335, 50-243, 50-324, 50-405, 50-529, 51-406, 52-287, 52-308, 52-311, 52-325, 53-301, 53-336, 53-344, 54-361, 55-376, 57-276, 58-865, 59-285, 59-307, 59-337, 59-886, 62-605, 63-366, 64-407, 65-232, 65-336, 65-383, 65-654, 70-581, 75-337, 76-318, 83-368, 87-634, 89-313, 90-375, 95-865, 116-715, 140-414, 140-449, 144-720, 153-761, 176-463, 184-462, 185-787, 200-735, 214-871, 218-484, 218-866, 219-459, 221-501, 223-490, 226-952, 234-475, 236-661, 243-517, 245-1009, 246-964, 251-517, 254-783, 259-596, 265-963, 268-496, 289-955, 290-817, 293-550, 294-720, 319-621, 323-963, 339-1190, 343-653, 347-932, 362-877, 363-594, 372-623, 374-619, 380-883, 387-663, 402-935, 414-702, 445-720, 455-890, 458-1044, 474-773, 475-1016, 476-959, 477-934, 46 494-1022, 496-763, 503-789, 512-738, 512-994, 516-764, 521-826, 536-1003, 537-1004, 538-739, 538-1037, 540- 845, 542-821, 542-993, 542-1005, 543-992, 546-1153, 547-993, 550-1005, 550-1171, 557-1005, 564-1005, 569- 1092, 575-993, 577-1211, 579-993, 598-1005, 599-1018, 602-808, 602-1155, 607-880, 612-821, 612-1194, 613-872, 617-1011, 621-1003, 624-1247, 632-767, 640-1242, 641-1005, 644-1167, 650-947, 650-1091, 653-1019, 654-939, 666-1073, 669-898, 671-933, 676-980, 684-1005, 685-1262, 687-1240, 702-994, 714-1005, 721-1005, 739-873, 742- 1019, 743-1019, 748-867, 748-959, 764-1069, 766-993, 768-846, 772-1113, 802-1005, 810-1061, 810-1202, 873- 1152, 934-1011, 936-1211, 947-1198, 949-1233, 957-1272, 958-1221, 960-1121, 976-1271, 981-1264, 993-1181, 1006-1283, 1012-1214, 1012-1232, 1014-1285, 1026-1215, 1026-1281, 1034-1299, 1049-1310, 1058-1303, 1083- 1287, 1095-1268, 1272-1656, 1277-1659, 1316-1539, 1328-1988, 1330-1944, 1340-1739, 1356-1634, 1361-1648, 1366-1633, 1397- 1705, 1401-2006, 1418-1682, 1422-1878, 1437-1615, 1440-1935, 1443-1711, 1445-1712, 1445-1713, 1445-1846, 1450-1915, 1471-1790, 1480-1659, 1487-1757, 1488-2132, 1495-2239, 1502-1746, 1502-1818, 1516-2160, 1527- 1831, 1539-1810, 1544-1774, 1548-1714, 1553-1829, 1553-1835, 1560-2154, 1570-1808, 1577-2226, 1580-2113, 1582-1825, 1582-2234, 1584-1802, 1587-2031, 1599-1880, 1600-2170, 1607-1790, 1613-1829, 1618-1906, 1619- 1872, 1635-1969, 1645-1905, 1651-2039, 1651-2093, 1657-1924, 1659-2147, 1660-1840, 1660-1924, 1660-1940, 1660-1956, 1660-1961, 1662-1938, 1666-1806, 1666-1906, 1668-1907, 1675-1996, 1681-2019, 1684-1962, 1686- 2199, 1689-1946, 1690-1936, 1690-1961, 1691-1982, 1693-2200, 1694-1863, 1694-2199, 1695-2016, 1715-1970, 1718-1944, 1725-2051, 1745-1917, 1769- 2041, 1774-2040, 1777-2050, 1792-2064, 1792-2367, 1813-2058, 1827-2199, 1827-2236, 1830-2094, 1831-1878, 1831-2096, 1835-2101, 1835-2147, 1839-2136, 1840-2096, 1842-2105, 1857-2111, 1861-2140, 1866-2148, 1875- 2242, 1877-2231, 1882-2130, 1895-2188, 1897-2139, 1903-2142, 1919-2202, 1923-2229, 1974-2242, 1975-2246, 1978-2223, 1986-2258, 1991-2280, 1998-2235, 2026-2146, 2028-2138, 2028-2179, 2036-2619, 2056-2248, 2085- 2204, 2109-2379, 2117-2417, 2132-2822, 2153-2363, 2157-2812, 2160-2374, 2 162-2627, 2188-2656, 2189-2586, 2190-2457, 2198-2416, 2198-2437, 2198-2496, 2199-2463, 2206-2481, 2210-2690, 2211-2461, 2211-2573, 2213- 2479, 2215-2463, 2216-2452, 2218-2516, 2220-2515, 2223-2793, 2223-2801, 2224-2428, 46 2225-2478, 2225-2542, 2228-2500, 2233-2513, 2233-2521, 2234-2496, 2235-2481, 2238-2494, 2240-2429, 2240- 2690, 2243-2492, 2243-2558, 2251-2548, 2256-2506, 2258-2725, 2261-2540, 2263-2495, 2265-2514, 2265-2538, 2290-2604, 2291-2533, 2292-2512, 2302-2876, 2304-2831, 2333-2567, 2333-2606, 2344-2482, 2344-2608, 2356- 2637, 2357-2602, 2363-2627, 2371-2627, 2380-2634, 2382-2573, 2382-2601, 2382-2616, 2382-2629, 2384-2677, 2401-2653, 2413-2689, 2418-2669, 2431-2701, 2434-2897, 2437-2666, 2437-2679, 2437-2709, 2438-2704, 2438- 2709, 2445-2710, 2448-2617, 2453-2703, 2454-2723, 2468-2719, 2478-2776, 2480-2777, 2513-2824, 2515-2791, 2533-2959, 2535-2742, 2537-2827, 2539-2801, 2550-2794, 2551-2797, 2553-2841, 2562-2842, 2573-2798, 2582- 2824, 2593-2780, 2623-2759, 2637-2843, 2672-2776

[0513] TABLE 5 Polynucleotide SEQ ID NO: Incyte Project ID: Representative Library 24 71230017CB1 LUNGNOT35 25 3125036CB1 LIVRNON08 26 1758089CB1 BRAITDR03 27 3533891CB1 HELATXT05 28 1510943CB1 OVARTUE01 29 2119377CB1 PANCNOT05 30 3176058CB1 ADRENON04 31 2299818CB1 BRABDIR01 32 2729451CB1 PROSNON01 33 878534CB1 PITUNOT03 34 2806157CB1 BLADTUT08 35 5883626CB1 LIVRNON08 36 2674016CB1 BEPINOT01 37 5994159CB1 SKINNOT05 38 2457335CB1 ENDANOT01 39 2267802CB1 EPIPNOT01 40 3212060CB1 THYMNOT08 41 3121069CB1 COLNTUT02 42 3280626CB1 STOMFET02 43 484404CB1 PROSTUT09 44 2830063CB1 TLYMNOT03 45 7506096CB1 TLYMNOT05 46 7505914CB1 TLYMTXT02

[0514] TABLE 6 Library Vector Library Description ADRENON04 PSPORT1 Normalized library was constructed from 1.36 × 1e6 independent clones from an adrenal tissue library. Starting RNA was made from adrenal gland tissue removed from a 20-year-old Caucasian male, who died from head trauma. The library was normalized in two rounds using conditions adapted from Soares et al. (PNAS (1994) 91: 9228- 9232) and Bonaldo et al. (Genome Res (1996) 6: 791-806), using a significantly longer (48-hours/round) reannealing hybridization period. BEPINOT01 PSPORT1 Library was constructed using RNA isolated from a bronchial epithelium primary cell line derived from a 54-year- old Caucasian male. BLADTUT08 pINCY Library was constructed using RNA isolated from bladder tumor tissue removed from a 72-year-old Caucasian male during a radical cystectomy and prostatectomy. Pathology indicated an invasive grade 3 (of 3) transitional cell carcinoma in the right bladder base. Patient history included pure hypercholesterolemia and tobacco abuse. Family history included myocardial infarction, cerebrovascular disease, and brain cancer. BRABDIR01 pINCY Library was constructed using RNA isolated from diseased cerebellum tissue removed from the brain of a 57-year-old Caucasian male, who died from a cerebrovascular accident. Patient history included Huntington's disease, emphysema, and tobacco abuse. BRAITDR03 PCDNA2.1 This random primed library was constructed using RNA isolated from allocortex, cingulate posterior tissue removed from a 55-year-old Caucasian female who died from cholangiocarcinoma. Pathology indicated mild meningeal fibrosis predominately over the convexities, scattered axonal spheroids in the white matter of the cingulate cortex and the thalamus, and a few scattered neurofibrillary tangles in the entorhinal cortex and the periaqueductal gray region. Pathology for the associated tumor tissue indicated well-differentiated cholangiocarcinoma of the liver with residual or relapsed tumor. Patient history included cholangiocarcinoma, post-operative Budd-Chiari syndrome, biliary ascites, hydrothorax, dehydration, malnutrition, oliguria and acute renal failure. Previous surgeries included cholecystectomy and resection of 85% of the liver. COLNTUT02 PSPORT1 Library was constructed using RNA isolated from colon tumor tissue removed from a 75-year-old Caucasian male during a hemicolectomy. Pathology indicated invasive grade 3 adenocarcinoma arising in a tubulovillous adenoma, which was distal to the ileocecal valve in the cecum. The tumor penetrated deeply into the muscularis propria but not through it. ENDANOT01 PBLUESCRIPT Library was constructed using RNA isolated from aortic endothelial cell tissue from an explanted heart removed from a male during a heart transplant. EPIPNOT01 pINCY Library was constructed using RNA isolated from prostatic epithelial cells removed from a 17-year-old Hispanic male. HELATXT05 pINCY Library was constructed using RNA isolated from a treated HeLa cell line, derived from cervical adenocarcinoma removed from a 31-year-old Black female. The cells were treated with 25 microM sodium butyrate for 24 hours. LIVRNON08 pINCY This normalized library was constructed from 5.7 million independent clones from a pooled liver tissue library. Starting RNA was made from pooled liver tissue removed from a 4-year-old Hispanic male who died from anoxia and a 16 week female fetus who died after 16-weeks gestation from anencephaly. Serologies were positive for cytolomegalovirus in the 4-year-old. Patient history included asthma in the 4-year-old. Family history included taking daily prenatal vitamins and mitral valve prolapse in the mother of the fetus. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91: 9228 and Bonaldo et al., Genome Research 6 (1996): 791, except that a significantly longer (48 hours/round) reannealing hybridization was used. LUNGNOT35 pINCY Library was constructed using RNA isolated from lung tissue removed from a 62-year-old Caucasian female. Pathology for the associated tumor tissue indicated a grade 1 spindle cell carcinoid forming a nodule. Patient history included depression, thrombophlebitis, and hyperlipidemia. Family history included cerebrovascular disease, atherosclerotic coronary artery disease, breast cancer, colon cancer, type II diabetes, and malignant skin melanoma. OVARTUE01 PCDNA2.1 This 5′ biased random primed library was constructed using RNA isolated from left ovary tumor tissue removed from a 44-year-old female. Pathology indicated grade 4 (of 4) serous carcinoma replacing both the right and left ovaries forming solid mass cystic masses. Neoplastic deposits were identified in para-ovarian soft tissue. PANCNOT05 PSPORT1 Library was constructed using RNA isolated from the pancreatic tissue of a 2-year-old Hispanic male who died from cerebral anoxia. PITUNOT03 PSPORT1 Library was constructed using RNA isolated from pituitary tissue of a 46-year-old Caucasian male, who died from colon cancer. Serologies were negative. Patient history included arthritis, peptic ulcer disease, and tobacco use. Patient medications included Tagamet and muscle relaxants. PROSNON01 PSPORT1 This normalized prostate library was constructed from 4.4 M independent clones from a prostate library. Starting RNA was made from prostate tissue removed from a 28-year-old Caucasian male who died from a self-inflicted gunshot wound. The normalization and hybridization conditions were adapted from Soares, M. B. et al. (1994) Proc. Natl. Acad. Sci. USA 91: 9228-9232, using a longer (19 hour) reannealing hybridization period. PROSTUT09 pINCY Library was constructed using RNA isolated from prostate tumor tissue removed from a 66-year-old Caucasian male during a radical prostatectomy, radical cystectomy, and urinary diversion. Pathology indicated grade 3 transitional cell carcinoma. The patient presented with prostatic inflammatory disease. Patient history included lung neoplasm, and benign hypertension. Family history included a malignant breast neoplasm, tuberculosis, cerebrovascular disease, atherosclerotic coronary artery disease and lung cancer. SKINNOT05 pINCY Library was constructed using RNA isolated from skin tissue removed from a Caucasian male fetus, who died from Patau's syndrome (trisomy 13) at 20-weeks' gestation. STOMFET02 pINCY Library was constructed using RNA isolated from stomach tissue removed from a Hispanic male fetus, who died at 18 weeks' gestation. THYMNOT08 pINCY Library was constructed using RNA isolated from thymus tissue removed from a 4-month-old Caucasian male during a total thymectomy and open heart repair of atrioventricular canal defect using hypothermia. Pathology indicated a grossly normal thymus. The patient presented with a congenital heart anomaly, congestive heart failure, and Down's syndrome. Patient history included abnormal thyroid function study and premature birth. Previous procedures included right and left heart angiocardiography. Patient medications included Digoxin, Synthroid, and Lasix. TLYMNOT03 pINCY Library was constructed using RNA isolated from nonactivated Th1 cells. These cells were differentiated from umbilical cord CD4 T cells with IL-12 and B7-transfected COS cells. TLYMNOT05 pINCY Library was constructed using RNA isolated from nonactivated Th2 cells. These cells were differentiated from umbilical cord CD4 T cells with IL-4 in the presence of anti-IL-12 antibodies and B7-transfected COS cells. TLYMTXT02 pINCY Library was constructed using RNA isolated from CD4+ T cells obtained from a pool of donors. The cells were treated with CD3 antibodies.

[0515] TABLE 7 Program Description Reference Parameter Threshold ABI A program that removes Applied Biosystems, Foster City, CA. FACTURA vector sequences and masks ambiguous bases in nucleic acid sequences. ABI/ A Fast Data Finder Applied Biosystems, Foster City, CA; Mismatch < 50% PARA- useful in comparing and Paracel Inc., Pasadena, CA. CEL annotating amino acid or FDF nucleic acid sequences. ABI A program that assembles Applied Biosystems, Foster City, CA. Auto- nucleic acid sequences. Assembler BLAST A Basic Local Alignment Altschul, S. F. et al. (1990) J. Mol. Biol. ESTs: Probability value = 1.0E−8 Search Tool useful in 215: 403-410; Altschul, S. F. et al. (1997) or less sequence similarity search Nucleic Acids Res. 25: 3389-3402. Full Length sequences: Probability for amino acid and value = 1.0E−10 or less nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx. FASTA A Pearson and Lipman Pearson, W. R. and D. J. Lipman (1988) Proc. ESTs: fasta E value = 1.06E−6 algorithm that searches for Natl. Acad Sci. USA 85: 2444-2448; Pearson, W. R. Assembled ESTs: fasta Identity = 95% similarity between a query (1990) Methods Enzymol. 183: 63-98; or greater and sequence and a group and Smith, T. F. and M. S. Waterman (1981) Match length = 200 bases or greater; of sequences of the same Adv. Appl. Math. 2: 482-489. fastx E value = 1.0E−8 or less type. FASTA comprises Full Length sequences: as least five functions: fastx score = 100 or greater fasta, tfasta, fastx, tfastx, and ssearch. BLIMPS A BLocks IMProved Henikoff, S. and J. G. Henikoff (1991) Nucleic Probability value = 1.0E−3 or less Searcher that matches a Acids Res. 19: 6565-6572; Henikoff, J. G. and sequence against those S. Henikoff (1996) Methods Enzymol. in BLOCKS, PRINTS, 266: 88-105; and Attwood, T. K. et al. (1997) J. DOMO, PRODOM, and Chem. Inf. Comput. Sci. 37: 417-424. PFAM databases to search for gene families, sequence homology, and structural fingerprint regions. HMMER An algorithm for Krogh, A. et al. (1994) J. Mol. Biol. PFAM hits: Probability value = 1.0E−3 searching a query sequence 235: 1501-1531; Sonnhammer, E. L. L. et al. or less against hidden Markov (1988) Nucleic Acids Res. 26: 320-322; Signal peptide hits: Score = 0 or model (HMM)-based Durbin, R. et al. (1998) Our World View, in a greater databases of protein Nutshell, Cambridge Univ. Press, pp. 1-350. family consensus sequences, such as PFAM. ProfileScan An algorithm that searches Gribskov, M. et al. (1988) CABIOS 4: 61-66; Normalized quality score ≧ GCG- for structural and sequence Gribskov, M. et al. (1989) Methods Enzymol. specified “HIGH” value for that motifs in protein sequences 183: 146-159; Bairoch, A. et al. (1997) particular Prosite motif. that match sequence Nucleic Acids Res. 25: 217-221. Generally, score = 1.4-2.1. patterns defined in Prosite. Phred A base-calling algorithm Ewing, B. et al. (1998) Genome Res. that examines automated 8: 175-185; Ewing, B. and P. Green sequencer traces with (1998) Genome Res. 8: 186-194. high sensitivity and probability. Phrap A Phils Revised Assembly Smith, T. F. and M. S. Waterman (1981) Adv. Score = 120 or greater; Program including SWAT and Appl. Math. 2: 482-489; Smith, T. F. and M. S. Waterman Match length = 56 or greater CrossMatch, programs (1981) J. Mol. Biol. 147: 195-197; based on efficient implementation and Green, P., University of Washington, of the Smith-Waterman Seattle, WA. algorithm, useful in searching sequence homology and assembling DNA sequences. Consed A graphical tool for Gordon, D. et al. (1998) Genome Res. 8: 195-202. viewing and editing Phrap assemblies. SPScan A weight matrix analysis Nielson, H. et al. (1997) Protein Engineering Score = 3.5 or greater program that scans protein 10: 1-6; Claverie, J. M. and S. Audic (1997) sequences for the presence CABIOS 12: 431-439. of secretory signal peptides. TMAP A program that uses Persson, B. and P. Argos (1994) J. Mol. Biol. weight matrices to delineate 237: 182-192; Persson, B. and P. Argos (1996) transmembrane segments Protein Sci. 5: 363-371. on protein sequences and determine orientation. TMHMMER A program that Sonnhammer, E. L. et al. (1998) Proc. Sixth Intl. uses a hidden Markov Conf. on Intelligent Systems for Mol. Biol., model (HMM) to delineate Glasgow et al., eds., The Am. Assoc. for Artificial transmembrane segments Intelligence Press, Menlo Park, CA, pp. 175-182. on protein sequences and determine orientation. Motifs A program that Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221; searches amino acid Wisconsin Package Program Manual, version 9, page sequences for patterns M51-59, Genetics Computer Group, Madison, WI. that matched those defined in Prosite.

[0516] TABLE 8 SEQ EST Caucasian African Asian Hispanic ID EST CBI Al- Allele Allele Amino Allele 1 Allele 1 Allele 1 Allele 1 NO: PID EST ID SNP ID SNP SNP lele 1 2 Acid frequency frequency frequency frequency 23 7505914 1243473H1 SNP00053642 20 916 T T G W235 n/a n/a n/a n/a 23 7505914 1378379H1 SNP00053642 107 916 T T G W235 n/a n/a n/a n/a 23 7505914 1892720H1 SNP00053642 246 916 T T G W235 n/a n/a n/a n/a 23 7505914 2278476H1 SNP00053642 263 916 T T G W235 n/a n/a n/a n/a 23 7505914 2926120H1 SNP00053642 148 913 T T G S234 n/a n/a n/a n/a 23 7505914 3032515H1 SNP00053642 141 912 T T G P233 n/a n/a n/a n/a 23 7505914 3249576H1 SNP00144526 24 2740 A A G noncoding n/a n/a n/a n/a 23 7505914 3902996H1 SNP00144526 19 2740 A A G noncoding n/a n/a n/a n/a 23 7505914 4723089H1 SNP00144526 23 2739 A A G noncoding n/a n/a n/a n/a 23 7505914 6199516H1 SNP00053642 423 916 T T G W235 n/a n/a n/a n/a 23 7505914 6266935H1 SNP00140788 169 2719 T T C noncoding n/a n/a n/a n/a 23 7505914 6266935H1 SNP00144526 190 2740 A A G noncoding n/a n/a n/a n/a 23 7505914 6588185H1 SNP00053642 316 916 T T G W235 n/a n/a n/a n/a 23 7505914 6830234H1 SNP00053642 305 916 G T G G235 n/a n/a n/a n/a 23 7505914 6990628H1 SNP00144526 7 2740 A A G noncoding n/a n/a n/a n/a 23 7505914 7428572H1 SNP00053642 370 916 T T G W235 n/a n/a n/a n/a 23 7505914 7684829H1 SNP00140788 219 2719 C T C noncoding n/a n/a n/a n/a 23 7505914 7684829H1 SNP00144526 240 2740 G A G noncoding n/a n/a n/a n/a 23 7505914 8618556J1 SNP00053642 611 916 T T G W235 n/a n/a n/a n/a

[0517]

1 46 1 485 PRT Homo sapiens misc_feature Incyte ID No 71230017CD1 1 Met Asp Pro Thr Ala Leu Val Glu Ala Ile Val Glu Glu Val Ala 1 5 10 15 Cys Pro Ile Cys Met Thr Phe Leu Arg Glu Pro Met Ser Ile Asp 20 25 30 Cys Gly His Ser Phe Cys His Ser Cys Leu Ser Gly Leu Trp Glu 35 40 45 Ile Pro Gly Glu Ser Gln Asn Trp Gly Tyr Thr Cys Pro Leu Cys 50 55 60 Arg Ala Pro Val Gln Pro Arg Asn Leu Arg Pro Asn Trp Gln Leu 65 70 75 Ala Asn Val Val Glu Lys Val Arg Leu Leu Arg Leu His Pro Gly 80 85 90 Met Gly Leu Lys Gly Asp Leu Cys Glu Arg His Gly Glu Lys Leu 95 100 105 Lys Met Phe Cys Lys Glu Asp Val Leu Ile Met Cys Glu Ala Cys 110 115 120 Ser Gln Ser Pro Glu His Glu Ala His Ser Val Val Pro Met Glu 125 130 135 Asp Val Ala Trp Glu Tyr Lys Trp Glu Leu His Glu Ala Leu Glu 140 145 150 His Leu Lys Lys Glu Gln Glu Glu Ala Trp Lys Leu Glu Val Gly 155 160 165 Glu Arg Lys Arg Thr Ala Thr Trp Lys Ile Gln Val Glu Thr Arg 170 175 180 Lys Gln Ser Ile Val Trp Glu Phe Glu Lys Tyr Gln Arg Leu Leu 185 190 195 Glu Lys Lys Gln Pro Pro His Arg Gln Leu Gly Ala Glu Val Ala 200 205 210 Ala Ala Leu Ala Ser Leu Gln Arg Glu Ala Ala Glu Thr Met Gln 215 220 225 Lys Leu Glu Leu Asn His Ser Glu Leu Ile Gln Gln Ser Gln Val 230 235 240 Leu Trp Arg Met Ile Ala Glu Leu Lys Glu Arg Ser Gln Arg Pro 245 250 255 Val Arg Trp Met Leu Gln Asp Ile Gln Glu Val Leu Asn Arg Ser 260 265 270 Lys Ser Trp Ser Leu Gln Gln Pro Glu Pro Ile Ser Leu Glu Leu 275 280 285 Lys Thr Asp Cys Arg Val Leu Gly Leu Arg Glu Ile Leu Lys Thr 290 295 300 Tyr Ala Ala Asp Val Arg Leu Asp Pro Asp Thr Ala Tyr Ser Arg 305 310 315 Leu Ile Val Ser Glu Asp Arg Lys Arg Val His Tyr Gly Asp Thr 320 325 330 Asn Gln Lys Leu Pro Asp Asn Pro Glu Arg Phe Tyr Arg Tyr Asn 335 340 345 Ile Val Leu Gly Ser Gln Cys Ile Ser Ser Gly Arg His Tyr Trp 350 355 360 Glu Val Glu Val Gly Asp Arg Ser Glu Trp Gly Leu Gly Val Cys 365 370 375 Lys Gln Asn Val Asp Arg Lys Glu Val Val Tyr Leu Ser Pro His 380 385 390 Tyr Gly Phe Trp Val Ile Arg Leu Arg Lys Gly Asn Glu Tyr Arg 395 400 405 Ala Gly Thr Asp Glu Tyr Pro Ile Leu Ser Leu Pro Val Pro Pro 410 415 420 Arg Arg Val Gly Ile Phe Val Asp Tyr Glu Ala His Asp Ile Ser 425 430 435 Phe Tyr Asn Val Thr Asp Cys Gly Ser His Ile Phe Thr Phe Pro 440 445 450 Arg Tyr Pro Phe Pro Gly Arg Leu Leu Pro Tyr Phe Ser Pro Cys 455 460 465 Tyr Ser Ile Gly Thr Asn Asn Thr Ala Pro Leu Ala Ile Cys Ser 470 475 480 Leu Asp Gly Glu Asp 485 2 1404 PRT Homo sapiens misc_feature Incyte ID No 3125036CD1 2 Met Glu Ser Ser Ser Ser Asp Tyr Tyr Asn Lys Asp Asn Glu Glu 1 5 10 15 Glu Ser Leu Leu Ala Asn Val Ala Ser Leu Arg His Glu Leu Lys 20 25 30 Ile Thr Glu Trp Ser Leu Gln Ser Leu Gly Glu Glu Leu Ser Ser 35 40 45 Val Ser Pro Ser Glu Asn Ser Asp Tyr Ala Pro Asn Pro Ser Arg 50 55 60 Ser Glu Lys Leu Ile Leu Asp Val Gln Pro Ser His Pro Gly Leu 65 70 75 Leu Asn Tyr Ser Pro Tyr Glu Asn Val Cys Lys Ile Ser Gly Ser 80 85 90 Ser Thr Asp Phe Gln Lys Lys Pro Arg Asp Lys Met Phe Ser Ser 95 100 105 Ser Ala Pro Val Asp Gln Glu Ile Lys Ser Leu Arg Glu Lys Leu 110 115 120 Asn Lys Leu Arg Gln Gln Asn Ala Cys Leu Val Thr Gln Asn His 125 130 135 Ser Leu Met Thr Lys Phe Glu Ser Ile His Phe Glu Leu Thr Gln 140 145 150 Ser Arg Ala Lys Val Ser Met Leu Glu Ser Ala Gln Gln Gln Ala 155 160 165 Ala Ser Val Pro Ile Leu Glu Glu Gln Ile Ile Asn Leu Glu Ala 170 175 180 Glu Val Ser Ala Gln Asp Lys Val Leu Arg Glu Ala Glu Asn Lys 185 190 195 Leu Glu Gln Ser Gln Lys Met Val Ile Glu Lys Glu Gln Ser Leu 200 205 210 Gln Glu Ser Lys Glu Glu Cys Ile Lys Leu Lys Val Asp Leu Leu 215 220 225 Glu Gln Thr Lys Gln Gly Lys Arg Ala Glu Arg Gln Arg Asn Glu 230 235 240 Ala Leu Tyr Asn Ala Glu Glu Leu Ser Lys Ala Phe Gln Gln Tyr 245 250 255 Lys Lys Lys Val Ala Glu Lys Leu Glu Lys Val Lys Gly Ser Cys 260 265 270 Ala Asn Ser Val Phe Cys Ile Thr Val Tyr Ile Pro Thr Val Lys 275 280 285 Val Gln Ala Glu Glu Glu Ile Leu Glu Arg Asn Leu Thr Asn Cys 290 295 300 Glu Lys Glu Asn Lys Arg Leu Gln Glu Arg Cys Gly Leu Tyr Lys 305 310 315 Ser Glu Leu Glu Ile Leu Lys Glu Lys Leu Arg Gln Leu Lys Glu 320 325 330 Glu Asn Asn Asn Gly Lys Glu Lys Leu Arg Ile Met Ala Val Lys 335 340 345 Asn Ser Glu Val Met Ala Gln Leu Thr Glu Ser Arg Gln Ser Ile 350 355 360 Leu Lys Leu Glu Ser Glu Leu Glu Asn Lys Asp Glu Ile Leu Arg 365 370 375 Asp Lys Phe Ser Leu Met Asn Glu Asn Arg Glu Leu Lys Val Arg 380 385 390 Val Ala Ala Gln Asn Glu Arg Leu Asp Leu Cys Gln Gln Glu Ile 395 400 405 Glu Ser Ser Arg Val Glu Leu Arg Ser Leu Glu Lys Ile Ile Ser 410 415 420 Gln Leu Pro Leu Lys Arg Glu Leu Phe Gly Phe Lys Ser Tyr Leu 425 430 435 Ser Lys Tyr Gln Met Ser Ser Phe Ser Asn Lys Glu Asp Arg Cys 440 445 450 Ile Gly Cys Cys Glu Ala Asn Lys Leu Val Ile Ser Glu Leu Arg 455 460 465 Ile Lys Leu Ala Ile Lys Glu Ala Glu Ile Gln Lys Leu His Ala 470 475 480 Asn Leu Thr Ala Asn Gln Leu Ser Gln Ser Leu Ile Thr Cys Asn 485 490 495 Asp Ser Gln Glu Ser Ser Lys Leu Ser Ser Leu Glu Thr Glu Pro 500 505 510 Val Lys Leu Gly Gly His Gln Val Ala Glu Ser Val Lys Asp Gln 515 520 525 Asn Gln His Thr Met Asn Lys Gln Tyr Glu Lys Glu Arg Gln Arg 530 535 540 Leu Val Thr Gly Ile Glu Glu Leu Arg Thr Lys Leu Ile Gln Ile 545 550 555 Glu Ala Glu Asn Ser Asp Leu Lys Val Asn Met Ala His Arg Thr 560 565 570 Ser Gln Phe Gln Leu Ile Gln Glu Glu Leu Leu Glu Lys Ala Ser 575 580 585 Asn Ser Ser Lys Leu Glu Ser Glu Met Thr Lys Lys Cys Ser Gln 590 595 600 Leu Leu Thr Leu Glu Lys Gln Leu Glu Glu Lys Ile Val Ala Tyr 605 610 615 Ser Ser Ile Ala Ala Lys Asn Ala Glu Leu Glu Gln Glu Leu Met 620 625 630 Glu Lys Asn Glu Lys Ile Arg Ser Leu Glu Thr Asn Ile Asn Thr 635 640 645 Glu His Glu Lys Ile Cys Leu Ala Phe Glu Lys Ala Lys Lys Ile 650 655 660 His Leu Glu Gln His Lys Glu Met Glu Lys Gln Ile Glu Arg Val 665 670 675 Arg Gln Leu Asp Ser Ala Leu Glu Ile Cys Lys Glu Glu Leu Val 680 685 690 Leu His Leu Asn Gln Leu Glu Gly Asn Lys Glu Lys Phe Glu Lys 695 700 705 Gln Leu Lys Lys Lys Ser Glu Glu Val Tyr Cys Leu Gln Lys Glu 710 715 720 Leu Lys Ile Lys Asn His Ser Leu Gln Glu Thr Ser Glu Gln Asn 725 730 735 Val Ile Leu Gln His Thr Leu Gln Gln Gln Gln Gln Met Leu Gln 740 745 750 Gln Glu Thr Ile Arg Asn Gly Glu Leu Glu Asp Thr Gln Thr Lys 755 760 765 Leu Glu Lys Gln Val Ser Lys Leu Glu Gln Glu Leu Gln Lys Gln 770 775 780 Arg Glu Ser Ser Ala Glu Lys Leu Arg Lys Met Glu Glu Lys Cys 785 790 795 Glu Ser Ala Ala His Glu Ala Asp Leu Lys Arg Gln Lys Val Ile 800 805 810 Glu Leu Thr Gly Thr Ala Arg Gln Val Lys Ile Glu Met Asp Gln 815 820 825 Tyr Lys Glu Glu Leu Ser Lys Met Glu Lys Glu Ile Met His Leu 830 835 840 Lys Arg Asp Gly Glu Asn Lys Ala Met His Leu Ser Gln Leu Asp 845 850 855 Met Ile Leu Asp Gln Thr Lys Thr Glu Leu Glu Lys Lys Thr Asn 860 865 870 Ala Val Lys Glu Leu Glu Lys Leu Gln His Ser Thr Glu Thr Glu 875 880 885 Leu Thr Glu Ala Leu Gln Lys Arg Glu Val Leu Glu Thr Glu Leu 890 895 900 Gln Asn Ala His Gly Glu Leu Lys Ser Thr Leu Arg Gln Leu Gln 905 910 915 Glu Leu Arg Asp Val Leu Gln Lys Ala Gln Leu Ser Leu Glu Glu 920 925 930 Lys Tyr Thr Thr Ile Lys Asp Leu Thr Ala Glu Leu Arg Glu Cys 935 940 945 Lys Met Glu Ile Glu Asp Lys Lys Gln Glu Leu Leu Glu Met Asp 950 955 960 Gln Ala Leu Lys Glu Arg Asn Trp Glu Leu Lys Gln Arg Ala Ala 965 970 975 Gln Val Thr His Leu Asp Met Thr Ile Arg Glu His Arg Gly Glu 980 985 990 Met Glu Gln Lys Ile Ile Lys Leu Glu Gly Thr Leu Glu Lys Ser 995 1000 1005 Glu Leu Glu Leu Lys Glu Cys Asn Lys Gln Ile Glu Ser Leu Asn 1010 1015 1020 Asp Lys Leu Gln Asn Ala Lys Glu Gln Val Arg Glu Lys Glu Phe 1025 1030 1035 Ile Met Leu Gln Asn Glu Gln Glu Ile Ser Gln Leu Lys Lys Glu 1040 1045 1050 Ile Glu Arg Thr Gln Gln Arg Met Lys Glu Met Glu Ser Val Met 1055 1060 1065 Lys Glu Gln Glu Gln Tyr Ile Ala Thr Gln Tyr Lys Glu Ala Ile 1070 1075 1080 Asp Leu Gly Gln Glu Leu Arg Leu Thr Arg Glu Gln Val Gln Asn 1085 1090 1095 Ser His Thr Glu Leu Ala Glu Ala Arg His Gln Gln Val Gln Ala 1100 1105 1110 Gln Arg Glu Ile Glu Arg Leu Ser Ser Glu Leu Glu Asp Met Lys 1115 1120 1125 Gln Leu Ser Lys Glu Lys Asp Ala His Gly Asn His Leu Ala Glu 1130 1135 1140 Glu Leu Gly Ala Ser Lys Val Arg Glu Ala His Leu Glu Ala Arg 1145 1150 1155 Met Gln Ala Glu Ile Lys Lys Leu Ser Ala Glu Val Glu Ser Leu 1160 1165 1170 Lys Glu Ala Tyr His Met Glu Met Ile Ser His Gln Glu Asn His 1175 1180 1185 Ala Lys Trp Lys Ile Ser Ala Asp Ser Gln Lys Ser Ser Val Gln 1190 1195 1200 Gln Leu Asn Glu Gln Leu Glu Lys Ala Lys Leu Glu Leu Glu Glu 1205 1210 1215 Ala Gln Asp Thr Val Ser Asn Leu His Gln Gln Val Gln Asp Arg 1220 1225 1230 Asn Glu Val Ile Glu Ala Ala Asn Glu Ala Leu Leu Thr Lys Glu 1235 1240 1245 Ser Glu Leu Thr Arg Leu Gln Ala Lys Ile Ser Gly His Glu Lys 1250 1255 1260 Ala Glu Asp Ile Lys Phe Leu Pro Ala Pro Phe Thr Ser Pro Thr 1265 1270 1275 Glu Ile Met Pro Asp Val Gln Asp Pro Lys Phe Ala Lys Cys Phe 1280 1285 1290 His Thr Ser Phe Ser Lys Cys Thr Lys Leu Arg Arg Ser Ile Ser 1295 1300 1305 Ala Ser Asp Leu Thr Phe Lys Ile His Gly Asp Glu Asp Leu Ser 1310 1315 1320 Glu Glu Leu Leu Gln Asp Leu Lys Lys Met Gln Leu Glu Gln Pro 1325 1330 1335 Ser Thr Leu Glu Glu Ser His Lys Asn Leu Thr Tyr Thr Gln Pro 1340 1345 1350 Asp Ser Phe Lys Pro Leu Thr Tyr Asn Leu Glu Ala Asp Ser Ser 1355 1360 1365 Glu Asn Asn Asp Phe Asn Thr Leu Ser Gly Met Leu Arg Tyr Ile 1370 1375 1380 Asn Lys Glu Val Arg Leu Leu Lys Lys Ser Ser Met Gln Thr Gly 1385 1390 1395 Ala Gly Leu Asn Gln Gly Glu Asn Val 1400 3 1096 PRT Homo sapiens misc_feature Incyte ID No 1758089CD1 3 Met Gly Ser Glu Asp His Gly Ala Gln Asn Pro Ser Cys Lys Ile 1 5 10 15 Met Thr Phe Arg Pro Thr Met Glu Glu Phe Lys Asp Phe Asn Lys 20 25 30 Tyr Val Ala Tyr Ile Glu Ser Gln Gly Ala His Arg Ala Gly Leu 35 40 45 Ala Lys Ile Ile Pro Pro Lys Glu Trp Lys Pro Arg Gln Thr Tyr 50 55 60 Asp Asp Ile Asp Asp Val Val Ile Pro Ala Pro Ile Gln Gln Val 65 70 75 Val Thr Gly Gln Ser Gly Leu Phe Thr Gln Tyr Asn Ile Gln Lys 80 85 90 Lys Ala Met Thr Val Gly Glu Tyr Arg Arg Leu Ala Asn Ser Glu 95 100 105 Lys Tyr Cys Thr Pro Arg His Gln Asp Phe Asp Asp Leu Glu Arg 110 115 120 Lys Tyr Trp Lys Asn Leu Thr Phe Val Ser Pro Ile Tyr Gly Ala 125 130 135 Asp Ile Ser Gly Ser Leu Tyr Asp Asp Asp Val Ala Gln Trp Asn 140 145 150 Ile Gly Ser Leu Arg Thr Ile Leu Asp Met Val Glu Arg Glu Cys 155 160 165 Gly Thr Ile Ile Glu Gly Val Asn Thr Pro Tyr Leu Tyr Phe Gly 170 175 180 Met Trp Lys Thr Thr Phe Ala Trp His Thr Glu Asp Met Asp Leu 185 190 195 Tyr Ser Ile Asn Tyr Leu His Phe Gly Glu Pro Lys Ser Trp Tyr 200 205 210 Ala Ile Pro Pro Glu His Gly Lys Arg Leu Glu Arg Leu Ala Ile 215 220 225 Gly Phe Phe Pro Gly Ser Ser Gln Gly Cys Asp Ala Phe Leu Arg 230 235 240 His Lys Met Thr Leu Ile Ser Pro Ile Ile Leu Lys Lys Tyr Gly 245 250 255 Ile Pro Phe Ser Arg Ile Thr Gln Glu Ala Gly Glu Phe Met Ile 260 265 270 Thr Phe Pro Tyr Gly Tyr His Ala Gly Phe Asn His Gly Phe Asn 275 280 285 Cys Ala Glu Ser Thr Asn Phe Ala Thr Leu Arg Trp Ile Asp Tyr 290 295 300 Gly Lys Val Ala Thr Gln Cys Thr Cys Arg Lys Asp Met Val Lys 305 310 315 Ile Ser Met Asp Val Phe Val Arg Ile Leu Gln Pro Glu Arg Tyr 320 325 330 Glu Leu Trp Lys Gln Gly Lys Asp Leu Thr Val Leu Asp His Thr 335 340 345 Arg Pro Thr Ala Leu Thr Ser Pro Glu Leu Ser Ser Trp Ser Ala 350 355 360 Ser Arg Ala Ser Leu Lys Ala Lys Leu Leu Arg Arg Ser His Arg 365 370 375 Lys Arg Ser Gln Pro Lys Lys Pro Lys Pro Glu Asp Pro Lys Phe 380 385 390 Pro Gly Glu Gly Thr Ala Gly Ala Ala Leu Leu Glu Glu Ala Gly 395 400 405 Gly Ser Val Lys Glu Glu Ala Gly Pro Glu Val Asp Pro Glu Glu 410 415 420 Glu Glu Glu Glu Pro Gln Pro Leu Pro His Gly Arg Glu Ala Glu 425 430 435 Gly Ala Glu Glu Asp Gly Arg Gly Lys Leu Arg Pro Thr Lys Ala 440 445 450 Lys Ser Glu Arg Lys Lys Lys Ser Phe Gly Leu Leu Pro Pro Gln 455 460 465 Leu Pro Pro Pro Pro Ala His Phe Pro Ser Glu Glu Ala Leu Trp 470 475 480 Leu Pro Ser Pro Leu Glu Pro Pro Val Leu Gly Pro Gly Pro Ala 485 490 495 Ala Met Glu Glu Ser Pro Leu Pro Ala Pro Leu Asn Val Val Pro 500 505 510 Pro Glu Val Pro Ser Glu Glu Leu Glu Ala Lys Pro Arg Pro Ile 515 520 525 Ile Pro Met Leu Tyr Val Val Pro Arg Pro Gly Lys Ala Ala Phe 530 535 540 Asn Gln Glu His Val Ser Cys Gln Gln Ala Phe Glu His Phe Ala 545 550 555 Gln Lys Gly Pro Thr Trp Lys Glu Pro Val Ser Pro Met Glu Leu 560 565 570 Thr Gly Pro Glu Asp Gly Ala Ala Ser Ser Gly Ala Gly Arg Met 575 580 585 Glu Thr Lys Ala Arg Ala Gly Glu Gly Gln Ala Pro Ser Thr Phe 590 595 600 Ser Lys Leu Lys Met Glu Ile Lys Lys Ser Arg Arg His Pro Leu 605 610 615 Gly Arg Pro Pro Thr Arg Ser Pro Leu Ser Val Val Lys Gln Glu 620 625 630 Ala Ser Ser Asp Glu Glu Ala Ser Pro Phe Ser Gly Glu Glu Asp 635 640 645 Val Ser Asp Pro Asp Ala Leu Arg Pro Leu Leu Ser Leu Gln Trp 650 655 660 Lys Asn Arg Ala Ala Ser Phe Gln Ala Glu Arg Lys Phe Asn Ala 665 670 675 Ala Ala Ala Arg Thr Glu Pro Tyr Cys Ala Ile Cys Thr Leu Phe 680 685 690 Tyr Pro Tyr Cys Gln Ala Leu Gln Thr Glu Lys Glu Ala Pro Ile 695 700 705 Ala Ser Leu Gly Glu Gly Cys Pro Ala Thr Leu Pro Ser Lys Ser 710 715 720 Arg Gln Lys Thr Arg Pro Leu Ile Pro Glu Met Cys Phe Thr Ser 725 730 735 Gly Gly Glu Asn Thr Glu Pro Leu Pro Ala Asn Ser Tyr Ile Gly 740 745 750 Asp Asp Gly Thr Ser Pro Leu Ile Ala Cys Gly Lys Cys Cys Leu 755 760 765 Gln Val His Ala Ser Cys Tyr Gly Ile Arg Pro Glu Leu Val Asn 770 775 780 Glu Gly Trp Thr Cys Ser Arg Cys Ala Ala His Ala Trp Thr Ala 785 790 795 Glu Cys Cys Leu Cys Asn Leu Arg Gly Gly Ala Leu Gln Met Thr 800 805 810 Thr Asp Arg Arg Trp Ile His Val Ile Cys Ala Ile Ala Val Pro 815 820 825 Glu Ala Arg Phe Leu Asn Val Ile Glu Arg His Pro Val Asp Ile 830 835 840 Ser Ala Ile Pro Glu Gln Arg Trp Lys Leu Lys Cys Val Tyr Cys 845 850 855 Arg Lys Arg Met Lys Lys Val Ser Gly Ala Cys Ile Gln Cys Ser 860 865 870 Tyr Glu His Cys Ser Thr Ser Phe His Val Thr Cys Ala His Ala 875 880 885 Ala Gly Val Leu Met Glu Pro Asp Asp Trp Pro Tyr Val Val Ser 890 895 900 Ile Thr Cys Leu Lys His Lys Ser Gly Gly His Ala Val Gln Leu 905 910 915 Leu Arg Ala Val Ser Leu Gly Gln Val Val Ile Thr Lys Asn Arg 920 925 930 Asn Gly Leu Tyr Tyr Arg Cys Arg Val Ile Gly Ala Ala Ser Gln 935 940 945 Thr Cys Tyr Glu Val Asn Phe Asp Asp Gly Ser Tyr Ser Asp Asn 950 955 960 Leu Tyr Pro Glu Ser Ile Thr Ser Arg Asp Cys Val Gln Leu Gly 965 970 975 Pro Pro Ser Glu Gly Glu Leu Val Glu Leu Arg Trp Thr Asp Gly 980 985 990 Asn Leu Tyr Lys Ala Lys Phe Ile Ser Ser Val Thr Ser His Ile 995 1000 1005 Tyr Gln Val Glu Phe Glu Asp Gly Ser Gln Leu Thr Val Lys Arg 1010 1015 1020 Gly Asp Ile Phe Thr Leu Glu Glu Glu Leu Pro Lys Arg Val Arg 1025 1030 1035 Ser Arg Leu Ser Leu Ser Thr Gly Ala Pro Gln Glu Pro Ala Phe 1040 1045 1050 Ser Gly Glu Glu Ala Lys Ala Ala Lys Arg Pro Arg Val Gly Thr 1055 1060 1065 Pro Leu Ala Thr Glu Asp Ser Gly Arg Ser Gln Asp Tyr Val Ala 1070 1075 1080 Phe Val Glu Ser Leu Leu Gln Val Gln Gly Arg Pro Gly Ala Pro 1085 1090 1095 Phe 4 167 PRT Homo sapiens misc_feature Incyte ID No 3533891CD1 4 Met Tyr Met Gly Met Met Cys Thr Ala Lys Lys Cys Gly Ile Arg 1 5 10 15 Phe Gln Pro Pro Ala Ile Ile Leu Ile Tyr Glu Ser Glu Ile Lys 20 25 30 Gly Lys Ile Arg Gln Arg Ile Met Pro Val Arg Asn Phe Ser Lys 35 40 45 Phe Ser Asp Cys Thr Arg Ala Ala Glu Gln Leu Lys Asn Asn Pro 50 55 60 Arg His Lys Ser Tyr Leu Glu Gln Val Ser Leu Arg Gln Leu Glu 65 70 75 Lys Leu Phe Ser Phe Leu Arg Gly Tyr Leu Ser Gly Gln Ser Leu 80 85 90 Ala Glu Thr Met Glu Gln Ile Gln Arg Glu Thr Thr Ile Asp Pro 95 100 105 Glu Glu Asp Leu Asn Lys Leu Asp Asp Lys Glu Leu Ala Lys Arg 110 115 120 Lys Ser Ile Met Asp Glu Leu Phe Glu Lys Asn Gln Lys Lys Lys 125 130 135 Asp Asp Pro Asn Phe Val Tyr Asp Ile Glu Val Glu Phe Pro Gln 140 145 150 Asp Asp Gln Leu Gln Ser Cys Gly Trp Asp Thr Glu Ser Ala Asp 155 160 165 Glu Phe 5 1523 PRT Homo sapiens misc_feature Incyte ID No 1510943CD1 5 Met Thr Ser Val Trp Lys Arg Leu Gln Arg Val Gly Lys Arg Ala 1 5 10 15 Ala Lys Phe Gln Phe Val Ala Cys Tyr His Glu Leu Val Leu Glu 20 25 30 Cys Thr Lys Lys Trp Gln Pro Asp Lys Leu Val Val Val Trp Thr 35 40 45 Arg Arg Asn Arg Arg Ile Cys Ser Lys Ala His Ser Trp Gln Pro 50 55 60 Gly Ile Gln Asn Pro Tyr Arg Gly Thr Val Val Trp Met Val Pro 65 70 75 Glu Asn Val Asp Ile Ser Val Thr Leu Tyr Arg Asp Pro His Val 80 85 90 Asp Gln Tyr Glu Ala Lys Glu Trp Thr Phe Ile Ile Glu Asn Glu 95 100 105 Ser Lys Gly Gln Arg Lys Val Leu Ala Thr Ala Glu Val Asp Leu 110 115 120 Ala Arg His Ala Gly Pro Val Pro Val Gln Val Pro Leu Arg Leu 125 130 135 Arg Leu Lys Pro Lys Ser Val Lys Val Val Gln Ala Glu Leu Ser 140 145 150 Leu Thr Leu Ser Gly Val Leu Leu Arg Glu Gly Arg Ala Thr Asp 155 160 165 Asp Asp Met Gln Ser Leu Ala Ser Leu Met Ser Val Lys Pro Ser 170 175 180 Asp Val Gly Asn Leu Asp Asp Phe Ala Glu Ser Asp Glu Asp Glu 185 190 195 Ala His Gly Pro Gly Ala Pro Glu Ala Arg Ala Arg Val Pro Gln 200 205 210 Pro Asp Pro Ser Arg Glu Leu Lys Thr Leu Cys Glu Glu Glu Glu 215 220 225 Glu Gly Gln Gly Arg Pro Gln Gln Ala Val Ala Ser Pro Ser Asn 230 235 240 Ala Glu Asp Thr Ser Pro Ala Pro Val Ser Ala Pro Ala Pro Pro 245 250 255 Ala Arg Thr Ser Arg Gly Gln Gly Ser Glu Arg Ala Asn Glu Ala 260 265 270 Gly Gly Gln Val Gly Pro Glu Ala Pro Arg Pro Pro Glu Thr Ser 275 280 285 Pro Glu Met Arg Ser Ser Arg Gln Pro Ala Gln Asp Thr Ala Pro 290 295 300 Thr Pro Ala Pro Arg Leu Arg Lys Gly Ser Asp Ala Leu Arg Pro 305 310 315 Pro Val Pro Gln Gly Glu Asp Glu Val Pro Lys Ala Ser Gly Ala 320 325 330 Pro Pro Ala Gly Leu Gly Ser Ala Arg Glu Thr Gln Ala Gln Ala 335 340 345 Cys Pro Gln Glu Gly Thr Glu Ala His Gly Ala Arg Leu Gly Pro 350 355 360 Ser Ile Glu Asp Lys Gly Ser Gly Asp Pro Phe Gly Arg Gln Arg 365 370 375 Leu Lys Ala Glu Glu Met Asp Thr Glu Asp Arg Pro Glu Ala Ser 380 385 390 Gly Val Asp Thr Glu Pro Arg Ser Gly Gly Arg Glu Ala Asn Thr 395 400 405 Lys Arg Ser Gly Val Arg Ala Gly Glu Ala Glu Glu Ser Ser Ala 410 415 420 Val Cys Gln Val Asp Ala Glu Gln Arg Ser Lys Val Arg His Val 425 430 435 Asp Thr Lys Gly Pro Glu Ala Thr Gly Val Met Pro Glu Ala Arg 440 445 450 Cys Arg Gly Thr Pro Glu Ala Pro Pro Arg Gly Ser Gln Gly Arg 455 460 465 Leu Gly Val Arg Thr Arg Asp Glu Ala Pro Ser Gly Leu Ser Leu 470 475 480 Pro Pro Ala Glu Pro Ala Gly His Ser Gly Gln Leu Gly Asp Leu 485 490 495 Glu Gly Ala Arg Ala Ala Ala Gly Gln Glu Arg Glu Gly Ala Glu 500 505 510 Val Arg Gly Gly Ala Pro Gly Ile Glu Gly Thr Gly Leu Glu Gln 515 520 525 Gly Pro Ser Val Gly Ala Ile Ser Thr Arg Pro Gln Val Ser Ser 530 535 540 Trp Gln Gly Ala Leu Leu Ser Thr Ala Gln Gly Ala Ile Ser Arg 545 550 555 Gly Leu Gly Gly Trp Glu Ala Glu Ala Gly Gly Ser Gly Val Leu 560 565 570 Glu Thr Glu Thr Glu Val Val Gly Leu Glu Val Leu Gly Thr Gln 575 580 585 Glu Lys Glu Val Glu Gly Ser Gly Phe Pro Glu Thr Arg Thr Leu 590 595 600 Glu Ile Glu Ile Leu Gly Ala Leu Glu Lys Glu Ala Ala Arg Ser 605 610 615 Arg Val Leu Glu Ser Glu Val Ala Gly Thr Ala Gln Cys Glu Gly 620 625 630 Leu Glu Thr Gln Glu Thr Glu Val Gly Val Ile Glu Thr Pro Gly 635 640 645 Thr Glu Thr Glu Val Leu Gly Thr Gln Lys Thr Glu Ala Gly Gly 650 655 660 Ser Gly Val Leu Gln Thr Arg Thr Thr Ile Ala Glu Thr Glu Val 665 670 675 Leu Val Thr Gln Glu Ile Ser Gly Asp Leu Gly Pro Leu Lys Ile 680 685 690 Glu Asp Thr Ile Gln Ser Glu Met Leu Gly Thr Gln Glu Thr Glu 695 700 705 Val Glu Ala Ser Arg Val Pro Glu Ser Glu Ala Glu Gly Thr Glu 710 715 720 Ala Lys Ile Leu Gly Thr Gln Glu Ile Thr Ala Arg Asp Ser Gly 725 730 735 Val Arg Glu Ile Glu Ala Glu Ile Ala Glu Ser Asp Ile Leu Val 740 745 750 Ala Gln Glu Ile Glu Val Gly Leu Leu Gly Val Leu Gly Ile Glu 755 760 765 Thr Gly Ala Ala Glu Gly Ala Ile Leu Gly Thr Gln Glu Ile Ala 770 775 780 Ser Arg Asp Ser Gly Val Pro Gly Leu Glu Ala Asp Thr Thr Gly 785 790 795 Ile Gln Val Lys Glu Val Gly Gly Ser Glu Val Pro Glu Ile Ala 800 805 810 Thr Gly Thr Ala Glu Thr Glu Ile Leu Gly Thr Gln Glu Ile Ala 815 820 825 Ser Arg Ser Ser Gly Val Pro Gly Leu Glu Ser Glu Val Ala Gly 830 835 840 Ala Gln Glu Thr Glu Val Gly Gly Ser Gly Ile Ser Gly Pro Glu 845 850 855 Ala Gly Met Ala Glu Ala Arg Val Leu Met Thr Arg Lys Thr Glu 860 865 870 Ile Ile Val Pro Glu Ala Glu Lys Glu Glu Ala Gln Thr Ser Gly 875 880 885 Val Gln Glu Ala Glu Thr Arg Val Gly Ser Ala Leu Lys Tyr Glu 890 895 900 Ala Leu Arg Ala Pro Val Thr Gln Pro Arg Val Leu Gly Ser Gln 905 910 915 Glu Ala Lys Ala Glu Ile Ser Gly Val Gln Gly Ser Glu Thr Gln 920 925 930 Val Leu Arg Val Gln Glu Ala Glu Ala Gly Val Trp Gly Met Ser 935 940 945 Glu Gly Lys Ser Gly Ala Trp Gly Ala Gln Glu Ala Glu Met Lys 950 955 960 Val Leu Glu Ser Pro Glu Asn Lys Ser Gly Thr Phe Lys Ala Gln 965 970 975 Glu Ala Glu Ala Gly Val Leu Gly Asn Glu Lys Gly Lys Glu Ala 980 985 990 Glu Gly Ser Leu Thr Glu Ala Ser Leu Pro Glu Ala Gln Val Ala 995 1000 1005 Ser Gly Ala Gly Ala Gly Ala Pro Arg Ala Ser Ser Pro Glu Lys 1010 1015 1020 Ala Glu Glu Asp Arg Arg Leu Pro Gly Ser Gln Ala Pro Pro Ala 1025 1030 1035 Leu Val Ser Ser Ser Gln Ser Leu Leu Glu Trp Cys Gln Glu Val 1040 1045 1050 Thr Thr Gly Tyr Arg Gly Val Arg Ile Thr Asn Phe Thr Thr Ser 1055 1060 1065 Trp Arg Asn Gly Leu Ala Phe Cys Ala Ile Leu His Arg Phe Tyr 1070 1075 1080 Pro Asp Lys Ile Asp Tyr Ala Ser Leu Asp Pro Leu Asn Ile Lys 1085 1090 1095 Gln Asn Asn Lys Gln Ala Phe Asp Gly Phe Ala Ala Leu Gly Val 1100 1105 1110 Ser Arg Leu Leu Glu Pro Ala Asp Met Val Leu Leu Ser Val Pro 1115 1120 1125 Asp Lys Leu Ile Val Met Thr Tyr Leu Cys Gln Ile Arg Ala Phe 1130 1135 1140 Cys Thr Gly Gln Glu Leu Gln Leu Val Gln Leu Glu Gly Gly Gly 1145 1150 1155 Gly Ala Gly Thr Tyr Arg Val Gly Ser Ala Gln Pro Ser Pro Pro 1160 1165 1170 Asp Asp Leu Asp Ala Gly Gly Leu Ala Gln Arg Leu Arg Gly His 1175 1180 1185 Gly Ala Glu Gly Pro Gln Glu Pro Lys Glu Ala Ala Asp Arg Ala 1190 1195 1200 Asp Gly Ala Ala Pro Gly Val Ala Ser Arg Asn Ala Val Ala Gly 1205 1210 1215 Arg Ala Ser Lys Asp Gly Gly Ala Glu Ala Pro Arg Glu Ser Arg 1220 1225 1230 Pro Ala Glu Val Pro Ala Glu Gly Leu Val Asn Gly Ala Gly Ala 1235 1240 1245 Pro Gly Gly Gly Gly Val Arg Leu Arg Arg Pro Ser Val Asn Gly 1250 1255 1260 Glu Pro Gly Ser Val Pro Pro Pro Arg Ala His Gly Ser Phe Ser 1265 1270 1275 His Val Arg Asp Ala Asp Leu Leu Lys Lys Arg Arg Ser Arg Leu 1280 1285 1290 Arg Asn Ser Ser Ser Phe Ser Met Asp Asp Pro Asp Ala Gly Ala 1295 1300 1305 Met Gly Ala Ala Ala Ala Glu Gly Gln Ala Pro Asp Pro Ser Pro 1310 1315 1320 Ala Pro Gly Pro Pro Thr Ala Ala Asp Ser Gln Gln Pro Pro Gly 1325 1330 1335 Gly Ser Ser Pro Ser Glu Glu Pro Pro Pro Ser Pro Gly Glu Glu 1340 1345 1350 Ala Gly Leu Gln Arg Phe Gln Asp Thr Ser Gln Tyr Val Cys Ala 1355 1360 1365 Glu Leu Gln Ala Leu Glu Gln Glu Gln Arg Gln Ile Asp Gly Arg 1370 1375 1380 Ala Ala Glu Val Glu Met Gln Leu Arg Ser Leu Met Glu Ser Gly 1385 1390 1395 Ala Asn Lys Leu Gln Glu Glu Val Leu Ile Gln Glu Trp Phe Thr 1400 1405 1410 Leu Val Asn Lys Lys Asn Ala Leu Ile Arg Arg Gln Asp Gln Leu 1415 1420 1425 Gln Leu Leu Met Glu Glu Gln Asp Leu Glu Arg Arg Phe Glu Leu 1430 1435 1440 Leu Ser Arg Glu Leu Arg Ala Met Leu Ala Ile Glu Asp Trp Gln 1445 1450 1455 Lys Thr Ser Ala Gln Gln His Arg Glu Gln Leu Leu Leu Glu Glu 1460 1465 1470 Leu Val Ser Leu Val Asn Gln Arg Asp Glu Leu Val Arg Asp Leu 1475 1480 1485 Asp His Lys Glu Arg Ile Ala Leu Glu Glu Asp Glu Arg Leu Glu 1490 1495 1500 Arg Gly Leu Glu Gln Arg Arg Arg Lys Leu Ser Arg Gln Leu Ser 1505 1510 1515 Arg Arg Glu Arg Cys Val Leu Ser 1520 6 273 PRT Homo sapiens misc_feature Incyte ID No 2119377CD1 6 Met Gly Gln Lys Leu Ser Gly Ser Leu Lys Ser Val Glu Val Arg 1 5 10 15 Glu Pro Ala Leu Arg Pro Ala Lys Arg Glu Leu Arg Gly Ala Glu 20 25 30 Pro Gly Arg Pro Ala Arg Leu Asp Gln Leu Leu Asp Met Pro Ala 35 40 45 Ala Gly Leu Ala Val Gln Leu Arg His Ala Trp Asn Pro Glu Asp 50 55 60 Arg Ser Leu Asn Val Phe Val Lys Asp Asp Asp Arg Leu Thr Phe 65 70 75 His Arg His Pro Val Ala Gln Ser Thr Asp Gly Ile Arg Gly Lys 80 85 90 Val Gly His Ala Arg Gly Leu His Ala Trp Gln Ile Asn Trp Pro 95 100 105 Ala Arg Gln Arg Gly Thr His Ala Val Val Gly Val Ala Thr Ala 110 115 120 Arg Ala Pro Leu His Ser Val Gly Tyr Thr Ala Leu Val Gly Ser 125 130 135 Asp Ala Glu Ser Trp Gly Trp Asp Leu Gly Arg Ser Arg Leu Tyr 140 145 150 His Asp Gly Lys Asn Gln Pro Gly Val Ala Tyr Pro Ala Phe Leu 155 160 165 Gly Pro Asp Glu Ala Phe Ala Leu Pro Asp Ser Leu Leu Val Val 170 175 180 Leu Asp Met Asp Glu Gly Thr Leu Ser Phe Ile Val Asp Gly Gln 185 190 195 Tyr Leu Gly Val Ala Phe Arg Gly Leu Lys Gly Lys Lys Leu Tyr 200 205 210 Pro Val Val Ser Ala Val Trp Gly His Cys Glu Val Thr Met Arg 215 220 225 Tyr Ile Asn Gly Leu Asp Pro Glu Pro Leu Pro Leu Met Asp Leu 230 235 240 Cys Arg Arg Ser Ile Arg Ser Ala Leu Gly Arg Gln Arg Leu Gln 245 250 255 Asp Ile Ser Ser Leu Pro Leu Pro Gln Ser Leu Lys Asn Tyr Leu 260 265 270 Gln Tyr Gln 7 341 PRT Homo sapiens misc_feature Incyte ID No 3176058CD1 7 Met Asp Gly Leu Leu Asn Pro Arg Glu Ser Ser Lys Phe Ile Ala 1 5 10 15 Glu Asn Ser Arg Asp Val Phe Ile Asp Ser Gly Gly Val Arg Arg 20 25 30 Val Ala Glu Leu Leu Leu Ala Lys Ala Ala Gly Pro Glu Leu Arg 35 40 45 Val Glu Gly Trp Lys Ala Leu His Glu Leu Asn Pro Arg Ala Ala 50 55 60 Asp Glu Ala Ala Val Asn Trp Val Phe Val Thr Asp Thr Leu Asn 65 70 75 Phe Ser Phe Trp Ser Glu Gln Asp Glu His Lys Cys Val Val Arg 80 85 90 Tyr Arg Gly Lys Thr Tyr Ser Gly Tyr Trp Ser Leu Cys Ala Ala 95 100 105 Val Asn Arg Ala Leu Asp Glu Gly Ile Pro Ile Thr Ser Ala Ser 110 115 120 Tyr Tyr Ala Thr Val Thr Leu Asp Gln Val Arg Asn Ile Leu Arg 125 130 135 Ser Asp Thr Asp Val Ser Met Pro Leu Val Glu Glu Arg His Arg 140 145 150 Ile Leu Asn Glu Thr Gly Lys Ile Leu Leu Glu Lys Phe Gly Gly 155 160 165 Ser Phe Leu Asn Cys Val Arg Glu Ser Glu Asn Ser Ala Gln Lys 170 175 180 Leu Met His Leu Val Val Glu Ser Phe Pro Ser Tyr Arg Asp Val 185 190 195 Thr Leu Phe Glu Gly Lys Arg Val Ser Phe Tyr Lys Arg Ala Gln 200 205 210 Ile Leu Val Ala Asp Thr Trp Ser Val Leu Glu Gly Lys Gly Asp 215 220 225 Gly Cys Phe Lys Asp Ile Ser Ser Ile Thr Met Phe Ala Asp Tyr 230 235 240 Arg Leu Pro Gln Val Leu Ala His Leu Gly Ala Leu Lys Tyr Ser 245 250 255 Asp Asp Leu Leu Lys Lys Leu Leu Lys Gly Glu Met Leu Ser Tyr 260 265 270 Gly Asp Arg Gln Glu Val Glu Ile Arg Gly Cys Ser Leu Trp Cys 275 280 285 Val Glu Leu Ile Arg Asp Cys Leu Leu Glu Leu Ile Glu Gln Lys 290 295 300 Gly Glu Lys Pro Asn Gly Glu Ile Asn Ser Ile Leu Leu Asp Tyr 305 310 315 Tyr Leu Trp Asp Tyr Ala His Asp His Arg Glu Asp Met Lys Gly 320 325 330 Ile Pro Phe His Arg Ile Arg Cys Ile Tyr Tyr 335 340 8 341 PRT Homo sapiens misc_feature Incyte ID No 2299818CD1 8 Met Asn Phe Lys Leu Gly Asn Phe Ser Tyr Gln Lys Asn Pro Leu 1 5 10 15 Lys Leu Gly Glu Leu Gln Gly Asn His Phe Thr Val Val Leu Arg 20 25 30 Asn Ile Thr Gly Thr Asp Asp Gln Val Gln Gln Ala Met Asn Ser 35 40 45 Leu Lys Glu Ile Gly Phe Ile Asn Tyr Tyr Gly Met Gln Arg Phe 50 55 60 Gly Thr Thr Ala Val Pro Thr Tyr Gln Val Gly Arg Ala Ile Leu 65 70 75 Gln Asn Ser Trp Thr Glu Val Met Asp Leu Ile Leu Lys Pro Arg 80 85 90 Ser Gly Ala Glu Lys Gly Tyr Leu Val Lys Cys Arg Glu Glu Trp 95 100 105 Ala Lys Thr Lys Asp Pro Thr Ala Ala Leu Arg Lys Leu Pro Val 110 115 120 Lys Arg Cys Val Glu Gly Gln Leu Leu Arg Gly Leu Ser Lys Tyr 125 130 135 Gly Met Lys Asn Ile Val Ser Ala Phe Gly Ile Ile Pro Arg Asn 140 145 150 Asn Arg Leu Met Tyr Ile His Ser Tyr Gln Ser Tyr Val Trp Asn 155 160 165 Asn Met Val Ser Lys Arg Ile Glu Asp Tyr Gly Leu Lys Pro Val 170 175 180 Pro Gly Asp Leu Val Leu Lys Gly Ala Thr Ala Thr Tyr Ile Glu 185 190 195 Glu Asp Asp Val Asn Asn Tyr Ser Ile His Asp Val Val Met Pro 200 205 210 Leu Pro Gly Phe Asp Val Ile Tyr Pro Lys His Lys Ile Gln Glu 215 220 225 Ala Tyr Arg Glu Met Leu Thr Ala Asp Asn Leu Asp Ile Asp Asn 230 235 240 Met Arg His Lys Ile Arg Asp Tyr Ser Leu Ser Gly Ala Tyr Arg 245 250 255 Lys Ile Ile Ile Arg Pro Gln Asn Val Ser Trp Glu Val Val Ala 260 265 270 Tyr Asp Asp Pro Lys Ile Pro Leu Phe Asn Thr Asp Val Asp Asn 275 280 285 Leu Glu Gly Lys Thr Pro Pro Val Phe Ala Ser Glu Gly Lys Tyr 290 295 300 Arg Ala Leu Lys Met Asp Phe Ser Leu Pro Pro Ser Thr Tyr Ala 305 310 315 Thr Met Ala Ile Arg Glu Val Leu Lys Met Asp Thr Ser Ile Lys 320 325 330 Asn Gln Thr Gln Leu Asn Thr Thr Trp Leu Arg 335 340 9 1185 PRT Homo sapiens misc_feature Incyte ID No 2729451CD1 9 Met Glu Pro Asn Ser Leu Gln Trp Val Gly Ser Pro Cys Gly Leu 1 5 10 15 His Gly Pro Tyr Ile Phe Tyr Lys Ala Phe Gln Phe His Leu Glu 20 25 30 Gly Lys Pro Arg Ile Leu Ser Leu Gly Asp Phe Phe Phe Val Arg 35 40 45 Cys Thr Pro Lys Asp Pro Ile Cys Ile Ala Glu Leu Gln Leu Leu 50 55 60 Trp Glu Glu Arg Thr Ser Arg Gln Leu Leu Ser Ser Ser Lys Leu 65 70 75 Tyr Phe Leu Pro Glu Asp Thr Pro Gln Gly Arg Asn Ser Asp His 80 85 90 Gly Glu Asp Glu Val Ile Ala Val Ser Glu Lys Val Ile Val Lys 95 100 105 Leu Glu Asp Leu Val Lys Trp Val His Ser Asp Phe Ser Lys Trp 110 115 120 Arg Cys Gly Phe His Ala Gly Pro Val Lys Thr Glu Ala Leu Gly 125 130 135 Arg Asn Gly Gln Lys Glu Ala Leu Leu Lys Tyr Arg Gln Ser Thr 140 145 150 Leu Asn Ser Gly Leu Asn Phe Lys Asp Val Leu Lys Glu Lys Ala 155 160 165 Asp Leu Gly Glu Asp Glu Glu Glu Thr Asn Val Ile Val Leu Ser 170 175 180 Tyr Pro Gln Tyr Cys Arg Tyr Arg Ser Met Leu Lys Arg Ile Gln 185 190 195 Asp Lys Pro Ser Ser Ile Leu Thr Asp Gln Phe Ala Leu Ala Leu 200 205 210 Gly Gly Ile Ala Val Val Ser Arg Asn Pro Gln Ile Leu Tyr Cys 215 220 225 Arg Asp Thr Phe Asp His Pro Thr Leu Ile Glu Asn Glu Ser Ile 230 235 240 Cys Asp Glu Phe Ala Pro Asn Leu Lys Gly Arg Pro Arg Lys Lys 245 250 255 Lys Pro Cys Pro Gln Arg Arg Asp Ser Phe Ser Gly Val Lys Asp 260 265 270 Ser Asn Asn Asn Ser Asp Gly Lys Ala Val Ala Lys Val Lys Cys 275 280 285 Glu Ala Arg Ser Ala Leu Thr Lys Pro Lys Asn Asn His Asn Cys 290 295 300 Lys Lys Val Ser Asn Glu Glu Lys Pro Lys Val Ala Ile Gly Glu 305 310 315 Glu Cys Arg Ala Asp Glu Gln Ala Phe Leu Val Ala Leu Tyr Lys 320 325 330 Tyr Met Lys Glu Arg Lys Thr Pro Ile Glu Arg Ile Pro Tyr Leu 335 340 345 Gly Phe Lys Gln Ile Asn Leu Trp Thr Met Phe Gln Ala Ala Gln 350 355 360 Lys Leu Gly Gly Tyr Glu Thr Ile Thr Ala Arg Arg Gln Trp Lys 365 370 375 His Ile Tyr Asp Glu Leu Gly Gly Asn Pro Gly Ser Thr Ser Ala 380 385 390 Ala Thr Cys Thr Arg Arg His Tyr Glu Arg Leu Ile Leu Pro Tyr 395 400 405 Glu Arg Phe Ile Lys Gly Glu Glu Asp Lys Pro Leu Pro Pro Ile 410 415 420 Lys Pro Arg Lys Gln Glu Asn Ser Ser Gln Glu Asn Glu Asn Lys 425 430 435 Thr Lys Val Ser Gly Thr Lys Arg Ile Lys His Glu Ile Pro Lys 440 445 450 Ser Lys Lys Glu Lys Glu Asn Ala Pro Lys Pro Gln Asp Ala Ala 455 460 465 Glu Val Ser Ser Glu Gln Glu Lys Glu Gln Glu Thr Leu Ile Ser 470 475 480 Gln Lys Ser Ile Pro Glu Pro Leu Pro Ala Ala Asp Met Lys Lys 485 490 495 Lys Ile Glu Gly Tyr Gln Glu Phe Ser Ala Lys Pro Leu Ala Ser 500 505 510 Arg Val Asp Pro Glu Lys Asp Asn Glu Thr Asp Gln Gly Ser His 515 520 525 Ser Glu Lys Val Ala Glu Glu Ala Gly Glu Lys Gly Pro Thr Pro 530 535 540 Pro Leu Pro Ser Ala Pro Leu Ala Pro Glu Lys Asp Ser Ala Leu 545 550 555 Val Pro Gly Ala Ser Lys Gln Pro Leu Thr Ser Pro Ser Ala Leu 560 565 570 Val Asp Ser Lys Gln Glu Ser Lys Leu Cys Cys Phe Thr Glu Ser 575 580 585 Pro Glu Ser Glu Pro Gln Glu Ala Ser Phe Pro Thr Thr Gln Pro 590 595 600 Pro Leu Ala Asn Gln Asn Glu Thr Glu Asp Asp Lys Leu Pro Ala 605 610 615 Met Ala Asp Tyr Ile Ala Asn Cys Thr Val Lys Val Asp Gln Leu 620 625 630 Gly Ser Asp Asp Ile His Asn Ala Leu Lys Gln Thr Pro Lys Val 635 640 645 Leu Val Val Gln Ser Phe Asp Met Phe Lys Asp Lys Asp Leu Thr 650 655 660 Gly Pro Met Asn Glu Asn His Gly Leu Asn Tyr Thr Pro Leu Leu 665 670 675 Tyr Ser Arg Gly Asn Pro Gly Ile Met Ser Pro Leu Ala Lys Lys 680 685 690 Lys Leu Leu Ser Gln Val Ser Gly Ala Ser Leu Ser Ser Ser Tyr 695 700 705 Pro Tyr Gly Ser Pro Pro Pro Leu Ile Ser Lys Lys Lys Leu Ile 710 715 720 Ala Arg Asp Asp Leu Cys Ser Ser Leu Ser Gln Thr His His Gly 725 730 735 Gln Ser Thr Asp His Met Ala Val Ser Arg Pro Ser Val Ile Gln 740 745 750 His Val Gln Ser Phe Arg Ser Lys Pro Ser Glu Glu Arg Lys Thr 755 760 765 Ile Asn Asp Ile Phe Lys His Glu Lys Leu Ser Arg Ser Asp Pro 770 775 780 His Arg Cys Ser Phe Ser Lys His His Leu Asn Pro Leu Ala Asp 785 790 795 Ser Tyr Val Leu Lys Gln Glu Ile Gln Glu Gly Lys Asp Lys Leu 800 805 810 Leu Glu Lys Arg Ala Leu Pro His Ser His Met Pro Ser Phe Leu 815 820 825 Ala Asp Phe Tyr Ser Ser Pro His Leu His Ser Leu Tyr Arg His 830 835 840 Thr Glu His His Leu His Asn Glu Gln Thr Ser Lys Tyr Pro Ser 845 850 855 Arg Asp Met Tyr Arg Glu Ser Glu Asn Ser Ser Phe Pro Ser His 860 865 870 Arg His Gln Glu Lys Leu His Val Asn Tyr Leu Thr Ser Leu His 875 880 885 Leu Gln Asp Lys Lys Ser Ala Ala Ala Glu Ala Pro Thr Asp Asp 890 895 900 Gln Pro Thr Asp Leu Ser Leu Pro Lys Asn Pro His Lys Pro Thr 905 910 915 Gly Lys Val Leu Gly Leu Ala His Ser Thr Thr Gly Pro Gln Glu 920 925 930 Ser Lys Gly Ile Ser Gln Phe Gln Val Leu Gly Ser Gln Ser Arg 935 940 945 Asp Cys His Pro Lys Ala Cys Arg Val Ser Pro Met Thr Met Ser 950 955 960 Gly Pro Lys Lys Tyr Pro Glu Ser Leu Ser Arg Ser Gly Lys Pro 965 970 975 His His Val Arg Leu Glu Asn Phe Arg Lys Met Glu Gly Met Val 980 985 990 His Pro Ile Leu His Arg Lys Met Ser Pro Gln Asn Ile Gly Ala 995 1000 1005 Ala Arg Pro Ile Lys Arg Ser Leu Glu Asp Leu Asp Leu Val Ile 1010 1015 1020 Ala Gly Lys Lys Ala Arg Ala Val Ser Pro Leu Asp Pro Ser Lys 1025 1030 1035 Glu Val Ser Gly Lys Glu Lys Ala Ser Glu Gln Glu Ser Glu Gly 1040 1045 1050 Ser Lys Ala Ala His Gly Gly His Ser Gly Gly Gly Ser Glu Gly 1055 1060 1065 His Lys Leu Pro Leu Ser Ser Pro Ile Phe Pro Gly Leu Tyr Ser 1070 1075 1080 Gly Ser Leu Cys Asn Ser Gly Leu Asn Ser Arg Leu Pro Ala Gly 1085 1090 1095 Tyr Ser His Ser Leu Gln Tyr Leu Lys Asn Gln Thr Val Leu Ser 1100 1105 1110 Pro Leu Met Gln Pro Leu Ala Phe His Ser Leu Val Met Gln Arg 1115 1120 1125 Gly Ile Phe Thr Ser Pro Thr Asn Ser Gln Gln Leu Tyr Arg His 1130 1135 1140 Leu Ala Ala Ala Thr Pro Val Gly Ser Ser Tyr Gly Asp Leu Leu 1145 1150 1155 His Asn Ser Ile Tyr Pro Leu Ala Ala Ile Asn Pro Gln Ala Ala 1160 1165 1170 Phe Pro Ser Ser Gln Leu Ser Ser Val His Pro Ser Thr Lys Leu 1175 1180 1185 10 1042 PRT Homo sapiens misc_feature Incyte ID No 878534CD1 10 Met Ala Ala Met Ala Pro Ala Leu Thr Asp Ala Ala Ala Glu Ala 1 5 10 15 His His Ile Arg Phe Lys Leu Ala Pro Pro Ser Ser Thr Leu Ser 20 25 30 Pro Gly Ser Ala Glu Asn Asn Gly Asn Ala Asn Ile Leu Ile Ala 35 40 45 Ala Asn Gly Thr Lys Arg Lys Ala Ile Ala Ala Glu Asp Pro Ser 50 55 60 Leu Asp Phe Arg Asn Asn Pro Thr Lys Glu Asp Leu Gly Lys Leu 65 70 75 Gln Pro Leu Val Ala Ser Tyr Leu Cys Ser Asp Val Thr Ser Val 80 85 90 Pro Ser Lys Glu Ser Leu Lys Leu Gln Gly Val Phe Ser Lys Gln 95 100 105 Thr Val Leu Lys Ser His Pro Leu Leu Ser Gln Ser Tyr Glu Leu 110 115 120 Arg Ala Glu Leu Leu Gly Arg Gln Pro Val Leu Glu Phe Ser Leu 125 130 135 Glu Asn Leu Arg Thr Met Asn Thr Ser Gly Gln Thr Ala Leu Pro 140 145 150 Gln Ala Pro Val Asn Gly Leu Ala Lys Lys Leu Thr Lys Ser Ser 155 160 165 Thr His Ser Asp His Asp Asn Ser Thr Ser Leu Asn Gly Gly Lys 170 175 180 Arg Ala Leu Thr Ser Ser Ala Leu His Gly Gly Glu Met Gly Gly 185 190 195 Ser Glu Ser Gly Asp Leu Lys Gly Gly Met Thr Asn Cys Thr Leu 200 205 210 Pro His Arg Ser Leu Asp Val Glu His Thr Ile Leu Tyr Ser Asn 215 220 225 Asn Ser Thr Ala Asn Lys Ser Ser Val Asn Ser Met Glu Gln Pro 230 235 240 Ala Leu Gln Gly Ser Ser Arg Leu Ser Pro Gly Thr Asp Ser Ser 245 250 255 Ser Asn Leu Gly Gly Val Lys Leu Glu Gly Lys Lys Ser Pro Leu 260 265 270 Ser Ser Ile Leu Phe Ser Ala Leu Asp Ser Asp Thr Arg Ile Thr 275 280 285 Ala Leu Leu Arg Arg Gln Ala Asp Ile Glu Ser Arg Ala Arg Arg 290 295 300 Leu Gln Lys Arg Leu Gln Val Val Gln Ala Lys Gln Val Glu Arg 305 310 315 His Ile Gln His Gln Leu Gly Gly Phe Leu Glu Lys Thr Leu Ser 320 325 330 Lys Leu Pro Asn Leu Glu Ser Leu Arg Pro Arg Ser Gln Leu Met 335 340 345 Leu Thr Arg Lys Ala Glu Ala Ala Leu Arg Lys Ala Ala Ser Glu 350 355 360 Thr Thr Thr Ser Glu Gly Leu Ser Asn Phe Leu Lys Ser Asn Ser 365 370 375 Ile Ser Glu Glu Leu Glu Arg Phe Thr Ala Ser Gly Ile Ala Asn 380 385 390 Leu Arg Cys Ser Glu Gln Ala Phe Asp Ser Asp Val Thr Asp Ser 395 400 405 Ser Ser Gly Gly Glu Ser Asp Ile Glu Glu Glu Glu Leu Thr Arg 410 415 420 Ala Asp Pro Glu Gln Arg His Val Pro Leu Arg Arg Arg Ser Glu 425 430 435 Trp Lys Trp Ala Ala Asp Arg Ala Ala Ile Val Ser Arg Trp Asn 440 445 450 Trp Leu Gln Ala His Val Ser Asp Leu Glu Tyr Arg Ile Arg Gln 455 460 465 Gln Thr Asp Ile Tyr Lys Gln Ile Arg Ala Asn Lys Gly Leu Ile 470 475 480 Val Leu Gly Glu Val Pro Pro Pro Glu His Thr Thr Asp Leu Phe 485 490 495 Leu Pro Leu Ser Ser Glu Val Lys Thr Asp His Gly Thr Asp Lys 500 505 510 Leu Ile Glu Ser Val Ser Gln Pro Leu Glu Asn His Gly Ala Pro 515 520 525 Ile Ile Gly His Ile Ser Glu Ser Leu Ser Thr Lys Ser Cys Gly 530 535 540 Ala Leu Arg Pro Val Asn Gly Val Ile Asn Thr Leu Gln Pro Val 545 550 555 Leu Ala Asp His Ile Pro Gly Asp Ser Ser Asp Ala Glu Glu Gln 560 565 570 Leu His Lys Lys Gln Arg Leu Asn Leu Val Ser Ser Ser Ser Asp 575 580 585 Gly Thr Cys Val Ala Ala Arg Thr Arg Pro Val Leu Ser Cys Lys 590 595 600 Lys Arg Arg Leu Val Arg Pro Asn Ser Ile Val Pro Leu Ser Lys 605 610 615 Lys Val His Arg Asn Ser Thr Ile Arg Pro Gly Cys Asp Val Asn 620 625 630 Pro Ser Cys Ala Leu Cys Gly Ser Gly Ser Ile Asn Thr Met Pro 635 640 645 Pro Glu Ile His Tyr Glu Ala Pro Leu Leu Glu Arg Leu Ser Gln 650 655 660 Leu Asp Ser Cys Val His Pro Val Leu Ala Phe Pro Asp Asp Val 665 670 675 Pro Thr Ser Leu His Phe Gln Ser Met Leu Lys Ser Gln Trp Gln 680 685 690 Asn Lys Pro Phe Asp Lys Ile Lys Pro Pro Lys Lys Leu Ser Leu 695 700 705 Lys His Arg Ala Pro Met Pro Gly Ser Leu Pro Asp Ser Ala Arg 710 715 720 Lys Asp Arg His Lys Leu Val Ser Ser Phe Leu Thr Thr Ala Met 725 730 735 Leu Lys His His Thr Asp Met Ser Ser Ser Ser Tyr Leu Ala Ala 740 745 750 Thr His His Pro Pro His Ser Pro Leu Val Arg Gln Leu Ser Thr 755 760 765 Ser Ser Asp Ser Pro Ala Pro Ala Ser Ser Ser Ser Gln Val Thr 770 775 780 Ala Ser Thr Ser Gln Gln Pro Val Arg Arg Arg Arg Gly Glu Ser 785 790 795 Ser Phe Asp Ile Asn Asn Ile Val Ile Pro Met Ser Val Ala Ala 800 805 810 Thr Thr Arg Val Glu Lys Leu Gln Tyr Lys Glu Ile Leu Thr Pro 815 820 825 Ser Trp Arg Glu Val Asp Leu Gln Ser Leu Lys Gly Ser Pro Asp 830 835 840 Glu Glu Asn Glu Glu Ile Glu Asp Leu Ser Asp Ala Ala Phe Ala 845 850 855 Ala Leu His Ala Lys Cys Glu Glu Met Glu Arg Ala Arg Trp Leu 860 865 870 Trp Thr Thr Ser Val Pro Pro Gln Arg Arg Gly Ser Arg Ser Tyr 875 880 885 Arg Ser Ser Asp Gly Arg Thr Thr Pro Gln Leu Gly Ser Ala Asn 890 895 900 Pro Ser Thr Pro Gln Pro Ala Ser Pro Asp Val Ser Ser Ser His 905 910 915 Ser Leu Ser Glu Tyr Ser His Gly Gln Ser Pro Arg Ser Pro Ile 920 925 930 Ser Pro Glu Leu His Ser Ala Pro Leu Thr Pro Val Ala Arg Asp 935 940 945 Thr Leu Arg His Leu Ala Ser Glu Asp Thr Arg Cys Ser Thr Pro 950 955 960 Glu Leu Gly Leu Asp Glu Gln Ser Val Gln Pro Trp Glu Arg Arg 965 970 975 Thr Phe Pro Leu Ala His Ser Pro Gln Ala Glu Cys Glu Asp Gln 980 985 990 Leu Asp Ala Gln Glu Arg Ala Ala Arg Cys Thr Arg Arg Thr Ser 995 1000 1005 Gly Ser Lys Thr Gly Arg Glu Thr Glu Ala Ala Pro Thr Ser Pro 1010 1015 1020 Pro Ile Val Pro Leu Lys Ser Arg His Leu Val Ala Ala Ala Thr 1025 1030 1035 Ala Gln Arg Pro Thr His Arg 1040 11 86 PRT Homo sapiens misc_feature Incyte ID No 2806157CD1 11 Met Pro Lys Cys Gly Gly Val Arg Val Trp Ile Lys Asp Trp Asn 1 5 10 15 Val Ala Ser Leu Cys Pro Trp Trp Lys Gly Pro Gln Thr Val Val 20 25 30 Leu Ile Thr Pro Thr Ala Val Asn Val Glu Arg Ile Leu Ala Trp 35 40 45 Ile His His Asn Arg Val Lys Pro Ala Ala Pro Glu Ser Trp Glu 50 55 60 Ala Arg Pro Ser Leu Asp Asn Pro Cys Arg Val Thr Leu Lys Lys 65 70 75 Met Thr Ser Pro Ala Pro Val Thr Pro Arg Ser 80 85 12 138 PRT Homo sapiens misc_feature Incyte ID No 5883626CD1 12 Met Lys Met Met Val Val Leu Leu Met Leu Ser Ser Leu Ser Arg 1 5 10 15 Leu Leu Gly Leu Met Arg Pro Ser Ser Leu Arg Gln Tyr Leu Asp 20 25 30 Ser Val Pro Leu Pro Pro Cys Gln Glu Gln Gln Pro Lys Ala Ser 35 40 45 Ala Glu Leu Asp His Lys Ala Cys Tyr Leu Cys His Ser Leu Leu 50 55 60 Met Leu Ala Gly Val Val Val Ser Cys Gln Asp Ile Thr Pro Asp 65 70 75 Gln Trp Gly Glu Leu Gln Leu Leu Cys Met Gln Leu Asp Arg His 80 85 90 Ile Ser Thr Gln Ile Arg Glu Ser Pro Gln Ala Met His Arg Thr 95 100 105 Met Leu Lys Asp Leu Ala Thr Gln Thr Tyr Ile Arg Trp Gln Glu 110 115 120 Leu Leu Thr His Cys Gln Pro Gln Ala Gln Tyr Phe Ser Pro Trp 125 130 135 Lys Asp Ile 13 805 PRT Homo sapiens misc_feature Incyte ID No 2674016CD1 13 Met Trp Asp Gln Gly Gly Gln Pro Trp Gln Gln Trp Pro Leu Asn 1 5 10 15 Gln Gln Gln Trp Met Gln Ser Phe Gln His Gln Gln Asp Pro Ser 20 25 30 Gln Ile Asp Trp Ala Ala Leu Ala Gln Ala Trp Ile Ala Gln Arg 35 40 45 Glu Ala Ser Gly Gln Gln Ser Met Val Glu Gln Pro Pro Gly Met 50 55 60 Met Pro Asn Gly Gln Asp Met Ser Thr Met Glu Ser Gly Pro Asn 65 70 75 Asn His Gly Asn Phe Gln Gly Asp Ser Asn Phe Asn Arg Met Trp 80 85 90 Gln Pro Glu Trp Gly Met His Gln Gln Pro Pro His Pro Pro Pro 95 100 105 Asp Gln Pro Trp Met Pro Pro Thr Pro Gly Pro Met Asp Ile Val 110 115 120 Pro Pro Ser Glu Asp Ser Asn Ser Gln Asp Ser Gly Glu Phe Ala 125 130 135 Pro Asp Asn Arg His Ile Phe Asn Gln Asn Asn His Asn Phe Gly 140 145 150 Gly Pro Pro Asp Asn Phe Ala Val Gly Pro Val Asn Gln Phe Asp 155 160 165 Tyr Gln His Gly Ala Ala Phe Gly Pro Pro Gln Gly Gly Phe His 170 175 180 Pro Pro Tyr Trp Gln Pro Gly Pro Pro Gly Pro Pro Ala Pro Pro 185 190 195 Gln Asn Arg Arg Glu Arg Pro Ser Ser Phe Arg Asp Arg Gln Arg 200 205 210 Ser Pro Ile Ala Leu Pro Val Lys Gln Glu Pro Pro Gln Ile Asp 215 220 225 Ala Val Lys Arg Arg Thr Leu Pro Ala Trp Ile Arg Glu Gly Leu 230 235 240 Glu Lys Met Glu Arg Glu Lys Gln Lys Lys Leu Glu Lys Glu Arg 245 250 255 Met Glu Gln Gln Arg Ser Gln Leu Ser Lys Lys Glu Lys Lys Ala 260 265 270 Thr Glu Asp Ala Glu Gly Gly Asp Gly Pro Arg Leu Pro Gln Arg 275 280 285 Ser Lys Phe Asp Ser Asp Glu Glu Glu Glu Asp Thr Glu Asn Val 290 295 300 Glu Ala Ala Ser Ser Gly Lys Val Thr Arg Ser Pro Ser Pro Val 305 310 315 Pro Gln Glu Glu His Ser Asp Pro Glu Met Thr Glu Glu Glu Lys 320 325 330 Glu Tyr Gln Met Met Leu Leu Thr Lys Met Leu Leu Thr Glu Ile 335 340 345 Leu Leu Asp Val Thr Asp Glu Glu Ile Tyr Tyr Val Ala Lys Asp 350 355 360 Ala His Arg Lys Ala Thr Lys Ala Pro Ala Lys Gln Leu Ala Gln 365 370 375 Ser Ser Ala Leu Ala Ser Leu Thr Gly Leu Gly Gly Leu Gly Gly 380 385 390 Tyr Gly Ser Gly Asp Ser Glu Asp Glu Arg Ser Asp Arg Gly Ser 395 400 405 Glu Ser Ser Asp Thr Asp Asp Glu Glu Leu Arg His Arg Ile Arg 410 415 420 Gln Lys Gln Glu Ala Phe Trp Arg Lys Glu Lys Glu Gln Gln Leu 425 430 435 Leu His Asp Lys Gln Met Glu Glu Glu Lys Gln Gln Thr Glu Arg 440 445 450 Val Thr Lys Glu Met Asn Glu Phe Ile His Lys Glu Gln Asn Ser 455 460 465 Leu Ser Leu Leu Glu Ala Arg Glu Ala Asp Gly Asp Val Val Asn 470 475 480 Glu Lys Lys Arg Thr Pro Asn Glu Thr Thr Ser Val Leu Glu Pro 485 490 495 Lys Lys Glu His Lys Glu Lys Glu Lys Gln Gly Arg Ser Arg Ser 500 505 510 Gly Ser Ser Ser Ser Gly Ser Ser Ser Ser Asn Ser Arg Thr Ser 515 520 525 Ser Thr Ser Ser Thr Val Ser Ser Ser Ser Tyr Ser Ser Ser Ser 530 535 540 Gly Ser Ser Arg Thr Ser Ser Arg Ser Ser Ser Pro Lys Arg Lys 545 550 555 Lys Arg His Ser Arg Ser Arg Ser Pro Thr Ile Lys Ala Arg Arg 560 565 570 Ser Arg Ser Arg Ser Tyr Ser Arg Arg Ile Lys Ile Glu Ser Asn 575 580 585 Arg Ala Arg Val Lys Ile Arg Asp Arg Arg Arg Ser Asn Arg Asn 590 595 600 Ser Ile Glu Arg Glu Arg Arg Arg Asn Arg Ser Pro Ser Arg Glu 605 610 615 Arg Arg Arg Ser Arg Ser Arg Ser Arg Asp Arg Arg Thr Asn Arg 620 625 630 Ala Ser Arg Ser Arg Ser Arg Asp Arg Arg Lys Ile Asp Asp Gln 635 640 645 Arg Gly Asn Leu Ser Gly Asn Ser His Lys His Lys Gly Glu Ala 650 655 660 Lys Glu Gln Glu Arg Lys Lys Glu Arg Ser Arg Ser Ile Asp Lys 665 670 675 Asp Arg Lys Lys Lys Asp Lys Glu Arg Glu Arg Glu Gln Asp Lys 680 685 690 Arg Lys Glu Lys Gln Lys Arg Glu Glu Lys Asp Phe Lys Phe Ser 695 700 705 Ser Gln Asp Asp Arg Leu Lys Arg Lys Arg Glu Ser Glu Arg Thr 710 715 720 Phe Ser Arg Ser Gly Ser Ile Ser Val Lys Ile Ile Arg His Asp 725 730 735 Ser Arg Gln Asp Ser Lys Lys Ser Thr Thr Lys Asp Ser Lys Lys 740 745 750 His Ser Gly Ser Asp Ser Ser Gly Arg Ser Ser Ser Glu Ser Pro 755 760 765 Gly Ser Ser Lys Glu Lys Lys Ala Lys Lys Pro Lys His Ser Arg 770 775 780 Ser Arg Ser Val Glu Lys Ser Pro Arg Ser Gly Lys Lys Ala Ser 785 790 795 Arg Lys His Lys Ser Lys Ser Arg Ser Arg 800 805 14 426 PRT Homo sapiens misc_feature Incyte ID No 5994159CD1 14 Met Val Gly Ala Ala His Arg Ala Gln Ala Val Phe Thr Val Val 1 5 10 15 Ser Ser Glu Leu Lys Gly Met Cys Phe His Leu Pro Met Arg Thr 20 25 30 Ala Pro Ser Val Ser Val Trp Leu Glu Thr Cys Pro Ala Ser Leu 35 40 45 Leu Ser Val Leu Leu Ala Pro Val Arg Pro Pro His Arg Arg Ile 50 55 60 Ala Val Leu Val Phe Gln Ala Asp Gly Ser Val Ser Cys Lys Arg 65 70 75 Thr Asp Cys Val Asp Ser Cys Pro His Pro Ile Arg Ile Pro Gly 80 85 90 Gln Cys Cys Pro Asp Cys Ser Ala Gly Cys Thr Tyr Thr Gly Arg 95 100 105 Ile Phe Tyr Asn Asn Glu Thr Phe Pro Ser Val Leu Asp Pro Cys 110 115 120 Leu Ser Cys Ile Cys Leu Leu Gly Ser Val Ala Cys Ser Pro Val 125 130 135 Asp Cys Pro Ile Thr Cys Thr Tyr Pro Phe His Pro Asp Gly Glu 140 145 150 Cys Cys Pro Val Cys Arg Asp Cys Asn Tyr Glu Gly Arg Lys Val 155 160 165 Ala Asn Gly Gln Val Phe Thr Leu Asp Asp Glu Pro Cys Thr Arg 170 175 180 Cys Thr Cys Gln Leu Gly Glu Val Ser Cys Glu Lys Val Pro Cys 185 190 195 Gln Arg Ala Cys Ala Asp Pro Ala Leu Leu Pro Gly Asp Cys Cys 200 205 210 Ser Ser Cys Pro Asp Ser Leu Ser Pro Leu Glu Glu Lys Gln Gly 215 220 225 Leu Ser Pro His Gly Asn Val Ala Phe Ser Lys Ala Gly Arg Ser 230 235 240 Leu His Gly Asp Thr Glu Ala Pro Val Asn Cys Ser Ser Cys Pro 245 250 255 Gly Pro Pro Thr Ala Ser Pro Ser Arg Pro Val Leu His Leu Leu 260 265 270 Gln Leu Leu Leu Arg Thr Asn Leu Met Lys Thr Gln Thr Leu Pro 275 280 285 Thr Ser Pro Ala Gly Ala His Gly Pro His Ser Leu Ala Leu Gly 290 295 300 Leu Thr Ala Thr Phe Pro Gly Glu Pro Gly Ala Ser Pro Arg Leu 305 310 315 Ser Pro Gly Pro Ser Thr Pro Pro Gly Ala Pro Thr Leu Pro Leu 320 325 330 Ala Ser Pro Gly Ala Pro Gln Pro Pro Pro Val Thr Pro Glu Arg 335 340 345 Ser Phe Ser Ala Ser Gly Ala Gln Ile Val Ser Arg Trp Pro Pro 350 355 360 Leu Pro Gly Thr Leu Leu Thr Glu Ala Ser Ala Leu Ser Met Met 365 370 375 Asp Pro Ser Pro Ser Lys Thr Pro Ile Thr Leu Leu Gly Pro Arg 380 385 390 Val Leu Ser Pro Thr Thr Ser Arg Leu Ser Thr Ala Leu Ala Ala 395 400 405 Thr Thr His Pro Gly Pro Gln Gln Pro Pro Val Gly Ala Ser Arg 410 415 420 Gly Glu Glu Ser Thr Met 425 15 267 PRT Homo sapiens misc_feature Incyte ID No 2457335CD1 15 Met Tyr Leu Arg Arg Ala Val Ser Lys Thr Leu Ala Leu Pro Leu 1 5 10 15 Arg Ala Pro Pro Asn Pro Ala Pro Leu Gly Lys Asp Ala Ser Leu 20 25 30 Arg Arg Met Ser Ser Asn Arg Phe Pro Gly Ser Ser Gly Ser Asn 35 40 45 Met Ile Tyr Tyr Leu Val Val Gly Val Thr Val Ser Ala Gly Gly 50 55 60 Tyr Tyr Ala Tyr Lys Thr Val Thr Ser Asp Gln Ala Lys His Thr 65 70 75 Glu His Lys Thr Asn Leu Lys Glu Lys Thr Lys Ala Glu Ile His 80 85 90 Pro Phe Gln Gly Glu Lys Glu Asn Val Ala Glu Thr Glu Lys Ala 95 100 105 Ser Ser Glu Ala Pro Glu Glu Leu Ile Val Glu Ala Glu Val Val 110 115 120 Asp Ala Glu Glu Ser Pro Ser Ala Thr Val Val Val Ile Lys Glu 125 130 135 Ala Ser Ala Cys Pro Gly His Val Glu Ala Ala Pro Glu Thr Thr 140 145 150 Ala Val Ser Ala Glu Thr Gly Pro Glu Val Thr Asp Ala Ala Ala 155 160 165 Arg Glu Thr Thr Glu Val Asn Pro Glu Thr Thr Pro Glu Val Thr 170 175 180 Asn Ala Ala Leu Asp Glu Ala Val Thr Ile Asp Asn Asp Lys Asp 185 190 195 Thr Thr Lys Asn Glu Thr Ser Asp Glu Tyr Ala Glu Leu Glu Glu 200 205 210 Glu Asn Ser Pro Ala Glu Ser Glu Ser Ser Ala Gly Asp Asp Leu 215 220 225 Gln Glu Glu Ala Ser Val Gly Ser Glu Ala Ala Ser Ala Gln Gly 230 235 240 Asn Leu Gln Pro Val Asp Ile Ser Ala Thr Asn Ala Ile Gly Cys 245 250 255 Leu Ile Ser Ala Leu Val Phe Leu Val His Leu Val 260 265 16 928 PRT Homo sapiens misc_feature Incyte ID No 2267802CD1 16 Met Glu Gly Ala Gly Glu Asn Ala Pro Glu Ser Ser Ser Ser Ala 1 5 10 15 Pro Gly Ser Glu Glu Ser Ala Arg Asp Pro Gln Val Pro Pro Pro 20 25 30 Glu Glu Glu Ser Gly Asp Cys Ala Arg Ser Leu Glu Ala Val Pro 35 40 45 Lys Lys Leu Cys Gly Tyr Leu Ser Lys Phe Gly Gly Lys Gly Pro 50 55 60 Ile Arg Gly Trp Lys Ser Arg Trp Phe Phe Tyr Asp Glu Arg Lys 65 70 75 Cys Gln Leu Tyr Tyr Ser Arg Thr Ala Gln Asp Ala Asn Pro Leu 80 85 90 Asp Ser Ile Asp Leu Ser Ser Ala Val Phe Asp Cys Lys Ala Asp 95 100 105 Ala Glu Glu Gly Ile Phe Glu Ile Lys Thr Pro Ser Arg Val Ile 110 115 120 Thr Leu Lys Ala Ala Thr Lys Gln Ala Met Leu Tyr Trp Leu Gln 125 130 135 Gln Leu Gln Met Lys Arg Trp Glu Phe His Asn Ser Pro Pro Ala 140 145 150 Pro Pro Ala Thr Pro Asp Ala Ala Leu Ala Gly Asn Gly Pro Val 155 160 165 Leu His Leu Glu Leu Gly Gln Glu Glu Ala Glu Leu Glu Glu Phe 170 175 180 Leu Cys Pro Val Lys Thr Pro Pro Gly Leu Val Gly Val Ala Ala 185 190 195 Ala Leu Gln Pro Phe Pro Ala Leu Gln Asn Ile Ser Leu Lys His 200 205 210 Leu Gly Thr Glu Ile Gln Asn Thr Met His Asn Ile Arg Gly Asn 215 220 225 Lys Gln Ala Gln Gly Thr Gly His Glu Pro Pro Gly Glu Asp Ser 230 235 240 Thr Gln Ser Gly Glu Pro Gln Arg Glu Glu Gln Pro Ser Ala Ser 245 250 255 Asp Ala Ser Thr Pro Val Arg Glu Pro Glu Asp Ser Pro Lys Pro 260 265 270 Ala Pro Lys Pro Ser Leu Thr Ile Ser Phe Ala Gln Lys Ala Lys 275 280 285 Arg Gln Asn Asn Thr Phe Pro Phe Phe Ser Glu Gly Ile Thr Arg 290 295 300 Asn Arg Thr Ala Gln Glu Lys Val Ala Ala Leu Glu Gln Gln Val 305 310 315 Leu Met Leu Thr Lys Glu Leu Lys Ser Gln Lys Glu Leu Val Lys 320 325 330 Ile Leu His Lys Ala Leu Glu Ala Ala Gln Gln Glu Lys Arg Ala 335 340 345 Ser Ser Ala Tyr Leu Ala Ala Ala Glu Asp Lys Asp Arg Leu Glu 350 355 360 Leu Val Arg His Lys Val Arg Gln Ile Ala Glu Leu Gly Arg Arg 365 370 375 Val Glu Ala Leu Glu Gln Glu Arg Glu Ser Leu Ala His Thr Ala 380 385 390 Ser Leu Arg Glu Gln Gln Val Gln Glu Leu Gln Gln His Val Gln 395 400 405 Leu Leu Met Asp Lys Asn His Ala Glu Gln Gln Val Ile Cys Lys 410 415 420 Leu Ser Glu Lys Val Thr Gln Asp Phe Thr His Pro Pro Asp Gln 425 430 435 Ser Pro Leu Arg Pro Asp Ala Ala Asn Arg Asp Phe Leu Ser Gln 440 445 450 Gln Gly Lys Ile Glu His Leu Lys Asp Asp Met Glu Ala Tyr Arg 455 460 465 Thr Gln Asn Cys Phe Leu Asn Ser Glu Ile His Gln Val Thr Lys 470 475 480 Ile Trp Arg Lys Val Ala Glu Lys Glu Lys Ala Leu Leu Thr Lys 485 490 495 Cys Ala Tyr Leu Gln Ala Arg Asn Cys Gln Val Glu Ser Lys Tyr 500 505 510 Leu Ala Gly Leu Arg Arg Leu Gln Glu Ala Leu Gly Asp Glu Ala 515 520 525 Ser Glu Cys Ser Glu Leu Leu Arg Gln Leu Val Gln Glu Ala Leu 530 535 540 Gln Trp Glu Ala Gly Glu Ala Ser Ser Asp Ser Ile Glu Leu Ser 545 550 555 Pro Ile Ser Lys Tyr Asp Glu Tyr Gly Phe Leu Thr Val Pro Asp 560 565 570 Tyr Glu Val Glu Asp Leu Lys Leu Leu Ala Lys Ile Gln Ala Leu 575 580 585 Glu Ser Arg Ser His His Leu Leu Gly Leu Glu Ala Val Asp Arg 590 595 600 Pro Leu Arg Glu Arg Trp Ala Ala Leu Gly Asp Leu Val Pro Ser 605 610 615 Ala Glu Leu Lys Gln Leu Leu Arg Ala Gly Val Pro Arg Glu His 620 625 630 Arg Pro Arg Val Trp Arg Trp Leu Val His Leu Arg Val Gln His 635 640 645 Leu His Thr Pro Gly Cys Tyr Gln Glu Leu Leu Ser Arg Gly Gln 650 655 660 Ala Arg Glu His Pro Ala Ala Arg Gln Ile Glu Leu Asp Leu Asn 665 670 675 Arg Thr Phe Pro Asn Asn Lys His Phe Thr Cys Pro Thr Ser Ser 680 685 690 Phe Pro Asp Lys Leu Arg Arg Val Leu Leu Ala Phe Ser Trp Gln 695 700 705 Asn Pro Thr Ile Gly Tyr Cys Gln Gly Leu Asn Arg Leu Ala Ala 710 715 720 Ile Ala Leu Leu Val Leu Glu Glu Glu Glu Ser Ala Phe Trp Cys 725 730 735 Leu Val Ala Ile Val Glu Thr Ile Met Pro Ala Asp Tyr Tyr Cys 740 745 750 Asn Thr Leu Thr Ala Ser Gln Val Asp Gln Arg Val Leu Gln Asp 755 760 765 Leu Leu Ser Glu Lys Leu Pro Arg Leu Met Ala His Leu Gly Gln 770 775 780 His His Val Asp Leu Ser Leu Val Thr Phe Asn Trp Phe Leu Val 785 790 795 Val Phe Ala Asp Ser Leu Ile Ser Asn Ile Leu Leu Arg Val Trp 800 805 810 Asp Ala Phe Leu Tyr Glu Gly Thr Lys Val Val Phe Arg Tyr Ala 815 820 825 Leu Ala Ile Phe Lys Tyr Asn Glu Lys Glu Ile Leu Arg Leu Gln 830 835 840 Asn Gly Leu Glu Ile Tyr Gln Tyr Leu Arg Phe Phe Thr Lys Thr 845 850 855 Ile Ser Asn Ser Arg Lys Leu Met Asn Ile Ala Phe Asn Asp Met 860 865 870 Asn Pro Phe Arg Met Lys Gln Leu Arg Gln Leu Arg Met Val His 875 880 885 Arg Glu Arg Leu Glu Ala Glu Leu Arg Glu Leu Glu Gln Leu Lys 890 895 900 Ala Glu Tyr Leu Glu Arg Arg Ala Ser Arg Arg Arg Ala Val Ser 905 910 915 Glu Gly Cys Ala Ser Glu Asp Glu Val Glu Gly Glu Ala 920 925 17 684 PRT Homo sapiens misc_feature Incyte ID No 3212060CD1 17 Met Trp Val Leu Leu Arg Ser Gly Tyr Pro Leu Arg Ile Leu Leu 1 5 10 15 Pro Leu Arg Gly Glu Trp Met Gly Arg Arg Gly Leu Pro Arg Asn 20 25 30 Leu Ala Pro Gly Pro Pro Arg Arg Arg Tyr Arg Lys Glu Thr Leu 35 40 45 Gln Ala Leu Asp Met Pro Val Leu Pro Val Thr Ala Thr Glu Ile 50 55 60 Arg Gln Tyr Leu Arg Gly His Gly Ile Pro Phe Gln Asp Gly His 65 70 75 Ser Cys Leu Arg Ala Leu Ser Pro Phe Ala Glu Ser Ser Gln Leu 80 85 90 Lys Gly Gln Thr Gly Val Thr Thr Ser Phe Ser Leu Phe Ile Asp 95 100 105 Lys Thr Thr Gly His Phe Leu Cys Met Thr Ser Leu Ala Glu Gly 110 115 120 Ser Trp Glu Asp Phe Gln Ala Ser Val Glu Gly Arg Gly Asp Gly 125 130 135 Ala Arg Glu Gly Phe Leu Leu Ser Lys Ala Pro Glu Phe Glu Asp 140 145 150 Ser Glu Glu Val Arg Arg Ile Trp Asn Arg Ala Ile Pro Leu Trp 155 160 165 Glu Leu Pro Asp Gln Glu Glu Val Gln Leu Ala Asp Thr Met Phe 170 175 180 Gly Leu Thr Lys Val Thr Asp Asp Thr Leu Lys Arg Phe Ser Val 185 190 195 Arg Tyr Leu Arg Pro Ala Arg Ser Leu Val Phe Pro Trp Phe Ser 200 205 210 Pro Gly Gly Ser Gly Leu Arg Gly Leu Lys Leu Leu Glu Ala Lys 215 220 225 Cys Gln Gly Asp Gly Val Ser Tyr Glu Glu Thr Thr Ile Pro Arg 230 235 240 Pro Ser Ala Tyr His Asn Leu Phe Gly Leu Pro Leu Ile Ser Arg 245 250 255 Arg Asp Ala Glu Val Val Leu Thr Ser Arg Glu Leu Asp Ser Leu 260 265 270 Ala Leu Asn Gln Ser Thr Gly Leu Pro Thr Leu Thr Leu Pro Arg 275 280 285 Gly Thr Thr Cys Leu Pro Pro Ala Leu Leu Pro Tyr Leu Glu Gln 290 295 300 Phe Arg Arg Ile Val Phe Trp Leu Gly Asp Asp Leu Arg Ser Trp 305 310 315 Glu Ala Ala Lys Leu Phe Ala Arg Lys Leu Asn Pro Lys Arg Cys 320 325 330 Phe Leu Val Arg Pro Gly Asp Gln Gln Pro Arg Pro Leu Glu Ala 335 340 345 Leu Asn Gly Gly Phe Asn Leu Ser Arg Ile Leu Arg Thr Ala Leu 350 355 360 Pro Ala Trp His Lys Ser Ile Val Ser Phe Arg Gln Leu Arg Glu 365 370 375 Glu Val Leu Gly Glu Leu Ser Asn Val Glu Gln Ala Ala Gly Leu 380 385 390 Arg Trp Ser Arg Phe Pro Asp Leu Asn Arg Ile Leu Lys Gly His 395 400 405 Arg Lys Gly Glu Leu Thr Val Phe Thr Gly Pro Thr Gly Ser Gly 410 415 420 Lys Thr Thr Phe Ile Ser Glu Tyr Ala Leu Asp Leu Cys Ser Gln 425 430 435 Gly Val Asn Thr Leu Trp Gly Ser Phe Glu Ile Ser Asn Val Arg 440 445 450 Leu Ala Arg Val Met Leu Thr Gln Phe Ala Glu Gly Arg Leu Glu 455 460 465 Asp Gln Leu Asp Lys Tyr Asp His Trp Ala Asp Arg Phe Glu Asp 470 475 480 Leu Pro Leu Tyr Phe Met Thr Phe His Gly Gln Gln Ser Ile Arg 485 490 495 Thr Val Ile Asp Thr Met Gln His Ala Val Tyr Val Tyr Asp Ile 500 505 510 Cys His Val Ile Ile Asp Asn Leu Gln Phe Met Met Gly His Glu 515 520 525 Gln Leu Ser Thr Asp Arg Ile Ala Ala Gln Asp Tyr Ile Ile Gly 530 535 540 Val Phe Arg Lys Phe Ala Thr Asp Asn Asn Cys His Val Thr Leu 545 550 555 Val Ile His Pro Arg Lys Glu Asp Asp Asp Lys Glu Leu Gln Thr 560 565 570 Ala Ser Ile Phe Gly Ser Ala Lys Ala Ser Gln Glu Ala Asp Asn 575 580 585 Val Leu Ile Leu Gln Asp Arg Lys Leu Val Thr Gly Pro Gly Lys 590 595 600 Arg Tyr Leu Gln Val Ser Lys Asn Arg Phe Asp Gly Asp Val Gly 605 610 615 Val Phe Pro Leu Glu Phe Asn Lys Asn Ser Leu Thr Phe Ser Ile 620 625 630 Pro Pro Lys Asn Lys Ala Arg Leu Lys Lys Ile Lys Asp Asp Thr 635 640 645 Gly Pro Val Ala Lys Lys Pro Ser Ser Gly Lys Lys Gly Ala Thr 650 655 660 Thr Gln Asn Ser Glu Ile Cys Ser Gly Gln Ala Pro Thr Pro Asp 665 670 675 Gln Pro Asp Thr Ser Lys Arg Ser Lys 680 18 267 PRT Homo sapiens misc_feature Incyte ID No 3121069CD1 18 Met Thr Lys Thr Ala Leu Leu Lys Leu Phe Val Ala Ile Val Ile 1 5 10 15 Thr Phe Ile Leu Ile Leu Pro Glu Tyr Phe Lys Thr Pro Lys Glu 20 25 30 Arg Thr Leu Glu Leu Ser Cys Leu Glu Val Cys Leu Gln Ser Asn 35 40 45 Phe Thr Tyr Ser Leu Ser Ser Leu Asn Phe Ser Phe Val Thr Phe 50 55 60 Leu Gln Pro Val Arg Glu Thr Gln Ile Ile Met Arg Ile Phe Leu 65 70 75 Asn Pro Ser Asn Phe Arg Asn Phe Thr Arg Thr Cys Gln Asp Ile 80 85 90 Thr Val Leu Ile Arg Arg Gly Ser Met Glu Val Lys Ala Asn Asp 95 100 105 Phe His Ser Pro Cys Gln His Phe Asn Phe Ser Val Ala Pro Leu 110 115 120 Val Asp His Leu Glu Glu Tyr Asn Thr Thr Cys His Leu Lys Asn 125 130 135 His Thr Gly Arg Ser Thr Ile Met Glu Asp Glu Pro Ser Lys Glu 140 145 150 Lys Ser Ile Asn Tyr Thr Cys Arg Ile Met Glu Tyr Pro Asn Asp 155 160 165 Cys Ile His Ile Ser Leu His Leu Glu Met Asp Ile Lys Asn Ile 170 175 180 Thr Cys Ser Met Lys Ile Thr Trp Tyr Ile Leu Val Leu Leu Val 185 190 195 Phe Ile Phe Leu Ile Ile Leu Thr Ile Arg Lys Ile Leu Glu Gly 200 205 210 Gln Arg Arg Val Gln Lys Trp Gln Ser His Arg Asp Lys Pro Thr 215 220 225 Ser Val Leu Leu Arg Gly Ser Asp Ser Glu Lys Leu Arg Ala Leu 230 235 240 Asn Val Gln Val Leu Ser Glu Thr Thr Gln Arg Leu Pro Leu Asp 245 250 255 Gln Val Gln Glu Val Leu Pro Pro Ile Pro Glu Leu 260 265 19 537 PRT Homo sapiens misc_feature Incyte ID No 3280626CD1 19 Met Ala Asp Asn Leu Asp Glu Phe Ile Glu Glu Gln Lys Ala Arg 1 5 10 15 Leu Ala Glu Asp Lys Ala Glu Leu Glu Ser Asp Pro Pro Tyr Met 20 25 30 Glu Met Lys Gly Lys Leu Ser Ala Lys Leu Ser Glu Asn Ser Lys 35 40 45 Ile Leu Ile Ser Met Ala Lys Glu Asn Ile Pro Pro Asn Ser Gln 50 55 60 Gln Thr Arg Gly Ser Leu Gly Ile Asp Tyr Gly Leu Ser Leu Pro 65 70 75 Leu Gly Glu Asp Tyr Glu Arg Lys Lys His Lys Leu Lys Glu Glu 80 85 90 Leu Arg Gln Asp Tyr Arg Arg Tyr Leu Thr Gln Glu Arg Leu Lys 95 100 105 Leu Glu Arg Asn Lys Glu Tyr Asn Gln Phe Leu Arg Gly Lys Glu 110 115 120 Glu Ser Ser Glu Lys Phe Arg Gln Val Glu Lys Ser Thr Glu Pro 125 130 135 Lys Ser Gln Arg Asn Lys Lys Pro Ile Gly Gln Val Lys Pro Asp 140 145 150 Leu Thr Ser Gln Ile Gln Thr Ser Cys Glu Asn Ser Glu Gly Pro 155 160 165 Arg Lys Asp Val Leu Thr Pro Ser Glu Ala Tyr Glu Glu Leu Leu 170 175 180 Asn Gln Arg Arg Leu Glu Glu Asp Arg Tyr Arg Gln Leu Asp Asp 185 190 195 Glu Ile Glu Leu Arg Asn Arg Arg Ile Ile Lys Lys Ala Asn Glu 200 205 210 Glu Val Gly Ile Ser Asn Leu Lys His Gln Arg Phe Ala Ser Lys 215 220 225 Ala Gly Ile Pro Asp Arg Arg Phe His Arg Phe Asn Glu Asp Arg 230 235 240 Val Phe Asp Arg Arg Tyr His Arg Pro Asp Gln Asp Pro Glu Val 245 250 255 Ser Glu Glu Met Asp Glu Arg Phe Arg Tyr Glu Ser Asp Phe Asp 260 265 270 Arg Arg Leu Ser Arg Val Tyr Thr Asn Asp Arg Met His Arg Asn 275 280 285 Lys Arg Gly Asn Met Pro Pro Met Glu His Asp Gly Asp Val Ile 290 295 300 Glu Gln Ser Asn Ile Arg Ile Ser Ser Ala Glu Asn Lys Ser Ala 305 310 315 Pro Asp Asn Glu Thr Ser Lys Ser Ala Asn Gln Asp Thr Cys Ser 320 325 330 Pro Phe Ala Gly Met Leu Phe Gly Gly Glu Asp Arg Glu Leu Ile 335 340 345 Gln Arg Arg Lys Glu Lys Tyr Arg Leu Glu Leu Leu Glu Gln Met 350 355 360 Ala Glu Gln Gln Arg Asn Lys Arg Arg Glu Lys Asp Leu Glu Leu 365 370 375 Arg Val Ala Ala Ser Gly Ala Gln Asp Pro Glu Lys Ser Pro Asp 380 385 390 Arg Leu Lys Gln Phe Ser Val Ala Pro Arg His Phe Glu Glu Met 395 400 405 Ile Pro Pro Glu Arg Pro Arg Ile Ala Phe Gln Thr Pro Leu Pro 410 415 420 Pro Leu Ser Ala Pro Ser Val Pro Pro Ile Pro Ser Val His Pro 425 430 435 Val Pro Ser Gln Asn Glu Asp Leu Arg Ser Gly Leu Ser Ser Ala 440 445 450 Leu Gly Glu Met Val Ser Pro Arg Ile Ala Pro Leu Pro Pro Pro 455 460 465 Pro Leu Leu Pro Pro Leu Ala Thr Asn Tyr Arg Thr Pro Tyr Asp 470 475 480 Asp Ala Tyr Tyr Phe Tyr Gly Ser Arg Asn Thr Phe Asp Pro Ser 485 490 495 Leu Ala Tyr Tyr Gly Ser Gly Met Met Gly Val Gln Pro Ala Ala 500 505 510 Tyr Val Ser Ala Pro Val Thr His Gln Leu Ala Gln Pro Val Val 515 520 525 Val Ser Pro Cys His Pro Gly Trp Ser Thr Met Leu 530 535 20 312 PRT Homo sapiens misc_feature Incyte ID No 484404CD1 20 Met Trp Ser Glu Gly Arg Tyr Glu Tyr Glu Arg Ile Pro Arg Glu 1 5 10 15 Arg Ala Pro Pro Arg Ser His Pro Ser Asp Glu Ser Gly Tyr Arg 20 25 30 Trp Thr Arg Asp Asp His Ser Ala Ser Arg Gln Pro Glu Tyr Arg 35 40 45 Asp Met Arg Asp Gly Phe Arg Arg Lys Ser Phe Tyr Ser Ser His 50 55 60 Tyr Ala Arg Glu Arg Ser Pro Tyr Lys Arg Asp Asn Thr Phe Phe 65 70 75 Arg Glu Ser Pro Val Gly Arg Lys Asp Ser Pro His Ser Arg Ser 80 85 90 Gly Ser Ser Val Ser Ser Arg Ser Tyr Ser Pro Glu Arg Ser Lys 95 100 105 Ser Tyr Ser Phe His Gln Ser Gln His Arg Lys Ser Val Arg Pro 110 115 120 Gly Ala Ser Tyr Lys Arg Gln Asn Glu Gly Asn Pro Glu Arg Asp 125 130 135 Lys Glu Arg Pro Val Gln Ser Leu Lys Thr Ser Arg Asp Thr Ser 140 145 150 Pro Ser Ser Gly Ser Ala Val Ser Ser Ser Lys Val Leu Asp Lys 155 160 165 Pro Ser Arg Leu Thr Glu Lys Glu Leu Ala Glu Ala Ala Ser Lys 170 175 180 Trp Ala Ala Glu Lys Leu Glu Lys Ser Asp Glu Ser Asn Leu Pro 185 190 195 Glu Ile Ser Glu Tyr Glu Ala Gly Ser Thr Ala Pro Leu Phe Thr 200 205 210 Asp Gln Pro Glu Glu Pro Glu Ser Asn Thr Thr His Gly Ile Glu 215 220 225 Leu Phe Glu Asp Ser Gln Leu Thr Thr Arg Ser Lys Ala Ile Ala 230 235 240 Ser Lys Thr Lys Glu Ile Glu Gln Val Tyr Arg Gln Asp Cys Glu 245 250 255 Thr Phe Gly Met Val Val Lys Met Leu Ile Glu Lys Asp Pro Ser 260 265 270 Leu Glu Lys Ser Ile Gln Phe Ala Leu Arg Gln Asn Leu His Glu 275 280 285 Ile Gly Glu Arg Cys Val Glu Glu Leu Lys His Phe Ile Ala Glu 290 295 300 Tyr Asp Thr Ser Thr Gln Asp Phe Gly Glu Pro Phe 305 310 21 1400 PRT Homo sapiens misc_feature Incyte ID No 2830063CD1 21 Met Met Ala Ser Phe Gln Arg Ser Asn Ser His Asp Lys Val Arg 1 5 10 15 Arg Ile Val Ala Glu Glu Gly Arg Thr Ala Arg Asn Leu Ile Ala 20 25 30 Trp Ser Val Pro Leu Glu Ser Lys Asp Asp Asp Gly Lys Pro Lys 35 40 45 Cys Gln Thr Gly Gly Lys Ser Lys Arg Thr Ile Gln Gly Thr His 50 55 60 Lys Thr Thr Lys Gln Ser Thr Ala Val Asp Cys Lys Ile Thr Ser 65 70 75 Ser Thr Thr Gly Asp Lys His Phe Asp Lys Ser Pro Thr Lys Thr 80 85 90 Arg His Pro Arg Lys Ile Asp Leu Arg Ala Arg Tyr Trp Ala Phe 95 100 105 Leu Phe Asp Asn Leu Arg Arg Ala Val Asp Glu Ile Tyr Val Thr 110 115 120 Cys Glu Ser Asp Gln Ser Val Val Glu Cys Lys Glu Val Leu Met 125 130 135 Met Leu Asp Asn Tyr Val Arg Asp Phe Lys Ala Leu Ile Asp Trp 140 145 150 Ile Gln Leu Gln Glu Lys Leu Glu Lys Thr Asp Ala Gln Ser Arg 155 160 165 Pro Thr Ser Leu Ala Trp Glu Val Lys Lys Met Ser Pro Gly Arg 170 175 180 His Val Ile Pro Ser Pro Ser Thr Asp Arg Ile Asn Val Thr Ser 185 190 195 Asn Ala Arg Arg Ser Leu Asn Phe Gly Gly Ser Thr Gly Thr Val 200 205 210 Pro Ala Pro Arg Leu Ala Pro Thr Gly Val Ser Trp Ala Asp Lys 215 220 225 Val Lys Ala His His Thr Gly Ser Thr Ala Ser Ser Glu Ile Thr 230 235 240 Pro Ala Gln Ser Cys Pro Pro Met Thr Val Gln Lys Ala Ser Arg 245 250 255 Lys Asn Glu Arg Lys Asp Ala Glu Gly Trp Glu Thr Val Gln Arg 260 265 270 Gly Arg Pro Ile Arg Ser Arg Ser Thr Ala Val Met Pro Lys Val 275 280 285 Ser Leu Ala Thr Glu Ala Thr Arg Ser Lys Asp Asp Ser Asp Lys 290 295 300 Glu Asn Val Cys Leu Leu Pro Asp Glu Ser Ile Gln Lys Gly Gln 305 310 315 Phe Val Gly Asp Gly Thr Ser Asn Thr Ile Glu Ser His Pro Lys 320 325 330 Asp Ser Leu His Ser Cys Asp His Pro Leu Ala Glu Lys Thr Gln 335 340 345 Phe Thr Val Ser Thr Leu Asp Asp Val Lys Asn Ser Gly Ser Ile 350 355 360 Arg Asp Asn Tyr Val Arg Thr Ser Glu Ile Ser Ala Val His Ile 365 370 375 Asp Thr Glu Cys Val Ser Val Met Leu Gln Ala Gly Thr Pro Pro 380 385 390 Leu Gln Val Asn Glu Glu Lys Phe Pro Ala Glu Lys Ala Arg Ile 395 400 405 Glu Asn Glu Met Asp Pro Ser Asp Ile Ser Asn Ser Met Ala Glu 410 415 420 Val Leu Ala Lys Lys Glu Glu Leu Ala Asp Arg Leu Glu Lys Ala 425 430 435 Asn Glu Glu Ala Ile Ala Ser Ala Ile Ala Glu Glu Glu Gln Leu 440 445 450 Thr Arg Glu Ile Glu Ala Glu Glu Asn Asn Asp Ile Asn Ile Glu 455 460 465 Thr Asp Asn Asp Ser Asp Phe Ser Ala Ser Met Gly Ser Gly Ser 470 475 480 Val Ser Phe Cys Gly Met Ser Met Asp Trp Asn Asp Val Leu Ala 485 490 495 Asp Tyr Glu Ala Arg Glu Ser Trp Arg Gln Asn Thr Ser Trp Gly 500 505 510 Asp Ile Val Glu Glu Glu Pro Ala Arg Pro Pro Gly His Gly Ile 515 520 525 His Met His Glu Lys Leu Ser Ser Pro Ser Arg Lys Arg Thr Ile 530 535 540 Ala Glu Ser Lys Lys Lys His Glu Glu Lys Gln Met Lys Ala Gln 545 550 555 Gln Leu Arg Glu Lys Leu Arg Glu Glu Lys Thr Leu Lys Leu Gln 560 565 570 Lys Leu Leu Glu Arg Glu Lys Asp Val Arg Lys Trp Lys Glu Glu 575 580 585 Leu Leu Asp Gln Arg Arg Arg Met Met Glu Glu Lys Leu Leu His 590 595 600 Ala Glu Phe Lys Arg Glu Val Gln Leu Gln Ala Ile Val Lys Lys 605 610 615 Ala Gln Glu Glu Glu Ala Lys Val Asn Glu Ile Ala Phe Ile Asn 620 625 630 Thr Leu Glu Ala Gln Asn Lys Arg His Asp Val Leu Ser Lys Leu 635 640 645 Lys Glu Tyr Glu Gln Arg Leu Asn Glu Leu Gln Glu Glu Arg Gln 650 655 660 Arg Arg Gln Glu Glu Lys Gln Ala Arg Asp Glu Ala Val Gln Glu 665 670 675 Arg Lys Arg Ala Leu Glu Ala Glu Arg Gln Ala Arg Val Glu Glu 680 685 690 Leu Leu Met Lys Arg Lys Glu Gln Glu Ala Arg Ile Glu Gln Gln 695 700 705 Arg Gln Glu Lys Glu Lys Ala Arg Glu Asp Ala Ala Arg Glu Arg 710 715 720 Ala Arg Asp Arg Glu Glu Arg Leu Ala Ala Leu Thr Ala Ala Gln 725 730 735 Gln Glu Ala Met Glu Glu Leu Gln Lys Lys Ile Gln Leu Lys His 740 745 750 Asp Glu Ser Ile Arg Arg His Met Glu Gln Ile Glu Gln Arg Lys 755 760 765 Glu Lys Ala Ala Glu Leu Ser Ser Gly Arg His Ala Asn Thr Asp 770 775 780 Tyr Ala Pro Lys Leu Thr Pro Tyr Glu Arg Lys Lys Gln Cys Ser 785 790 795 Leu Cys Asn Val Leu Ile Ser Ser Glu Val Tyr Leu Phe Ser His 800 805 810 Val Lys Gly Arg Lys His Gln Gln Ala Val Arg Glu Asn Thr Ser 815 820 825 Ile Gln Gly Arg Glu Leu Ser Asp Glu Glu Val Glu His Leu Ser 830 835 840 Leu Lys Lys Tyr Ile Ile Asp Ile Val Val Glu Ser Thr Ala Pro 845 850 855 Ala Glu Ala Leu Lys Asp Gly Glu Glu Arg Gln Lys Asn Lys Lys 860 865 870 Lys Ala Lys Lys Ile Lys Ala Arg Met Asn Phe Arg Ala Lys Glu 875 880 885 Tyr Glu Ser Leu Met Glu Thr Lys Asn Ser Gly Ser Asp Ser Pro 890 895 900 Tyr Lys Ala Lys Leu Gln Arg Leu Ala Lys Asp Leu Leu Lys Gln 905 910 915 Val Gln Val Gln Asp Ser Gly Ser Trp Ala Asn Asn Lys Val Ser 920 925 930 Ala Leu Asp Arg Thr Leu Gly Glu Ile Thr Arg Ile Leu Glu Lys 935 940 945 Glu Asn Val Ala Asp Gln Ile Ala Phe Gln Ala Ala Gly Gly Leu 950 955 960 Thr Ala Leu Glu His Ile Leu Gln Ala Val Val Pro Ala Thr Asn 965 970 975 Val Asn Thr Val Leu Arg Ile Pro Pro Lys Ser Leu Cys Asn Ala 980 985 990 Ile Asn Val Tyr Asn Leu Thr Cys Asn Asn Cys Ser Glu Asn Cys 995 1000 1005 Ser Asp Val Leu Phe Ser Asn Lys Ile Thr Phe Leu Met Asp Leu 1010 1015 1020 Leu Ile His Gln Leu Thr Val Tyr Val Pro Asp Glu Asn Asn Thr 1025 1030 1035 Ile Leu Gly Arg Asn Thr Asn Lys Gln Val Phe Glu Gly Leu Thr 1040 1045 1050 Thr Gly Leu Leu Lys Val Ser Ala Val Val Leu Gly Cys Leu Ile 1055 1060 1065 Ala Asn Arg Pro Asp Gly Asn Cys Gln Pro Ala Thr Pro Lys Ile 1070 1075 1080 Pro Thr Gln Glu Met Lys Asn Lys Thr Ser Gln Gly Asp Pro Phe 1085 1090 1095 Asn Asn Arg Val Gln Asp Leu Ile Ser Tyr Val Val Asn Met Gly 1100 1105 1110 Leu Ile Asp Lys Leu Cys Ala Cys Phe Leu Ser Val Gln Gly Pro 1115 1120 1125 Val Asp Glu Asn Pro Lys Met Ala Ile Phe Leu Gln His Ala Ala 1130 1135 1140 Gly Leu Leu His Ala Met Cys Thr Leu Cys Phe Ala Val Thr Gly 1145 1150 1155 Arg Ser Tyr Ser Ile Phe Asp Asn Asn Arg Gln Asp Pro Thr Gly 1160 1165 1170 Leu Thr Ala Ala Leu Gln Ala Thr Asp Leu Ala Gly Val Leu His 1175 1180 1185 Met Leu Tyr Cys Val Leu Phe His Gly Thr Ile Leu Asp Pro Ser 1190 1195 1200 Thr Ala Ser Pro Lys Glu Asn Tyr Thr Gln Asn Thr Ile Gln Val 1205 1210 1215 Ala Ile Gln Ser Leu Arg Phe Phe Asn Ser Phe Ala Ala Leu His 1220 1225 1230 Leu Pro Ala Phe Gln Ser Ile Val Gly Ala Glu Gly Leu Ser Leu 1235 1240 1245 Ala Phe Arg His Met Ala Ser Ser Leu Leu Gly His Cys Ser Gln 1250 1255 1260 Val Ser Cys Glu Ser Leu Leu His Glu Val Ile Val Cys Val Gly 1265 1270 1275 Tyr Phe Thr Val Asn His Pro Asp Asn Gln Val Ile Val Gln Ser 1280 1285 1290 Gly Arg His Pro Thr Val Leu Gln Lys Leu Cys Gln Leu Pro Phe 1295 1300 1305 Gln Tyr Phe Ser Asp Pro Arg Leu Ile Lys Val Leu Phe Pro Ser 1310 1315 1320 Leu Ile Ala Ala Cys Tyr Asn Asn His Gln Asn Lys Ile Ile Leu 1325 1330 1335 Glu Gln Glu Met Ser Cys Val Leu Leu Ala Thr Phe Ile Gln Asp 1340 1345 1350 Leu Ala Gln Thr Pro Gly Gln Ala Glu Asn Gln Pro Tyr Gln Pro 1355 1360 1365 Lys Gly Lys Cys Leu Gly Ser Gln Asp Tyr Leu Glu Leu Ala Asn 1370 1375 1380 Arg Phe Pro Gln Gln Ala Trp Glu Glu Ala Arg Gln Phe Phe Leu 1385 1390 1395 Lys Lys Glu Lys Lys 1400 22 1384 PRT Homo sapiens misc_feature Incyte ID No 7506096CD1 22 Met Glu Ser Ser Ser Ser Asp Tyr Tyr Asn Lys Asp Asn Glu Glu 1 5 10 15 Glu Ser Leu Leu Ala Asn Val Ala Ser Leu Arg His Glu Leu Lys 20 25 30 Ile Thr Glu Trp Ser Leu Gln Ser Leu Gly Glu Glu Leu Ser Ser 35 40 45 Val Ser Pro Ser Glu Asn Ser Asp Tyr Ala Pro Asn Pro Ser Arg 50 55 60 Ser Glu Lys Leu Ile Leu Asp Val Gln Pro Ser His Pro Gly Leu 65 70 75 Leu Asn Tyr Ser Pro Tyr Glu Asn Val Cys Lys Ile Ser Gly Ser 80 85 90 Ser Thr Asp Phe Gln Lys Lys Pro Arg Asp Lys Met Phe Ser Ser 95 100 105 Ser Ala Pro Val Asp Gln Glu Ile Lys Ser Leu Arg Glu Lys Leu 110 115 120 Asn Lys Leu Arg Gln Gln Asn Ala Cys Leu Val Thr Gln Asn His 125 130 135 Ser Leu Met Thr Lys Phe Glu Ser Ile His Phe Glu Leu Thr Gln 140 145 150 Ser Arg Ala Lys Val Ser Met Leu Glu Ser Ala Gln Gln Gln Ala 155 160 165 Ala Ser Val Pro Ile Leu Glu Glu Gln Ile Ile Asn Leu Glu Ala 170 175 180 Glu Val Ser Ala Gln Asp Lys Val Leu Arg Glu Ala Glu Asn Lys 185 190 195 Leu Glu Gln Ser Gln Lys Met Val Ile Glu Lys Glu Gln Ser Leu 200 205 210 Gln Glu Ser Lys Glu Glu Cys Ile Lys Leu Lys Val Asp Leu Leu 215 220 225 Glu Gln Thr Lys Gln Gly Lys Arg Ala Glu Arg Gln Arg Asn Glu 230 235 240 Ala Leu Tyr Asn Ala Glu Glu Leu Ser Lys Ala Phe Gln Gln Tyr 245 250 255 Lys Lys Lys Val Ala Glu Lys Leu Glu Lys Val Gln Ala Glu Glu 260 265 270 Glu Ile Leu Glu Arg Asn Leu Thr Asn Cys Glu Lys Glu Asn Lys 275 280 285 Arg Leu Gln Glu Arg Cys Gly Leu Tyr Lys Ser Glu Leu Glu Ile 290 295 300 Leu Lys Glu Lys Leu Arg Gln Leu Lys Glu Glu Asn Asn Asn Gly 305 310 315 Lys Glu Lys Leu Arg Ile Met Ala Val Lys Asn Ser Glu Val Met 320 325 330 Ala Gln Leu Thr Glu Ser Arg Gln Ser Ile Leu Lys Leu Glu Ser 335 340 345 Glu Leu Glu Asn Lys Asp Glu Ile Leu Arg Asp Lys Phe Ser Leu 350 355 360 Met Asn Glu Asn Arg Glu Leu Lys Val Arg Val Ala Ala Gln Asn 365 370 375 Glu Arg Leu Asp Leu Cys Gln Gln Glu Ile Glu Ser Ser Arg Val 380 385 390 Glu Leu Arg Ser Leu Glu Lys Ile Ile Ser Gln Leu Pro Leu Lys 395 400 405 Arg Glu Leu Phe Gly Phe Lys Ser Tyr Leu Ser Lys Tyr Gln Met 410 415 420 Ser Ser Phe Ser Asn Lys Glu Asp Arg Cys Ile Gly Cys Cys Glu 425 430 435 Ala Asn Lys Leu Val Ile Ser Glu Leu Arg Ile Lys Leu Ala Ile 440 445 450 Lys Glu Ala Glu Ile Gln Lys Leu His Ala Asn Leu Thr Ala Asn 455 460 465 Gln Leu Ser Gln Ser Leu Ile Thr Cys Asn Asp Ser Gln Glu Ser 470 475 480 Ser Lys Leu Ser Ser Leu Glu Thr Glu Pro Val Lys Leu Gly Gly 485 490 495 His Gln Val Ala Glu Ser Val Lys Asp Gln Asn Gln His Thr Met 500 505 510 Asn Lys Gln Tyr Glu Lys Glu Arg Gln Arg Leu Val Thr Gly Ile 515 520 525 Glu Glu Leu Arg Thr Lys Leu Ile Gln Ile Glu Ala Glu Asn Ser 530 535 540 Asp Leu Lys Val Asn Met Ala His Arg Thr Ser Gln Phe Gln Leu 545 550 555 Ile Gln Glu Glu Leu Leu Glu Lys Ala Ser Asn Ser Ser Lys Leu 560 565 570 Glu Ser Glu Met Thr Lys Lys Cys Ser Gln Leu Leu Thr Leu Glu 575 580 585 Lys Gln Leu Glu Glu Lys Ile Val Ala Tyr Ser Ser Ile Ala Ala 590 595 600 Lys Asn Ala Glu Leu Glu Gln Glu Leu Met Glu Lys Asn Glu Lys 605 610 615 Ile Arg Ser Leu Glu Thr Asn Ile Asn Thr Glu His Glu Lys Ile 620 625 630 Cys Leu Ala Phe Glu Lys Ala Lys Lys Ile His Leu Glu Gln His 635 640 645 Lys Glu Met Glu Lys Gln Ile Glu Arg Val Arg Gln Leu Asp Ser 650 655 660 Ala Leu Glu Ile Cys Lys Glu Glu Leu Val Leu His Leu Asn Gln 665 670 675 Leu Glu Gly Asn Lys Glu Lys Phe Glu Lys Gln Leu Lys Lys Lys 680 685 690 Ser Glu Glu Val Tyr Cys Leu Gln Lys Glu Leu Lys Ile Lys Asn 695 700 705 His Ser Leu Gln Glu Thr Ser Glu Gln Asn Val Ile Leu Gln His 710 715 720 Thr Leu Gln Gln Gln Gln Gln Met Leu Gln Gln Glu Thr Ile Arg 725 730 735 Asn Gly Glu Leu Glu Asp Thr Gln Thr Lys Leu Glu Lys Gln Val 740 745 750 Ser Lys Leu Glu Gln Glu Leu Gln Lys Gln Arg Glu Ser Ser Ala 755 760 765 Glu Lys Leu Arg Lys Met Glu Glu Lys Cys Glu Ser Ala Ala His 770 775 780 Glu Ala Asp Leu Lys Arg Gln Lys Val Ile Glu Leu Thr Gly Thr 785 790 795 Ala Arg Gln Val Lys Ile Glu Met Asp Gln Tyr Lys Glu Glu Leu 800 805 810 Ser Lys Met Glu Lys Glu Ile Met His Leu Lys Arg Asp Gly Glu 815 820 825 Asn Lys Ala Met His Leu Ser Gln Leu Asp Met Ile Leu Asp Gln 830 835 840 Thr Lys Thr Glu Leu Glu Lys Lys Thr Asn Ala Val Lys Glu Leu 845 850 855 Glu Lys Leu Gln His Ser Thr Glu Thr Glu Leu Thr Glu Ala Leu 860 865 870 Gln Lys Arg Glu Val Leu Glu Thr Glu Leu Gln Asn Ala His Gly 875 880 885 Glu Leu Lys Ser Thr Leu Arg Gln Leu Gln Glu Leu Arg Asp Val 890 895 900 Leu Gln Lys Ala Gln Leu Ser Leu Glu Glu Lys Tyr Thr Thr Ile 905 910 915 Lys Asp Leu Thr Ala Glu Leu Arg Glu Cys Lys Met Glu Ile Glu 920 925 930 Asp Lys Lys Gln Glu Leu Leu Glu Met Asp Gln Ala Leu Lys Glu 935 940 945 Arg Asn Trp Glu Leu Lys Gln Arg Ala Ala Gln Val Thr His Leu 950 955 960 Asp Met Thr Ile Arg Glu His Arg Gly Glu Met Glu Gln Lys Ile 965 970 975 Ile Lys Leu Glu Gly Thr Leu Glu Lys Ser Glu Leu Glu Leu Lys 980 985 990 Glu Cys Asn Lys Gln Ile Glu Ser Leu Asn Asp Lys Leu Gln Asn 995 1000 1005 Ala Lys Glu Gln Leu Arg Glu Lys Glu Phe Ile Met Leu Gln Asn 1010 1015 1020 Glu Gln Glu Ile Ser Gln Leu Lys Lys Glu Ile Glu Arg Thr Gln 1025 1030 1035 Gln Arg Met Lys Glu Met Glu Ser Val Met Lys Glu Gln Glu Gln 1040 1045 1050 Tyr Ile Ala Thr Gln Tyr Lys Glu Ala Ile Asp Leu Gly Gln Glu 1055 1060 1065 Leu Arg Leu Thr Arg Glu Gln Val Gln Asn Ser His Thr Glu Leu 1070 1075 1080 Ala Glu Ala Arg His Gln Gln Val Gln Ala Gln Arg Glu Ile Glu 1085 1090 1095 Arg Leu Ser Ser Glu Leu Glu Asp Met Lys Gln Leu Ser Lys Glu 1100 1105 1110 Lys Asp Ala His Gly Asn His Leu Ala Glu Glu Leu Gly Ala Ser 1115 1120 1125 Lys Val Arg Glu Ala His Leu Glu Ala Arg Met Gln Ala Glu Ile 1130 1135 1140 Lys Lys Leu Ser Ala Glu Val Glu Ser Leu Lys Glu Ala Tyr His 1145 1150 1155 Met Glu Met Ile Ser His Gln Glu Asn His Ala Lys Trp Lys Ile 1160 1165 1170 Ser Ala Asp Ser Gln Lys Ser Ser Val Gln Gln Leu Asn Glu Gln 1175 1180 1185 Leu Glu Lys Ala Lys Leu Glu Leu Glu Glu Ala Gln Asp Thr Val 1190 1195 1200 Ser Asn Leu His Gln Gln Val Gln Asp Arg Asn Glu Val Ile Glu 1205 1210 1215 Ala Ala Asn Glu Ala Leu Leu Thr Lys Glu Ser Glu Leu Thr Arg 1220 1225 1230 Leu Gln Ala Lys Ile Ser Gly His Glu Lys Ala Glu Asp Ile Lys 1235 1240 1245 Phe Leu Pro Ala Pro Phe Thr Ser Pro Thr Glu Ile Met Pro Asp 1250 1255 1260 Val Gln Asp Pro Lys Phe Ala Lys Cys Phe His Thr Ser Phe Ser 1265 1270 1275 Lys Cys Thr Lys Leu Arg Arg Ser Ile Ser Ala Ser Asp Leu Thr 1280 1285 1290 Phe Lys Ile His Gly Asp Glu Asp Leu Ser Glu Glu Leu Leu Gln 1295 1300 1305 Asp Leu Lys Lys Met Gln Leu Glu Gln Pro Ser Thr Leu Glu Glu 1310 1315 1320 Ser His Lys Asn Leu Thr Tyr Thr Gln Pro Asp Ser Phe Lys Pro 1325 1330 1335 Leu Thr Tyr Asn Leu Glu Ala Asp Ser Ser Glu Asn Asn Asp Phe 1340 1345 1350 Asn Thr Leu Ser Gly Met Leu Arg Tyr Ile Asn Lys Glu Val Arg 1355 1360 1365 Leu Leu Lys Lys Ser Ser Met Gln Thr Gly Ala Gly Leu Asn Gln 1370 1375 1380 Gly Glu Asn Val 23 787 PRT Homo sapiens misc_feature Incyte ID No 7505914CD1 23 Met Trp Asp Gln Gly Gly Gln Pro Trp Gln Gln Trp Pro Leu Asn 1 5 10 15 Gln Gln Gln Trp Met Gln Ser Phe Gln His Gln Gln Asp Pro Ser 20 25 30 Gln Ile Asp Trp Ala Ala Leu Ala Gln Ala Trp Ile Ala Gln Arg 35 40 45 Glu Ala Ser Gly Gln Gln Ser Met Val Glu Gln Pro Pro Gly Met 50 55 60 Met Pro Asn Gly Gln Asp Met Ser Thr Met Glu Ser Gly Pro Asn 65 70 75 Asn His Gly Asn Phe Gln Gly Asp Ser Asn Phe Asn Arg Met Trp 80 85 90 Gln Pro Glu Trp Gly Met His Gln Gln Pro Pro His Pro Pro Pro 95 100 105 Asp Gln Pro Trp Met Pro Pro Thr Pro Gly Pro Met Asp Ile Val 110 115 120 Pro Pro Ser Glu Asp Ser Asn Ser Gln Asp Ser Gly Glu Phe Ala 125 130 135 Pro Asp Asn Arg His Ile Phe Asn Gln Asn Asn His Asn Phe Gly 140 145 150 Gly Pro Pro Asp Asn Phe Ala Val Gly Pro Val Asn Gln Phe Asp 155 160 165 Tyr Gln His Gly Ala Ala Phe Gly Pro Pro Gln Gly Gly Phe His 170 175 180 Pro Pro Tyr Trp Gln Pro Gly Pro Pro Gly Pro Pro Ala Pro Pro 185 190 195 Gln Asn Arg Arg Glu Arg Pro Ser Ser Phe Arg Asp Arg Gln Arg 200 205 210 Ser Pro Ile Ala Leu Pro Val Lys Gln Glu Pro Pro Gln Ile Asp 215 220 225 Ala Val Lys Arg Arg Thr Leu Pro Ala Trp Ile Arg Glu Gly Leu 230 235 240 Glu Lys Met Glu Arg Glu Lys Gln Lys Lys Leu Glu Lys Glu Arg 245 250 255 Met Glu Gln Gln Arg Ser Gln Leu Ser Lys Lys Glu Lys Lys Ala 260 265 270 Thr Glu Asp Ala Glu Gly Gly Asp Gly Pro Arg Leu Pro Gln Arg 275 280 285 Ser Lys Phe Asp Ser Asp Glu Glu Glu Glu Asp Thr Glu Asn Val 290 295 300 Glu Ala Ala Ser Ser Gly Lys Val Thr Arg Ser Pro Ser Pro Val 305 310 315 Pro Gln Glu Glu His Ser Asp Pro Glu Met Thr Glu Glu Glu Lys 320 325 330 Glu Tyr Gln Met Met Leu Leu Thr Lys Met Leu Leu Thr Glu Ile 335 340 345 Leu Leu Asp Val Thr Asp Glu Glu Ile Tyr Tyr Val Ala Lys Asp 350 355 360 Ala His Arg Lys Ala Thr Lys Gly Gly Leu Gly Gly Tyr Gly Ser 365 370 375 Gly Asp Ser Glu Asp Glu Arg Ser Asp Arg Gly Ser Glu Ser Ser 380 385 390 Asp Thr Asp Asp Glu Glu Leu Arg His Arg Ile Arg Gln Lys Gln 395 400 405 Glu Ala Phe Trp Arg Lys Glu Lys Glu Gln Gln Leu Leu His Asp 410 415 420 Lys Gln Met Glu Glu Glu Lys Gln Gln Thr Glu Arg Val Thr Lys 425 430 435 Glu Met Asn Glu Phe Ile His Lys Glu Gln Asn Ser Leu Ser Leu 440 445 450 Leu Glu Ala Arg Glu Ala Asp Gly Asp Val Val Asn Glu Lys Lys 455 460 465 Arg Thr Pro Asn Glu Thr Thr Ser Val Leu Glu Pro Lys Lys Glu 470 475 480 His Lys Glu Lys Glu Lys Gln Gly Arg Ser Arg Ser Gly Ser Ser 485 490 495 Ser Ser Gly Ser Ser Ser Ser Asn Ser Arg Thr Ser Ser Thr Ser 500 505 510 Ser Thr Val Ser Ser Ser Ser Tyr Ser Ser Ser Ser Gly Ser Ser 515 520 525 Arg Thr Ser Ser Arg Ser Ser Ser Pro Lys Arg Lys Lys Arg His 530 535 540 Ser Arg Ser Arg Ser Pro Thr Ile Lys Ala Arg Arg Ser Arg Ser 545 550 555 Arg Ser Tyr Ser Arg Arg Ile Lys Ile Glu Ser Asn Arg Ala Arg 560 565 570 Val Lys Ile Arg Asp Arg Arg Arg Ser Asn Arg Asn Ser Ile Glu 575 580 585 Arg Glu Arg Arg Arg Asn Arg Ser Pro Ser Arg Glu Arg Arg Arg 590 595 600 Ser Arg Ser Arg Ser Arg Asp Arg Arg Thr Asn Arg Ala Ser Arg 605 610 615 Ser Arg Ser Arg Asp Arg Arg Lys Ile Asp Asp Gln Arg Gly Asn 620 625 630 Leu Ser Gly Asn Ser His Lys His Lys Gly Glu Ala Lys Glu Gln 635 640 645 Glu Arg Lys Lys Glu Arg Ser Arg Ser Ile Asp Lys Asp Arg Lys 650 655 660 Lys Lys Asp Lys Glu Arg Glu Arg Glu Gln Asp Lys Arg Lys Glu 665 670 675 Lys Gln Lys Arg Glu Glu Lys Asp Phe Lys Phe Ser Ser Gln Asp 680 685 690 Asp Arg Leu Lys Arg Lys Arg Glu Ser Glu Arg Thr Phe Ser Arg 695 700 705 Ser Gly Ser Ile Ser Val Lys Ile Ile Arg His Asp Ser Arg Gln 710 715 720 Asp Ser Lys Lys Ser Thr Thr Lys Asp Ser Lys Lys His Ser Gly 725 730 735 Ser Asp Ser Ser Gly Arg Ser Ser Ser Glu Ser Pro Gly Ser Ser 740 745 750 Lys Glu Lys Lys Ala Lys Lys Pro Lys His Ser Arg Ser Arg Ser 755 760 765 Val Glu Lys Ser Gln Arg Ser Gly Lys Lys Ala Ser Arg Lys His 770 775 780 Lys Ser Lys Ser Arg Ser Arg 785 24 3332 DNA Homo sapiens misc_feature Incyte ID No 71230017CB1 24 gccgggcttt gggttctggg cctctgccgc tctctggccc taagtgctga gctgccggga 60 acggcagctt ctgacgctgg gccattggac gctgcggaac caggcttctt cactttgagt 120 ttccgccgcg aagcgccagt ccgggccgag gagggagcct ttactacttc tccctggttt 180 cattcatgtt ctgaggaggg tgtgagaagg aaccatggat cccacagcct tggtggaagc 240 cattgtggaa gaagtggcct gtcccatctg tatgaccttc ctgagggagc ccatgagcat 300 tgactgtggc cacagcttct gccacagctg tctctctgga ctctgggaga tcccaggaga 360 atcccagaac tggggttaca cctgtcccct ctgtcgagct cctgtccagc caaggaacct 420 gcggcctaat tggcagctgg ccaatgttgt agaaaaagtc cgtctgctaa ggctacatcc 480 aggaatgggg ctgaagggtg acctgtgtga gcgccatggg gaaaagctga agatgttctg 540 caaagaggat gtcttgataa tgtgtgaggc ctgcagccag tccccagagc atgaggccca 600 cagtgttgtg ccaatggagg atgttgcctg ggagtacaag tgggaacttc atgaggccct 660 cgaacatctg aagaaagagc aagaagaggc ctggaagctt gaagttggtg aaaggaaacg 720 aactgccacc tggaagatac aggtggaaac ccgaaaacag agtattgtat gggagtttga 780 aaaataccag cgattactag agaaaaagca gccaccacat cggcagctgg gggcagaggt 840 agcagcagct ctggccagcc tacagcggga ggcagcggag accatgcaga aactggagtt 900 gaaccatagc gagctcatcc agcagagcca ggtcctgtgg aggatgattg cagagttgaa 960 agagaggtcg cagaggcctg tccgctggat gttgcaggat attcaggaag tgttaaacag 1020 gagcaaatct tggagcttgc agcagccaga accaatctcc ctggagttga agacagattg 1080 ccgtgtgctg gggctaagag agatcctgaa gacttatgca gctgatgtgc gcttggatcc 1140 agatactgct tactcccgtc tcatcgtgtc tgaggacaga aaacgtgtgc actatggaga 1200 caccaaccag aaactgccag acaatcctga gagattttac cgctataata tcgtcctggg 1260 aagccagtgc atctcctcag gccggcacta ctgggaggtg gaggtgggag acaggtctga 1320 gtggggcctg ggagtatgta agcaaaatgt agaccggaag gaggtggtct acttatcccc 1380 ccactatgga ttctgggtga taaggctgag gaagggaaat gagtaccgag caggcaccga 1440 tgagtaccca atcctgtcct tgccggtccc tcctcgccgg gtgggaatct tcgtggatta 1500 tgaggcccat gacatttctt tctacaatgt gactgactgt ggctcccaca tcttcacttt 1560 cccccgctat cccttccctg ggcgcctcct gccctatttt agtccttgct acagcattgg 1620 aaccaacaac actgctcctc tggccatctg ctccctggat ggggaggact aagaaagcta 1680 ccaccctaac cacagaggct tggaattggg cctggccccc atggggcttg gaggaccgag 1740 ccactgacag gtatcccctg aaactgagct gagcccagta tccaaggatt cctctgtctg 1800 atcctttggt ctttgctacc aggctgaagt ctgtcatgaa accacttatt ttaaaaagca 1860 gaggcccagt caaatgagca ttgcatccca tgagggaagc acgacagggc tgatggtgag 1920 gatcagagca gttctaaggt gactcgttgg ggtaaggatc aggactttgt ccatgtagta 1980 gccaaccacc ctcttccctg attcccgtcc ggtgtcacag ttcagtcagt gaggatgatg 2040 aagtagatac agtcttcagg acaccattag atgggctttc ccaataggcc aaaaaaatgc 2100 tgcgcatacc cagagctggt tgttgtgctg aggccagtca gaggatgctt cccctgaggt 2160 ttgctataac taagcaacct ttatgtgact ctcaccttct gacctcctgg caagagaaat 2220 tcagtgcagc agggggacac agacctgccc aagccacccc actgccgttc cctctctgag 2280 cacaagctgg gcaaatcact gtcccttgga ctccagtaga ccagtgtcct agtcttgcct 2340 tttttctcta agtggcagga tcagaaaacc tgcgagcttt agtttgtatt ttcactttat 2400 gaatgaggaa actgaaatgg ccttaaggga gcaagttatt tctttttttt tgacacggag 2460 tctcgctctg ttgcccaggc tggagtgcag tggcacgatc tcggctcact gcaggctctg 2520 cctcctgggt tcacgccatt ctcctgcctc agcttcccga gtagctggga ctacaggcgc 2580 ccaccacgac gcctggctca tttttttgta tttttagtag agacggggtt tcaccatgtt 2640 agctaggatg gtctcgatct cctgacctca tgatccgccc tcctcagcct cccacagtgc 2700 tgggattaga ggcatgagcc actgcgcccg gcccctggag caagttattt cttacaaagc 2760 tgctgaaggt aagattatca aaattataaa gcatttttca cactcaagtg aaacaaggtt 2820 gacaaactca cttcgcaggt cacatgccta tacatcactt attatatttg ggtctgaaac 2880 ttctcacatg tttgggaggt tttatgtgtc ctcattggga aaatgggtgt aattcagcat 2940 aaaacctcat atgattgtcc tgcctcatgg agctgttgta tagatcccag atccatccca 3000 tgatttgttc ctgtctgagg catagaggca ggcaagccgt ggattttgca catggtgact 3060 ttcccactgt gccatgatac agtctgcatc ttatagcagt gcctttgtct cagggcctct 3120 gctggcagtc tagacctttt gggcagaaag gagcttcaaa tggctgtgat aaggaatatt 3180 aaaaattgtg tttctacttt aattgtattg gctgttcatg tatgtaggag ttaaaatagg 3240 ccaaactgga gaaataaacg cattctgtcc accatgaaaa aaaaaaaaaa aaaaaaaaaa 3300 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 3332 25 4410 DNA Homo sapiens misc_feature Incyte ID No 3125036CB1 25 atggaatcta gttcatcaga ctactataat aaagacaatg aagaggaaag tttgcttgca 60 aatgttgctt ccttaagaca tgaactgaag ataacagaat ggagtttgca gagtttaggg 120 gaagagttat ccagtgttag tccaagtgaa aattctgatt atgcccctaa tccttcaagg 180 tctgaaaagc taattttgga tgttcagcct agccaccctg gacttttgaa ttattcacct 240 tatgaaaacg tctgtaaaat atctggtagc agcactgatt ttcaaaaaaa gccaagagat 300 aagatgtttt catcttctgc ccctgtggat caggagatta aaagccttcg agagaaacta 360 aataaactta ggcaacagaa tgcttgtttg gtcacacaga atcattcctt aatgactaaa 420 tttgaatcta ttcactttga attaacacag tcaagagcaa aagtttctat gcttgagtct 480 gctcaacagc aggcagccag tgtcccaatc ttagaagaac agattataaa tttggaagca 540 gaggtttcag ctcaagataa agttttgaga gaggcagaaa ataagctgga acagagccag 600 aaaatggtaa ttgaaaagga acagagtttg caggagtcca aagaggaatg tataaaatta 660 aaggtggact tacttgaaca aaccaaacaa ggaaaaagag ctgaacgaca aaggaatgaa 720 gcactatata atgccgaaga gctgagtaaa gctttccaac aatataaaaa aaaagtggct 780 gaaaaactgg aaaaggtaaa aggcagttgt gcaaattcag tgttttgtat tactgtctat 840 attccaacag taaaggttca agctgaagaa gaaatattag agagaaatct aactaactgt 900 gaaaaagaaa ataaaaggct acaagaaagg tgtggtctat ataaaagtga acttgaaatt 960 ctgaaagaga aattaaggca gttaaaagaa gaaaataaca acggaaaaga aaaattaagg 1020 atcatggcag tgaaaaattc agaagtcatg gcacaactaa ctgaatctag acaaagtatt 1080 ttgaagctag agagtgagtt agagaacaaa gacgaaatac ttagagacaa attttcttta 1140 atgaatgaaa accgagaatt aaaggtccgt gttgcagcac agaatgagcg actagattta 1200 tgtcaacaag aaattgaaag ttcaagggta gaactaagaa gtttggaaaa gattatatcc 1260 cagttgccat taaaaagaga attatttggc tttaaatcat atctttctaa ataccagatg 1320 agtagcttct caaacaagga agaccgttgc attggctgct gtgaggcaaa taaattggtg 1380 atttcggaat tgagaattaa gcttgcaata aaagaggcag aaattcaaaa gcttcatgca 1440 aacctgactg caaatcagtt atctcagagt cttattactt gtaatgacag ccaagaaagt 1500 agcaaattaa gtagtttaga aacagaacct gtaaagctag gtggtcatca agtagcagaa 1560 agcgtaaaag atcaaaatca acatactatg aacaagcaat atgaaaaaga gaggcaaaga 1620 cttgttactg gaatagaaga actacgtact aagctgatac aaatagaagc tgaaaattct 1680 gatttgaagg ttaacatggc tcacagaact agtcagtttc agctgattca agaggagctg 1740 ctagagaaag cttcaaactc cagcaaactg gaaagtgaaa tgacaaagaa atgttctcaa 1800 cttttaactc ttgagaaaca gctggaagaa aagatagttg cttattcctc tattgctgca 1860 aaaaatgcag aactagaaca ggagcttatg gaaaagaatg aaaagataag gagtctagaa 1920 accaatatta atacagagca tgagaaaatt tgtttagcct ttgaaaaagc aaagaaaatt 1980 cacttggaac agcataaaga aatggaaaag cagattgaaa gagttaggca actagattca 2040 gcattggaaa tttgtaagga agaacttgtc ttgcatttga atcaattgga aggaaataag 2100 gaaaagtttg aaaaacagtt aaagaagaaa tctgaagagg tatattgttt acagaaagag 2160 ctaaagataa aaaatcacag tcttcaagag acttctgagc aaaacgttat tctacagcat 2220 actcttcagc aacagcagca aatgttacaa caagagacaa ttagaaatgg agagctagaa 2280 gatactcaaa ctaaacttga aaaacaggtg tcaaaactgg aacaagaact tcaaaaacaa 2340 agggaaagtt cagctgaaaa gttgagaaaa atggaggaga aatgtgaatc agctgcacat 2400 gaagcagatt tgaaaaggca aaaagtgatt gagcttactg gcactgccag gcaagtaaag 2460 attgagatgg atcagtacaa agaagagctg tctaaaatgg aaaaggaaat aatgcaccta 2520 aaacgagatg gagaaaataa agcaatgcac ctctctcaat tagatatgat cttagatcag 2580 acaaagacag agctagaaaa gaaaacaaat gctgtaaagg agttagaaaa gttacagcac 2640 agtactgaaa ctgaactaac agaagccttg caaaaacggg aagtacttga gactgaacta 2700 caaaatgctc atggagaatt aaaaagtact ttaagacaac tccaggaatt gagagatgta 2760 ctacagaagg ctcaattatc attagaggaa aaatacacta ctataaagga tctcacagct 2820 gaacttagag aatgcaagat ggagattgaa gacaaaaagc aggagctcct tgaaatggat 2880 caggcactta aagagagaaa ttgggaacta aagcaaagag cagctcaggt tacacatttg 2940 gatatgacta ttcgtgagca cagaggagaa atggaacaaa aaataattaa attagaaggt 3000 actctggaga aatcagaatt ggaacttaaa gaatgtaaca aacagataga aagtctgaat 3060 gacaaattac aaaatgctaa agaacaggtt cgagaaaaag agtttataat gctacaaaat 3120 gaacaggaga taagtcaact gaaaaaagaa attgaaagaa cacaacaaag gatgaaagaa 3180 atggagagtg ttatgaaaga gcaagaacag tacattgcca ctcagtacaa ggaggccata 3240 gatttggggc aagaattgag gctgacccgg gagcaggtgc agaactctca tacagaattg 3300 gcagaggctc gtcatcagca agtccaagca cagagagaaa tagaaaggct ctctagtgaa 3360 ctggaggata tgaagcaact ctctaaagag aaagatgctc atggaaacca tttagctgaa 3420 gaactggggg cttctaaagt acgtgaagct catttagaag caagaatgca agcagaaatc 3480 aagaaattgt cagcagaagt agaatctctc aaagaagctt atcatatgga gatgatttca 3540 catcaagaga accatgcaaa gtggaagatt tctgctgact ctcaaaagtc ttctgttcag 3600 caactaaacg aacagttaga gaaggcaaaa ttggaattag aagaagctca ggatactgta 3660 agcaatttgc atcaacaagt ccaagatagg aatgaagtaa ttgaagctgc aaatgaagca 3720 ttacttacta aagaatcaga attaaccaga ttacaggcca aaatttctgg acatgaaaag 3780 gcagaagaca tcaagtttct gccagcccca tttacatctc caacagaaat tatgcctgat 3840 gttcaagatc caaaatttgc taaatgtttt cacacatctt tttccaagtg tacaaaatta 3900 cgtcgctcta ttagtgccag tgatcttact ttcaaaattc atggtgatga agatctttct 3960 gaagaattac tacaggactt aaagaaaatg caattagaac agccttcaac attagaagaa 4020 agccataaga atctgactta cacccagcca gactcattta aacctctcac atataaccta 4080 gaagctgata gttctgagaa taatgacttt aacacgctta gtgggatgct aagatacata 4140 aacaaagaag taagactatt aaaaaagtct tctatgcaaa caggtgctgg tttaaatcag 4200 ggagaaaatg tgtaattcaa agaagatact gatgtgttga aaaaatggaa tttttggtac 4260 tgtgctgttt acttattata tgtagctcat acttcataga agctgttatt ttgcttttga 4320 ataaatttta tatttcaata ttttaaaaga aagcccttct aaaacttaat tatattttta 4380 aagaaaattt aaaaaaaaaa aaaaaggggg 4410 26 5032 DNA Homo sapiens misc_feature Incyte ID No 1758089CB1 26 ccggcccgag cggggcctgg gggtgcgacg ccgagggcgg gggagagcgc gccgctgctc 60 ccggaccggg ccgcgcacgc cgcctcagga accatcactg ttgctggagg cacctgacaa 120 atcctagcga atttttggag catctccacc caggaacctc gccatccaga agtgtgcttc 180 ccgcacagct gcagccatgg ggtctgagga ccacggcgcc cagaacccca gctgtaaaat 240 catgacgttt cgcccaacca tggaagaatt taaagacttc aacaaatacg tggcctacat 300 agagtcgcag ggagcccacc gggcgggcct ggccaagatc atccccccga aggagtggaa 360 gccgcggcag acgtatgatg acatcgacga cgtggtgatc ccggcgccca tccagcaggt 420 ggtgacgggc cagtcgggcc tcttcacgca gtacaatatc cagaagaagg ccatgacagt 480 gggcgagtac cgccgcctgg ccaacagcga gaagtactgt accccgcggc accaggactt 540 tgacgacctt gaacgcaaat actggaagaa cctcaccttt gtctccccga tctacggggc 600 tgacatcagc ggctctttgt atgatgacga cgtggcccag tggaacatcg ggagcctccg 660 gaccatcctg gacatggtgg agcgcgagtg cggcaccatc atcgagggcg tgaacacgcc 720 ctacctgtac ttcggcatgt ggaagaccac cttcgcctgg cacaccgagg acatggacct 780 gtacagcatc aactacctgc actttgggga gcctaagtcc tggtacgcca tcccaccaga 840 gcacggcaag cgcctggagc ggctggccat cggcttcttc cccgggagct cgcagggctg 900 cgacgccttc ctgcggcata agatgaccct catctcgccc atcatcctga agaagtacgg 960 gatccccttc agccggatca cgcaggaggc cggggaattc atgatcacat ttccctacgg 1020 ctaccacgcc ggcttcaatc acgggttcaa ctgcgcagaa tctaccaact tcgccaccct 1080 gcggtggatt gactacggca aagtggccac tcagtgcacg tgccggaagg acatggtcaa 1140 gatctccatg gacgtgttcg tgcgcatcct gcagcccgag cgctacgagc tgtggaagca 1200 gggcaaggac ctcacggtgc tggaccacac gcggcccacg gcgctcacca gccccgagct 1260 gagctcctgg agtgcgtccc gggcctcgct gaaggccaag ctcctccgca ggtctcaccg 1320 gaaacggagc cagcccaaga agccgaagcc cgaagacccc aagttccctg gggagggtac 1380 ggctggggca gcgctcctag aggaggctgg gggcagcgtg aaggaggagg ctgggccgga 1440 ggttgacccc gaggaggagg aggaggagcc gcagccactg ccacacggcc gggaggccga 1500 gggcgcagaa gaggacggga ggggcaagct gcggccaacc aaggccaaga gcgagcggaa 1560 gaagaagagc ttcggcctgc tgcccccaca gctgccgccc ccgcctgctc acttcccctc 1620 agaggaggcg ctgtggctgc catccccact ggagcccccg gtgctgggcc caggccctgc 1680 agccatggag gagagccccc tgccggcacc ccttaatgtc gtgccccctg aggtgcccag 1740 tgaggagcta gaggccaagc ctcggcccat catccccatg ctgtacgtgg tgccgcggcc 1800 gggcaaggca gccttcaacc aggagcacgt gtcctgccag caggcctttg agcactttgc 1860 ccagaagggt ccgacctgga aggaaccagt ttcccccatg gagctgacgg ggccagagga 1920 cggtgcagcc agcagtgggg caggtcgcat ggagaccaaa gcccgggccg gagaggggca 1980 ggcaccgtcc acattttcca aattgaagat ggagatcaag aagagccggc gccatcccct 2040 gggccggccg cccacccggt ccccactgtc ggtggtgaag caggaggcct caagtgacga 2100 ggaggcatcc cctttctccg gggaggaaga tgtgagtgac ccggacgcct tgaggccgct 2160 gctgtctctg cagtggaaga acagggcggc cagcttccag gccgagagga agttcaacgc 2220 agcggctgcg cgcacggagc cctactgcgc catctgcacg ctcttctacc cctactgcca 2280 ggccctacag actgagaagg aggcacccat agcctccctc ggagagggct gcccggccac 2340 attaccctcc aaaagccgtc agaagacccg accgctcatc cctgagatgt gcttcacctc 2400 tggcggtgag aacacggagc cgctgcctgc caactcctac atcggcgacg acgggaccag 2460 ccccctgatc gcctgcggca agtgctgcct gcaggtccat gccagttgct atggcatccg 2520 tcccgagctg gtcaatgaag gctggacgtg ttcccggtgc gcggcccacg cctggactgc 2580 ggagtgttgc ctgtgcaacc tgcgaggagg tgcgctgcag atgaccaccg ataggaggtg 2640 gatccacgtg atctgtgcca tcgcagtccc cgaggcgcgc ttcctgaacg tgattgagcg 2700 ccaccctgtg gacatcagcg ccatccccga gcagcggtgg aagctgaaat gcgtgtactg 2760 ccggaagcgg atgaagaagg tgtcaggtgc ctgtatccag tgctcctacg agcactgctc 2820 cacgtccttc cacgtgacct gcgcccacgc cgcaggcgtg ctcatggagc cggacgactg 2880 gccctatgtg gtctccatca cctgcctcaa gcacaagtcg gggggtcacg ctgtccaact 2940 cctgagggcc gtgtccctag gccaggtggt catcaccaag aaccgcaacg ggctgtacta 3000 ccgctgtcgc gtcatcggtg ccgcctcgca gacctgctac gaagtgaact tcgacgatgg 3060 ctcctacagc gacaacctgt accctgagag catcacgagt agggactgtg tccagctggg 3120 acccccttcc gagggggagc tggtggagct ccggtggact gacggcaacc tctacaaggc 3180 caagttcatc tcctccgtca ccagccacat ctaccaggtg gagtttgagg acgggtccca 3240 gctgacggtg aagcgtgggg acatcttcac cctggaggag gagctgccca agagggtccg 3300 ctctcggctg tcactgagca cgggggcacc gcaggagccc gccttctcgg gggaggaggc 3360 caaggccgcc aagcgcccgc gtgtgggcac cccgcttgcc acggaggact ccgggcggag 3420 ccaggactac gtggccttcg tggagagcct cctgcaggtg cagggccggc ccggagcccc 3480 cttctaggac agctggccgc tcaggcgacc ctcagcccgg cggggaggcc atggcatgcc 3540 ccgggcgttc gcttgctgtg aattcctgtc ctcgtgtccc cgacccccga gaggccacct 3600 ccaagccgcg ggtgccccct agggcgacag gagccagcgg gacgccgcac gcggccccag 3660 actcagggag cagggccagg cgggctcggg ggccggccag gggagcaccc cactcaacta 3720 ctcagaattt taaaccatgt aagctctctt cttctcgaaa aggtgctact gcaatgccct 3780 actgagcaac ctttgagatt gtcacttctg tacataaacc acctttgtga ggctctttct 3840 ataaatacat attgtttaaa aaaaagcaag aaaaaaagga aaacaaagga aaatatcccc 3900 aaagttgttt tctagatttg tggctttaag aaaaacaaaa caaaacaaac acattgtttt 3960 tctcagaacc aggattctct gagaggtcag agcatctcgc tgtttttttg ttgttgtttt 4020 aaaatattat gatttggcta cagaccaggc agggaaagag acccggtaat tggagggtga 4080 gcctcggggg gggggcagga cgccccggtt tcggcacagc ccggtcactc acggcctcgc 4140 tctcgcctca ccccggctcc tgggctttga tggtctggtg ccagtgcctg tgcccactct 4200 gtgcctgctg ggaggaggcc caggctctct ggtggccgcc cctgtgcacc tggccagggg 4260 aagcccgggg gtctggggcc tccctccgtc tgcgcccacc tttgcagaat aaactctctc 4320 ctggggtttg tctatctttg tttctctcac ccgagagaaa cgcaggtgtt ccagaggctt 4380 ccttgcagac aaagcacccc tgcacctccc atggctcagg atgagggagg cccccaggcc 4440 cttctggttg gtagtgagtg tggacagctt cccagctctt cgggtacaac cctgagcagg 4500 tcgggggaca cagggccgag gcaggccttc ggggcccctt tcgcctgctt ccgggcaggg 4560 acgaggcctg gtgtcctcgc tccacccacc cacgctgctg tcacctgagg ggaatctgct 4620 tcttaggagt gggttgagct gatagagaaa aaacggcctt cagcccaggc tgggaagcgc 4680 cttctccagg tgcctctccc tcaccagctc tgcacccctc tggggagcct tccccacctt 4740 agctgtctcc tgccccaggg agggatggag gagataattt gcttatatta aaaacaaaaa 4800 atggctgagg caggagtttg ggaccagcct gggctatata gcaagacccc atcactacaa 4860 attttttaca aattagctag gtgtggtggt gcgcacctgt ggtcccagct actcgggagg 4920 ctgtggtggg aggattgctt gagtccagga ggttgaggct gcagtcagct cagattgcac 4980 cactgcactc cagcctgggc aacagagcga gaccctgtct ccaaaaaaaa aa 5032 27 1355 DNA Homo sapiens misc_feature Incyte ID No 3533891CB1 27 cggggacgcg cgcccggcct gtcgctgtgg aaaccgctag gccagcgctc gccgggacct 60 ggaatccctg tacgccgagg tgggagccgg tggaccggtc ccccagccgg cccccacctc 120 cgcttcccgg tgtttgaggg ttcgggcctc ccgccgggga gttcacccct cgggctcgtc 180 agtagggctg tggctgtcgc ctcttcctgc agcgccaggc tccgcccggt ctcacagtcg 240 gcttaggggc tttgcgtgca ctgcggttgg gtggaaaaac ccactcctgg ttgtttagac 300 gttggcctgc agacgatgtc atttctgtat tcctctaagg caggaagtca ttatgcaact 360 tacacatatt catcagattt cctctgactt acccggacat gtacatggga atgatgtgca 420 ctgccaagaa atgtgggatt aggtttcagc ctccagctat tatcttaatc tatgagagtg 480 aaatcaaggg gaaaattcgc cagcgcatta tgccagttcg aaacttttca aagttttcag 540 attgcaccag agctgctgaa caattaaaga ataatccgcg acacaagagt tacctagaac 600 aagtatccct gaggcagcta gagaagctat tcagtttttt acgaggttac ttgtcggggc 660 agagtctggc agaaacaatg gaacaaattc aacgggaaac aaccattgat cctgaggaag 720 acctgaacaa actagatgac aaggagcttg ccaaaagaaa gagcatcatg gatgaacttt 780 ttgagaaaaa tcagaagaag aaggatgatc caaattttgt ttatgacatt gaggttgaat 840 ttccacagga cgatcaactg cagtcctgtg gctgggacac agagtcagct gatgagttct 900 gataccaaac actcaaaaca tgcattgggc tagcagaata tccatgttta ttaccagact 960 ggttctggaa gaagctgtaa agaatactaa atatgttggg ttatagggga ttgaccatgt 1020 tacttttcaa aaccaggaca tttaaagcat ctactatgta ggtgcatgag gagtatggga 1080 aaaacagaat aaaggaatct gcctttaagg agcttacaat catgccgggt gcggtggctc 1140 acgcctgtaa tcccagcact ttgggaggct gaggcgggtg gatcacctaa ggtcaggagt 1200 tcgagaccag cctagccaac atggtgaaac ctcgcctcta ctaaaaatac aaaaattagc 1260 caggcgtggt ggcgggtgcc tgtaatcccg gctactcagg aggctgaggc aggagattcg 1320 cttgaacctg ggattaactg acgttgcagt gagcc 1355 28 4912 DNA Homo sapiens misc_feature Incyte ID No 1510943CB1 28 cgggccccag cggcggcagc ggagagcgcg gtcccgggtc ggagcctggg acacctccgc 60 acggacgggg cgggcggcgc ggacaggcca tggggacccg ggccgggcca gcggtggcgg 120 gccagcggga gccccgggcc tgagaagtgg gcggcggggt ggcgggggcc atgacctcgg 180 tgtggaagcg cctgcagcgc gtgggcaagc gggcggccaa gttccagttc gtggcctgtt 240 accacgagct agtgttggag tgcaccaaga aatggcagcc agataagctg gtggtggtat 300 ggacccgtcg gaaccgacgc atctgctcca aggcccacag ctggcagccg ggcatccaga 360 acccataccg gggcaccgtg gtgtggatgg tacctgagaa tgtggacatc tctgtgaccc 420 tctacaggga cccccacgtg gaccagtatg aggccaaaga gtggacattt attattgaaa 480 atgagtctaa ggggcagcgg aaggtgctgg ccacggccga ggtggacctg gcccgccatg 540 cagggcccgt gcctgtccaa gtcccactga ggctgcggct gaagccaaag tcagtgaagg 600 tggtgcaggc tgagctgagc ctcactcttt ccggggtgct gctgcgggag ggccgtgcca 660 cggacgatga catgcagagt ctcgcaagcc tcatgagtgt gaagcctagt gatgtgggca 720 acttggatga ctttgctgag agtgatgaag atgaggctca tggcccagga gccccggagg 780 cccgggctcg agtcccccag ccagatccct ctcgagagct gaagacgctt tgtgaggagg 840 aggaggaagg ccaaggacga ccccagcagg cagttgccag cccttctaat gctgaggata 900 ccagcccagc ccctgtgagt gctcctgcac ccccagccag aacctcccga ggccaggggt 960 cagaacgagc taatgaagcg gggggccagg taggccctga ggccccaagg cccccggaaa 1020 cctcaccaga gatgaggtct tcaaggcagc cagcccagga cacggccccc accccagccc 1080 ctcggctccg gaaaggctct gatgccctcc ggcccccagt cccccagggg gaagatgagg 1140 tccccaaagc ctcaggggct cctccagcag gattgggctc tgctagggag acccaggccc 1200 aggcatgccc tcaggaaggg acagaagccc atggagctag gctgggcccg agcattgagg 1260 ataaaggttc tggagaccct tttggaaggc agagactcaa ggctgaagag atggacactg 1320 aggacaggcc agaggccagt ggggtggaca ctgagccaag gtcaggaggc agagaggcaa 1380 acactaagag gtcaggagtc agagctgggg aggctgaaga gagttcagca gtttgtcaag 1440 tggatgctga gcagaggtca aaggtgagac atgtggacac taagggacca gaggcgacag 1500 gggtgatgcc tgaggcaaga tgcaggggga cccctgaggc tcctccaagg ggctctcagg 1560 ggaggctggg agtcaggacc agggatgagg ctccctcagg cctgagcctg cccccagcgg 1620 agcctgcagg gcactctggg caacttggtg acctcgaggg ggccagggct gctgcaggcc 1680 aggagagaga gggtgcagaa gtgaggggtg gagcacctgg tattgagggg acaggcctgg 1740 agcagggccc ttctgttgga gcaataagca ccaggcccca ggtgagcagc tggcaggggg 1800 ccctgttatc aactgcccag ggggcaatat ccaggggtct gggaggctgg gaggcagaag 1860 ctgggggttc aggggtcctg gaaacagaga ctgaggtggt agggttggag gtgctgggaa 1920 cccaggagaa agaagttgag gggtcagggt tcccagagac taggacacta gaaattgaga 1980 tattgggggc cttggagaaa gaagcagcaa gatcaagggt cctggagtca gaggttgctg 2040 ggacagcaca gtgtgaggga ctggagaccc aggaaacaga ggtgggggtc atagagaccc 2100 cagggacaga gactgaggta ttggggaccc agaaaacaga agctgggggt tcaggagttt 2160 tgcagacaag aactacgata gcagagactg aggtactggt gacccaggag atatctgggg 2220 atttagggcc actgaagata gaagatacaa tacagtctga gatgctgggg acccaggaga 2280 cagaggtgga agcttctagg gtaccagagt cagaggctga ggggacagaa gctaaaatat 2340 tagggaccca ggagataaca gctagggatt caggggtcag agagatagaa gcagagatag 2400 cagagtctga catattggta gcccaggaga tagaggtggg acttttgggg gttctgggaa 2460 tagagactgg ggcagcagaa ggtgcgatat tggggaccca agagatagca tctagggatt 2520 caggggtccc agggttagaa gctgatacaa cagggatcca ggtgaaagag gttgggggtt 2580 cagaggttcc agagatagcg actgggacag cagaaactga gatattgggg acccaagaga 2640 tagcatctag gagttcaggg gtcccagggc tagaatctga ggtagctggg gcccaggaga 2700 cagaggtcgg gggttcaggg atctcagggc ccgaggctgg aatggcagag gcccgagtac 2760 tgatgacccg taagacagaa attatagttc cagaggctga gaaggaagag gctcagactt 2820 cgggggtcca ggaagcagag actagagttg ggagtgctct caaatatgag gctttaaggg 2880 ccccagtcac tcagccaaga gttttaggat cccaggaagc aaaagcagag atttcaggag 2940 tacaagggtc agagactcaa gttctgagag tccaggaggc agaggctggg gtttggggga 3000 tgtcagaggg caaatctggg gcttgggggg cccaggaagc agagatgaag gttttagagt 3060 ctccagagaa caaatctggt acttttaagg cccaggaagc ggaggctggg gtcttgggaa 3120 atgagaaggg gaaagaagct gagggaagcc tcacagaggc cagcctgcct gaagcacagg 3180 tggccagtgg ggcaggggct ggggcgccca gggcctcttc cccagagaag gctgaagagg 3240 acaggaggct gccgggcagc caggcaccac ctgccctggt cagctccagc cagtccctgc 3300 tggagtggtg ccaggaagtc accactggct accgtggcgt ccgcatcacc aacttcacca 3360 catcctggcg caacggcttg gccttctgtg ccatcctgca ccgattctac ccagacaaga 3420 ttgactatgc ctcgctagac ccactcaaca tcaagcagaa caacaagcag gccttcgatg 3480 gcttcgcggc tctgggcgtg tcgcggctgc tggagcccgc ggacatggtg ctactgtcgg 3540 tgcccgacaa gctcatcgtc atgacgtacc tgtgccagat ccgcgccttc tgcaccgggc 3600 aggagctgca gctggtacaa ctggagggcg gcggcggcgc cggcacgtac cgcgtgggca 3660 gcgcccagcc cagcccgccc gacgacctgg acgccggagg cctggcgcag cggctgcgcg 3720 gtcacggggc cgaggggccc caggagccca aggaggccgc agaccgcgca gacggggcgg 3780 ccccgggggt ggcctccagg aacgcggtcg cgggccgcgc ctccaaggac ggcggggccg 3840 aggccccccg agagtcgcga cccgcggagg tcccggccga ggggctggtg aacggggcgg 3900 gggcaccggg cggcggcggc gtgaggctgc gacggccctc ggtcaacggg gagcccgggt 3960 cggtgccccc gccccgcgcg cacggctcct tctcccacgt gcgcgacgcg gacctgctca 4020 agaagaggcg ctcgcggctg cggaacagca gctcgttctc gatggacgat ccggacgcgg 4080 gagccatggg agctgcggct gcagaaggcc aggcccctga ccccagccct gccccaggcc 4140 cacccacagc tgcagactct caacagcccc ctggtgggag ttccccctcg gaggaaccac 4200 ccccaagccc aggggaggag gctgggctgc aacggttcca ggacacaagt cagtacgtgt 4260 gtgcagagct gcaggccctg gaacaggagc agaggcagat agatgggcgg gcggctgagg 4320 tggagatgca gctgaggagc ctcatggagt caggtgccaa caagctgcag gaggaggtgc 4380 tgatccagga gtggttcacc ctggtcaaca agaagaacgc tctcatccgg aggcaggacc 4440 agctgcagct gctcatggag gagcaggact tggagcgaag gttcgagctg ctgagccgcg 4500 agctgcgggc catgctggcc atcgaagact ggcagaaaac gtccgctcag cagcaccgag 4560 agcagctcct actggaggag ctggtgtcgc tggtgaacca gcgcgatgag ctagtccggg 4620 acctggacca caaggagcgg atcgccctgg aggaggacga gcgcctggag cgcggcctgg 4680 aacagcggcg ccgcaagctg agccggcagt tgagccggcg ggagcgctgc gtgctgagct 4740 gaggccgccg gcccgggtgg cccataactt ctcgcgtccc cggcgtccgc cgccgccccg 4800 ggcctgcgct gcggacgacc cggccgtccc ggaggccgcg cgcgtgtccg ctaggggccg 4860 ccggcgccct tccccgtata gggcagggcg gatccccgac cccacgggcg gg 4912 29 2241 DNA Homo sapiens misc_feature Incyte ID No 2119377CB1 29 cccacgcgtc cgcgaggtag cggtggcctg cagcggcctc ctccccgcag tgaagcatgg 60 gccagaagct ctcggggagc ctcaagtcag tggaggtgcg agagccggcg ctgcggccgg 120 ccaagcggga gctgcggggt gcagagcccg ggcggccggc gcggctggac cagctgttgg 180 acatgccagc ggcggggctg gctgtgcagc tgcggcacgc gtggaacccc gaggaccgct 240 cgctcaacgt cttcgtcaag gacgacgacc ggctcacctt ccaccggcac cccgtggccc 300 agagcaccga cggcatccgc ggcaaggtgg gccacgcccg cggcctgcac gcctggcaga 360 tcaactggcc ggctcggcag cgcggcaccc acgctgtagt tggtgtggcc acggcccgtg 420 ctcccctgca ctccgtgggc tacacggcgc tggtaggcag tgacgccgag tcgtggggct 480 gggacctggg ccgcagccgc ctctaccacg acggcaagaa ccagcccggc gtggcctacc 540 cggcctttct ggggcccgac gaggcctttg cgctgcccga ctcgctgctc gtggtgctgg 600 acatggatga gggcacactc agcttcatcg tggatggcca gtacctgggc gtggccttcc 660 gaggtctcaa gggcaagaag ctgtacccgg tggtgagtgc cgtgtggggc cactgtgaag 720 tcaccatgcg ctacatcaac ggccttgacc ccgagcccct gccactgatg gacctgtgcc 780 ggagatccat ccgctcggcc ctgggccgcc agcgcctgca ggacatcagc tccctgcccc 840 tgcctcagtc tctcaaaaac tatctgcagt accagtgagc caagcctgat gggcagcaca 900 gacacagaca cacaccgcag ggcccgaccc tcctgtcatt cacagtccca tggcacatag 960 gggaaaggat ctacccttct cctggctccc caggacactc agttctttca aagaccagga 1020 tgtggtacca actttggaaa cgaaaggtct cttgccaaca gtatctactg ccctcgaggc 1080 agccctccca agtcagacac ctccttcgga gccacagaga gcctggagtc tgcacctcct 1140 ggaaatcctg ccaccaacca ggacacagca gccaccgtat tgatcagaga gcctgtttcc 1200 ttattcaaga gaatgaataa aacatttagg caggagactt tctattgtgt gccccgttgc 1260 agacagggcc agggagaaat tagccagtgc agggggaaaa ttgcctctga ataatgaatg 1320 atgaaagcct gacgccgtgc ccctcctggc ccatacgcct tgccagggcg gcaggattgt 1380 cacaccgttt taggactctg tgccactttg agagactgtt cccaggaggc ccaaccgcag 1440 acctggcaag tggacagtgc agtgtggaga caccttccgg cttacctctt tgaacgttgt 1500 ttacctaccc ctttccacgt gctccccttc ccagccactg actcacagtt ctctggatgc 1560 ccagacacct ctcttcaggg aagatgagtc tgactggttt gccccaggga agagcgtatc 1620 cttaccatta ttttaagtag catttgcatt ttaaaagagg aatgcggaga ggacagtact 1680 tagtccaaag gtgctaacgg gggaactggg ggcattgtga cacccaagtc tgatgtgtcc 1740 tgggttgggg ggccttcctg gagtgtcagg gtctctgggc aacgtccatt cagggtgcgg 1800 catggctgtc acaaagcttt atttgagcaa attatttttt cactttagga gacttctaca 1860 agtttgtttc ctgtttcaaa tgtgtgtgtg atgtgctgtt tatttatcag cttgaggtcc 1920 atgggggcag ccttgtgact ggaagggtgg atatgggaga cacattctct acctgctccg 1980 agcctggtcc tctcgcagga atgctgctgc tgcctccgcc gccactgctg ctgccacctc 2040 ttatatgttt cagacactct ctgcccagac tcatttttaa ctggaaatca tcacagcagt 2100 gggatatcag agccccagac agcactgcct cttcctcccc accccactgc ccccacctta 2160 atgtgaattt gactgatgaa tgaagagcgt ttctaataaa gtttgtcatt cagtccttaa 2220 aaaaaaaaaa aaaaaaaaaa a 2241 30 1853 DNA Homo sapiens misc_feature Incyte ID No 3176058CB1 30 gaacgggacc gctttcccgg aagtgcttgc ggcctctgcc cagcgagctg ccccggggtc 60 tctctggttt cctaatcagg gcaacgccgc gggagagaac ctttaccttg gctgcactaa 120 gttctcggtg ccactccctg gcagggcggg accttgttta ggccctgtga tcgcgcggtt 180 cgtagtagcg caaggcgcag agtggacctt gacccgccta gggcgggaag agtttggccc 240 gccgggtccc aaagggcaga atggacgggc tcctaaatcc cagggaatcc tctaaattca 300 ttgcagaaaa cagtcgggat gtgtttattg acagcggagg cgtacggagg gtggcagagc 360 tgctgctggc caaggcggcg gggccagagc tgcgcgtgga ggggtggaaa gcccttcatg 420 agctgaaccc cagggcggcc gacgaggccg cggtcaactg ggtgttcgtg acagacacgc 480 tcaacttctc cttttggtcg gagcaggacg agcacaagtg tgtggtgagg tacagaggga 540 aaacatacag tgggtactgg tccctgtgcg ccgccgtcaa cagagccctc gacgaaggga 600 taccaataac tagtgcctcg tactacgcga cagtgaccct ggatcaggtt cggaatatac 660 ttcgttctga cacagacgtt tccatgcctt tagtagaaga gaggcatcgg attctcaatg 720 aaaccgggaa aattctgctg gagaagtttg gaggctcttt tctcaactgc gtccgagaaa 780 gtgagaatag tgcgcagaag ttaatgcacc tggtggttga aagttttcct tcttacagag 840 atgtgactct gtttgagggg aaaagagttt ctttttacaa acgagcccaa atccttgtag 900 cagatacgtg gagtgtattg gaaggaaaag gagatggctg cttcaaggac atctccagta 960 tcaccatgtt tgctgattat agattacctc aggttcttgc tcatcttgga gccctgaaat 1020 actctgatga cctactgaag aagcttctca aaggagaaat gctctcatat ggagacaggc 1080 aagaggtgga aatcagaggg tgctcgcttt ggtgtgttga gctgatccgg gattgtcttc 1140 tggagcttat tgaacaaaag ggtgaaaaac ctaatggaga gatcaattcc attcttctgg 1200 attattactt atgggactat gcccatgacc atagggaaga tatgaaagga attccgtttc 1260 atcgcatacg ttgcatatat tattgacctc aagtgtaaac tgatccaaag aaaaccccct 1320 gcgttttata tcatatcatc tgtacagttt tgctttgata tttagagaac atgatcgagg 1380 ttataggaaa ttgattgccc attctcactt gaaaaatact tcctaggccg ggcacagtgg 1440 tttatgcctg taatcccagc actgtgggag gctgaggcgg gtggatcatc tgaggtcagg 1500 agtttgagac cacctggcca acatggtgaa accccatctc tactaaaaat acaaaattag 1560 ctgggcgtgg tggcacgtgc ctgtaatccc agttacttgg gaggctgagg caagagaatc 1620 gcttgaactc agaaggtgga ggttgcagtg aggcgagatt aggccattgc actccagcct 1680 cagcaacaag agtgaaactt tgtctcaaaa aacaacaaca acaacaacaa caacaacaaa 1740 acttcctagg ccagatgtgg tggctcatat gtataatctt agcactttgg gaggccaagg 1800 caggaggatt gcttgaggcg aggagttcaa gaccagccta ggcaacatag gga 1853 31 2541 DNA Homo sapiens misc_feature Incyte ID No 2299818CB1 31 aaaacattct tggccaaaat ctaggggaag ttactgccac ttcgtactat ataaggaaaa 60 caaagacacc atggatgcta ttaatgtact ctccaaatac ttaagagtca agccaaatat 120 attctcctac atgggaacca aagataaaag ggctataaca gttcaagaaa ttgctgttct 180 caaaataact gcacaaagac ttgcccacct gaataagtgc ttgatgaact ttaagctagg 240 gaatttcagc tatcaaaaaa acccactgaa attgggagag cttcaaggaa accacttcac 300 tgttgttctc agaaatataa caggaactga tgaccaagta cagcaagcta tgaactctct 360 caaggagatt ggatttatta actactatgg aatgcaaaga tttggaacca cagctgtccc 420 tacgtatcag gttggaagag ctatactaca aaattcctgg acagaagtca tggatttaat 480 attgaaaccc cgctctggag ctgaaaaggg ctacttggtt aaatgcagag aagaatgggc 540 aaagaccaaa gacccaactg ctgccctcag aaaactacct gtcaaaaggt gtgtggaagg 600 gcagctgctt cgaggacttt caaaatatgg aatgaagaat atagtctctg catttggcat 660 aatacccaga aataatcgct taatgtatat tcatagctac caaagctatg tgtggaataa 720 catggtaagc aagaggatag aagactatgg actaaaacct gttccagggg acctcgttct 780 caaaggagcc acagccacct atattgagga agatgatgtt aataattact ctatccatga 840 tgtggtaatg cccttgcctg gtttcgatgt tatctaccca aagcataaaa ttcaagaagc 900 ctacagggaa atgctcacag ctgacaatct tgatattgac aacatgagac acaaaattcg 960 agattattcc ttgtcagggg cctaccgaaa gatcattatt cgtcctcaga atgttagctg 1020 ggaagtcgtt gcatatgatg atcccaaaat tccacttttc aacacagatg tggacaacct 1080 agaagggaag acaccaccag tttttgcttc tgaaggcaaa tacagggctc tgaaaatgga 1140 tttttctcta cccccttcta cttacgccac catggccatt cgagaagtgc taaaaatgga 1200 taccagtatc aagaaccaga cgcagctgaa tacaacctgg cttcgctgag cagtaccttg 1260 tccacagatt agaaaacgta cacaagtgtt tgcttcctgg ctccctgtgc atttttgtct 1320 tagttcagac tcatatatgg atttcaaatc tttgtaataa aaattatttg tatttttaag 1380 tttttattag cttaaagaaa taatttgcaa tatttgtaca tgtacacaaa tcctgaggtt 1440 cttaatttta gctcagaata taaattagtc aaaatacact tcaggtgctt aaatcagagt 1500 aaaatgtcag ctttacaata ataaaaaaag gactttggtt taaagtagca ggtttaggtt 1560 ttgctacatt ctcaaaagac agcaggagta tttgacacat ctgtgatgga gtatacaaca 1620 atgcatttta agagcaaatg caacaaaaca aatctggact atggataaat aatttgagag 1680 ctgccaccca caaatataaa tacagtactc atgctgactg aaataataag acatctacaa 1740 atttataaac aaaaagtgat tgtcattatc ctgcttatgt actagattca ggcaagcatt 1800 atagactttt tggttgcggt ggcttttgca tttatattat caatgccttg caggaacgtt 1860 gcattgatag gcccatttta tttttttatt ttttttttcg agacaggatc tcactctgta 1920 gcacaggctg gattgcagtg caatcctgca attctcaatc ttgcactgca gcctcgacct 1980 cccaggctcc agtgactctc ccacctcagc ctcctaagta gctgggagta caggcgcgca 2040 ccaccacgcc tagctgattt ttgtattttt ttgtagagac gggggtttgg ccatgttgcc 2100 gaggctaact cctgggatta caggcatgag ctgtgctggc cgggtttttt tttcttgatg 2160 taaacgtgta cagctgtttt attagttaag gtctaatttt tactctaggt gccttttatg 2220 ttcagaactc tttccactgg actggtattt gctcaaaaat aaataatggt agagaagaaa 2280 actataaaaa tggacaaggc tttcttctat cagtagcgtt taccctttgt caccagtggc 2340 tttggtattt ccatgtctgg cattgcataa acttctctgg tgtgaaagga taaatatgcc 2400 tttctaaagt tgtatatcaa aattgtatca atttttattt tctatgattt ctagaaacaa 2460 atgtaataaa tatttttaaa atctcctttc tactggttat gtaaataaat caaataaata 2520 tatcaaaaaa aaaaaaaaaa a 2541 32 4144 DNA Homo sapiens misc_feature Incyte ID No 2729451CB1 32 gtcgagatgg agcccaactc actccagtgg gtcggctcac cgtgtggctt gcacggacct 60 tacattttct acaaggcttt tcaattccac cttgaaggca aaccaagaat tttgtccctt 120 ggcgactttt tctttgtaag atgtacgcca aaggatccga tttgcatagc ggagctccag 180 ctgttgtggg aagagaggac cagccggcaa cttttatcca gctctaaact ttatttcctc 240 ccagaagaca ctccccaggg cagaaatagc gaccatggcg aggatgaagt cattgctgtt 300 tccgaaaagg tgattgtgaa gcttgaagac ctggtcaagt gggtacattc tgatttctcc 360 aagtggagat gtggcttcca cgctggacca gtgaaaactg aggccttggg aaggaatgga 420 cagaaggaag ctctgctgaa gtacaggcag tcaaccctaa acagtggact caacttcaaa 480 gacgttctca aggagaaggc agacctgggg gaggacgagg aagaaacgaa cgtgatagtt 540 ctcagctacc cccagtactg ccggtaccgc tcgatgctga aacgcatcca ggataagcca 600 tcttccattc taacggacca gtttgcattg gccctggggg gcattgcagt ggtcagcagg 660 aaccctcaga tcctgtactg tcgggacacc tttgaccacc cgactctcat agaaaacgag 720 agtatatgcg atgagtttgc gccaaatctt aaaggcagac cacgcaaaaa gaaaccatgc 780 ccacaaagaa gagattcatt cagtggtgtt aaggattcca acaacaattc cgatggcaaa 840 gccgttgcca aggtgaaatg tgaggccagg tcagccttga ccaagccgaa gaataaccat 900 aactgtaaaa aagtctcaaa tgaagaaaaa ccaaaggttg ccattggtga agagtgcagg 960 gcagatgaac aagccttctt ggtggcactt tataaataca tgaaagaaag gaaaacgccg 1020 atagaacgaa taccctattt aggttttaaa cagattaacc tttggactat gtttcaagct 1080 gctcaaaaac tgggaggata tgaaacaata acagcccgcc gtcagtggaa acatatttat 1140 gatgaattag gcggtaatcc tgggagcacc agcgctgcca cttgtacccg cagacattat 1200 gaaagattaa tcctaccata tgaaagattt attaaaggag aagaagataa gcccctgcct 1260 ccaatcaaac ctcggaaaca ggagaacagt tcacaggaaa atgagaacaa aacaaaagta 1320 tctggaacca aacgcatcaa acatgaaata cctaaaagca agaaagaaaa agaaaatgcc 1380 ccaaagcccc aggatgcagc agaggtttca tcagagcaag aaaaagaaca agagacttta 1440 ataagccaga aaagcatccc tgagcctctc ccagcagcag acatgaagaa aaaaatagaa 1500 gggtatcagg aattttcagc gaagcccctg gcatccagag tagacccaga gaaggacaac 1560 gaaacagacc aaggttcaca cagtgagaag gtggcagagg aggcgggaga gaaggggccc 1620 acacctccac tcccaagtgc tcctctggcc ccagaaaaag attcagcctt ggtccctggg 1680 gccagcaaac agccactcac ctctcctagt gccctggtgg actcaaaaca agaatccaaa 1740 ctgtgctgtt ttacagagag ccctgaaagt gaaccccaag aagcatcctt ccccaccaca 1800 cagccaccgc tggcaaacca gaatgagacg gaggatgaca aactgcccgc catggcagat 1860 tacattgcca actgcaccgt gaaggtggac cagctgggca gtgacgacat ccacaatgcg 1920 ctcaagcaga ccccaaaggt ccttgtggtc cagtcgtttg acatgttcaa agacaaagac 1980 ctgactgggc ccatgaacga gaaccatgga cttaattaca cgcccctgct ctactctagg 2040 ggcaacccag gcatcatgtc cccactggcc aagaaaaagc ttttgtccca agtgagtggg 2100 gccagcctct ccagcagcta cccttatggc tccccacccc ctttgatcag caaaaagaaa 2160 ctgattgcta gggatgactt gtgttccagt ttgtcccaga cccaccatgg ccaaagcact 2220 gaccatatgg cggtcagccg gccatcagtg attcagcacg tccagagttt cagaagcaag 2280 ccctcggaag agagaaagac catcaatgac atctttaagc atgagaaact gagtcgatca 2340 gatccccacc gctgcagctt ctccaagcat caccttaacc cccttgctga ctcctacgtc 2400 ctgaagcaag aaattcagga gggcaaggat aaactcttag agaaaagggc cctcccccat 2460 tcccacatgc ctagcttcct ggctgacttc tactcgtccc ctcatctcca tagcctctac 2520 agacacaccg agcaccatct tcataatgaa cagacatcca aatacccttc cagggacatg 2580 tacagggaat cggaaaacag ttcttttcct tcccacagac accaagaaaa gctccatgta 2640 aattatctca cgtccctgca cctgcaagac aaaaagtcgg cggcagcaga agcccctacg 2700 gatgatcagc ctacagatct gagccttccc aagaacccgc acaaacctac cggcaaggtc 2760 ctgggcctgg ctcattccac cacagggccc caggagagca aaggcatctc ccagttccag 2820 gtcttaggca gccagagtcg agactgtcac cccaaagcct gtcgggtatc acccatgacc 2880 atgtcaggcc ctaaaaaata ccctgaatcg ctttcaagat caggaaaacc tcaccatgtg 2940 agactggaga atttcaggaa gatggaaggc atggtccacc caatcctgca ccggaaaatg 3000 agcccgcaga acattggggc ggcgcggccg atcaagcgca gcctggagga tttggacctt 3060 gtgattgcag ggaaaaaggc ccgggcagtg tctcccttag acccatccaa ggaggtctct 3120 gggaaggaga aggcctctga gcaggagagt gaaggcagca aagcagcgca cggtgggcat 3180 tccgggggcg gatcagaagg ccacaagctt cccctctcct cccctatctt cccaggtctg 3240 tattccggga gcctgtgtaa ctcgggcctc aactccaggc tcccggctgg gtattctcat 3300 tctctgcagt acttgaaaaa ccagactgtg ctttctccac tcatgcagcc cctggctttc 3360 cactcgcttg tgatgcaaag aggaattttt acatcaccga caaattctca gcagctgtac 3420 agacacttgg ctgcggctac acctgtagga agttcatatg gggacctttt gcataacagc 3480 atttaccctt tagctgctat aaatcctcaa gctgcctttc catcttccca gctgtcatcc 3540 gtgcacccca gtacaaaact gtaggctcag ctctgcccag cagtccaaag cggcatggcc 3600 aacagagctt cactccttac ccaggagtgc tggcttatag agttagaagt cagtatttct 3660 tctaatctga ggctatgatc agtcccagct gtaggggccc agaggggagg tgaacatgcc 3720 tgatttttgt gggacaactg tagcccacaa actgactggc tggtgagtct tgactccctt 3780 ccaacacaga tgcccaggca cctccagatc attcacttcg cacgtgggcc ttgtgaaggg 3840 atttgtgaat atccaggaag aacttagagg accccatctg agttcggatg gtcaggaaac 3900 aatctgggca aaaaagaggc aggcatttca aaggaagggg caaggaagac tggcaaacag 3960 atggcaaggg atgcccctct ttttcataaa actctccaag gttcaatcaa tgcaatgtat 4020 agtgaaactt caatagatct ttcattttga cactattaaa caatccagag aagtaaacac 4080 tgttaaattg actgtatata tttgcttctt aaaactacct gtatcactgt ttgctcacct 4140 aatt 4144 33 5218 DNA Homo sapiens misc_feature Incyte ID No 878534CB1 33 attcgcgcgc gccttcccta gccacccggg gttgcctcct aacatggaat ggccaaagga 60 gcgccccttg cgggaagtga gggtgggttg ggactgggtc cgcgttgggg gaggtgcaat 120 cttcgggttt cgcctctcgg ctccctctgg ctctggagtt gggacccctt gtgggctctg 180 gaagtccgcc tgagacttgg gtcaaggagt caaactgtcg ccccccgctc ctcccccaga 240 aatccggtga gcggtaagga aagtgatgcc aagtcttcga agcctcagtg acaaacgcat 300 agcaagaaca catccactcc agagatacct tctcgaaaca aaagattttc ctacctgctt 360 atacttggta accgagggaa ttactaagac ttcttgctca tttctgagta ttgtctttat 420 atcctgacac tatgaatgct acttggatgc ctcttaagtc tgttctctgg ggaggcagta 480 aggggccgtg gagctggcct cggcctcggc atcgggagag gctggacttc ctgtctctct 540 gtgctgaatg gctgcgatgg cgcccgctct cactgacgca gcagctgaag cacaccatat 600 ccggttcaaa ctggctcccc catcctctac cttgtcccct ggcagtgccg aaaataacgg 660 caacgccaac atccttattg ctgccaacgg aaccaaaaga aaagccattg ctgcagagga 720 tcccagccta gatttccgaa ataatcctac caaggaagac ttgggaaagc tgcaaccact 780 ggtggcatct tatctctgct ctgatgtaac atctgttccc tcaaaggagt ctttgaagtt 840 gcaaggggtc ttcagcaagc agacagtcct taaatctcat cctctcttat ctcagtccta 900 tgaactccga gctgagctgt tggggagaca gccagttttg gagttttcct tagaaaatct 960 tagaaccatg aatacgagtg gtcagacagc tctgccacaa gcacctgtaa atgggttggc 1020 taagaaattg actaaaagtt caacacattc tgatcatgac aattccactt ccctcaatgg 1080 gggaaaacgg gctctcactt catctgctct tcatgggggt gaaatgggag gatctgaatc 1140 tggggacttg aaggggggta tgaccaattg cactcttcca catagaagcc ttgatgtaga 1200 acacacaatt ttgtatagca ataatagcac tgcaaacaaa tcctctgtca attccatgga 1260 acagccggca cttcaaggaa gcagtagatt atcacctggt acagactcca gctctaactt 1320 ggggggtgtc aaattggagg gtaaaaagtc tcccctgtct tccattcttt tcagtgcttt 1380 agattctgac acaaggataa cagctttact gcggcgacag gctgacattg agagccgtgc 1440 ccgcagatta caaaagcgct tacaggttgt gcaagccaag caggttgaga ggcatataca 1500 acatcagctg ggtggatttt tggagaagac tttgagcaaa ctgccaaact tggaatcctt 1560 gagaccacgg agccagttga tgctgactcg aaaggctgaa gctgccttga gaaaagctgc 1620 cagtgagacc accacttcag agggacttag caactttctg aaaagcaatt caatttcaga 1680 agaattggag agatttacag ctagtggcat agccaacttg aggtgcagtg aacaggcatt 1740 tgattcagat gtcactgaca gtagttcagg aggggagtct gatattgaag aggaagaact 1800 gaccagagct gatcccgagc agcgtcatgt acccctgaga cgcaggtcag aatggaaatg 1860 ggctgcagac cgggcagcta ttgtcagccg ctggaactgg cttcaggctc atgtttctga 1920 cttggaatat cgaattcgtc agcaaacaga catttacaaa cagatacgtg ctaataaggg 1980 gttgatagtt cttggggagg tacctccccc agagcataca acagacttat ttcttccact 2040 tagttctgag gtgaagacag atcatgggac tgataaattg attgagtctg tttctcagcc 2100 attggaaaac catggtgccc ctattattgg tcatatttca gagtcactgt ctaccaaatc 2160 atgtggagca ctcagacctg tcaatggagt tattaacact cttcagcctg tcttggcaga 2220 ccacattcca ggtgacagct ctgatgctga ggaacaatta cataagaagc aacgactgaa 2280 tctcgtctct tcatcatctg atggcacctg tgtggcagcc cggacacgtc ctgtactgag 2340 ctgtaagaag cggaggcttg ttcgacccaa cagcatcgtt cctctttcca agaaggttca 2400 ccggaacagc acaatccgcc ctggctgtga tgtgaatccc tcctgcgcac tgtgtggttc 2460 aggcagcatc aacaccatgc ctcccgaaat tcactatgaa gcccctctgt tggaacgtct 2520 ttcccagttg gactcttgtg ttcatcctgt tctagcattt ccagatgatg ttcccacaag 2580 cctgcatttc cagagcatgc tgaaatctca gtggcagaac aagccttttg acaaaatcaa 2640 acctcccaaa aagttatcgc ttaagcacag agcacccatg ccgggcagtc tgccagattc 2700 agctcgtaag gacaggcaca aattggtcag ctccttccta acaacagcca tgttgaagca 2760 tcacacagac atgagcagtt cgagctactt ggcagccacc caccatcctc cacacagtcc 2820 cttggtgcga cagctctcca cctcctcaga ttcccctgca cccgccagct ctagctcaca 2880 ggttacagcc agcacatcgc agcagccagt aaggaggaga aggggagaga gctcatttga 2940 tattaacaac attgtcatcc caatgtctgt tgctgcaaca actcgcgtag agaaactgca 3000 atacaaggaa atccttacgc ccagctggcg ggaggttgat cttcagtctc tgaaggggag 3060 tcctgatgag gagaatgaag agattgagga cctatccgac gcagccttcg ccgccctgca 3120 tgccaaatgt gaggagatgg agagggcacg gtggctgtgg accacgagtg tgccacccca 3180 gcggcggggc agcaggtcct acaggtcatc agacggccgg acaacccccc agctgggcag 3240 tgccaacccc tccacccccc agcctgcctc ccctgatgtc agcagtagcc actctttgtc 3300 agaatactcc catggtcagt cccctaggag ccccattagc ccggaactgc actcagcacc 3360 cctcacccct gtggctcggg acactctgcg acacttagcc agtgaggata cccgttgttc 3420 cacaccagag ctggggctgg atgaacagtc tgtccagccc tgggagcggc ggaccttccc 3480 cctggcgcac agtccccagg cggagtgtga ggaccagctg gatgcacagg agcgagcagc 3540 ccgctgcact cgacgcacct caggcagcaa gactggccgg gagacagagg cagcgcccac 3600 ctcgcctccc attgtccccc tcaagagtcg gcatctggtg gcagcagcca cagctcagcg 3660 cccgactcac agatgagcgg gagacagcca tctaaacaga ctcactaact attggcatta 3720 aagcttcaga aatctctgcg tttgatattc aaacatcata tgccggaaat tttcacagtt 3780 tttagtgaac ttaaggaatt tagatcctac tttggtattt ttttttcttg ttttaatttt 3840 tgttttgttt ttgtttccat gttttcttgt cacacacctg agcacttcct cccgttggca 3900 aacagaagtt caggatgaga ccctgctggc ctggtcctgg cacatcctct gcactgttga 3960 atcactggac ttactgatct tagatgacca ccccctccct cacacctgtg ggcagggcag 4020 aacagcctgg cgggctacag tttagcatgg ccttcttgag ctagggtgga atggggcagg 4080 gtgctctgga ctcttacccc ctcccctccc atctgtggct tggctctgct gtggccctcc 4140 tggctgggtc cccttggttt ttcgtgctgg aacatcccca ccagagcctc tctgccataa 4200 ctgccagctg ctctccccga gtgctcagct ggcagaacac ctttccttct cacccagaac 4260 ttaagagact gattttttgt ttcatctgca tttggtcttc tctgttttga ctctttcact 4320 gcagtaacct ggctgtggct gctcaggttc ccctcctcat gccccttggt acccttccct 4380 gtctgctctc ccatgccatg tacacaccca caacccgtcc ttccacttgg aatattttta 4440 ccacctatcc tgatctttga aggtagggtt aggactactt aacctctatt cccactcccc 4500 tgcaaactgg gggttgtggg aagtgagcag ccatctccct gtgtgatttt tttttttttt 4560 ccctctgatt cactttgcca tgtttccttc acatccagat ccctgtcggt gttagttcca 4620 ctcttggtct ttcacgctcc ccttgcctgt ggaacattgt ctggtcctag ctgtggttcc 4680 cattgttccc ccttcaccct tctctgttaa ccttgtgcct gtctcctgta tgatcacatc 4740 accaaaaagg gggagggggg agaagactct ttttttttgg ccattttgta atcgtataaa 4800 aatagtagac aactgcttaa tggttggggt tttttcacaa ttttcaacat tagtgatttt 4860 tttttctgtt tgcaagttaa agggtttgtc attgtttctt taaaaaaaaa tacaataatg 4920 caccatatcc ctatgcataa agtgcttctt ctatttataa ggttgaaaat tctgaataac 4980 ccttttagca ttgaaaaaaa aaacaaaaac aaaaaatgga aaaaaaaaac cttgtatttt 5040 gtaaatattt tcttttcctg ctttggagct gtgtaatggc agcgaaacat gtagctgtct 5100 ttgttctata gaaatgcttt tcttcagaga agctgatctt tgttaatgtc ttgattctgt 5160 tcgcaaagca cagactagtg cttaaaaaaa aaaaagaagg aaaaattgaa aaaaatat 5218 34 763 DNA Homo sapiens misc_feature Incyte ID No 2806157CB1 34 ggcaaaacag tgacgcagca gtgtgttacc tgccgacagc ataatgtgag gcaaggtcta 60 gctgttcccc cccggcatac aagcttatag agcagcctcc tttgaagatc tccaggtgga 120 cttcacagag atgccaaagt gtggaggtgt tcgagtgtgg atcaaggact ggaacgtagc 180 ctctttgtgc ccatggtgga aaggacccca gactgtcgtc ctgatcactc ccactgctgt 240 gaacgtagag agaatcctag cctggatcca tcacaaccgt gtaaaacctg cagcgcctga 300 atcctgggag gcaagaccaa gtctggacaa cccctgcaga gtgaccctga agaagatgac 360 aagccctgct ccagtcacac ccagaagctg actggtccac gcacagccga agcatgagga 420 agctcattgt gggcttcatt tttcttaaat tttggactta cagtaagggc ttcaactgtt 480 cttactcaaa ctggggacta ttcccagtgt attcatcagg tcagtgaggt aggacagcaa 540 atgaaaacaa tctttctgtt ctatagttat tatcaatgta tgggaacgtt aaaagagact 600 tgtttgtata atgccactca gtacaaggta tgtagcccag gaaatgactg acctgatgtg 660 tgttataacc catctgagcc ccctacaacc accagttttg aaataagatt aagaactggc 720 cttttcctag gtgatacaag tgaaataata actagaacag aag 763 35 869 DNA Homo sapiens misc_feature Incyte ID No 5883626CB1 35 gcgagaaggg gagtggaagg caggggctga agacacaggc caggcggaat gaagatgatg 60 gtggtcttgc tcatgctgtc ctcgctcagc cggctcctgg gcctcatgag gccatcatct 120 ctcaggcaat acctggactc tgtgcccttg ccaccctgcc aggagcaaca gccaaaggct 180 agtgccgagc tagaccacaa ggcctgctac ctgtgccaca gcttgctgat gctggccggg 240 gtagttgtta gctgccagga catcactcca gaccagtggg gcgagctgca gctgctgtgc 300 atgcagttgg accgccacat cagcacgcag atccgggaga gcccccaggc catgcaccgc 360 accatgctca aggacctggc tacccagacc tacatccgtt ggcaggagct gctgacccac 420 tgccagcccc aggcccagta tttcagcccc tggaaagaca tctaaaggga cagggtcagg 480 gcagcccagg gctcctggct tcagcaggaa gtgaacaggc tcagggaact ggaggaagcg 540 aagcatcaag gccagaggag gccacatgct gaccagcctg atgaggcaag agcctgcccc 600 tgccaccgcc ccgacccctc tcctctctgc aagagcctgc ctctgccacc gccccgaccc 660 cctctcctct cagcaaggga tgggcctctc tgcctcgccc acccctcagc cctcctccca 720 gccatctcct cttccctaag gcctctgtct ccatagctct ggtttccctg ggcctcagtc 780 ctccccaccc tccttcctct gtctccctgt cactaatgtg aggtttcttt gtgcacatta 840 aagtcttctt tcagcaaaaa aaaaaaaaa 869 36 2875 DNA Homo sapiens misc_feature Incyte ID No 2674016CB1 36 ggggcgccat cttgtcttgt tcccgaagaa gtagaagcat cgaaagcgtt ggagaggtgt 60 taccggaacg gcggcgacaa gggtgttccc gaactagagt ggggcataca taatcttgct 120 gctatgcttc gaagctgtag tctgaatcaa cctaagtttt aaacagaagg tgaacctctg 180 agatagaaaa tcaagtatat tttaaaagaa gggatgtggg atcaaggagg acagccttgg 240 cagcagtggc ccttgaacca gcaacaatgg atgcagtcat tccagcacca acaggatcca 300 agccagattg attgggctgc attggcccaa gcttggattg cccaaagaga agcttcagga 360 cagcaaagca tggtagaaca accaccagga atgatgccaa atggacaaga tatgtctaca 420 atggaatctg gtccaaacaa tcatgggaat ttccaagggg attcaaactt caacagaatg 480 tggcaaccag aatggggaat gcatcagcaa cccccacacc cccctccaga tcagccatgg 540 atgccaccaa caccaggccc aatggacatt gttcctcctt ctgaagacag caacagtcag 600 gacagtgggg aatttgcccc tgacaacagg catatattta accagaacaa tcacaacttt 660 ggtggaccac ccgataattt tgcagtgggg ccagtgaacc agtttgacta tcagcatggg 720 gctgcttttg gtccaccgca aggtggattt catcctcctt attggcaacc aggacctcca 780 ggacctccag cacctcccca gaatcgaaga gaaaggccat catcattcag ggatcgtcag 840 cgttcaccta ttgcacttcc tgtgaagcag gagcctccac aaattgacgc agtaaaacgc 900 aggactcttc ccgcttggat tcgcgaaggt cttgaaaaaa tggaacgtga aaagcagaag 960 aaattggaga aagaaagaat ggaacaacaa cgttcacaat tgtccaaaaa agaaaaaaag 1020 gccacagaag atgctgaagg aggggatggc cctcgtttac ctcagagaag taaatttgat 1080 agtgatgagg aagaagaaga cactgaaaat gttgaggctg caagtagtgg gaaagtcacc 1140 agaagtccat ccccagttcc tcaagaagag cacagtgacc ctgagatgac tgaagaggag 1200 aaagagtatc aaatgatgtt gctgacaaaa atgcttctaa cagaaattct gctggatgtc 1260 acagatgaag aaatttatta cgtagccaaa gatgcacacc gcaaagcaac gaaagctcct 1320 gcaaaacagc tggcacagtc cagtgcactg gcttccctca ctggactcgg tggactgggt 1380 ggttatggat caggagacag tgaagatgag aggagtgaca gaggatctga gtcatctgac 1440 actgatgatg aagaattacg gcatcgaatc cggcaaaaac aggaagcttt ttggagaaaa 1500 gaaaaagaac agcagctatt acatgataaa cagatggaag aagaaaagca gcaaacagaa 1560 agggttacaa aagagatgaa tgaatttatc cataaagagc aaaatagttt atcactacta 1620 gaagcaagag aagcagacgg tgatgtggtt aatgaaaaga agagaactcc aaatgaaacc 1680 acatcagttt tagaaccaaa aaaagagcat aaagaaaaag aaaaacaagg aaggagtagg 1740 tcgggaagtt ctagtagtgg tagttccagt agcaatagca gaactagtag tactagtagt 1800 actgtctcta gctcttcata cagttctagc tcaggtagta gtcgtacttc ttctcggtct 1860 tcttctccta aaaggaaaaa gagacacagt aggagtagat ctccaacaat caaagctaga 1920 cgtagcagga gtagaagcta ttctcgcaga attaaaatag agagcaatag ggctagggta 1980 aagattagag atagaaggag atctaataga aatagcattg aaagagaaag acgacgaaat 2040 cggagtcctt cccgagagag acgtagaagt agaagtcgct caagggatag acgaaccaat 2100 cgtgccagtc gcagtaggag tcgagatagg cgtaaaattg atgatcaacg tggaaatctt 2160 agtgggaaca gtcataagca taaaggtgag gctaaagaac aagagaggaa aaaggagagg 2220 agtcgaagta tagataaaga taggaaaaag aaagacaaag aaagggaacg tgaacaggat 2280 aaaagaaaag agaaacaaaa aagggaagaa aaagatttta agttcagtag tcaggatgat 2340 agattaaaaa ggaaacgaga aagtgaaaga acattttcta ggagtggttc tatatctgtt 2400 aaaatcataa gacatgattc tagacaggat agtaagaaaa gtactaccaa agatagtaaa 2460 aaacattcag gctctgattc tagtggaagg agcagttctg agtctccagg aagtagcaaa 2520 gaaaagaagg ctaagaagcc taaacatagt cgatcgcgat ccgtggagaa atctccaagg 2580 tctggtaaga aggcaagccg caaacacaag tctaagtccc gatccaggta gtatactttt 2640 taaagtattt tgtctgattt ttaaaaaaaa ttgactgaat ttattccaag ttgaaagtgt 2700 cctttctctc tctctttaat aaactcagtt tggtacttga taaataatca tagtcttaaa 2760 tgttagaaat cctatataat attatttatt taaaattgca gatttttaat ttaaaataca 2820 tttttatttt taaattttgt cttttccctt tttttttcag atcacaaccc ctccc 2875 37 1839 DNA Homo sapiens misc_feature Incyte ID No 5994159CB1 37 ctcgaggggc cctctccctg ctggcacctg ggagccatgc atgaatcaag gagtcgctgg 60 acagagcctg ggtgttccca gtgctggtgc gaggacggga aggtgacctg tgaaaaggtg 120 aggtgtgaag ctgcttgttc ccacccaatt ccctccagag atggtgggtg ctgcccatcg 180 tgcacaggct gttttcacag tggtgtcgtc cgagctgaag gggatgtgtt ttcacctccc 240 aatgagaact gcaccgtctg tgtctgtctg gctggaaacg tgtcctgcat ctctcctgag 300 tgtccttctg gcccctgtca gaccccccca cagacggatt gctgtacttg tgttccaggc 360 agatggctcg gtgagctgca agaggacaga ctgtgtggac tcctgccctc acccgatccg 420 gatccctgga cagtgctgcc cagactgttc agcaggctgc acctacacag gcagaatctt 480 ctataacaac gagaccttcc cgtctgtgct ggacccatgt ctgagctgca tctgcctgct 540 gggctcagtg gcctgttccc ccgtggactg ccccatcacc tgtacctacc ctttccaccc 600 tgacggggag tgctgccccg tgtgccgaga ctgcaactac gagggaagga aggtggcgaa 660 tggccaggtg ttcaccttgg atgatgaacc ctgcacccgg tgcacgtgcc agctgggaga 720 ggtgagctgt gagaaggttc cctgccagcg ggcctgtgcc gaccctgccc tgcttcctgg 780 ggactgctgc tcttcctgtc cagattccct gtctcctctg gaagaaaagc aggggctctc 840 ccctcacgga aatgtggcat tcagcaaagc tggtcggagc ctgcatggag acactgaggc 900 ccctgtcaac tgtagctcct gtcctgggcc cccgacagca tcaccctcga ggccggtgct 960 tcatctcctc cagctccttt taagaacgaa cttgatgaaa acacagactt tacctacaag 1020 cccggcagga gctcatggtc cacactcact cgctttgggg ctgacagcca ctttcccagg 1080 ggagcctggg gcctcccctc gactctcacc agggccttcg acccctccag gagcccccac 1140 tctacctcta gcttccccag gggctcctca gccacctcct gtgactccag agcgctcgtt 1200 ctcagcctct ggggcccaga tagtgtccag gtggcctcct ctgcctggca ccctcctgac 1260 ggaagcttca gcactttcca tgatggaccc cagcccctcg aagaccccca tcaccctcct 1320 cgggcctcgc gtgctttctc ccaccacctc tagactctcc acagcccttg cagccaccac 1380 ccaccctggc ccccagcagc ccccagtggg ggcttctcgg ggggaagagt ccaccatgta 1440 aggaggtcac tgtgtccggg agactctgga gagaggacct ctgccagtgg cccagggtgt 1500 gtgcagggca gctccaagga tgaacctggt ggggatgcct gggctccctc ctgcaggggc 1560 cctggtgagg atggaagacc cccaaggctg gatgtaacct tgttcccaag aagtgtttgg 1620 aatgtgctgt aagaatggag gaagtcgttt ccactgtcag catcctccct ggaccgcgtg 1680 gctggctcat cttttgagaa gggttgggac tgccaagttc tcctggagga agagttgcgt 1740 ccggctggga ttccactcac tgggactgta ccgccaggtg tcatgcgtct ctctgaggtt 1800 tcctgattaa aggttgtctc ggtttcaaaa aaaaaaaaa 1839 38 1232 DNA Homo sapiens misc_feature Incyte ID No 2457335CB1 38 gggcagcctg cgcctgggta ccgaggctgc tgcgcggcgg acagcgggcg cgatgtatct 60 ccgcagggcg gtctccaaga ctctggcgct gccgctgagg gcgcccccca accccgcgcc 120 gctcggaaag gacgcatctc tgcgccggat gtcatctaac agattccctg gatcatctgg 180 atcaaatatg atttattatc tggttgtagg cgtcacagtc agtgctggtg gatattatgc 240 ttacaagaca gtaacatcag accaagccaa acacacagaa cataaaacaa atttgaaaga 300 aaaaacaaaa gcagagatac atccatttca aggtgaaaag gagaatgttg cggaaactga 360 gaaagcaagt tcagaagccc cagaagaact tatagtggaa gctgaggtgg tagatgctga 420 agaaagtccc agtgctacag ttgtggtcat aaaagaggca tctgcctgtc caggtcacgt 480 ggaggctgct ccggagacca cagcagtcag tgctgaaacc gggccagagg tcacagatgc 540 agcggcgagg gaaaccacgg aagtaaaccc tgaaacgacc ccagaggtta caaatgctgc 600 cctggatgaa gctgtcacca tcgataatga taaagataca acaaagaacg aaacctctga 660 tgaatatgct gaactagaag aagaaaattc tccagctgag tcagagtcct ctgctggaga 720 tgatttacag gaggaagcca gtgttggctc tgaggctgct tcggctcaag gcaatctcca 780 gccggtagac atttcagcaa caaatgccat agggtgtctg ataagtgctt tggtgttttt 840 agtacactta gtttaaaaaa aaaaagactt attttctaga aaacgttaag gggtctggaa 900 gattttgggc atccactgat agattttagg actgagagac ttgagattgg tacatttctt 960 actactcttc tacggtctga gatcagaata tgacattgca gtaaagagct taaatagttt 1020 catcttgggt ttttttttct agacactttt cttttatccc agtcatctct gaatttacat 1080 tttatattaa agaaatggag ctatccataa aacctgtatt tactttaatt tcaccatgct 1140 ttcagcttac tttatggtat gatatgtgag gctaacatat agttggggtc caataaaatt 1200 tgaaaacgtg taaaaaaaaa aaaggggggc cg 1232 39 3250 DNA Homo sapiens misc_feature Incyte ID No 2267802CB1 39 ggcccccgcc caggtgtctc cctttgggaa gctgcccgcc gagtctccga gatttgtccc 60 tggtggtccc gcggacccct cgtccctccg cagtctccgg ctggcagcga tggagggcgc 120 tggggagaac gccccggagt ccagctcctc tgcccctggg tccgaagagt ctgccaggga 180 tccacaggtg ccgcctccgg aggaagaatc gggggactgc gcccggtccc tggaggcggt 240 ccccaagaaa ctctgtgggt atttaagtaa gttcggcggc aaagggccca tccggggctg 300 gaaatcccgc tggttcttct acgacgaaag gaaatgtcag ctgtattact cgcggaccgc 360 tcaggatgcc aatcccttgg acagcatcga cctctccagt gcagtgtttg actgtaaggc 420 ggacgctgag gaggggatct tcgaaatcaa gactcccagc cgggttatta ccctgaaggc 480 cgccaccaag caagcgatgc tgtactggct gcagcagctg cagatgaagc gctgggaatt 540 ccacaacagc ccgccggcac ctcctgccac ccctgatgcc gccctggctg ggaatgggcc 600 cgtcctgcac ctcgagctag ggcaagaaga ggcagagctg gaggagttcc tgtgccctgt 660 gaaaacaccc cctgggctag tgggcgtggc agctgccttg cagcccttcc ctgcccttca 720 gaatatttcc ctcaagcacc tggggactga aatacagaac acaatgcaca acatccgtgg 780 caacaagcag gcccagggaa caggccatga acctccaggg gaagattcta cacagagtgg 840 ggagcctcag agggaggagc agccctcggc ctctgacgcc agcaccccag tgagagagcc 900 agaggattct ccaaagcctg cacccaagcc ttctctgacc atcagtttcg ctcagaaagc 960 caagcgccag aacaacacct tcccattctt ttctgaagga atcacacgga accgaactgc 1020 ccaggagaaa gtggcagcct tggagcaaca ggttctgatg ctcaccaagg agttaaagtc 1080 tcagaaggag ctagtgaaga tcctgcacaa ggcactggag gccgcccagc aggagaagcg 1140 ggcgtccagc gcatacctgg cggcggctga ggacaaggac cggctggagc tggtgcggca 1200 caaagtgcgg cagatcgcgg agctgggccg gcgggtggag gccctggagc aggagcggga 1260 gagcctggcg cacacagcga gcctgcggga gcagcaggtg caggagctac agcagcacgt 1320 gcagctgctt atggacaaga accacgccga gcagcaggtc atctgcaagc tctctgagaa 1380 ggtcacccag gacttcacgc acccccctga ccagtctcct ttgcgccccg acgctgccaa 1440 cagggacttc ctgagccagc aggggaagat agagcacctg aaggatgaca tggaagctta 1500 ccggacccag aactgcttcc tcaactccga gatccaccag gtcacaaaga tctggagaaa 1560 ggtggctgag aaggagaagg cccttctgac gaagtgcgcc tacctccaag ccagaaactg 1620 ccaggtggaa agcaagtacc tggccggtct gagaaggctg caggaggccc tgggggacga 1680 agccagcgag tgctcagagc tgctgaggca gcttgtccag gaggcactgc agtgggaagc 1740 tggggaggcc tcatctgaca gcatcgagct gagccccatc agtaagtatg atgagtacgg 1800 cttcctgacg gtgcccgact atgaggtgga agacctgaag ctgctggcca agatccaggc 1860 attggagtca cgatcccacc acctgctggg cctcgaggct gtggatcggc cgctgaggga 1920 gcgctgggct gccctgggcg atcttgtgcc ctcagccgag ctcaagcagc tactgcgggc 1980 aggagtaccc cgtgaacacc ggcctcgtgt ctggaggtgg ctggtccacc tccgtgtcca 2040 gcacctgcac actccaggct gctaccagga actgctgagc cggggccagg cccgcgagca 2100 ccctgctgcc cgccagattg agctggacct gaaccggacc ttccccaaca acaaacactt 2160 cacctgcccc acctccagct tccccgacaa gctccgccgg gtgctgctgg ccttctcctg 2220 gcagaacccc accatcggct actgccaggg cctgaacagg ctggcggcca ttgccctgct 2280 ggtcctagag gaggaggaga gcgccttctg gtgcctggtg gccattgtgg agaccatcat 2340 gcccgctgat tactactgca acacgctgac ggcatcccag gtggaccagc gggtgctcca 2400 ggacctgctc tcggagaagc tgcccaggct gatggcccat ctggggcagc accacgtgga 2460 tctctccctc gtcaccttca actggttcct cgtggtcttt gcggacagtc tcattagcaa 2520 catcctcctt cgggtctggg atgccttcct gtacgagggg acgaaggtgg tgtttcgcta 2580 tgccttggcc attttcaagt acaacgagaa ggagatcttg aggctacaga atggcctgga 2640 aatctaccag tacctgcgct tcttcaccaa gaccatctcc aacagccgga agctgatgaa 2700 catcgccttc aatgacatga accccttccg catgaaacag ctgcggcagc tgcgcatggt 2760 ccaccgggag cggctggagg ctgagctgcg ggagctggag cagcttaagg cagagtacct 2820 ggagaggcgg gcatcccggc gcagagctgt gtccgagggc tgtgccagcg aggacgaggt 2880 ggagggggaa gcctgacttg gccacctccc ctccccacag ccttcctcac ccttggctgg 2940 cagacccact ggaggtcagg cacggaccag tggcccagcc ctgggtgtcc catcaccatg 3000 tgaccttgga catgtccctt cccctctctg gccctcagtt tccccactgg gacattgtgt 3060 gctgcaaagc cattggttgg gctacttctt cataggcact tacttaccca gggatgccac 3120 cctttcgtca cctcttccac agagcacttt ggcatgtaaa caagcaagag cactgcctct 3180 atagggtaac ctggaacatt ctctaggtta tatcaatata aaacaatgta aatggtggaa 3240 aaaaaaaaaa 3250 40 3621 DNA Homo sapiens misc_feature Incyte ID No 3212060CB1 40 aaggcgagta gcatgtgcgg gagactcacg ttgccggcga agtgggagag agaaaagtgg 60 taacctgggg ctgggggccg gcgcggcgga gctcggagta gtagagcgga gtgaagacac 120 gggggaggat agagactggc attcctttgg gccgggggat tggcgggagt cgtgctgggt 180 gctctcgccg tgttgaggtc ccagtgaggg gaaggagaag cggaagaggg tctctagtcg 240 gggcctaggg caaagggact acaaaaagga tgcagatgac tatagaaatg aggacgacga 300 ggagatgctg tggaggagca gtagaggtga gaagatgatg caaagaaact gtgtcagtga 360 ggaactgtat agagggtcat agaggtgagg tggcggagag aaactaacta acggaccata 420 gaggtggggg agccattgta gaaggacgtg gacgcgaaag ggtcgtgtag atgggcatat 480 gtgtgaagca gcaacgtaga ggggctgaag aggagaaatt catggagaga aagaatgcac 540 ctagagtgag ctctgcagag tgctgcgtgg gatatcccta gagtttggtc tagtgaaggc 600 acgctaacca ggcacctaag gcatttcaag tagtgacttc ccacatttgg ctaggaatgt 660 gggtcctcct ccgaagtggg taccccctcc gtatcttgtt acccctgcgt ggggagtgga 720 tgggtcggag gggcctgccc cgaaacttgg ccccaggccc tcctcgcaga cgttacagga 780 aggagactct ccaagccttg gatatgccag tgttgcctgt aactgcaact gaaatccgcc 840 agtatttgcg ggggcatggg atccccttcc aggatggtca cagttgcctg cgggcactga 900 gcccctttgc agagtcttca cagctcaaag gccagactgg tgttaccact tccttcagcc 960 tcttcattga caagaccaca ggccactttc tctgcatgac cagcctagca gaagggagct 1020 gggaagactt ccaggccagc gtggaggggc gaggggatgg ggccagggag gggtttctgc 1080 ttagcaaggc accagaattt gaggacagcg aggaggtccg gaggatctgg aaccgagcaa 1140 tacctctctg ggagctgcct gatcaggagg aggttcagct ggctgataca atgtttggcc 1200 ttaccaaggt tacagatgac acactcaagc gtttcagtgt gcgatatctg cgacctgctc 1260 gcagtcttgt cttcccttgg ttctcccctg ggggttcagg attacgaggc ctgaagctcc 1320 tagaggctaa atgccagggg gatggagtga gctacgagga aaccactatt ccccgaccca 1380 gcgcctacca caatctgttt ggattaccac tgattagtcg tcgagatgct gaggtggtac 1440 tgacgagtcg tgagcttgac agcctggcct tgaaccagtc cacggggctg cctaccctta 1500 ctctaccccg aggaacgacc tgcttacccc ctgccttact cccttacctg gaacagttcc 1560 ggcggattgt attctggttg ggggatgacc ttcggtcctg ggaagccgcc aagttgtttg 1620 cacgaaaact gaaccccaaa cgatgcttct tggtgcgacc aggagaccag caaccccgtc 1680 ccctggaggc cctgaacgga ggcttcaatc tttctcgtat tcttcgtacc gccctgcctg 1740 cctggcacaa gtccatcgta tctttccggc agcttcggga ggaggtgcta ggagaactgt 1800 cgaatgtgga gcaagcagct ggcctccgct ggagccgctt tccagacctc aatcgtatct 1860 tgaagggaca tcgaaagggc gagctgacgg tcttcacagg gccaacaggc agtggaaaga 1920 cgacattcat cagtgagtat gccctggatt tgtgttccca gggggtgaac acactgtggg 1980 gtagcttcga gatcagcaat gtgagactag cccgggtcat gctgacacag tttgccgagg 2040 ggcggctgga agatcaactg gacaaatatg atcactgggc tgaccgcttt gaggacctgc 2100 ccctctattt catgactttc catggacagc aaagcatcag gactgtaata gatacaatgc 2160 aacatgcagt ctacgtctat gacatttgtc atgtgatcat cgacaacctg cagttcatga 2220 tgggtcacga gcagctgtcc acagacagga tcgcagctca agactacatc atcggggtct 2280 ttcggaagtt tgcaacagac aataactgcc atgtgacact ggtcattcac ccccggaaag 2340 aggatgatga caaggaactg cagacagcgt ccatttttgg ctcagccaaa gcaagccagg 2400 aagcagacaa tgttctgatc ctgcaggaca ggaagctggt aaccgggcca gggaaacggt 2460 atctgcaggt gtccaagaac cgctttgatg gagatgtagg tgtcttcccg cttgagttca 2520 acaagaactc cctcaccttc tccattccac caaagaacaa ggcccggctc aagaagatca 2580 aggatgacac tggaccagtg gccaaaaagc cctcttctgg caaaaagggg gctacgacac 2640 agaactctga gatttgctca ggccaggccc ccactcccga ccagccagac acctccaagc 2700 gttcaaagtg aaggccgtgc agagctggtc actgaaatga gcctgatagg ataggctgga 2760 gcataaaact ctgcaagggc tcctctatcc tgtggtcctg agctgtgtgc ccttctcagt 2820 ctgaggggcc taacctagag caggtttcca tagtgagaaa attcaatgta gcagactact 2880 gagaaactac tgtgttgctc aggctttgtt tgaggtcctg tatatacagc actgaaaaga 2940 gagataaagt ccctgcctgc atgcattctg gcggaagaga caagcaagca atgaacaaat 3000 tagcagaaaa cctagtttta gtgaaaaatg ctgtaaagaa aatagaaatg cgatagagtg 3060 ctggcaggct agtgtagata agtggtctga aaaggtgtct ctgagccgag ggcatgtgag 3120 ctggggccta aacaactaga aggagagagc cacgtgaaca tccggcgaag gggacccagg 3180 cagagagaaa aggaaatcca agccctgagg taggaatgag caggtcagat tcaaggcagt 3240 gaggtcaggc cgcatgaacc tggaggggaa tcggggactt catgcgaaac tccagcctag 3300 gctttcaaag tcaaagggtg atacagtggg taccaagctc ctctgctccc cactttgtag 3360 agcctagcat gaggtggcat gtactagaat tggatcctag gtgcttagcc ctgcaatatc 3420 agggcctcac tggtgggagc tgcctcgggc tgggttgctt ggtcatagag ccatagaagg 3480 aagctgtcag cccggagtgc ctgccaccta gacactgatg ccattgtgtg ctgcctcaag 3540 actgctggag tcaggacatt ttatagagcc ttttccagtt ttactaaaaa atttttccat 3600 tgaaaaaaaa aaaaaaaaaa a 3621 41 1693 DNA Homo sapiens misc_feature Incyte ID No 3121069CB1 41 catgaatgta ctgcaaggga acacatttgt gtcatgtgaa gagacatgac aaaaacagcc 60 ctccttaaat tatttgtggc aatagtgatc acattcattt taattttgcc ggaatatttc 120 aagacaccga aagaaagaac attggagcta tcatgtctgg aagtgtgttt gcaatctaat 180 tttacctatt cactctcctc cttaaatttt tcttttgtga cttttctgca accagtaagg 240 gaaactcaga ttatcatgag aatctttcta aatccctcca attttcgtaa cttcaccagg 300 acttgccaag acatcacagt tcttatcagg agaggatcaa tggaagtgaa agcaaatgat 360 tttcattcac cttgtcagca ctttaacttc agtgtagctc ctctggttga ccacttggag 420 gaatataaca ctacctgtca tctaaaaaac cacactggaa gatcaacaat catggaggat 480 gagccaagca aggagaaatc gataaactac acttgtagaa tcatggaata cccgaatgat 540 tgtatacaca tttctttgca cttggagatg gatataaaaa atatcacttg ttccatgaag 600 atcacttggt atattttagt tctattagtt tttatatttt tgatcatcct cactatccgc 660 aaaatacttg aaggccagag aagagtgcaa aagtggcaga gtcatagaga caaacctaca 720 tctgttctct taagaggaag tgattcggag aaactgagag cattgaatgt gcaggttctt 780 tcagagacca cgcagaggct gcctttggat caagtccagg aagtgcttcc cccaattcca 840 gaactataag ttacttccac agtgcatcag tgagatcaat atacacgaat atccccgggc 900 aagttggacc gagccctttg aagaatactc agaagtttat tttgtgaatg agtagactgg 960 aaaatgtttg tgtccagctg aggatgcaca gttggaaagc aggaggaatg ctgactggtt 1020 gatgaaaact agcttaagag cattcattcg ctccatgaga tcaagggaac aagagtgttt 1080 gcaagaagcc attatgagtc atggaaaaaa agatgatgaa acccatggaa acagcaagag 1140 aattcccact ctctctcttc ttaaaaaaaa tctatcatta tacagcacag agtggagcca 1200 agtttttaat tttgaggaac caaaaacagg atcaaatatg aaaacccttt cttttattgg 1260 gccacattgt agatgctgat ttgataattg tttcctatgc agatagatta tttttatttc 1320 acagattatt taaaagggaa gagggcctgg ttgtttattt atatgtttgt ttgcatttat 1380 gaatcttgct gccttttagc accaggatgt ttttaaaaaa attcaaagag gccaggcgca 1440 gtggctcatg cctgtaatcc cagcactttg ggattctgag gtgggaggat catgaggtca 1500 agggatcgag accatcctgg ccaacatggt gaaaccctgt ctctactaaa aacacaaaaa 1560 ttagctgggt gtggtggtgc gcgcctgtag tcccagctcc tcaggaggct gaggcaggag 1620 aatcacttga acctggcagg cagagtttgc agtgaaccaa gatcacgcca ctgcattaca 1680 gcctagacaa gca 1693 42 2289 DNA Homo sapiens misc_feature Incyte ID No 3280626CB1 42 ggccgctgta acctcttcgg tccgcgacga tcctctagag cactgtgtgt ctccccggac 60 gcgagcccgc tcccctgagt aagagtcagc cagccgcgga tggggagcgt gagtggcgag 120 aatctgcaaa atggctgata atttggatga atttattgaa gagcaaaaag ccagattggc 180 cgaagacaaa gcagagttgg aaagtgatcc accttacatg gaaatgaagg gaaagttgtc 240 agcgaagctt tctgaaaaca gtaagatact gatctctatg gctaaggaaa acataccacc 300 aaatagtcaa cagaccaggg gttccttagg aattgattat ggattaagtt taccacttgg 360 agaagactat gaacggaaga aacataaatt aaaagaagaa ttgcggcaag attacagacg 420 ttatcttact caggaaaggt tgaaacttga acgtaacaaa gaatacaatc agtttctcag 480 gggtaaggaa gaatccagtg aaaagttcag gcaggtggaa aagagtactg agcccaagag 540 tcagagaaat aaaaaaccta ttggtcaagt taagcctgat ctaacttcac aaatacagac 600 atcttgtgaa aattcagagg gtcctagaaa agatgtctta actccttcag aggcatatga 660 agaacttctg aaccaaagac gactagagga ggacagatac cgacaactag atgatgaaat 720 cgaattaagg aatagaagaa ttattaaaaa agcaaatgaa gaagtgggca tttccaacct 780 aaaacatcaa aggtttgcaa gcaaggctgg cattccagat agaagatttc acagatttaa 840 tgaggatcgt gtttttgata gacggtatca tagaccagac caagatcctg aagtaagtga 900 agaaatggat gagaggttta gatatgaaag tgattttgat agaagacttt cgagagtgta 960 tacaaatgac aggatgcaca ggaacaaacg agggaatatg cctcctatgg aacatgatgg 1020 ggatgttata gaacagtcaa acataagaat ttcatctgct gaaaataaaa gtgctccaga 1080 caatgaaaca tccaaatctg ctaatcaaga tacctgtagt ccttttgcag ggatgctctt 1140 tggaggtgaa gatcgagaac ttattcagag aaggaaagag aaatacagac tagaactgtt 1200 ggaacaaatg gctgagcaac agaggaacaa gagacgagaa aaagatttag aactcagggt 1260 tgcagcgtct ggagcacaag accctgagaa atcgcctgat agactaaagc agtttagtgt 1320 ggcaccaaga cactttgaag agatgatacc acctgaaaga cccagaatag ctttccagac 1380 acctctccct cctttatctg ccccatctgt cccacccatc ccatcagttc atcctgttcc 1440 ttctcaaaat gaagatttgc gcagtggact cagcagcgcc cttggtgaaa tggtgtctcc 1500 caggattgca cctctgcctc cacctcccct actaccacct ttggctacta actatcgaac 1560 tccttatgat gatgcatact atttttatgg gtccaggaat actttcgatc ccagtcttgc 1620 ttattatggt tcaggaatga tgggcgtaca gcctgcagct tatgttagtg ctcctgtcac 1680 ccaccaacta gcacaacctg ttgtagtctc accctgtcac ccaggctgga gtacaatgtt 1740 gtgaacttgg ctcactgcaa cctccgcctc ctgagttcaa gtgattcttc tggctcagcc 1800 tcctgagaaa ctgggattaa aggcgtgcac cactatgccc ggctaagttt ttgtatcttt 1860 agtagagaca gggtttcacc atgttggcca ggctggtctc gaactcctga ccttgtgatc 1920 tgcctgcctc agcctcccaa agtcctggga ttacaggaat acggttggac agaatgaact 1980 gaagattaca agtgatcaag tgataaattc aggattgatt tttgaagata aaccgaaacc 2040 ttccaaacag tcacttcagt cttaccaaga ggctttgcag cagcagattc gggaaaaaaa 2100 aaaaaagagg ggggcggcga atattgagct cgtgaccgcg gaataaattc gggcgcgaac 2160 ctgcaggcga gagggaggga atctatatca agatatcgat accgggaccc gaaggggggc 2220 gcggacccaa ttcgctaagg gagcgataag gcggcaaggc gcggtaaacg cgggtggaac 2280 ctgcgtcac 2289 43 1304 DNA Homo sapiens misc_feature Incyte ID No 484404CB1 43 ctcgcccacg cgtccggggc aggtaacagc tgcatcattg accgcacagc gccatctctc 60 cctgagaata aagccgatag ccaccctcct ccggctccga gcctgcttct gccacacctc 120 gctctcagtt ctctccacat ttccatagag accgtgtggt ttttgttcac ccgggccccc 180 catttatagg cataaaatcc actgtctgcc agcctccctt ccctcccacc tttttgtttt 240 acatttttta caccaatgta ccaaaaaggc ggacggctgc atttacgggg tctcccggag 300 ggccagagtc gtggcttaca gaagagacga aatgtggtct gagggacgat atgaatatga 360 aagaattccg agagaacgag cacctcctcg aagtcatccc agtgatgaat ctggttatag 420 atggacaaga gacgatcatt ctgcaagcag gcaacctgaa tacagggaca tgagagatgg 480 ctttagaaga aaaagtttct actcttccca ttatgcgaga gagcggtctc cttataaaag 540 ggacaatact tttttcagag aatcacctgt tggccgaaag gattctccac acagcagatc 600 tggttccagt gtcagtagca gaagctactc tccagaaagg agcaaatcat actctttcca 660 tcagtctcaa catagaaagt ccgtgcgtcc tggtgcctcc tacaaacggc agaatgaagg 720 aaatcctgaa agagataaag agaggcctgt ccagtctttg aaaacatcaa gagatacttc 780 accctcaagt ggttcagcag tttcttcatc aaaggtgtta gacaaaccca gtaggctaac 840 tgaaaaggaa cttgctgagg ctgcaagcaa gtgggctgct gaaaagctag agaaatcaga 900 tgaaagtaac ttgcctgaaa tttctgagta tgaggcggga tccacagcac cattgtttac 960 tgaccagcca gaggaacctg agtcaaacac aacacatggg atagaattat ttgaagatag 1020 tcagctaacc actcgctcta aagcaatagc atcaaaaacc aaagagattg aacaggttta 1080 ccgacaagac tgtgaaactt tcgggatggt ggtgaaaatg ctgattgaaa aagatccttc 1140 attagaaaag tctatacagt ttgcattgag gcagaattta catgaaatag gtgagcggtg 1200 tgttgaagaa ctcaagcatt tcattgcaga gtatgatact tccactcaag attttggaga 1260 gcctttttag atttttctgc tcaggctaaa aaaaaaaaaa aagg 1304 44 4850 DNA Homo sapiens misc_feature Incyte ID No 2830063CB1 44 gtgcagcggc tgagatcacg tggtgcgccg ggaagccacc ccgcctctcc gaggcctccc 60 tgccccgccc cgtcacgccc ctttcccggc gggacgcttt gagccgcccc gaactaagca 120 gggcggtcgg gggagtcata ctccatgggt ttatgtgata aatgatcttg gcatagaaga 180 gaatttaaag aatgatggct tcattccagc gctccaatag tcatgacaaa gtaaggagaa 240 tagttgcaga ggagggtcgt acagcaagaa acctaatagc ttggagtgtt ccactagaaa 300 gcaaagatga tgatggaaaa cctaaatgtc aaactggtgg aaaatctaag aggaccattc 360 aaggcactca taaaactact aaacagagta ctgcagtgga ctgtaaaata acatcgtcta 420 cgactggaga taaacacttt gataaaagtc ccactaaaac aaggcaccct cggaaaattg 480 atctaagagc tcgatactgg gcatttcttt ttgataatct tcgccgagca gtagatgaaa 540 tctatgtaac ttgcgaatca gatcagagtg tggtcgaatg taaggaggtg ctaatgatgc 600 tggataacta tgtaagagat ttcaaagcat tgattgactg gattcagctt caggaaaagc 660 tagagaagac agatgctcaa agcagaccaa catcattggc atgggaagta aagaagatgt 720 ctccgggacg ccatgtgatt ccaagtccat caacagatag aataaatgta acatcaaatg 780 ctcgacgaag cttaaatttt ggaggttcaa ctggcacagt gccagctcct cgtctggctc 840 ccacaggtgt cagttgggct gacaaggtaa aggctcatca tacaggctct actgcttctt 900 cagaaataac acccgcccag tcttgcccac caatgacagt gcagaaggcc tcacgcaaaa 960 atgaacggaa agatgctgaa ggatgggaga ccgttcagag aggaaggcct attcgttctc 1020 gatcaacagc agtgatgcca aaagtttcat tggcaacaga agccacaaga tcaaaggatg 1080 acagtgataa agaaaatgta tgtcttttac ctgatgaaag catacagaaa ggtcaatttg 1140 ttggagatgg aacttctaat actatagaat ctcatcccaa agactcatta cactcttgtg 1200 accatcctct tgccgaaaaa acccagttca cagtgagtac attggatgat gtgaagaatt 1260 ctggcagtat tcgagacaat tatgttcgaa cttctgaaat atctgctgtc cacattgata 1320 cagagtgtgt ttcagttatg ctgcaagctg gtacacctcc tttacaagta aatgaagaaa 1380 aatttccagc agagaaagca aggatagaaa atgaaatgga cccttcagat atttcaaatt 1440 ccatggcaga agtccttgct aaaaaagaag agctagcaga tcgtctagaa aaggccaatg 1500 aagaagccat tgctagtgct attgctgaag aagaacagtt aactagagaa attgaagctg 1560 aagaaaacaa tgatattaac attgaaactg acaacgacag tgatttttct gccagcatgg 1620 gcagtgggag tgtttctttc tgtggtatgt ccatggactg gaacgatgtc cttgcagatt 1680 atgaagctcg tgagtcttgg cgccaaaata catcctgggg ggacattgta gaagaagaac 1740 ctgctagacc tccagggcat ggaattcaca tgcatgaaaa actttcttca ccctctcgta 1800 aaagaacaat tgcagaatct aagaagaaac atgaagaaaa acaaatgaaa gcacagcagc 1860 taagggaaaa gttacgcgaa gagaaaacat tgaagcttca gaaattgtta gaaagggaga 1920 aggatgtccg gaagtggaag gaagaattgc tagatcaacg acgcaggatg atggaagaaa 1980 aattacttca tgctgagttt aagcgagaag tgcagttaca agcaattgtg aaaaaagcac 2040 aagaagaaga agctaaggta aatgaaattg cctttataaa tacccttgaa gcccagaata 2100 aacgtcatga tgttttatca aaattgaagg aatatgaaca gaggcttaat gagctacagg 2160 aagagcgtca gagaagacag gaagaaaagc aagcacgtga tgaagctgtg caggaacgca 2220 agagagctct agaggcagag cggcaggccc gtgtagaaga attgttaatg aagaggaaag 2280 aacaagaagc ccgaattgaa caacagaggc aagaaaagga aaaagcccgt gaggatgcag 2340 cccgggaaag agctagagac agggaagaac gattggcagc actcacagct gctcaacaag 2400 aagctatgga agagttacag aaaaaaattc agctcaagca tgatgaaagt attcgaaggc 2460 acatggaaca gattgaacaa agaaaagaaa aagctgctga gctaagcagt gggcgacatg 2520 caaatactga ttatgccccc aaactgaccc cttatgaaag aaagaagcag tgttctctct 2580 gcaatgtcct gatctcttca gaggtatatc tttttagcca tgttaaaggg agaaaacacc 2640 agcaagccgt gagagagaat accagcatcc aggggcgtga actgtcagat gaagaagtgg 2700 agcatctttc cttgaagaag tacattattg acattgtggt tgaaagtaca gctccagcag 2760 aagctttgaa agatggagaa gagcggcaaa aaaataaaaa aaaagccaaa aagataaaag 2820 cccggatgaa cttcagggct aaggaatatg agagtttaat ggaaaccaaa aattctggct 2880 ctgattcacc ttataaagca aagcttcagc gattagccaa agatcttcta aaacaagtac 2940 aagttcaaga cagtggctca tgggcaaaca ataaagtgtc tgctttggat cggaccctag 3000 gagagatcac tagaatactg gaaaaagaga atgtggcaga tcagattgca tttcaagctg 3060 ctggtggatt aacagccctt gaacacatcc ttcaagcagt agtcccagcc acaaatgtga 3120 acacagtttt aagaattcct cctaagtctc tctgcaatgc aatcaatgtt tacaacctca 3180 cctgcaataa ctgttcagaa aactgcagtg atgttctgtt tagtaacaag attaccttct 3240 taatggacct cctgatacac cagttgacgg tttatgttcc agatgaaaat aatactattt 3300 tggggagaaa tacaaataaa caagtttttg aaggcttgac aactggactt ctcaaagtca 3360 gtgctgtggt tttgggctgc ctgattgcca atcgaccaga tggaaactgc cagccagcta 3420 ccccaaaaat accaacacag gaaatgaaaa acaaaacctc acaaggtgat ccttttaaca 3480 atcgagttca ggaccttatc agctacgtgg tgaacatggg tctgattgac aaactgtgtg 3540 cctgcttcct ctcggtgcaa ggcccagtgg atgagaatcc caagatggcc atatttctgc 3600 agcatgccgc aggactctta catgcaatgt gtacactgtg ctttgctgtc actggaaggt 3660 catacagcat atttgacaat aatcgccagg atcccacagg gctgacagct gctcttcagg 3720 caaccgacct ggctggagtt cttcatatgc tctactgtgt cctcttccat ggcaccatct 3780 tggaccccag cactgccagt cccaaggaga attacactca aaataccatc caagtggcca 3840 ttcagagttt acgtttcttc aacagctttg cagctcttca tctgcctgct tttcagtcta 3900 ttgtaggggc agagggcttg tcccttgcat tccggcacat ggccagctcc ctgctgggcc 3960 actgcagcca agtctcctgt gaaagcctcc ttcatgaggt catcgtctgt gtgggctact 4020 tcactgtcaa ccacccagat aaccaggtga tcgtgcagtc cggccgccac cccacagtgc 4080 tgcagaagct ctgccagttg cccttccagt atttcagtga cccacggctg atcaaagtac 4140 tgttcccttc acttatcgct gcttgttaca acaaccatca gaacaagatc attctggagc 4200 aagagatgag ctgtgtttta ctggccactt tcattcagga tttggcacag actccaggtc 4260 aagcggaaaa ccagccttac caacccaaag ggaaatgcct tggttcccaa gactatcttg 4320 agctggctaa cagatttcct cagcaggcct gggaagaagc tcgacagttt ttcttgaaaa 4380 aagagaaaaa ataaatgttt tggttgattc tgtatttgag tacccttgtt aatattttaa 4440 attgtccaaa caaacattct aattgttcct taagaactca ttttcccatg tttatactct 4500 tcccacactg tagatatggc atgtacttta cactatttat aatgactgta gatacttgaa 4560 tgttctactt gctaattttg caagttgagt ttatttcatt tatgcagagt atcttggagt 4620 tggtaatttc catcttatga taatatatac tttgcatttg tgatatgggt gaaaggagac 4680 ataaaattag caagtctgtt tgttcttgta ataaagtaac ttattctgtt ttcattgttg 4740 acttttcatg ttaaggaaat acgaatctga aagaaaaatg ttaactccag ctcttgaagt 4800 atcttaaata aagacttaat taaagtttaa caaaaaaaaa aaaaaaaaaa 4850 45 4350 DNA Homo sapiens misc_feature Incyte ID No 7506096CB1 45 atggaatcta gttcatcaga ctactataat aaagacaatg aagaggaaag tttgcttgca 60 aatgttgctt ccttaagaca tgaactgaag ataacagaat ggagtttgca gagtttaggg 120 gaagagttat ccagtgttag tccaagtgaa aattctgatt atgcccctaa tccttcaagg 180 tctgaaaagc taattttgga tgttcagcct agccaccctg gacttttgaa ttattcacct 240 tatgaaaacg tctgtaaaat atctggtagc agcactgatt ttcaaaaaaa gccaagagat 300 aagatgtttt catcttctgc ccctgtggat caggagatta aaagccttcg agagaaacta 360 aataaactta ggcaacagaa tgcttgtttg gtcacacaga atcattcctt aatgactaaa 420 tttgaatcta ttcactttga attaacacag tcaagagcaa aagtttctat gcttgagtct 480 gctcaacagc aggcagccag tgtcccaatc ttagaagaac agattataaa tttggaagca 540 gaggtttcag ctcaagataa agttttgaga gaggcagaaa ataagctgga acagagccag 600 aaaatggtaa ttgaaaagga acagagtttg caggagtcca aagaggaatg tataaaatta 660 aaggtggact tacttgaaca aaccaaacaa ggaaaaagag ctgaacgaca aaggaatgaa 720 gcactatata atgccgaaga gctgagtaaa gctttccaac aatataaaaa aaaagtggct 780 gaaaaactgg aaaaggttca agctgaagaa gaaatattag agagaaatct aactaactgt 840 gaaaaagaaa ataaaaggct acaagaaagg tgtggtctat ataaaagtga acttgaaatt 900 ctgaaagaga aattaaggca gttaaaagaa gaaaataaca acggaaaaga aaaattaagg 960 atcatggcag tgaaaaattc agaagtcatg gcacaactaa ctgaatctag acaaagtatt 1020 ttgaagctag agagtgagtt agagaacaaa gacgaaatac ttagagacaa attttcttta 1080 atgaatgaaa accgagaatt aaaggtccgt gttgcagcac agaatgagcg actagattta 1140 tgtcaacaag aaattgaaag ttcaagggta gaactaagaa gtttggaaaa gattatatcc 1200 cagttgccat taaaaagaga attatttggc tttaaatcat atctttctaa ataccagatg 1260 agtagcttct caaacaagga agaccgttgc attggctgct gtgaggcaaa taaattggtg 1320 atttcggaat tgagaattaa gcttgcaata aaagaggcag aaattcaaaa gcttcatgca 1380 aacctgactg caaatcagtt atctcagagt cttattactt gtaatgacag ccaagaaagt 1440 agcaaattaa gtagtttaga aacagaacct gtaaagctag gtggtcatca agtagcagaa 1500 agcgtaaaag atcaaaatca acatactatg aacaagcaat atgaaaaaga gaggcaaaga 1560 cttgttactg gaatagaaga actacgtact aagctgatac aaatagaagc tgaaaattct 1620 gatttgaagg ttaacatggc tcacagaact agtcagtttc agctgattca agaggagctg 1680 ctagagaaag cttcaaactc cagcaaactg gaaagtgaaa tgacaaagaa atgttctcaa 1740 cttttaactc ttgagaaaca gctggaagaa aagatagttg cttattcctc tattgctgca 1800 aaaaatgcag aactagaaca ggagcttatg gaaaagaatg aaaagataag gagtctagaa 1860 accaatatta atacagagca tgagaaaatt tgtttagcct ttgaaaaagc aaagaaaatt 1920 cacttggaac agcataaaga aatggaaaag cagattgaaa gagttaggca actagattca 1980 gcattggaaa tttgtaagga agaacttgtc ttgcatttga atcaattgga aggaaataag 2040 gaaaagtttg aaaaacagtt aaagaagaaa tctgaagagg tatattgttt acagaaagag 2100 ctaaagataa aaaatcacag tcttcaagag acttctgagc aaaacgttat tctacagcat 2160 actcttcagc aacagcagca aatgttacaa caagagacaa ttagaaatgg agagctagaa 2220 gatactcaaa ctaaacttga aaaacaggtg tcaaaactgg aacaagaact tcaaaaacaa 2280 agggaaagtt cagctgaaaa gttgagaaaa atggaggaga aatgtgaatc agctgcacat 2340 gaagcagatt tgaaaaggca aaaagtgatt gagcttactg gcactgccag gcaagtaaag 2400 attgagatgg atcagtacaa agaagagctg tctaaaatgg aaaaggaaat aatgcaccta 2460 aaacgagatg gagaaaataa agcaatgcac ctctctcaat tagatatgat cttagatcag 2520 acaaagacag agctagaaaa gaaaacaaat gctgtaaagg agttagaaaa gttacagcac 2580 agtactgaaa ctgaactaac agaagccttg caaaaacggg aagtacttga gactgaacta 2640 caaaatgctc atggagaatt aaaaagtact ttaagacaac tccaggaatt gagagatgta 2700 ctacagaagg ctcaattatc attagaggaa aaatacacta ctataaagga tctcacagct 2760 gaacttagag aatgcaagat ggagattgaa gacaaaaagc aggagctcct tgaaatggat 2820 caggcactta aagagagaaa ttgggaacta aagcaaagag cagctcaggt tacacatttg 2880 gatatgacta ttcgtgagca cagaggagaa atggaacaaa aaataattaa attagaaggt 2940 actctggaga aatcagaatt ggaacttaaa gaatgtaaca aacagataga aagtctgaat 3000 gacaaattac aaaatgctaa agaacagctt cgagaaaaag agtttataat gctacaaaat 3060 gaacaggaga taagtcaact gaaaaaagaa attgaaagaa cacaacaaag gatgaaagaa 3120 atggagagtg ttatgaaaga gcaagaacag tacattgcca ctcagtacaa ggaggccata 3180 gatttggggc aagaattgag gctgacccgg gagcaggtgc agaactctca tacagaattg 3240 gcagaggctc gtcatcagca agtccaagca cagagagaaa tagaaaggct ctctagtgaa 3300 ctggaggata tgaagcaact ctctaaagag aaagatgctc atggaaacca tttagctgaa 3360 gaactggggg cttctaaagt acgtgaagct catttagaag caagaatgca agcagaaatc 3420 aagaaattgt cagcagaagt agaatctctc aaagaagctt atcatatgga gatgatttca 3480 catcaagaga accatgcaaa gtggaagatt tctgctgact ctcaaaagtc ttctgttcag 3540 caactaaacg aacagttaga gaaggcaaaa ttggaattag aagaagctca ggatactgta 3600 agcaatttgc atcaacaagt ccaagatagg aatgaagtaa ttgaagctgc aaatgaagca 3660 ttacttacta aagaatcaga attaaccaga ttacaggcca aaatttctgg acatgaaaag 3720 gcagaagaca tcaagtttct gccagcccca tttacatctc caacagaaat tatgcctgat 3780 gttcaagatc caaaatttgc taaatgtttt cacacatctt tttccaagtg tacaaaatta 3840 cgtcgctcta ttagtgccag tgatcttact ttcaaaattc atggtgatga agatctttct 3900 gaagaattac tacaggactt aaagaaaatg caattagaac agccttcaac attagaagaa 3960 agccataaga atctgactta cacccagcca gactcattta aacctctcac atataaccta 4020 gaagctgata gttctgagaa taatgacttt aacacgctta gtgggatgct aagatacata 4080 aacaaagaag taagactatt aaaaaagtct tctatgcaaa caggtgctgg tttaaatcag 4140 ggagaaaatg tgtaattcaa agaagatact gatgtgttga aaaaatggaa tttttggtac 4200 tgtgctgttt acttattata tgtagctcat acttcataga agctgttatt ttgcttttga 4260 ataaatttta tatttcaata ttttaaaaga aagcccttct aaaacttaat tatattttta 4320 aagaaaattt aaaaaaaaaa aaaaaggggg 4350 46 2959 DNA Homo sapiens misc_feature Incyte ID No 7505914CB1 46 ggggcgccat cttgtcttgt tcccgaagaa gtagaagcat cgaaagcgtt ggagaggtgt 60 taccggaacg gcggcgacaa gggtgttccc gaactagagt ggggcataca taatcttgct 120 gctatgcttc gaagctgtag tctgaatcaa cctaagtttt aaacagaagg tgaacctctg 180 agatagaaaa tcaagtatat tttaaaagaa gggatgtggg atcaaggagg acagccttgg 240 cagcagtggc ccttgaacca gcaacaatgg atgcagtcat tccagcacca acaggatcca 300 agccagattg attgggctgc attggcccaa gcttggattg cccaaagaga agcttcagga 360 cagcaaagca tggtagaaca accaccagga atgatgccaa atggacaaga tatgtctaca 420 atggaatctg gtccaaacaa tcatgggaat ttccaagggg attcaaactt caacagaatg 480 tggcaaccag aatggggaat gcatcagcaa cccccacacc cccctccaga tcagccatgg 540 atgccaccaa caccaggccc aatggacatt gttcctcctt ctgaagacag caacagtcag 600 gacagtgggg aatttgcccc tgacaacagg catatattta accagaacaa tcacaacttt 660 ggtggaccac ccgataattt tgcagtgggg ccagtgaacc agtttgacta tcagcatggg 720 gctgcttttg gtccaccgca aggtggattt catcctcctt attggcaacc aggacctcca 780 ggacctccag cacctcccca gaatcgaaga gaaaggccat catcattcag ggatcgtcag 840 cgttcaccta ttgcacttcc tgtgaagcag gagcctccac aaattgacgc agtaaaacgc 900 aggactcttc ccgcttggat tcgcgaaggt cttgaaaaaa tggaacgtga aaagcagaag 960 aaattggaga aagaaagaat ggaacaacaa cgttcacaat tgtccaaaaa agaaaaaaag 1020 gccacagaag atgctgaagg aggggatggc cctcgtttac ctcagagaag taaatttgat 1080 agtgatgagg aagaagaaga cactgaaaat gttgaggctg caagtagtgg gaaagtcacc 1140 agaagtccat ccccagttcc tcaagaagag cacagtgacc ctgagatgac tgaagaggag 1200 aaagagtatc aaatgatgtt gctgacaaaa atgcttctaa cagaaattct gctggatgtc 1260 acagatgaag aaatttatta cgtagccaaa gatgcacacc gcaaagcaac gaaaggtgga 1320 ctgggtggtt atggatcagg agacagtgaa gatgagagga gtgacagagg atctgagtca 1380 tctgacactg atgatgaaga attacggcat cgaatccggc aaaaacagga agctttttgg 1440 agaaaagaaa aagaacagca gctattacat gataaacaga tggaagaaga aaagcagcaa 1500 acagaaaggg ttacaaaaga gatgaatgaa tttatccata aagagcaaaa tagtttatca 1560 ctactagaag caagagaagc agacggtgat gtggttaatg aaaagaagag aactccaaat 1620 gaaaccacat cagttttaga accaaaaaaa gagcataaag aaaaagaaaa acaaggaagg 1680 agtaggtcgg gaagttctag tagtggtagt tccagtagca atagcagaac tagtagtact 1740 agtagtactg tctctagctc ttcatacagt tctagctcag gtagtagtcg tacttcttct 1800 cggtcttctt ctcctaaaag gaaaaagaga cacagtagga gtagatctcc aacaatcaaa 1860 gctagacgta gcaggagtag aagctattct cgcagaatta aaatagagag caatagggct 1920 agggtaaaga ttagagatag aaggagatct aatagaaata gcattgaaag agaaagacga 1980 cgaaatcgga gtccttcccg agagagacgt agaagtagaa gtcgctcaag ggatagacga 2040 accaatcgtg ccagtcgcag taggagtcga gataggcgta aaattgatga tcaacgtgga 2100 aatcttagtg ggaacagtca taagcataaa ggtgaggcta aagaacaaga gaggaaaaag 2160 gagaggagtc gaagtataga taaagatagg aaaaagaaag acaaagaaag ggaacgtgaa 2220 caggataaaa gaaaagagaa acaaaaaagg gaagaaaaag attttaagtt cagtagtcag 2280 gatgatagat taaaaaggaa acgagaaagt gaaagaacat tttctaggag tggttctata 2340 tctgttaaaa tcataagaca tgattctaga caggatagta agaaaagtac taccaaagat 2400 agtaaaaaac attcaggctc tgattctagt ggaaggagca gttctgagtc tccaggaagt 2460 agcaaagaaa agaaggctaa gaagcctaaa catagtcgat cgcgatccgt ggagaaatct 2520 caaaggtctg gtaagaaggc aagccgcaaa cacaagtcta agtcccgatc aaggtagtat 2580 actttttaaa gtattttgtc tgatttttaa aaaaaattga ctgaatttat tcaaagttga 2640 aagtgtcctt tctctctctc tttaataaac tcagtttggt acttgataaa taatcatagt 2700 cttaaatgtt agaaatccta tataatatta tttatttaaa attgcagatt tttaatttaa 2760 aatacatttt tatttttaaa ttttgtcttt tccctttttt tttcagatca acaacccctc 2820 cccgtcgtaa acgctgagga atgatgtggc aagaatgcca tgatgttctt taaaaaattc 2880 catgagtttt aagggcttgt ctcaggatag aggcacattg tggctgtgta ggtgaaacag 2940 aatctttttt ttttttaat 2959 

What is claimed is:
 1. An isolated polypeptide selected from the group consisting of: a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-14, SEQ ID NO:17, and SEQ ID NO:19-23, c) a naturally occurring polypeptide comprising an amino acid sequence at least 99% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:15-16 and SEQ ID NO:18, d) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, and e) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-23.
 2. An isolated polypeptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23.
 3. An isolated polynucleotide encoding a polypeptide of claim
 1. 4. An isolated polynucleotide encoding a polypeptide of claim
 2. 5. An isolated polynucleotide of claim 4 comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46.
 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim
 3. 7. A cell transformed with a recombinant polynucleotide of claim
 6. 8. A transgenic organism comprising a recombinant polynucleotide of claim
 6. 9. A method of producing a polypeptide of claim 1, the method comprising: a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and b) recovering the polypeptide so expressed.
 10. A method of claim 9, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-23.
 11. An isolated antibody which specifically binds to a polypeptide of claim
 1. 12. An isolated polynucleotide selected from the group consisting of: a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46, c) a polynucleotide complementary to a polynucleotide of a), d) a polynucleotide complementary to a polynucleotide of b), and e) an RNA equivalent of a)-d).
 13. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim
 12. 14. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising: a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
 15. A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.
 16. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising: a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
 17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.
 18. A composition of claim 17, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-23.
 19. A method for treating a disease or condition associated with decreased expression of functional MDDT, comprising administering to a patient in need of such treatment the composition of claim
 17. 20. A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising: a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting agonist activity in the sample.
 21. A composition comprising an agonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.
 22. A method for treating a disease or condition associated with decreased expression of functional MDDT, comprising administering to a patient in need of such treatment a composition of claim
 21. 23. A method of screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising: a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting antagonist activity in the sample.
 24. A composition comprising an antagonist compound identified by a method of claim 23 and a pharmaceutically acceptable excipient.
 25. A method for treating a disease or condition associated with overexpression of functional MDDT, comprising administering to a patient in need of such treatment a composition of claim
 24. 26. A method of screening for a compound that specifically binds to the polypeptide of claim 1, the method comprising: a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim
 1. 27. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising: a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1, b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim
 1. 28. A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising: a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
 29. A method of assessing toxicity of a test compound, the method comprising: a) treating a biological sample containing nucleic acids with the test compound, b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof, c) quantifying the amount of hybridization complex, and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
 30. A diagnostic test for a condition or disease associated with the expression of MDDT in a biological sample, the method comprising: a) combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.
 31. The antibody of claim 11, wherein the antibody is: a) a chimneric antibody, b) a single chain antibody, c) a Fab fragment, d) a F(ab′)₂ fragment, or e) a humanized antibody.
 32. A composition comprising an antibody of claim 11 and an acceptable excipient.
 33. A method of diagnosing a condition or disease associated with the expression of MDDT in a subject, comprising administering to said subject an effective amount of the composition of claim
 32. 34. A composition of claim 32, wherein the antibody is labeled.
 35. A method of diagnosing a condition or disease associated with the expression of MDDT in a subject, comprising administering to said subject an effective amount of the composition of claim
 34. 36. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising: a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, or an immunogenic fragment thereof, under conditions to elicit an antibody response, b) isolating antibodies from said animal, and c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23.
 37. A polyclonal antibody produced by a method of claim
 36. 38. A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.
 39. A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising: a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-23, or an immunogenic fragment thereof, under conditions to elicit an antibody response, b) isolating antibody producing cells from the animal, c) fusing the antibody producing cells with immortaized cells to form monoclonal antibody-producing hybridoma cells, d) culturing the hybridoma cells, and e) isolating from the culture monoclonal antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23.
 40. A monoclonal antibody produced by a method of claim
 39. 41. A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.
 42. The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.
 43. The antibody of claim 11, wherein the antibody is produced by screening a recombinant immunoglobulin library.
 44. A method of detecting a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23 in a sample, the method comprising: a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23 in the sample.
 45. A method of purifying a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23 from a sample, the method comprising: a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and b) separating the antibody from the sample and obtaining the purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-23.
 46. A microarray wherein at least one element of the microarray is a polynucleotide of claim
 13. 47. A method of generating an expression profile of a sample which contains polynucleotides, the method comprising: a) labeling the polynucleotides of the sample, b) contacting the elements of the microarray of claim 46 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and c) quantifying the expression of the polynucleotides in the sample.
 48. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, and wherein said target polynucleotide is a polynucleotide of claim
 12. 49. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.
 50. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.
 51. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to said target polynucleotide.
 52. An array of claim 48, which is a microarray.
 53. An array of claim 48, further comprising said target polynucleotide hybridized to a nucleotide molecule comprising said first oligonucleotide or polynucleotide sequence.
 54. An array of claim 48, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.
 55. An array of claim 48, wherein each distinct physical location on the substrate contains multiple nucleotide molecules, and the multiple nucleotide molecules at any single distinct physical location have the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another distinct physical location on the substrate.
 56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.
 57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.
 58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.
 59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.
 60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.
 61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.
 62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.
 63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.
 64. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.
 65. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.
 66. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.
 67. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.
 68. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.
 69. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.
 70. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.
 71. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.
 72. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17.
 73. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:18.
 74. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:19.
 75. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:20.
 76. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:21.
 77. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:22.
 78. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:23.
 79. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:24.
 80. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:25.
 81. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:26.
 82. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:27.
 83. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:28.
 84. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:29.
 85. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:30.
 86. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:31.
 87. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:32.
 88. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:33.
 89. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:34.
 90. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:35.
 91. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:36.
 92. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:37.
 93. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:38.
 94. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:39.
 95. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:40.
 96. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:41.
 97. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ED NO:42.
 98. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:43.
 99. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:44.
 100. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:45.
 101. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:46. 